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‘Life is what happens to you, while you’re busy making other plans.’ 
John Winston Lennon 
‘And all the science I don’t understand, it’s just my job five days a week.’ 
Sir Elton Hercules John 
‘Sigh no more.’ 
Marcus Oliver Johnstone Mumford 
‘You can check-out any time you like, but you can never leave.’ 
Donald Hugh Henley 
‘It's a beautiful day. The sun is shining. I feel good. And no-one's gonna stop me now, oh 
yeah.’ 
Freddie Mercury 
‘Keep building these random memories. Turning our days into melodies. But since I can’t 
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The discovery of anticancer properties of cisplatin in the 1960s has sparked a wide array of 
research in the field of transition metal complexes as anticancer drugs. Through key 
examples of complexes in metal-based chemotherapy, photodynamic therapy, and 
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 A new hope: cisplatin 1.1
The story of cisplatin (cis-[PtCl2(NH3)2], Figure 1.1) is remarkable. For the first time 
synthesized by Michele Peyrone in 1844,1, 2 the actual structure of cisplatin was 
extensively described 50 years after its discovery by Alfred Werner’s ‘Beitrag zur 
Konstitution anorganischer Verbindungen’ in 1892.3 Finally, cisplatin played a 
central role in Werner’s theory of coordination chemistry, for which he was later 
awarded the Nobel Prize in Chemistry ‘in recognition of his work on the linkage of 
atoms in molecules by which he has thrown new light on earlier investigations and opened 
up new fields of research especially in inorganic chemistry.’4 
Attention for cisplatin settled until the 1960s, when its anticancer effects were 
discovered by Barnett Rosenberg. While originally studying the effect of an electric 
field on mitosis in prokaryotic cells, Rosenberg observed inhibition of cell division 
of Escherichia coli bacteria. After thorough research Rosenberg came to the 
conclusion that cisplatin was the prime candidate for this effect that in the initial 
experiments was formed as electrolysis product from a platinum electrode.5 After 
years of research it proved to be a promising anticancer drug candidate in both in 
vitro6 and in vivo studies.7 In these years Rosenberg not only investigated and 
developed a compound that has become one of the most successful 
chemotherapeutic agents; he also lay the foundation of a whole new field of 
research, that of metal-based anticancer drugs. Rosenberg’s work in the late 1960s 
and 1970s comprised platinum anticancer chemistry that included cisplatin 
analogues, different modes of action of cis and trans isomers,8 and the activation of 
platinum(IV) complexes by photoreduction,9 that all have present-day relevance.  
 
Figure 1.1 Chemical structure of cisplatin. 
As a chemotherapeutic agent that is still used in the clinics today, cisplatin is 
administered intravenously to cancer patients. Due to the high chloride 
concentration in the bloodstream (> 100 mM), the chloride ligands mostly remain 
coordinated.10 Cisplatin can then enter the cell either via passive diffusion or via 
 
11 
copper(II) transporters.11 In the cell the chloride concentration is much lower (3-20 
mM), thus allowing for hydrolysis of cisplatin into [Pt(NH3)2(OH2)Cl]+.12 Once 
inside the nucleus this species can form a coordination bond with thymine, 
guanine, cytosine, or adenine, the bases of nuclear DNA, of which guanine is the 
preferred coordination site. Once coordinated, the second chloride ligand is 
replaced via coordination to another DNA base, ultimately forming interstrand or 
intrastrand crosslinks.13 These crosslinks bend and unwind duplex DNA and this 
distortion attracts high-mobility group proteins.14 The attachment of these proteins 
shields the platinated DNA from excision repair and consequently sensitizes the 
cell for apoptosis.15 This cisplatin mechanism of action (MoA), as presented here, is 
the main paradigm in place. However, there is extensive scientific debate if and 
how interaction with biomolecules, before binding to nuclear DNA, plays a crucial 
role in the MoA.16  
The development and clinical success of cisplatin have sparked wide interest and 
allocation of funds to develop new platinum-based anticancer drugs. Cisplatin has 
a cure rate of over 95% for patients diagnosed with testicular cancer, and is also 
used in the treatment of bladder and ovarian cancer.17 However, side effects 
associated with cisplatin include nephrotoxicity, neurotoxicity, ototoxicity, and 
nausea. Another drawback is that some cancers have or can acquire cisplatin 
resistances.18 Therefore, cisplatin analogues have been developed in the clinic, for 
example carboplatin or oxaliplatin, that have significantly less side effects (Figure 
1.2). Other cisplatin analogues that have been approved in at least one country 
include nedaplatin, lobaplatin, and heptaplatin (Figure 1.2).19 All these cisplatin 
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Figure 1.2 Chemical structures of carboplatin, oxaliplatin, nedaplatin, lobaplatin, and 
heptaplatin. 
 Changing metal: the rise of ruthenium 1.2
There has been extensive research in metal-based non-platinum anticancer agents, 
to avoid cisplatin related side effects, to overcome cisplatin resistance, and to 
improve selectivity. In this context ruthenium complexes have been the most 
investigated alternative.20 This attention can be explained by the following 
properties of ruthenium as metal center for building transition metal complexes: a 
distinct coordination geometry (octahedron vs. square plane), specific binding 
preferences, access and physiological stability of +II and +III oxidation states, redox 
activity, and similar ligand exchange kinetics compared to platinum(II).21, 22 
Moreover, early reports describing promising ruthenium complexes were already 
published in the eighties and nineties.23, 24 This section is not intended to give a 
complete overview of ruthenium complexes that have been developed, reported, 
and tested in vitro or in vivo, but to describe a personal view on key ruthenium 
complexes that have been critical in the development of ruthenium anticancer 
chemistry. Ruthenium complexes in combination with phototherapy will be 
discussed more specifically in section 1.4. 
For a long time NAMI-A developed by Sava and Alessio, and KP1019 developed 
by Keppler et al., have been the ambassadors to the field of ruthenium anticancer 
chemistry (Figure 1.3). In a Phase I-II study NAMI-A was given to 32 patients with 
advanced non-small lung cell carcinoma in combination with clinically approved 
gemcitabine.25 At the highest dose remission was reported for only one patient, and 
 
13 
stable disease was reported for six to eight weeks for ten patients. Patients 
experienced nausea, vomiting, constipation, diarrhea, fatigue, renal toxicity, and 
blister formation. These results proved not to be promising enough and NAMI-A 
was, after many years, qualified as ‘insufficiently effective for further use’.25 
KP1019 was developed against colon cancer, caused no serious side effects in a 
Phase I study, and affected stability in five out of six patients up to 10 weeks.26 Due 
to limited solubility of the compound large infusion volumes were required.27 This 
low solubility ended the clinical testing of KP1019. However, the legacy of KP1019 
lives on in the form of its more water-soluble sodium salt analogue NKP-1339 
(Figure 1.3), which, according to its developers, is ‘the first ruthenium-based 
anticancer drug on the edge of clinical application’.28 In a phase I study NKP-1339 was 
administered to a total of 34 (heavily pre-treated) patients with various solid 
tumors. At the highest doses (780 mg.m−2), very minor side effects were observed, 
and a partial response was observed in one patient and disease stabilization in 
seven patients. These limited effects are a major advantage over current metal-
based anticancer drugs, and justify further development of NKP-1339. Despite the 
fact that NAMI-A and KP1019 did not end up as clinically approved drugs, their 
development has greatly contributed to ruthenium anticancer chemistry.29  
 
Figure 1.3 Chemical structures of NAMI-A, KP1019, and NKP1339. 
It is common to first assess the potential of any new complexes by evaluating their 
cytotoxicity. Cytotoxicity is commonly reported as the IC50 or EC50 value – the 
inhibiting or effective concentration at which 50% of the treated cells is dead, 
compared to untreated control cells. For the sake of clarity and uniformity in this 
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the parameters of the cytotoxicity assay, one of the most important being the drug 
incubation time, which in the literature typically varies from 1 to 72 hours.  
The two main types of compounds in ruthenium anticancer research are 
categorized as ruthenium arene complexes and ruthenium polypyridyl complexes. 
The first category of compounds contain a polyhapto-coordinated arene ligand. 
For example, RAPTA complexes developed by Dyson et al. comprise ruthenium 
η6-arene (RA, the core), the monodentate phosphine ligand 1,3,5-triaza-7-
phosphoadamantane (PTA), and two chloride ligands. Dissociation of these 
chloride ligands is possible, thereby mimicking the first steps of the MoA of 
cisplatin. The compound RAPTA-C (Figure 1.4) has shown inhibition of tumor 
growth in vivo by approximately 75%, and inhibition of angiogenesis in the chicken 
chorioallantoic membrane model was demonstrated.30 Similar RAED (ruthenium 
arene ethylenediamine) complexes reported by Sadler contain a η6-arene ligand, a 
bidentate 1,2-ethylenediamine ligand, and a chloride ligand. From this series the 
compound RM175 (Figure 1.4) has exhibited growth inhibition against A2780 
ovarian cancer cells (EC50 = 9 µM)31 and 46% tumor growth inhibition with two 
doses of 25 mg.kg-1 in A2780 xenografts and A2780cis xenografts.32 
 
 
Figure 1.4 Chemical structures of RAPTA-C and RM175. 
Ruthenium polypyridyl complexes have been extensively studied as well, not only 
as anticancer compounds but also as (redox) catalysts or imaging agents.33, 34 Due to 
the wide scope of mono-, bi-, tri-, tetra-, and pentadentate pyridyl ligands, an 
infinite number of different complexes is possible, and a vast amount of literature 
has been generated on this family of complexes. In 1995 the simple ruthenium 
polypyridyl complex [Ru(tpy)Cl3] (tpy = 2,2’:6’,2”-terpyridine, Figure 1.5) was 
 
15 
reported to have 50% growth inhibition of HeLa cells with 7 µM treatment after 72 
hours of exposure in vitro, and was claimed to exhibit ‘significant antitumor 
activity’ in vivo.35 Another example is the cyclometallated ruthenium complex 
RDC11 (Figure 1.5). In vivo it reduced the tumor volume and weight by 40% and 
performed better than the control compound cisplatin, without causing severe side 
effects to the liver, kidneys, or the neuronal sensory system.36  
 
Figure 1.5 Chemical structures of [Ru(tpy)Cl3] and RDC11. 
In conclusion, despite the early development of NAMI-A and KP1019 in the 1980s 
and clinical testing in the 1990s, the promise of (simple) ruthenium complexes has 
not been fulfilled yet. To date none of the second generation ruthenium complexes 
from the arene and polypyridyl groups have ended up in the clinics. The way to 
the clinic is complicated and lack of success can have many reasons, of which the 
investment climate is not the least important. Therefore, ruthenium-based 
anticancer drugs will only become clinically successful when they have superior 
properties, in terms of key issues such as selectivity, general toxicity, and/or 
resistance, compared to currently approved drugs and in particular cisplatin 
analogues.  
 No more side effects: in search of selectivity  1.3
Side effects caused by chemotherapy are primarily caused by a lack of selectivity. 
To sustain rapid cell division, cancer cells have a high uptake of molecules of all 
kinds, which may include anticancer agents. Such high uptake is not limited to 
cancer cells, but also includes fast-growing healthy cells such as hair cells, or 
microvilli located in the intestines. As the chemotherapeutic agent is usually 
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To sustain rapid cell division, cancer cells have a high uptake of molecules of all 
kinds, which may include anticancer agents. Such high uptake is not limited to 
cancer cells, but also includes fast-growing healthy cells such as hair cells, or 
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Therefore, improving selectivity would not only reduce side effects stemming from 
general toxicity, but also allow for more optimal treatment doses. 
In inorganic chemistry several approaches have been developed to acquire 
selectivity in chemotherapeutic compounds. The first one is the prodrug approach, 
which involves chemical binding of the drug to a moiety that deactivates or cages 
the active compound. Ideally, the caged or inactive form does not interfere with 
the cell biochemistry, which prevents non-specific cytotoxicity and undesired side 
effects. Selectivity can then be induced by local activation, but also by equipping 
the active compound with targeting moieties. The Keppler group has oxidized 
oxaliplatin, and introduced axial maleimide ligands to selectively couple the 
maleimide to the thiol group of cysteine-34 of human serum albumin (HSA) as 
shown in Figure 1.6.37 HSA is known to accumulate in malignant and 
inflammatory tissues due to the enhanced permeability and retention effect.38 Mice 
treated with HSA-functionalized oxaliplatin(IV) exhibited no significant loss of 
body weight, significant reduction in tumor growth (CT colon xenograft), and 
disease stabilization.37  
The group of Lippard has developed a cisplatin-based platinum(IV) compound 
containing a (D)-1-methyltryptophan ((D)-1-MT) ligand in one of the axial 
positions (Figure 1.6). (D)-1-MT inhibits indoleamine-2,3-dioxygenase, an 
immunosuppressive enzyme in human tumors, leading to immunomodulation and 
enhanced T-cell proliferation in vitro.39 EC50 values of these platinum(IV) complexes 
ranged from high nanomolar to micromolar concentrations against a panel of 
human ovarian cancer cell lines. In summary, square-planar cisplatin analogues 
can be oxidized into an octahedral platinum(IV) compound. After uptake of this 
prodrug, the platinum(IV) compound is subsequently reduced to the original 
cisplatin analogue, and then acts similar to the platinum(II)-based drugs. The two 
extra coordination sites can be used to couple the prodrug to ligands that have 
high target affinity. In the process alternative cell uptake mechanisms may be 




Figure 1.6 Chemical structures of maleimide functionalized oxaliplatin (left) and (D)1-
methyl tryptophan functionalized cisplatin (right).37, 39 
An alternative strategy in targeting cancer cells is to disturb their distinct and 
delicate redox balance. Healthy cells commonly have tight regulation of reactive 
oxygen species (ROS) and metal homeostasis to maintain this intracellular redox 
balance.40 Enzymatic reactions performed by reductases, oxidases, and 
peroxidases, and non-enzymatic reactions involving glutathione (GSH) and 
thioredoxin, are employed by cells to preserve this redox balance.41 For example, 
the disturbance of homeostasis caused by cisplatin increases the intracellular ROS 
levels, and is associated with cisplatin-induced side effects ototoxicity and 
nephrotoxicity.42, 43 Cancer cells are characterized by an imbalance in redox 
homeostasis that leads to enhanced intracellular ROS presence, and subsequently 
higher levels of oxidative stress.44, 45 The higher concentrations of ROS are not only 
caused by a high metabolic activity to sustain rapid cell division, but are also 
caused by lower levels of antioxidants. Cancer cells, thus, have a lower ROS-
buffering capacity and can deal less efficiently with extracellular stress compared 
to healthy cells. Anticancer compounds that are designed to induce ROS may thus 
be more cytotoxic toward cancer cells than toward healthy cells. 
Drawing inspiration from transfer hydrogenation catalysis by ruthenium-arene 
complexes, Sadler et al. have developed complexes capable of pushing the 
coenzyme NAD+ + H− ⇌ NADH equilibrium towards NADH in the presence of an 
excess sodium formate acting as the hydride donor.46 Excess NADH results in 
reductive stress causing the cells to die. Treatment of A2780 cancer cells with 
[Ru(p-cym)(MsEn)Cl] (MsEn = N-(2-aminoethyl)methanesulfonamide, Figure 1.7, 
left) without formate resulted in EC50 values of 11.9 µM. When co-treated with 
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Figure 1.6 Chemical structures of maleimide functionalized oxaliplatin (left) and (D)1-
methyl tryptophan functionalized cisplatin (right).37, 39 
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excess sodium formate acting as the hydride donor.46 Excess NADH results in 
reductive stress causing the cells to die. Treatment of A2780 cancer cells with 
[Ru(p-cym)(MsEn)Cl] (MsEn = N-(2-aminoethyl)methanesulfonamide, Figure 1.7, 
left) without formate resulted in EC50 values of 11.9 µM. When co-treated with 
formate, an enhanced antiproliferative activity, characterized by an EC50 lower 
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than 1.0 µM, was measured. In contrast, [(η5-Cpxbiph)Ir(phpy)py]PF6 (Cpxbiph = 
biphenyltetramethyl-cyclopentadienyl, Hphpy = phenylpyridine, py = pyridine, 
Figure 1.7, right) in vitro acts as an oxidation catalyst and pushes the NAD+ + H−⇌ 
NADH equilibrium towards NAD+, resulting in higher levels of H2O2.47 Co-
treatment with L-buthionine sulfoximine (BSO), an inhibitor of γ-glutamylcysteine 
synthetase, results in a two-fold increase of the activity of this compound, to EC50 
values of 60 nM. As BSO lowers the ability of cells to scavenge ROS, the enhanced 
cytotoxicity of the iridium complex is explained by its capacity to interfere with the 
redox balance of the cancer cell.  
  
Figure 1.7 Chemical structures of ruthenium reduction catalyst and iridium oxidation 
catalyst developed by Sadler. 
 Phototherapy in anticancer treatment 1.4
Phototherapy is a rapidly developing method in cancer research to increase the 
selectivity of chemotherapeutic drugs. It relies on the local activation of a prodrug 
by in vivo light irradiation of the tumor. Ideally, the prodrug is non-toxic and 
becomes highly toxic after activation in the irradiated tumor tissue. Phototoxicity is 
quantified as the ratio of the EC50 value obtained in a dark control and that 
obtained after light irradiation. This factor is commonly defined as the Photo Index 
(PI), and it should ideally be as large as possible. In phototherapy, light activation 
by lower-energy light (red light) is preferred over activation by high-energy light 
(UV- and blue light), because low-energy light is less scattered, less damaging to 
cells, and less absorbed in vivo, meaning that it can penetrate further in biological 
tissues.48 In contrast, UV light is carcinogenic in itself,49 and does not penetrate 
deeply in tissues, which limits in vivo applications. Several features determine the 
potential efficiency of phototherapy agents: (i) water solubility, (ii) stability in the 
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dark in aqueous media and serum, (iii) uptake by cells, (iv) PI, and (v) wavelength 
at which the compound can be activated.22  
Photodynamic therapy (PDT) relies on absorbance of light by a photosensitizer, 
and transfer of this energy to ground state triplet oxygen (3O2) to form highly 
reactive excited state singlet oxygen (1O2). The photogenerated 1O2 can induce 
damages to biomolecules, or react with biomolecules to form other ROS species 
such as H2O2. This type of PDT is commonly referred to as PDT type 2. PDT type 1 
involves the direct reaction between a photosensitizer and biomolecules without 
the direct involvement of dioxygen, but it is much less common than PDT type 2. 
To date, PDT photosensitizers approved in the clinic are the organic molecules 
Photofrin, Foscan, Levulan, and Metvixia cream. Among inorganic PDT 
photosensitizers the water-soluble palladium porphyrin complex, Padeliporfin 
(WST11), developed by Scherz and Salomon, is the only compound clinically tested 
and even approved in some countries (Figure 1.8, left).50 Phase II clinical trials 
demonstrated that 4 mg/kg WST11, and light doses of 200 J.cm−1 (λirr = 753 nm), are 
the optimal treatment conditions for patients with localized low-risk prostate 
cancer. Evaluation six months after treatment demonstrated that > 80% of patients 
were tested negatively for prostate cancer. WST11 has passed Latin America Phase 
III clinical trials, and is currently clinically available in Mexico. Results of a 
European Phase III clinical trial have been submitted to the European Medicine 
Agency in January 2016 and approval of WST11 is pending. In the field of 
ruthenium chemistry a highly promising PDT photosensitizer, TLD1433, has been 
developed by McFarland et al. (Figure 1.8, right). In vitro this compound has an 
EC50 value after light activation by red light (λirr = 625 nm) of 19 µM, while in the 
dark it remains higher than 300 µM in HL-60 cells.51 In 2016 TLD1433 finished 
Phase I-II clinical trials with promising outcomes as treatment for bladder cancer, 
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Figure 1.8 Chemical structure of Padeliporfin (WST11) and TLD1433. 
 Photoactivated chemotherapy 1.5
1.5.1 Introduction photoactivated chemotherapy  
Many sections of tumors are poorly oxygenated (hypoxic), while PDT type 2 relies 
on the presence and activation of dioxygen.53 PhotoActivated ChemoTherapy 
(PACT) is an alternative phototherapy that takes advantage of local photochemical 
activation of a prodrug to acquire high specificity. The concept of PACT relies on a 
(non-toxic) prodrug that upon light activation undergoes photolysis or 
photosubstitution.22 Whereas the prodrug has no biologicalactivity, at least one of 
its photoproducts is a biologically active molecule. Typically in anticancer 
treatment this is a prodrug that after light activation becomes cytotoxic.  
One of the key research areas in the field of PACT focuses on ruthenium 
polypyridyl complexes. Upon irradiation, this type of metal complexes first is 
excited to a singlet metal-to-ligand charge transfer (1MLCT) state, from which very 
fast (femtosecond time scale) intersystem crossing populates the corresponding 
triplet MLCT state (3MLCT). From this long-lived 3MLCT state the system can then 
either relax to the ground state by emission of a photon (phosphorescence) or 
thermally populate triplet metal-centered states (3MC) if these states are low 
enough in energy. 3MC states have a dissociative character because an antibonding 
dσ* orbital of the metal center is occupied by one electron.54 3MC population hence 
leads to increased lability of at least one of the ligands that subsequently may be 
photosubstituted. In other words, such light-activatable ruthenium complexes can 
undergo ligand photosubstitution.55-57 Ligands that can be photosubstituted are 
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typically bound to a ruthenium(II) center via nitrile, amine, pyridine, sulfoxide, or 
thioether functional groups.58-60 In the following sections several examples of 
ruthenium complexes will be described that have been reported as light-activatable 
anticancer drugs in vitro.  
1.5.2 PACT based on cis Ru complexes 
The complex [Ru(bpy)2(dmbpy)]Cl2 (bpy = 2,2’-bipyridine, dmbpy = 6,6’-dimethyl-
2,2’-bipyridine) developed by Glazer et al. was the first reported ruthenium-based 
PACT complex (Figure 1.9).61 Upon visible light irradiation (λirr > 450 nm) 
[Ru(bpy)2(dmbpy)]Cl2 releases its sterically demanding dmbpy ligand. In vitro this 
light activation increases cytotoxicity of the compound from an EC50 of over 150 
µM in the dark to an EC50 to 1.1 µM after light activation, which represents a 136-
fold increase in cytotoxicity. Similarly, [Ru(biq)(phen)2]Cl2 (biq = 2,2’-biquinoline, 
phen = 1,10-phenanthroline), displayed in Figure 1.9, was also shown by Glazer et 
al. to be a potential PACT compound. Photoejection of the biq ligand in vitro is 
accompanied by lowering of the EC50 from 52.5 µM in the dark to 1.2 µM after light 
activation with white light (λirr > 400 nm).62 Glazer attributed the enhanced toxicity 
of the compound to the two available cis coordination positions that become 
available upon photosubstitution of biq by two labile aqua ligands. Binding of the 
light activated ruthenium complex to DNA similar to cisplatin-DNA binding was 
suggested as a possible cause for light-enhanced cytotoxicity.  
The cyclometallated compound RDC11 – described in section 1.2 – also exhibited a 
14-fold increase in cytotoxicity after red-light activation (λirr = 690 nm), from an 
EC50 in the dark of 1.0 µM to an EC50 after light irradiation of 70 nM.63 The Turro 
lab has also developed PACT compounds such as [Ru(bpy)(dppn)(CH3CN)2](PF6)2 
(dppn = benzo[i]dipyrido[3,2-a;2’,3’-c]phenazine, Figure 1.9) that photosubstitutes 
both CH3CN ligands in H2O. In vitro on HeLa cells the toxicity of the complex 
increases from an EC50 of 331 µM in the dark to an EC50 of 0.47 µM after blue-light 
(λirr = 466 nm) activation. According to Turro the enhanced cytotoxicity is induced 
for this compound both by the generation of 1O2 (PDT type 2) and by 
photosubstitution of the CH3CN ligands (PACT). A double mechanism of action is 
always possible. The examples discussed in this section are all ruthenium(II) 
compounds with bidentate ligands similar to bpy. Photosubstitution of one of the 
bpy ligands offers available coordination sites in the cis configuration that are able 
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common that from the two photoproducts that are produced by photosubstitution 
reactions, i.e., the ruthenium bis-aqua complex and the free photosubstituted 
ligand, the metal fragment is usually believed to act as the active species, i.e., the 
metal-based drug is caged by an organic ligand that can be photosubstituted. 
 
Figure 1.9 Chemical structures of [Ru(bpy)2(dmbpy)]Cl2, [Ru(biq)(phen)2]Cl2, and 
[Ru(bpy)(dppn)(CH3CN)2](PF6)2, and photosubstitution reaction with 
[Ru(bpy)2(dmbpy)]Cl2. 
1.5.3 Photocaging 
The concept of PACT relies on light activation of a prodrug resulting in 
photosubstitution. In case of a mononuclear complex for example 
photosubstitution will lead to a metal-based and an organic fragment. In previous 
sections a PACT strategy was described wherein the metal fragment acts as the 
cytotoxic drug. An alternative PACT approach is a strategy wherein the 
photosubstituted organic part acts as the drug and the metal fragment as the 
caging agent. In light of this strategy Turro has coordinated 5-cyanouracil (5-CNU), 
the nitrile analogue of the clinically approved anticancer drug fluorouracil, to 
[Ru(bpy)2(OH2)2](PF6)2. Binding of [Ru(bpy)2(5-CNU)2](PF6)2 to DNA in gel 
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electrophoresis experiments could be photocontrolled (λirr > 395 nm), but no 
phototoxicity data was reported.64 In another example reported by Turro 
[Ru(tpy)(OH2)3]2+ was utilized as cage, to form [Ru(tpy)(5-CNU)3]Cl2.65 Activation 
using visible light (λirr > 395 nm) in water showed the formation of the bis-aqua 
species [Ru(tpy)(5-CNU)(OH2)2]Cl2 via the mono-aqua species [Ru(tpy)(5-
CNU)2(OH2)]Cl2 (Scheme 1.1). When HeLa cells were treated with [Ru(tpy)(5-
CNU)3]Cl2 a qualitative fluorescence (SYTOX) assay confirmed that cells were 
dying to a higher degree upon light activation (λirr > 400 nm), compared to a dark 
control. When in a control experiment cells were treated with 1 molar equivalent of 
free 5-CNU, the same cytotoxic activity was observed as with the photoactivated 
compound [Ru(tpy)(5-CNU)3]Cl2. Caging of existing drugs to improve selectivity 
could be a viable path to the development for new therapies, as pharmacological 
data on the existing drugs is present. Apart from chemotherapy this could also 
include other medication where selectivity and dosage are crucial such as 
antibiotics.  
 
Scheme 1.1 Photochemical reaction of the PACT compound [Ru(tpy)(5-CNU)3]Cl2. 
Photocaging is not limited to breaking coordination bonds between a metal and a 
ligand, but may also occur within one of the ligands. For example, Gasser has 
developed the compound [Ru(dppz)2(Cpp-DMNPB)](PF6)2 (dppz = dipyrido[3,2-a 
:2’,3’-c]phenazine, Cpp = 2-(2-pyridyl)pyrimidine-4-carboxylate, DMNPB = 2-(4,5-
dimethoxy-2-nitrophenyl)butene, Scheme 1.2) in which the DMNPB moiety can be 
cleaved off upon UV irradiation (λirr = 350 nm), to result in the cytotoxic 
carboxylate ruthenium complex and a non-toxic organic fragment.66 In vitro this 
reaction results in a 5-fold enhancement of cytotoxicity (EC50,dark > 100 µM,    EC50, 
light = 17 µM). This enhancement in cytotoxicity was attributed to the released metal 
fragment, as cytotoxicity studies of only the metal fragment resulted in an EC50, dark 
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Scheme 1.2 Photochemical reaction of the PACT compound [Ru(dppz)2(Cpp-
DMNPB)](PF6)2. 
1.5.4 PACT based on platinum complexes 
PACT is not limited to ruthenium complexes. In fact, many transition metal 
complexes based on rhodium, iridium, or platinum have been developed as PACT 
agents.67 For platinum(IV) complexes photoreduction to a platinum(II) species may 
occur upon irradiation with UV light or high-energy visible light. Apart from 
photolysis, this photoreaction typically results in a change from an octahedral 
platinum(IV) complex to a square-planar platinum(II) complex. This concept was 
first reported by Nagle.68 Photoactivation of trans,cis-[Pt(Cl2)(I2)(en)] (λirr = 410 nm, 
en = 1,2,-diamonoethane) resulted in [Pt(I2)(en)] (Scheme 1.3). However, when SK-
MEL-24 (melanoma cancer) or TCCSUP (bladder cancer) cells were treated with 
the platinum(IV) complex no significant enhanced cytotoxicity was observed when 
trans,cis-Pt(Cl2I2(en)] was light activated in vitro compared to the dark control.  
 
Scheme 1.3 Photochemical reaction of the PACT compound trans,cis-[Pt(Cl2)(I2)(en)]. 
Coordination of azides to a platinum(IV) metal center enables the photoactivation 
of platinum(IV) complexes. Irradiation of these PtIV-azide compounds may lead to 
reduction to a PtII complex and the release of nitrogen.69, 70 This concept was 
introduced by Sadler with cis,trans-[PtIV(en)(N3)2(OH)2] shown in Figure 1.10.71 
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Treatment of 5637-bladder cancer cells with cis,trans-[PtIV(en)(N3)2(OH)2] resulted 
in a 7-fold higher cytotoxicity (EC50, dark = 357 µM, EC50, light = 49 µM) and a more 
than 3-fold increase for the 5637-cisplatin resistant cell line (EC50, dark > 200 µM, EC50, 
light = 67 µM) after activation at λirr = 366 nm.72 In this assay the cytotoxicity of the 
[PtII(en)Cl2] was found to be much lower (EC50 = 2.3-14 µM) for both cell lines 
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noted, pharmacological and chemical properties are not the only drivers when it 
comes to successful development of a drug.  
The MoA of platinum(IV) compounds commonly relies on the reduction of a 
platinum complex to a (known) cisplatin analogue. Functionalization with ligands 
containing aromatic functional groups instead of the chloride or ammonia ligands 
or extension of aromaticity can increase the absorbance properties in the visible 
(and phototherapy relevant) domain, but would strongly alter the biochemical 
properties, potentially preventing a similar MoA as cisplatin.75 In addition, it is 
difficult to reach the red region of the spectrum using this strategy. The limited 
light absorption properties of platinum compounds in the phototherapeutic 
window strongly hampers development of this type of platinum(IV) compounds 
as PACT agents. Ruthenium(II) anticancer complexes on the other hand almost 
exclusively contain aromatic arene or polypyridyl ligands. Absorbance in the far 
red of the spectrum is feasible with these kind of ruthenium complexes, and as 
powerful lasers have become cheap, low absorbance is in principle sufficient to 
obtain photoactivation. Overall, the potential of ruthenium complexes as 
photosensitizers in PDT, and their robust photochemistry in PACT, make 
ruthenium polypyridyl complexes more promising compared to the known light-
activatable platinum systems. Furthermore, development of ruthenium complexes 
is not constrained by a powerful paradigm like the DNA targeting MoA of 
cisplatin is for research into new platinum based chemotherapy.  
 Aim and outline of this thesis 1.7
The aim of the research described in this thesis is to develop transition metal-based 
anticancer drugs. In Chapter 2, the potential of thiols and thioethers as 
photosubstitutionally labile ligands using [Ru(tpy)(bpy)(OH2)]2+ as model complex 
are compared. Thiols have been often overlooked as photosubstitutable ligands, 
although they are omnipresent in biotechnology.76 This omission is all the more 
remarkable as GSH is abundant in vitro and in vivo and known to interact with 
anticancer metallodrugs. It is shown in Chapter 2 that once coordinated to 
ruthenium, thiols are very sensitive to oxidation, leading to dissociation even in the 
dark. This specific reactivity makes them unsuitable as protective group for metal-
based PACT compounds. In Chapter 3, the use of the poorly toxic 
[Ru(tpy)(bpy)(OH2)]2+ fragment to cage an organic thioether-containing anticancer 
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compound is described. This cytotoxic thioether ligand is a microtubule-targeting 
rigidin moiety that can coordinate to ruthenium(II) and be released upon light 
irradiation. Upon green-light irradiation the rigidin drug is indeed shown to be 
released, which results in vitro in a 20-fold increase in cytotoxicity compared to the 
dark control. Further studies are also included that demonstrate that the 
photoreleased rigidin interfers with the polymerization of microtubule. 
In Chapter 4, two ruthenium complexes with photosubstitutionally labile sulfoxide 
or thioether ligands in trans positions are presented that are based on the 
tetrapyridyl ligand H2biqbpy (6,6’-bis[N-(isoquinolyl)-1-amino]-2,2’-bipyridine). 
This tetrapyridyl ligand was developed for iron(II)-based spin-crossover materials, 
but it is new in the context of ruthenium photochemistry. Upon coordination to a 
metal center in an octahedral geometry it leaves two trans coordination positions 
for the binding of (non-toxic) sulfur-based ligands. Upon green light irradiation a 
20-fold increase in cytotoxicity is demonstrated in vitro compared to the dark 
control. Green light activation of these compounds induces cell death via apoptosis, 
unlike PDT compounds that commonly induce necrosis. We also demonstrate that 
light-induced cell death is obtained even with insignificant 1O2 generation 
quantum yields. In Chapter 5, the synthesis of a series of three new ruthenium 
polypyridyl complexes based on the H2biqbpy ligand and the analogous H2bapbpy 
(6,6’-bis[N-(pyridyl)-1-amino]-2,2’-bipyridine) is described. The interaction of these 
complexes with a 12-mer oligonucleotide is demonstrated to be controlled by light. 
For the first time, the ruthenium-oligonucleotide adducts formed under light 
irradiation are analyzed by high-resolution mass spectrometry and gel 
electrophoresis.  
Investigations regarding tetrapyridyl ligands, already discussed in Chapter 4 and 
5, are extended in Chapters 6, 7, and 8, to ‘regular’, i.e. non light-activatable, 
chemotherapeutic metallodrugs based on column 10 transition metals. In Chapter 
6, the synthesis and anticancer properties of a series of three new complexes based 
on the H2bapbpy ligand coordinated to nickel(II), palladium(II), and platinum(II) 
are presented. The in vitro cytotoxic activity of these complexes ranges from EC50 
values in a mild micromolar range for the nickel complex, to sub-micromolar 
concentrations for the platinum analogue, and even spectacular nanomolar EC50 
values for the palladium complex. We further show that the activity of the 
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activity of the structurally similar platinum complex seems to depend on DNA 
interaction. A physicochemical study of the [Pd(H2bapbpy)]2+ and [Pt(H2bapbpy)]2+ 
complexes is presented in Chapter 7. In particular, deprotonation of the H2bapbpy 
ligand leads to a dramatic increase of the absorbance of these complexes in the 
visible domain; TD-DFT calculations confirm that Intra-Ligand-Charge-Transfer 
excited states responsible for the absorption changes are far less present in 
[Pd(H2bapbpy)]2+ than in [Pd(bapbpy)]. Crystal structures of each protonation state 
of the palladium(II) complex ([Pd(H2bapbpy)]2+, [Pd(Hbapbpy)]+, and 
[Pd(bapbpy)]) were obtained and described. In Chapter 8, the synthesis and 
characterization of [Pd(Hbbpya)]2+ and [Pt(Hbbpya)]2+ are described (Hbbpya = 
N,N-bis(2,2’-bipyrid-6-yl)amine),. Compared to H2bapbpy, the Hbbpya ligand is 
much more coordinated in a single plane to the metal center, and contains not two, 
but only one secondary amine. This difference causes marked changes in 
cytotoxicity, pKa, and uptake of [Pd(Hbbpya)]2+ and [Pt(Hbbpya)]2+ compared to 
the H2bapbpy analogues. In Chapter 9, a summary, general conclusion, and 
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The success of cisplatin and its second-generation derivatives (carboplatin and 
oxaliplatin) have inspired chemists to develop new metal-based anticancer agents.1, 
2 Although ruthenium-based frontrunners, NAMI-A and KP1019, have both failed 
to end up in the clinics, ruthenium-based compounds are still subject of intense 
research.3-5 A specific research area is the development of light-activatable 
ruthenium polypyridyl complexes. These complexes have been proposed as 
prodrugs that, upon light irradiation, can be locally activated to kill tumor cells 
resulting in fewer side effects for patients.6-10 Upon photochemical generation of a 
metal-to-ligand charge transfer (MLCT) excited state, such light-activatable 
complexes are capable of substituting one or two ligand(s) by water molecule(s). 
Ligands that can be photosubstituted are typically bound to ruthenium(II) via 
nitrile, amine, pyridine, or thioether functional groups, and up to now thiols have 
not been thoroughly investigated as photocleavable protecting groups. Naturally-
occurring thiols such as glutathione (GSH) are known to interact with many 
anticancer metallodrugs in cells. This interaction can be responsible for both 
detoxification and enhanced cytotoxicity.11-13 Therefore, the interaction of GSH, and 
of its simpler version cysteine, has been investigated with anticancer ruthenium-
based drug candidates by a few groups.6, 14-17 For instance, the Sadler group has 
found evidence for the oxidation of ruthenium-thiol arene compounds, wherein 
the metal-coordinated thiol ligand oxidizes with O2 to form sulfenato and sulfinato 
complexes.18, 19  
Our group started investigating the use of thioether-based protecting ligands for 
light-activatable anticancer ruthenium polypyridyl complexes.20, 21 The non-basic 
properties and soft nature of a thioether ligand allows for the formation of Ru-S 
coordination bonds that are much stronger in water and in the dark than, for 
example, Ru-Cl bonds. Thus, the aqua complex [Ru(tpy)(bpy)(OH2)]2+ ([1]2+) can be 
protected by coordination of N-acetyl-L-methionine (HAmet) to ruthenium, while 
deprotection is obtained using blue light irradiation.20, 21 Thioethers and methionine 
residues, however, are not as ubiquitous in biotechnologies as thiols and cysteine 
residues, and binding of ruthenium complexes to targeting peptides and proteins 
via coordination to thiols would open many doors in targeted photochemotherapy, 
provided that the Ru-S bond with thiol ligands is strong enough in the dark, and 
photocleavable. The photochemistry of thiolato-ruthenium complexes remains 
 
35 
largely unknown, however. In this chapter, we report hence the coordination 
studies between [1]2+and the three thiol ligands L-cysteine (H2Cys), N-acetyl-L-
cysteine (H2Acys), and N-acetyl-L-cysteine methyl ester (HAcysMe); the isolation 
of two ruthenium thiolato complexes [Ru(tpy)(bpy)(HCys)]PF6 ([2]PF6), and 
[Ru(tpy)(bpy)(HAcys)]PF6 ([3]PF6, see Scheme 2.1); and their thermal and 
photochemical reactivity in aqueous solution.  
 
Scheme 2.1 Reaction between complex [1](PF6)2 and thiol ligands H2Cys, H2Acys, or 
HAcysMe. 
 Results 2.2
2.2.1 Coordination chemistry of thiols and [Ru(tpy)(bpy)(OH2)](PF6)2 ([1](PF6)2) 
The reaction between [1](PF6)2 and H2Cys, H2Acys, or HAcysMe in aqueous 
solution was first studied under an argon atmosphere using 1H NMR spectroscopy. 
H2Cys can coordinate to ruthenium via the S, N, or O atoms, whereas for H2Acys 
N-coordination is impossible, and for HAcysMe only S-coordination is feasible. In 
all 1H NMR spectra the A6 proton of the bpy ligand was monitored as it appears at 
very low fields (9.0 to 11.0 ppm), and is very sensitive to the nature of the 
monodentate ligand coordinated to ruthenium. In the dark, in phosphate buffer 
(pD = 7.8) and at 298 K H2Cys hardly reacted with [1]2+ (), and after 15 days 
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monodentate ligand coordinated to ruthenium. In the dark, in phosphate buffer 
(pD = 7.8) and at 298 K H2Cys hardly reacted with [1]2+ (), and after 15 days 
unassigned signals at 10.15 and 9.69 ppm arose (Figure SII.1). When heated to 353 
 
36 
K, however (Figure 2.1), a new peak appeared at 10.08 ppm () after one day, 
together with a minor peak at 9.73 ppm that disappeared upon prolonged heating. 
3 days were required to almost completely convert [1]2+. Coordination of H2Cys to 
the complex is thus a thermally activated process, as has been observed for 
thioethers.20, 21 Although S-coordination is expected because of the softness of 
ruthenium(II), the possibility of N- or O-coordination cannot be excluded at this 
stage. 
 
Figure 2.1 Evolution of the A6 proton of coordinated bpy (see Scheme 2.1) followed by 1H 
NMR spectroscopy of a mixture of [1](PF6)2 and 1 equivalent of thiol ligand H2Cys at 
different time intervals at 353 K under argon in phosphate buffer (pD = 7.8) in the dark 
(10.4-9.4 ppm). Conditions: [Ru]0 = 5.0 mM. Notations:  = [1]2+;  = [2]2+. 
A similar reaction was performed in the dark using 1.2 equivalents of H2Acys, a 
ligand in which the amine can neither be protonated nor coordinate to the metal. 
At 298 K in phosphate buffer (pD = 7.8) a new peak () at 10.00 ppm was observed 
after 24 h (Figure 2.2A), and the red solution turned purple brown. At 353 K the 
same peak at 10.00 ppm () and a color change appeared within 1.5 h (Figure 
2.2B). Mass spectrometry at this point showed peaks at m/z = 508.0 and 653.1 
corresponding to the hydroxo complex [1 – H]+ (calc. m/z = 508.1) and to the 
 
37 
expected thiolato complex [Ru(tpy)(bpy)(HAcys)]+ (calc. m/z = 653.0). After 24 h at 
353 K a second peak at 10.12 ppm appeared () and after 72 h the former signal 
() was not present anymore. As shown by the evolution of the composition of the 
solution as a function of reaction time (Figure SII.2), [Ru(tpy)(bpy)(HAcys)]+ is a 
kinetic product, thus it is unstable under such conditions.  
An alternative way to produce [Ru(tpy)(bpy)(HAcys)]+ was to irradiate white light 
at 298 K on a D2O mixture of [1]2+ and H2Acys (Figure 2.2C); after 1.5 hour the peak 
at 10.00 ppm was clearly visible, and a similar color change as under thermal 
activation was observed. Mass spectrometry after 1.5 h irradiation showed two 
peaks at m/z = 254.6 and 653.1, confirming the presence of [1]2+ and of 
[Ru(tpy)(bpy)(HAcys)]+. Further irradiation, however, did not result in full 
conversion to the pure HAcys− adduct. After 3.5 h of irradiation the species at 10.12 
ppm () observed upon heating in the dark arose as well, and had become the 
major product after 10 h irradiation. Thus, coordination of H2Acys to ruthenium 
only occurs upon thermal or photochemical activation, and the adduct 
[Ru(tpy)(bpy)(HAcys)]+ is unstable. 
To exclude O-coordination the reaction between [1]2+ and HAcysMe was studied as 
well; CD3OD was chosen as solvent due to the poor solubility of the HAcysMe 
ligand in water, and to avoid ester hydrolysis during coordination. In presence of 
7.5 equivalents of HAcysMe, [1]2+ reacted in the dark and after 20 min at 353 K, to 
form two new species characterized by A6 doublets at 10.44 and 10.20 ppm (Figure 
SII.3); [1]2+ can still be observed by its A6 doublet at 9.55 ppm (). According to 
mass spectrometry the new signals correspond to the [Ru(tpy)(bpy)(AcysMe)]+ 
complex [4]+ (m/z = 667.1, calc m/z = 667.1) and [Ru(tpy)(bpy)Cl]+ (m/z = 525.9, calc 
m/z = 526.0), respectively. The chloride complex originated from chloride salts 
found in the commercial ligand HAcysMe. From this reaction and from TLC 
analysis of the reaction mixture it was concluded that the S-bound complex [4]+ is 
purple, and that the purple color observed in the reaction of [1]2+ with H2Cys or 
H2Acys is due to the formation of the κS complexes [2]+ and [3]+, respectively. 
Overall, the three different reactions with the three thiol ligands indicate a similar 
binding mode via the soft sulfur atom, i.e., the preferential formation of thiolato 
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Figure 2.2 Evolution of the A6 proton in the reaction between [1](PF6)2 and H2Acys at 
different time intervals under argon monitored by 1H NMR spectroscopy (region 10.3-9.3 
ppm). The 1H NMR peaks in this region correspond to the A6 proton for each complex. a) 
In phosphate buffer (pD = 7.8) at 298 K in the dark, [H2Acys] = 6.0 mM. b) in D2O at 353 K 
in the dark, [H2Acys] = 4.0 mM. c) in phosphate buffer (pD = 7.8) under white light 
irradiation at 298 K, [H2Acys] = 10.1 mM. [Ru]0 = 5.0 mM. Notations:  = [1]2+;  = [3]+;  = 
[Ru(tpy)(bpy)(HAcysO2)]+ (see text). 
DFT calculations were performed, first in vacuum and then in water using the 
COSMO model (see Experimental for details), to quantify the relative stability of S-
, N-, and O-coordination of cysteine in [2]+. For each binding mode (S, N, and O) 
two different minima were found. The optimized structures, their energies in 
vacuum and in water, are given in Figure SII.4 and Table SII.1, respectively. For the 
S- and O-bound isomers, the two different minima arise from different 
arrangements of the hydrogen atoms in the carboxylate and amine groups and for 
the N-bound isomer they come from the migration of a proton between the thiol 
and carboxylate groups. The S-bound isomer [κS-2]+ is the most stable, with the N-
bonded and the O-bonded isomers being, respectively, 15.7 kcal.mol−1 and 13.2 
kcal.mol−1 higher in energy in vacuum (relative stabilities: S > O > N) and 6.5 
kcal.mol−1 and 12.9 kcal.mol−1 higher in water (relative stabilities: S > N > O). It is 
noteworthy that the relative stabilities of the O-bound and N-bound isomers are 
different in vacuum and in water, which is probably due to the stabilization of the 
carboxylate group in water due to the polar environment. Overall, the energies in 
 
39 
water of the most stable conformers [κS-2]+, [κN-2]+, and [κO-2]+, confirmed that in 
[2]+ the κS binding mode of the HCys− ligand is preferred, and that the peak at 
10.08 ppm () observed in Figure 2.2 is that of [κS-2]+. Everything considered, DFT 
results confirm that H2Cys, and therefore probably H2Acys, coordinates to the 
ruthenium center via the sulfur atom in aqueous solution. 
2.2.2 Synthesis and characterization of two thiolato complexes [2]PF6 and [3]PF6 
As it was obvious that the thiolato complexes [2]+ and [3]+ are unstable even in 
presence of the trace amounts of oxygen present when working with Schlenk 
techniques, new conditions were investigated that would allow for isolating pure 
samples of the complexes. Full conversion into [2]PF6 and [3]PF6 without formation 
of oxidized side products was achieved by adding a large excess of the thiol ligand 
H2Cys or H2Acys to [1](PF6)2 in deionized water upon heating. As shown in Figure 
2.3, 50 equivalents of H2Cys, and 100 equivalents of H2Acys were required to 
quantitatively convert [1]2+ into [2]+ and [3]+ after 1.5 h at 353 K under argon.  
 
Figure 2.3 1H NMR spectra of the A6 proton of mixtures of [1](PF6)2 () with different 
equivalents of H2Acys (a) or H2Cys (b) after 1.5 hour at 353 K under argon in D2O (A6 
region, 10.2-9.3 ppm) forming [3]+ () or [2]+ (). Conditions: [Ru]0 = 5.0 mM, in the dark. 
The compounds were synthesized on a larger scale and purified from the excess 
ligand using size exclusion chromatography (see Experimental Part). [2]PF6 and 
[3]PF6 appeared to be too sensitive to oxidation to give correct elemental analysis 
data or to allow purification by HPLC. However, all spectroscopic data concluded 
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water of the most stable conformers [κS-2]+, [κN-2]+, and [κO-2]+, confirmed that in 
[2]+ the κS binding mode of the HCys− ligand is preferred, and that the peak at 
10.08 ppm () observed in Figure 2.2 is that of [κS-2]+. Everything considered, DFT 
results confirm that H2Cys, and therefore probably H2Acys, coordinates to the 
ruthenium center via the sulfur atom in aqueous solution. 
2.2.2 Synthesis and characterization of two thiolato complexes [2]PF6 and [3]PF6 
As it was obvious that the thiolato complexes [2]+ and [3]+ are unstable even in 
presence of the trace amounts of oxygen present when working with Schlenk 
techniques, new conditions were investigated that would allow for isolating pure 
samples of the complexes. Full conversion into [2]PF6 and [3]PF6 without formation 
of oxidized side products was achieved by adding a large excess of the thiol ligand 
H2Cys or H2Acys to [1](PF6)2 in deionized water upon heating. As shown in Figure 
2.3, 50 equivalents of H2Cys, and 100 equivalents of H2Acys were required to 
quantitatively convert [1]2+ into [2]+ and [3]+ after 1.5 h at 353 K under argon.  
 
Figure 2.3 1H NMR spectra of the A6 proton of mixtures of [1](PF6)2 () with different 
equivalents of H2Acys (a) or H2Cys (b) after 1.5 hour at 353 K under argon in D2O (A6 
region, 10.2-9.3 ppm) forming [3]+ () or [2]+ (). Conditions: [Ru]0 = 5.0 mM, in the dark. 
The compounds were synthesized on a larger scale and purified from the excess 
ligand using size exclusion chromatography (see Experimental Part). [2]PF6 and 
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to NMR-pure samples (> 95%) of the κS isomers as shown in Scheme 2.1. In mass 
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spectrometry peaks at m/z = 611.0 and m/z = 653.0 were observed, corresponding 
to [2]+ (calc. m/z = 611.1) and [3]+ (calc. m/z = 653.0), respectively. According to 1H 
NMR in CD3OD, the aliphatic protons of the S-coordinated ligands (2.86 (β) and 
1.75 ppm (α) for HCys− in [2]+; 3.77 (β), 1.85 (γ), and 1.71 ppm (α) for HAcys− in 
[3]+, see Figure SII.5 and Figure SII.6) are shielded in the ruthenium complexes, 
compared to the free thiol ligands (3.72 (β) and 3.00 ppm (α) for H2Cys and 4.60 
(β), 2.91 (α), and 2.02 ppm (γ) for H2Acys).  
According to NOESY analysis of [3]+ the α protons of the thiol ligand are closer 
from the aromatic A6 and T6 protons than the β proton (Figure SII.7), as expected 
for sulfur coordination. The characteristic aromatic A6 protons of the two 
compounds are both observed at 10.49 ppm in CD3OD, suggesting that both [2]+ 
and [3]+ have the same κS binding mode. UV-vis absorption spectra of [3]PF6 in 
water showed a maximum at 492 nm (Figure SII.8), which is 40 nm 
bathochromically shifted compared to its thioether analogue 
[Ru(tpy)(bpy)(HAmet)]Cl2 ([5]Cl2, HAmet = N-acetyl-L-methionine). Such redshift 
of the MLCT band can be explained by the anionic nature of the thiolate ligand, 
which increases the σ-donating properties of the sulfur atom of thiolates compared 
to thioethers, and thus increases the energy level of the t2g orbitals on the metal 
with respect to the π* orbitals of the polypyridyl ligands. This electronic effect is 
responsible for the different colors (purple vs. red) of aqueous solution of the N-
acetyl-L-cysteine and N-acetyl-L-methionine ruthenium complexes [3]+ and [5]2+, 
respectively. 
2.2.3 Thermal stability of the isolated thiolato ruthenium complex [3]PF6 
The thermal stability of complex [3]PF6 in the dark was studied by 1H NMR in D2O 
at 298 K under air and under an argon atmosphere (Figure 2.4A-B). The 
composition of the mixture was determined by relative integration of the 1H NMR 
signals in the A6 region (10.3-9.3 ppm, for overview see Table SII.2). When the 
NMR sample was prepared under air the signal initially present at 10.12 ppm () 
indicated that the starting compound [3]+ () decomposed even in the solid state. 
After 1 day the signal of [3]+ had decreased in intensity and the aqua complex [1]2+ 
had appeared (). After 3 weeks, [3]+ was fully decomposed; the final reaction 
mixture consisted of 26% of an oxidized side product (), of a major fraction (55%) 
of [1]2+, and of a second side product (19%) characterized by an A6 doublet at 9.71 
ppm. Mass spectrometry analysis after 3 weeks revealed, next to the expected 
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peaks at m/z = 507.9 and 653.0, new peaks at m/z = 684.9, 706.9, and 814.0 which 
correspond to the sulfinato complexes [3 + 2×O]+ (calc. m/z = 685.1) and [3 – H + Na 
+ 2×O]+ (calc. m/z = 707.1), and the disulfide complex [Ru(tpy)(bpy)(HAcys2)]+ (calc. 
m/z = 814.1), respectively. Interestingly, the reaction between the free disulfide 
ligand 6 (Figure 2.5) and [1]2+ in D2O at 353 K did not lead to any coordination 
(Figure SII.9). Preparing the NMR tube under argon allowed for slowing down 
decomposition of [3]+, as after 3 weeks at 298 K an 85:15 mixture of [3]+:[1]2+ was 
established. In this case mass spectrometry analysis also showed the presence of 
the aqua, thiolato, and sulfinato complexes. 
The thermal instability of [3]+ was also monitored by UV-vis spectroscopy in a 
phosphate buffer (pH = 7.4). Under argon a slow change of the UV-vis spectrum is 
observed, and under air the blue shift of the MLCT band of the ruthenium complex 
takes place significantly faster (Figure 2.4C). After 16.7 h at 298 K. mass 
spectrometry analysis resulted in peaks at m/z = 507.9, 653.0, 669.0, 691.0, and 
723.0, corresponding to [1]+, [3]+, to the sulfenato [3 + O]+ (calc. m/z = 669.1), to the 
[3 – H + Na + O]+ or [3 – H + K]+ cation (both calc. m/z = 691.1), and to the sulfinato 
species [3 – H + K + 2×O]+ (calc. m/z = 723.0). Overall, combined NMR, MS, and 
UV-vis data indicate that decomposition of [3]+ occurs via oxidation into the 
sulfenato, sulfinato, and disulfide complexes (an overview of the various oxidation 
states of N-acetyl-L-cysteine is given in Figure 2.5). Thermal decomposition of [3]+ 
can be slowed down significantly by preparing samples under argon using Schlenk 
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Figure 2.4 1H NMR spectra (10.2-9.4 ppm) of [3]PF6 in the dark at different time intervals 
under air (A) and under argon (B) at 298 K in D2O. Notations:  = sulfinato complex 
[Ru(tpy)(bpy)(HAcysO2)]+;  = [3]+;  = [1]2+. 1H NMR peaks in this region correspond to 
the A6 proton of the bipyridine ligand of each ruthenium complex. Conditions: [Ru]0 = 6.4 
mM. C) Evolution of the absorbance of a solution of [3]PF6 in the dark under air. Time: 0 
hour (red curve), 16.7 h (black curve). Conditions: [Ru]0 = 0.20 mM, pH = 7.4 in 3.00 mL 
phosphate buffer, T = 298 K. Inset: Plot of the absorbance at 450 nm as a function of time 




Figure 2.5 Formula of the oxidized sulfenate (H2AcysO), sulfinate (H2AcysO2), and 
disulfide (H2AcysO2) forms of N-acetyl-L-cysteine. 
2.2.4 Photoreactivity 
To investigate the stability of [3]PF6 under light irradiation, a solution of the 
complex in a phosphate buffer at pH = 7.4 was irradiated with blue light (λirr = 465 
nm) for 1000 min at 298 K. The evolution of the solution was monitored under 
argon and under air by UV-vis spectroscopy and mass spectrometry, and 
compared to a control reaction in the dark. The absorbance of the solutions 
changed over time following different patterns under irradiation in air and under 
argon, indicating that a different decomposition mechanism may be involved 
when oxygen is present. The mass spectrum of the sample irradiated under argon 
showed peaks next to the m/z = 653.1 and 691.1 peaks of [3]+ and [3 – H + K]+ (calc. 
m/z = 690.7), respectively, a weak signal at m/z = 522.9 matching with [1 – H2O + 
MeOH]+ (calc. m/z = 523.1), i.e., with a photosubstituted product. Under air 
additional peaks at m/z = 669.0 and 685.0 were clearly observed that can be 
attributed to the sulfenato ([3 + O]+, calc. m/z = 669.1) and sulfinato complexes ([3 + 
2×O]+, m/z = calc. 685.1). Full conversion to [1]2+ (Figure 2.6, dashed line) was not 
achieved under argon (Figure 2.6a) or under air (Figure 2.6B) after 1000 min. This 
was confirmed by mass spectrometry as the m/z = 653.0 peak for [3]+ was still 
present in both irradiated solutions.  
These UV-vis results were confirmed by 1H NMR spectroscopy (Figure 2.7). When 
a D2O solution of [3]PF6 in an NMR tube was irradiated under argon and at room 
temperature using white light, the peak of the aqua complex () appeared first, 
followed by smaller amounts of the signal at 10.12 ppm (), which is interpreted as 
the sulfinato species [Ru(tpy)(bpy)(HAcysO2)]+. Thus, photoproduction of the aqua 
complex [1]2+ can occur either without oxidation of the thiolate ligand, i.e., via a 
photosubstitution process releasing the free thiol ligand similar to that observed 
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followed by thermal substitution of the HAcysO2− ligand by H2O. Overall the 
photoreactivity of [3]+ is much slower than that of the thioether analogue complex 
[5]2+: indeed, less than 30% conversion was obtained after 4.5 h irradiation of [3]+ 
(Figure 2.7), whereas full conversion of [5]2+ into [1]2+ was obtained after only 65 
min irradiation under similar conditions.20 The slower photosubstitution for [3]+, 
compared to [5]2+, can also be linked to the difference in color between the two 
ruthenium complexes: if the thiolate cysteine ligand is more electron-donating than 
the thioether methionine, then the dissociative 3MC states are expected to be higher 
in energy in [3]+ than in [5]2+ compared to the 3MLCT states, which leads to a lower 
photosubstitution quantum yield for [3]+. 
 
Figure 2.6 Evolution of the absorbance (left axis) of a solution of [3]+ under argon (A) and 
under air atmosphere (B) upon blue-light irradiation (λ = 465 nm, Δλ1/2 = 25 nm, 3.8 × 10−8 
mol.s−1). As an indication the molar extinction coefficient of [1](PF6)2 (dashed curve, right 
axis) is also shown. Time: 0 min (red curve), 1000 min (black curve). Conditions: [Ru]0 = 




Figure 2.7 Evolution of the 1H NMR spectra (10.3-9.3 ppm) of the A6 proton of solution of 
[3]PF6 in D2O under white light irradiation at 298 K. Notations:  = 
[Ru(tpy)(bpy)(HAcysO2)]+;  = [3]+,  = [1]2+. 
 Discussion 2.3
The formation of [2]+ from [1]2+ and L-cysteine was previously studied by 1H NMR 
by Mijatović et al. However, in our hands these results were impossible to 
reproduce (Figure SII.10).14 Instead, [2]+ and [3]+ do not form at room temperature 
but need thermal or photochemical activation to appear in solution. In addition, 
these thiolato complexes are unstable even when working with Schlenk techniques, 
where minute traces of oxygen result in (slow) decomposition into several 
oxidation products. However, using a large excess of the thiol ligand, i.e., 50 
equivalents of H2Cys or 100 equivalents of H2Acys, allowed for isolating the 
thiolato compounds [2]PF6 and [3]PF6 without the formation of any sulfenato or 
sulfinato ruthenium complexes. Under such conditions, traces of oxygen in the 
reaction mixture are probably quenched by the excess of thiol, and as the disulfide 
ligand does not coordinate to the ruthenium center (Figure SII.9) an analytically 
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Possible binding and decomposition pathways of thiolato ruthenium complex [3]+ 
are summarized in Scheme 2.2. The results of spectroscopic and mass spectrometry 
investigations in aqueous solution suggest that in the strict absence of oxygen and 
in the dark the S-bound thiolato ruthenium complex [3]+ (hereafter Ru-SR) may 
directly decompose, either thermally (-a) or photolytically (-A), into [1]2+. The 
decomposition consists of a ligand substitution reaction, and is also accompanied 
by the release of non-oxidized thiol ligand. Photosubstitution of the thiolate ligand 
by water is significantly slower than for thioether complexes because of the higher 
electron density of the alkyl thiolate ligand. Back-binding of the thiolate ligand to 
the aqua ruthenium complex [1]2+ to produce the thiolato adduct [3]+ occurs via 
thermal (a) or photochemical (A) activation. While photochemical substitution of a 
sulfur-based ligand by an aqua ligand is a well-known phenomenon in ruthenium 
chemistry;20, 22-24 photochemical binding of a sulfur-based ligand to ruthenium is a 
much less common phenomenon, but should not be ignored.  
In the presence of even traces of oxygen irreversible decomposition of the thiolato 
complex takes place through the formation of a ruthenium sulfenato complex. 
Either thermal (b) or photochemical oxidation (B) may take place. Subsequently, 
the unstable sulfenato complex can be thermally hydrolyzed into [1]2+ and release 
the free sulfenate ligand HAcysO−, but the reverse reaction does not occur as [1]2+ is 
the final product of all stability experiments performed under air (e or E). The 
sulfenato complex can also be further oxidized to the slightly more stable sulfinato 
complex (c or C), which can be observed by 1H NMR but will subsequently be 
hydrolyzed to the aqua complex [1]2+ (d or D). Decomposition of [3]+ into the aqua 
complex may also occur via a disulfide complex [Ru(tpy)(bpy)(HAcys2)]+ observed 
by mass spectrometry, but this disulfide complex must be transient as it does not 
form by mixing the disulfide ligand and [1]2+. In all these pathways the ruthenium 
thiolato complex Ru-SR may be oxidized either via reaction of its ground state with 
molecular oxygen, or via excitation of Ru-SR to its singlet state, followed by 
intersystem crossing to the triplet excited state and reaction with dioxygen (3O2) to 
produce singlet oxygen (1O2). 1O2 has a higher reactivity than 3O2, which would 
explain the higher rate of formation of the oxidized complexes under visible light 
irradiation, compared to dark conditions. Finally, because of the low efficiency of 
the oxygen-independent thiol photosubstitution reaction, photosubstitution rates 
become negligible as soon as the oxygen concentration is non-zero, and release of 
the aqua complex [1]2+ occurs mostly via irreversible ligand (photo)oxidation 
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followed by thermal substitution by water of the sulfenate, sulfinate, or disulfide 
ligand. Basically, the electron-richness of alkyl thiolates is too high for the complex 
to resist oxygen. Using less basic thiols such as thiophenol might lower the 
propensity of thiolato ruthenium complexes to be thermally oxidized. 
 
Scheme 2.2 Proposed mechanism of the different reactions of [3]+ in the dark and under 
blue light irradiation, in the presence of either an argon or an air atmosphere. Lower case 
annotation represents a thermal reaction, and upper case represents a photoreaction. 
 Conclusion 2.4
Unlike their methionine analogues, cysteine derivatives cannot be used for the 
protection of ruthenium polypyridyl complexes such as [1]2+. First, a large excess of 
thiol is required to achieve full conversion of the aqua complex to the thiolato 
compound without formation of oxidized side products. Such preparation 
conditions seem poorly compatible with the preparation of cancer-targeted 
ruthenium compounds using cysteine-terminated peptides that directly coordinate 
to the metal center. Second, the isolated thiolato metal compound is unstable in the 
dark: it reacts with trace amounts of oxygen to form the sulfenato, sulfinato, or 
disulfide complexes, which eventually decompose in aqueous solution to release 
the aqua complex [1]2+. In this case, visible light irradiation in presence of trace 
amounts of oxygen acts as an accelerator of the oxidative decomposition of the 
complex, instead of a trigger inducing selective delivery of an active metallodrug 
at the place and time of irradiation. In contrast, the methionine complex [5]2+ shows 
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temperature,20 and blue light irradiation efficiently converts the Ru-S complex [5]2+ 
into the aqua complex [1]2+ by simple ligand substitution. Overall, light irradiation 
of thiolato ruthenium complexes such as [3]+ results in an intricate combination of 
reversible, oxygen-independent ligand exchange processes and irreversible, 
oxygen-dependent ligand oxidation processes, ultimately leading to the formation 
of oxidized thiol ligands and the aqua complex [1]2+. In contrast to thioethers, 
cysteine derivatives produce thermally unstable ruthenium complexes, i.e., they do 
not act as a protecting group for ruthenium complexes such as [1]2+. In turn, the 
ability of [1]2+ to oxidize cysteine derivatives upon light irradiation, possibly in the 
cell to induce oxidative stress, could be a cytotoxic concept worth pursuing. It 
would require the development of compounds that have much higher oxidation 
rates than achieved in this chapter to be considered as potential selective anticancer 
drugs. 
 Experimental 2.5
2.5.1 Materials and Methods 
The ligands 2,2’;6’,2’’-terpyridine (tpy), N-acetyl-L-cysteine (H2Acys), and N-acetyl-L-
cysteine methyl ester (HAcysMe), as well as lithium chloride (LiCl), and triethylamine 
(NEt3) were purchased from Sigma-Aldrich; silver hexafluorophosphate (AgPF6) and L-
cystine (6) from Acros Organics; L-cysteine (H2Cys) from Merck; N-acetyl-L-cystine 
(H2Acys2) from Bachem; and 2,2’-bipyridine (bpy) from Brunschwig Chemie. All reactants 
and solvents were used without further purification. The synthesis of complex [1](PF6)2 was 
carried out according to a modified literature procedure.25 [Ru(tpy)(bpy)Cl]Cl (200 mg, 0.356 
mmol) and AgPF6 (180 mg, 0.712 mmol) were dissolved in a 3:1 acetone/H2O mixture (20 
mL). The resulting mixture was stirred and heated to reflux under argon at 353 K overnight. 
The suspension was filtered hot over Celite, and acetone was removed by rotary 
evaporation. The mixture was stored in the refrigerator for 4 days resulting in the formation 
of a precipitate that was filtered and dried under vacuum. Yield: 160 mg (57%). 1H NMR 
data were in good agreement with literature references.26 All other metal complexes were 
synthesized in dim light and stored in darkness.  
NMR spectra were recorded on a Bruker DPX-300 spectrometer. Chemical shifts are 
indicated in ppm. For NMR experiments under argon, NMR tubes with PTFE stopper were 
used. For some NMR reactions phosphate buffers in D2O were used (0.01 M phosphate, pD 
= 7.8, equivalent to pH = 7.4). The preparation was carried out according to the literature 
procedure for H2O buffers and the pH was measured with a pH meter, taking into account 
that the measured pD = pH* + 0.4, where pH* is the meter reading in D2O solutions.27, 28 
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Mass spectra were recorded by using a Thermoquest Finnagen AQA Spectrometer and a 
MSQ Plus Spectrometer. For the irradiation experiments of NMR tubes, the light of a LOT 
1000 W Xenon Arc lamp filtered with an infrared filter was used. UV-vis experiments were 
performed on a Cary Varian spectrometer. When following photoreactions by UV-vis, a 
LED light source (λirr = 465 nm) with a light intensity of 2.78 mW was used. 
2.5.2 Reaction of [1](PF6)2 with thiols 
The synthesis procedure was adapted from the synthesis reported for 
[Ru(tpy)(bpy)(HAmet)]Cl2 ([5]Cl2).20 2.0 mg of compound [1](PF6)2 (2.5 µmol) and the 
desired number of equivalents of HSR (H2Cys, H2Acys, or HAcysMe) or RSSR (H2Acys2) 
were weighed in a NMR tube. When necessary, the further preparation of the NMR tube 
was done under argon. 0.5 mL of the (degassed) solvent (D2O, D2O-based phosphate buffer, 
or CD3OD) was added. The tube was kept in the dark either at 298 K or was heated at 353 K 
until the maximum conversion took place. 1H NMR spectra of the reaction were recorded for 
each sample at different time intervals. 
2.5.3 Photoreaction of [1](PF6)2 with H2Acys 
Compound [1](PF6)2 (2.7 mg, 3.4 µmol) and H2Acys (1.4 mg, 8.6 µmol) were weighed into a 
NMR tube and 0.5 mL of degassed D2O was added. The tube was prepared under argon and 
irradiated at 298 K by the white light of a Xenon 1000 W lamp with a thermostat. In 
addition, a control experiment without white light irradiation was performed. The reactions 
were monitored by 1H NMR at various time intervals.  
2.5.4 Synthesis of [Ru(tpy)(bpy)(HCys)]PF6 ([2]PF6) and [Ru(tpy)(bpy)(HAcys)]PF6 ([3]PF6) 
[1](PF6)2 (60 mg, 0.075 mmol) and H2Cys or H2Acys (7.5 mmol) were dissolved in degassed 
H2O (15 mL). The resultant mixture was stirred and heated to reflux under argon for 1.5 h at 
353 K. H2O was removed by freeze-drying. For purification, size exclusion column 
chromatography (Sephadex LH-20, MeOH) was performed for both complexes. Finally, 
methanol was removed by rotary evaporation to yield dark brown powders. Yield: [2]PF6 12 
mg (63%) and [3]PF6 36 mg (60%). 
[2]PF6: 1H NMR (300 MHz, CD3OD, 298 K, in ppm): δ = 10.48 (d, J = 5.6 Hz, 1H, A6), 8.75 (d, J = 
8.0 Hz, 1H, A3), 8.64 (d, J = 8.1 Hz, 2H, T3’), 8.55 – 8.48 (m, 3H, T3 + B3), 8.29 (td, J = 7.9, 1.5 
Hz, 1H, A4), 8.10 (t, J = 8.1 Hz, 1H, T4’), 8.01 (ddd, J = 7.2, 5.7, 1.2 Hz, 1H, A5), 7.91 (tdd, J = 
8.0, 2.8, 1.5 Hz, 2H, T4), 7.80 (td, J = 8.1, 1.5 Hz, 1H, B4), 7.68 (d, J = 5.5 Hz, 2H, T6), 7.35 – 
7.27 (m, 2H, T5), 7.26 – 7.21 (m, 1H, B6), 7.09 (ddd, J = 7.0, 5.7, 1.2 Hz, 1H, B5), 2.87 (dd, J = 
9.4, 3.7 Hz, 1H, β), 1.88 – 1.60 (m, 2H, α). ES MS m/z (calc): 610.9 (611.1, [M – H – 2×PF6]+)  
[3]PF6: 1H NMR (300 MHz, CD3OD, 298 K, in ppm): δ = 10.48 (d, J = 4.8 Hz, 1H, A6), 8.75 (d, J = 
8.0 Hz, 1H, A3), 8.63 (dd, J = 8.2, 0.9 Hz, 2H, T3’), 8.56 – 8.46 (m, 3H, T3 + B3), 8.29 (td, J = 7.7, 
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9.4, 3.7 Hz, 1H, β), 1.88 – 1.60 (m, 2H, α). ES MS m/z (calc): 610.9 (611.1, [M – H – 2×PF6]+)  
[3]PF6: 1H NMR (300 MHz, CD3OD, 298 K, in ppm): δ = 10.48 (d, J = 4.8 Hz, 1H, A6), 8.75 (d, J = 
8.0 Hz, 1H, A3), 8.63 (dd, J = 8.2, 0.9 Hz, 2H, T3’), 8.56 – 8.46 (m, 3H, T3 + B3), 8.29 (td, J = 7.7, 
1.5 Hz, 1H, A4), 8.10 (t, J = 8.1 Hz, 1H, T4’), 8.02 – 7.86 (m, 3H, A5 + T4), 7.86 – 7.75 (m, 1H, 
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B4), 7.73 – 7.61 (m, 2H, T6), 7.30 (ddd, J = 7.0, 5.5, 1.3 Hz, 2H, T5), 7.23 (ddd, J = 5.5, 1.5, 0.7 
Hz, 1H, B6), 7.09 (ddd, J = 7.1, 5.5, 1.3 Hz, 1H, B5), 3.75 (dd, J = 7.2, 5.1 Hz, 1H, β), 1.86 (s, 3H, 
γ), 1.79 – 1.60 (m, 2H, α). 13C NMR (75 MHz, CD3OD, 298 K, in ppm): δ = 174.78 (C=O acid), 
172.57 (C=O N-acetyl), 159.59, 159.54, 158.45, 158.39, 157.66 (T2 + T’2 + A2), 154.68 (A6), 
152.84 + 152.76 (T6), 150.97 (B6), 137.82 + 137.69 + 137.65 + 137.60 (A4 + B4 + T4), 133.28 (T4‘), 
128.37 + 127.98 + 127.54 (A5 + B5 + T5), 124.73 + 124.60 + 124.38 (A3 + B3 + T3), 123.69 (T3‘), 
56.50 (β), 28.13 (α), 22.49 (γ). UV-vis: λmax (ε in M−1∙cm−1) in H2O: 492 nm (7300). High 
resolution ES MS m/z (calc): 653.0901 (653.0911, [M – H – 2×PF6]+), 669.08500 (669.08599, [M + 
O – H – 2×PF6]+, 685.0805 (685.0809, [M + 2×O – H – 2×PF6]+). 
2.5.5 Stability measurements at room temperature of [3]PF6 
To measure the stability of compound [3]PF6 under argon or in the presence of air, [3]PF6 
(2.6 mg, 0.003 mmol) was weighed into a standard NMR tube and a NMR tube with PTFE 
stopper, respectively. 0.5 mL of (degassed) D2O was added to each tube and both tubes 
stored at 298 K in the dark. 1H NMR spectra of each sample were recorded after preparation 
and after 4 h, 1 day, 4 days, and 3 weeks.  
2.5.6 Photochemistry of [3]PF6 
UV-vis spectroscopy was performed using a UV-vis spectrometer equipped with 
temperature control set to 298 K and a magnetic stirrer. The measurements were performed 
in a quartz cuvette, containing 3 mL of solution. A stock solution of complex [3]PF6 (4.0 mg 
in 10 mL buffer, 5.01 × 10−4 M) was prepared. The buffer used was a phosphate buffer (pH 
7.4, I = 50 mM). 1 mL of the stock solution was added to a UV-vis cell and was completed to 
3 mL with pH 7.4 buffer (c = 1.67 × 10-4 M). After degassing the sample for 30 min, a UV-vis 
spectrum was measured under argon every 10 min for a total of 1000 min while a LED lamp 
was irradiating the sample at 465 nm. The experiment was repeated without argon. For both 
experiments, a control measurement under the same conditions but without visible light 
irradiation was performed.  
2.5.7 DFT 
Electronic structure calculations were performed using DFT to quantify the relative stability 
of the S-, N-, and O-bound isomers of complex [2]+. ORCA 3.0.2 code29 was used for all 
calculations. All structures were optimized in vacuum and their energies in water were 
obtained by performing single point energy calculations with the conductor-like screening 
model30 (COSMO) as implemented in ORCA.31 The PBE032 functional was used in 
combination with the last Grimme's empirical method33, 34 to take dispersion interactions 
into account (DFT-D3 method). The Ahlrichs triple-ξ quality basis set plus one polarization 
function (VTZP)35 was used for all atoms expect the ruthenium. For this last, the quasi-
relativistic Stuttgart-Dresden SD (28,MWB) effective core potential36 was used together with 
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Microtubules play an essential role in mitosis, specifically in the separation of 
duplicated chromosomes before the cell divides.1 This feature makes them a 
potential target for novel chemotherapeutic agents. Paclitaxel, a taxane drug used 
in clinics to treat various forms of breast, ovarian, and non-small cell lung cancer, 
promotes polymerization of stable and dysfunctional microtubules that in the end 
causes cell death.2 However, side effects associated with the use of paclitaxel are 
not uncommon, and include neutropenia, neurotoxicity, and disturbances in 
cardiac rhythm.3, 4 Additionally, cancer cell resistance to paclitaxel therapy limits 
its clinical efficacy making the development of alternative microtubule-targeting 
agents an important area of research.  
One family of alternative compounds are analogues derived from marine alkaloid 
rigidins.5, 6 These rigidins have shown cytotoxic activity in the low-nanomolar 
range, trigger complete collapse of mitotic microtubule organization in vitro, and 
result in significant tumor growth reduction in vivo. However, drug uptake by 
healthy tissues causing side effects can always jeopardize the success of a drug. In 
this work we investigated the functionalization of the original 7-
deaxahypoxanthines with a thioether group at the C2-position, and coordination of 
this thioether to a light-activatable ruthenium complex, a strategy called 
‘photocaging’.7-15 Upon light irradiation, the metal complex undergoes a 
photosubstitution reaction in which the ligand is released and can interact with its 
biological target. Photocaging is part of the phototherapeutic approach of 
photoactivated chemotherapy (PACT), a concept in which a metal complex is 
prevented from interaction with biological molecules in the dark.13 After light 
activation the metal complex is structurally modified, commonly through the 
release of a ligand, and then either the free ligand or complex (or both) may bind to 
their targets. Overall, the photochemical local activation of anticancer prodrugs in 
cancerous tissue should limit the toxicity of the treatment to the irradiated tumor, 
thus lowering side effects that stem from the general toxicity of biologically active 
compounds.  
Ruthenium(II) polypyridyl complexes belong to the most widely investigated 
PACT compounds due to their well-known and tunable light absorption 
properties. For example, irradiation of RuBiGABA-2 (see Figure 3.1) developed by 
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Etchenique releases γ-aminobutyric acid, which was shown to induce a 
motoneural response in leech ganglions.16 In another example from Turro the 
nitrile analogue 5CNU of clinically approved anticancer compound 5-fluorouracil 
was caged with ruthenium, triggering to form [Ru(tpy)(5-CNU)3]Cl2 (Figure 3.1) 
phototoxicity in HeLa cells as demonstrated by a qualitative SYTOX assay.7 
Recently, our group reported toxic ruthenium polypyridyl complexes that 
photosubstitute sulfoxide or thioether ligands upon blue or green light activation, 
and induce a phototoxic response in human cancer cell lines.17-19 In this chapter the 
successful caging of the thioether-containing rigidin 7-deazahypoxanthines 1 
(provided by Dr. Alexander Kornienko) by a [Ru(tpy)(bpy)]2+ moiety that can be 
released upon green light irradiation is reported. To the best of our knowledge, 
this is the first example of an anticancer drug with a well-defined target, which is 
caged by a ruthenium complex. Quantitative in vitro data on cancer cell 
cytotoxicity in the dark and after light irradiation is provided, including strong 
evidence that confirms the light-controllable the interaction of our drug with the 
microtubules.  
 




Complex [Ru(tpy)(bpy)(1)](PF6)2 ([2](PF6)2) was synthesized by reacting 1 with 2 
equivalents of [Ru(tpy)(bpy)(OH2)](PF6)2 ([3](PF6)2) as shown in Scheme 3.1. 1H 
NMR spectroscopy showed the characteristic upfield shift at 1.47 ppm of the 
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for these type of complexes. Comparison with the free ligand is lacking due to its 
poor solubility in protic solvents.20 Further NMR spectroscopy and elemental 
analysis showed that the compound was pure, and high resolution mass 
spectrometry confirmed the successful synthesis of [2](PF6)2. 
 
Scheme 3.1 Synthesis scheme of [2](PF6)2. * indicates the A6 proton of the bpy ligand. 
3.2.2 Photochemistry 
Under green light irradiation (λirr = 530 nm) of a solution of [2](PF6)2 in acetonitrile 
in a nitrogen atmosphere, a significant increase of the absorbance at 452 nm and a 
slight shift of the maximum of the 1MLCT band from 452 nm to 454 nm were 
observed (Figure 3.2). Under these conditions a steady state was obtained after 30 
minutes (inset in Figure 3.2). Mass spectrometry (MS) of the solution after light 
irradiation showed peaks at m/z = 266.4 corresponding to [Ru(tpy)(bpy)(CH3CN)]2+ 
(calc. m/z = 266.1, Figure SIII.1), whereas MS of the dark control showed a major 
signal at m/z = 447.0 corresponding to [2]2+ (calc. m/z = 447.1, Figure SIII.1). Thus, 
under irradiation ligand 1 was photosubstituted by a solvent molecule. Similar 
evolutions were observed under blue light irradiation (450 nm, Figure SIII.2) and 
under such conditions a photosubstitution quantum yield ΦPS of 0.0060 was 
obtained. The photoreaction was also monitored by 1H NMR. After 5 minutes 
irradiation by white light the characteristic A6 proton (Scheme 3.1) at 9.66 ppm 
from the bpy ligand was fully replaced by a peak at 9.59 ppm characteristic for 
[Ru(tpy)(bpy)(CH3CN)]2+, indicating full conversion of the photoreaction of [2]2+ 
(Figure SIII.3).21 Also, the initial singlet peak at 1.32 ppm indicating coordinated 
SMe is fully replaced by a singlet peak at 2.54 ppm for non-coordinated 1. When 
the same light irradiation reaction was performed in demineralized water and 
followed by UV-vis spectroscopy, Rayleigh scattering occurred quickly due to 
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precipitation of the free ligand 1, which is poorly soluble in water with a maximum 
solubility of 10 µM in demineralized water (Figure SIII.4). Thus, it can be 
concluded that the Ru-S bond of [2]2+ is photoactivatable in CH3CN and aqueous 
solution using either blue, green, or white light.  
 
 
Figure 3.2 Evolution of the electronic absorption spectra of a solution of [2](PF6)2 in 
acetonitrile upon green light irradiation under nitrogen (λ = 530 nm, Δλ1/2 = 17 nm, 6.0 
mW, photon flux 4.1× 10−8 mol.s−1). Time: 0 min (red curve) to 30 min (black curve) 
Conditions: [Ru]0 = 50 μM, V = 3.00 mL, T = 293 K. Inset: Plot of the absorbance at 452 nm 
as a function of irradiation time. 
3.2.3 (Photo)toxicity studies 
To demonstrate whether cytotoxicity of [2](PF6)2 could be controlled by light 
activation, an in vitro photocytotoxicity assay was performed. The cytotoxicity of 1, 
[2](PF6)2, and [3](PF6)2 was investigated against cancerous A375, A431, and A549 
cells, and non-cancerous MRC-5 cells. [3](PF6)2 was included in the assay to ensure 
that cytotoxicity does not originate from the metal cage, while cisplatin was 
included as positive control. Cell growth inhibition effective concentrations (EC50), 
defined as the compound concentration that reduces cell viability by 50% 
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3.2.3 (Photo)toxicity studies 
To demonstrate whether cytotoxicity of [2](PF6)2 could be controlled by light 
activation, an in vitro photocytotoxicity assay was performed. The cytotoxicity of 1, 
[2](PF6)2, and [3](PF6)2 was investigated against cancerous A375, A431, and A549 
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defined as the compound concentration that reduces cell viability by 50% 
compared to untreated cells, were measured in the dark and after light activation 
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following a protocol adapted from Hopkins et al.22 and the results are reported in 
Table 3.1. In the dark EC50 values between 0.16 µM and 0.23 µM were found for 1 
in A375, A431, and MRC-5 cells, and a higher value of 6.5 µM was found for A549 
cells. Compound [3](PF6)2 showed no activity across all tested cell lines, which is in 
agreement with previous findings,19 while treatment with cisplatin resulted in EC50 
values in the expected micromolar range, i.e. between 0.85-3.1 µM. For the caged 
compound [2](PF6)2 in the dark, EC50 values of 7-14 µM in A375, A431, and MRC-5 
cells were observed, while for A549 cells an EC50 value of 35 µM was measured. 
Thus, caging of 1 to the [Ru(tpy)(bpy)]2+ moiety strongly inhibited, up to 83 times 
for MRC-5 cells, the cytotoxicity of the microtubule inhibitor in the dark.  
Table 3.1 Cell growing inhibition effective concentrations (EC50 values with 95% 
confidence interval in μM) of 1, [2](PF6)2, [3](PF6)2, and cisplatin on skin (A375, A431) and 
lung (A549) cancer cell lines. The photo index (PI), defined as EC50,dark/EC50,light, are also 
indicated. Toxicity of the compounds in non-cancerous lung cell line (MRC-5) were also 
tested for comparison. 
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+0.31 
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Green light (520 nm) was chosen for photochemical activation since in vitro and in 
vivo it is much less toxic to living cells than blue or UV-light.22-24 Preliminary 
studies in a 96-well plate (Figure SIII.5) demonstrated that under the conditions of 
our cell-irradiation setup (21 mW.cm−2) a 30 minutes irradiation time, 
corresponding to a dose of 38 J.cm−2, was necessary to completely activate [2](PF6)2 
(60 µM). Although a 38 J.cm−2 dose of green light barely induced photocytotoxicity 
by itself, nor changed the cytotoxicity of the uncaged inhibitor 1, the caging 
complex [3](PF6)2, or cisplatin (Table 3.1), the effect observed when the caged 
inhibitor [2](PF6)2 was irradiated was remarkable for all cell lines tested. EC50 
values for A375, A431, A549, and MRC-5 cells were 0.33, 0.49, 9.2, and 0.67 µM, 
leading to phototoxic indices of 21, 28, 4, and 12, respectively. Figure 3.3 shows, as 
an example, the dose-response curves for A431 cells treated with 1 (brown curve), 
[2](PF6)2 in the dark (black curve), [2](PF6)2 irradiated with green light (green 
curve), and [3](PF6)2 in the dark (grey curve). The data suggests that 
[Ru(tpy)(bpy)]2+ is an excellent photocaging agent for 1 as Ru-coordination 
strongly reduces the cytotoxicity of 1, while photosubstitution performed in living 
cells restores a high toxicity typical for ligand 1.  
 
 
Figure 3.3 Dose response curves for A431 cells incubated with 1 in the dark (light brown), 
[2](PF6)2 in the dark (black), [2](PF6)2 with green light irradiation (green), and [3](PF6)2 in 
the dark (grey). Phototoxicity assay: cells seeded at 8 × 103 cells/well at t = 0 h, treated at t = 
24 h, irradiated at t = 30 h, and SRB assay performed at t = 96 h. Conditions: T = 37 °C, 
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3.2.4 Tubulin polymerization assay 
In order to investigate how caging and photoactivation influences the ability of 
compound [2](PF6)2 to interact with its biological microtubule target, a 
fluorescence-based tubulin polymerization assay was performed by Dr. Tania 
Betancourt to compare the tubulin polymerization properties of [2](PF6)2 in the 
dark and under light irradiation. In this assay tubulin polymerization leads to a 
marked increase of the fluorescence intensity. The control compound paclitaxel, 
which strongly stabilizes the polymerized microtubule, showed as expected a 
rapid rise in fluorescence that stabilized after 30 minutes, indicating nucleation, 
growth, and a steady state equilibrium, of the microtubule formulation as shown 
in Figure 3.4.5 Fluorescence of an untreated sample initially shows a slight 
reduction in intensity and then stabilizes around its original value as shown by the 
dashed curve in Figure 3.4. Treatment of the tubulin mixture with the caged 
inhibitor [2](PF6)2 (25 µM, black curve) showed, in the dark, an overall increase in 
fluorescence after 60 minutes which was slower and less prominent than that 
measured for paclitaxel. Treatment with the caged inhibitor [2](PF6)2 (25 µM) 
activated by green light irradiation (30 min, 21 mW.cm−2) showed no increase in 
fluorescence at all. These results demonstrate that indeed upon treatment with 
non-activated [2](PF6)2 tubulin polymerization is possible, i.e., the caged inhibitor 
does not inhibit polymerization, whereas after green light activation of [2](PF6)2 
tubulin polymerization is inhibited. In other words, green light irradiation uncages 
the inhibitor 1 efficiently. To conclude, microtubule polymerization is controlled by 
light. Green light activation of [2](PF6)2 inhibits microtubule polymerization by 





Figure 3.4 Evolution of tubulin polymerization [2](PF6)2 in the dark (25 μM, black curve), 
green light-activated [2](PF6)2 (25 μM, green curve), Paclitaxel (3 μM, blue curve), and 
untreated sample (black dashed curve).  
 Discussion & Conclusion 3.3
In this chapter we have demonstrated that the microtubulin-targeted rigidin 
thioether conjugate 1 can be caged by [Ru(tpy)(bpy)]2+. In vitro green light 
photosubstitution of the ruthenium-caged rigidin in [2](PF6)2 induces an up to 28-
fold increase in cytotoxicity with values that are similar to that of the uncaged 
compound 1. As many microtubule-targeting compounds are used in the clinic as 
anticancer compounds,1, 25, 26 the herein presented strategy of ruthenium caging and 
green light photorelease provides a basis for a new cancer-targeted photoactivated 
chemotherapy. This strategy is clearly distinct from the approach of organic 
chemists in photopharmacology, where azobenzene-functionalized protein 
inhibitors are switched ‘on’ and ‘off’ via cis-trans photoizomerization.27-30 
Coordination of an inhibitor to a light-sensitive metal complex, as proposed in this 
work, can overcome several issues associated with the azobenzene isomerization 
approach. First, in photopharmacology the light activation wavelength is crucial. 
Low-energy green or red light can penetrate into tissues much deeper, and is less 
harmful, than high-energy UV or blue light. Although recently some azobenzenes 
have been developed that can be activated by visible or even red light,31-33 
ruthenium polypyridyl chemistry provides a solid, tunable, and predictive 
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visible light.13, 34-37 Second, as azobenzenes have a low or no dipole moment, 
especially in their trans form, they are highly lipophilic and poorly water-soluble. 
Ruthenium complexes on the other hand are typically positively charged 
molecules, which can enhance water solubility. Next, contrary to azobenzenes the 
modification of the cage does not alter too much the photoactivation kinetics. Last 
but not least, light activation of metal-based PACT compounds usually entails an 
irreversible process, whereas cis-trans photoisomerization of azobenzenes is 
notoriously reversible. Permanent activation of azobenzene-functionalized 
compounds would require permanent irradiation to maintain activity. On the other 
hand, it may provide opportunities for limiting systemic toxicity to the activated 
area, as when not irradiated the compound turns back into a non-toxic form. With 
metal caging, irreversible activation at the place of irradiation may be followed by 
diffusion of the activated drugs in other places, which for in vivo applications, 
would need to be controlled.  
In the development of anticancer drugs both organic and inorganic chemists cope 
with similar problems, i.e. drug resistance, dose-limiting side effects, and poor 
water solubility. In this chapter the use of combining organic chemistry, which 
offers stable compounds and well-defined targets, with inorganic caging 
compounds, which can reduce dark toxicity, increase water solubility, and allow 
for irreversible uncaging using visible light, demonstrates how both fields are 
complementary. By crossing research borders, innovative solutions can be found 
that can contribute to ground-breaking developments in photopharmacology and 
science.  
 Experimental 3.4
3.4.1 Materials and methods 
All NMR spectra were recorded on a Bruker AV-500 spectrometer. Chemical shifts are 
indicated in ppm relative to tetramethylsilane. Mass spectra were recorded by using a MSQ 
Plus Spectrometer positive ionization mode. UV-vis experiments were performed on a Cary 
50 Varian spectrometer equipped with a Cary Single Cell Peltier for temperature control.  
3.4.2 Synthesis of [Ru(tpy)(bpy)(1)](PF6)2 ([2](PF6)2) 
First, 1 and [3](PF6)2 were synthesized according to literature procedures.5, 21 Then, in a 2-
necked round-bottom flask [3](PF6)2 (75 mg, 0.48 mmol) and 1 (22 mg, 0.25 mmol) were 
added in ethylene glycol (10 mL) under argon. The solution was stirred overnight at 100 °C 
 
63 
under argon resulting in a red solution. The reaction mixture was added to a CH2Cl2 and 
KPF6 saturated water mixture. After full extraction to the CH2Cl2 layer, the combined CH2Cl2 
layers were washed with KPF6 saturated water to remove ethylene glycol. After evaporation 
in vacuo, the crude was dissolved in acetone and purified by size exclusion chromatography 
(Sephadex LH-20, acetone). After evaporation in vacuo, the product was reprecipitated from 
acetone by the addition of diethyl ether, filtered, and obtained as a red powder. Yield: 13 mg 
(20%). 1H NMR (500 MHz, CD3OD, 293 K, in ppm): δ = 9.74 (d, J = 5.5 Hz, 1H, A6), 8.82 (d, J = 
8.0 Hz, 1H, A3), 8.72 (d, J = 8.0 Hz, 2H, D3 + D3’), 8.69 (d, J = 8.0 Hz, 1H, B3), 8.51 (t, J = 8.0 
Hz, 2H, C3 + C3’), 8.39 (dd, J = 8.0, 1.2 Hz, 1H, A4), 8.37 (dd, J = 8.4, 1H, D4), 8.03 (ddd, J = 7.8 
Hz, 5.5 Hz, 1.5 Hz, 1H, A5), 7.95 (dd, J = 8.0 Hz, 2H, C4 + C4’), 7.92 (dd, J = 7.5 Hz, 1.5 Hz), 
1H, B4), 7.73 (d, J = 5.5 Hz, 2H, C6), 7.52 (dd, J = 8.5, 1.0 Hz, 2H, Ph), 7.35 (ddd, J = 0.5, 6.0, 6.0 
Hz, 2H, C5), 7.32-7.18 (m, 5H, Ph + B5), 7.14-7.05 (m, 5H, Ph + B6), 2.63 (t, J = 6Hz, 2H, CH2), 
1.91 (p, J = 7.0 Hz, 2H, CH2), 1.91 (t, J = 7.5 Hz, 2H, CH2), 1.47 (s, 3H, CH3). 13C NMR (125 
MHz, CD3OD, 293 K, in ppm): δ = 190.4 (C=O), 161.7 (pp), 159.2 (pp), 158.8 (pp), 158.7 (pp), 
158.1 (pp), 158.1 (pp), 154.2 (Ph), 153.0 (Ph), 151.2 (Ph), 150.8 (Ph), 140.1 (Ph), 139.6 (C4), 
138.6 (py-q), 138.3 (D4), 133.7 (py-q), 133.3 (A6), 132.6 (Ar), 130.6 (Ar), 129.7 (Ar-q), 129.4 
(Ar-q), 129.2 (A5), 129.1 (C5), 128.9 (Ar), 126.1 (C3’), 126.0 (C3), 125.4 (A3), 125.2 (D3), 32.8 
(CH2-r), 32.80 (CH2-l), 23.7 (CH2), 14.6 (CH3). Elem. Anal. Calcd. for C48H40F12N8O2P2RuS: C, 
48.69; H, 3.41; N, 9.46. Found: C, 49.35; H, 3.53; N, 9.32. High resolution ES MS m/z (calc): 
447.10198 (447.1019, [M – 2×PF6]2+). 
3.4.3 Photochemistry 
The UV-vis spectroscopy study shown in Figure 3.2 was performed using a UV-vis 
spectrometer equipped with temperature control set to 298 K. The measurements were 
performed in a quartz cuvette, containing 3 mL of solution in CH3CN or water. The stirred 
sample was degassed by nitrogen, irradiated perpendicularly to the axis of the spectrometer 
by the beam of a green (λ = 530 nm, Δλ1/2 = 25 nm, 3.02 mW, photon flux 2.1 × 10−8 mol.s−1) or 
blue (λ = 445 nm, Δλ1/2 = 11 nm, 10.5 mW, photon flux 1.27 × 10−7 mol.s-1) LED fitted to the 
top of the cuvette, and an absorption spectrum was measured at regular time intervals and 
analyzed using Microsoft Excel. Mass spectrometry was performed at the beginning and at 
the end of the irradiation to confirm the nature of the reagent and products. The 1H NMR 
spectroscopy study of Figure SIII.3 was performed using the white light of a LOT 1000 W 
Xenon Arc lamp mounted with an infrared and a long pass filter.  
3.4.4 Green light irradiation in the cell irradiation set-up 
The photochemical reactivity of [2](PF6)2 was measured in 96-well plates by dissolving it in 
cell culturing medium (Opti-MEM complete, 31 µM), followed by irradiation using the 
green light of the irradiation setup used for cell irradiation (520 nm, 38 J.cm−²) to mimic the 
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necked round-bottom flask [3](PF6)2 (75 mg, 0.48 mmol) and 1 (22 mg, 0.25 mmol) were 
added in ethylene glycol (10 mL) under argon. The solution was stirred overnight at 100 °C 
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under argon resulting in a red solution. The reaction mixture was added to a CH2Cl2 and 
KPF6 saturated water mixture. After full extraction to the CH2Cl2 layer, the combined CH2Cl2 
layers were washed with KPF6 saturated water to remove ethylene glycol. After evaporation 
in vacuo, the crude was dissolved in acetone and purified by size exclusion chromatography 
(Sephadex LH-20, acetone). After evaporation in vacuo, the product was reprecipitated from 
acetone by the addition of diethyl ether, filtered, and obtained as a red powder. Yield: 13 mg 
(20%). 1H NMR (500 MHz, CD3OD, 293 K, in ppm): δ = 9.74 (d, J = 5.5 Hz, 1H, A6), 8.82 (d, J = 
8.0 Hz, 1H, A3), 8.72 (d, J = 8.0 Hz, 2H, D3 + D3’), 8.69 (d, J = 8.0 Hz, 1H, B3), 8.51 (t, J = 8.0 
Hz, 2H, C3 + C3’), 8.39 (dd, J = 8.0, 1.2 Hz, 1H, A4), 8.37 (dd, J = 8.4, 1H, D4), 8.03 (ddd, J = 7.8 
Hz, 5.5 Hz, 1.5 Hz, 1H, A5), 7.95 (dd, J = 8.0 Hz, 2H, C4 + C4’), 7.92 (dd, J = 7.5 Hz, 1.5 Hz), 
1H, B4), 7.73 (d, J = 5.5 Hz, 2H, C6), 7.52 (dd, J = 8.5, 1.0 Hz, 2H, Ph), 7.35 (ddd, J = 0.5, 6.0, 6.0 
Hz, 2H, C5), 7.32-7.18 (m, 5H, Ph + B5), 7.14-7.05 (m, 5H, Ph + B6), 2.63 (t, J = 6Hz, 2H, CH2), 
1.91 (p, J = 7.0 Hz, 2H, CH2), 1.91 (t, J = 7.5 Hz, 2H, CH2), 1.47 (s, 3H, CH3). 13C NMR (125 
MHz, CD3OD, 293 K, in ppm): δ = 190.4 (C=O), 161.7 (pp), 159.2 (pp), 158.8 (pp), 158.7 (pp), 
158.1 (pp), 158.1 (pp), 154.2 (Ph), 153.0 (Ph), 151.2 (Ph), 150.8 (Ph), 140.1 (Ph), 139.6 (C4), 
138.6 (py-q), 138.3 (D4), 133.7 (py-q), 133.3 (A6), 132.6 (Ar), 130.6 (Ar), 129.7 (Ar-q), 129.4 
(Ar-q), 129.2 (A5), 129.1 (C5), 128.9 (Ar), 126.1 (C3’), 126.0 (C3), 125.4 (A3), 125.2 (D3), 32.8 
(CH2-r), 32.80 (CH2-l), 23.7 (CH2), 14.6 (CH3). Elem. Anal. Calcd. for C48H40F12N8O2P2RuS: C, 
48.69; H, 3.41; N, 9.46. Found: C, 49.35; H, 3.53; N, 9.32. High resolution ES MS m/z (calc): 
447.10198 (447.1019, [M – 2×PF6]2+). 
3.4.3 Photochemistry 
The UV-vis spectroscopy study shown in Figure 3.2 was performed using a UV-vis 
spectrometer equipped with temperature control set to 298 K. The measurements were 
performed in a quartz cuvette, containing 3 mL of solution in CH3CN or water. The stirred 
sample was degassed by nitrogen, irradiated perpendicularly to the axis of the spectrometer 
by the beam of a green (λ = 530 nm, Δλ1/2 = 25 nm, 3.02 mW, photon flux 2.1 × 10−8 mol.s−1) or 
blue (λ = 445 nm, Δλ1/2 = 11 nm, 10.5 mW, photon flux 1.27 × 10−7 mol.s-1) LED fitted to the 
top of the cuvette, and an absorption spectrum was measured at regular time intervals and 
analyzed using Microsoft Excel. Mass spectrometry was performed at the beginning and at 
the end of the irradiation to confirm the nature of the reagent and products. The 1H NMR 
spectroscopy study of Figure SIII.3 was performed using the white light of a LOT 1000 W 
Xenon Arc lamp mounted with an infrared and a long pass filter.  
3.4.4 Green light irradiation in the cell irradiation set-up 
The photochemical reactivity of [2](PF6)2 was measured in 96-well plates by dissolving it in 
cell culturing medium (Opti-MEM complete, 31 µM), followed by irradiation using the 
green light of the irradiation setup used for cell irradiation (520 nm, 38 J.cm−²) to mimic the 
conditions of the photocytotoxicity assay. Figure SIII.5 shows that the absorbance change at 
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300 nm for [2](PF6)2 after 30 minutes irradiation is leveling off as in no further activation 
occurs after 30 minutes. 
3.4.5 Phototoxicity assay 
See Appendix I for comprehensive description of the assay.  
3.4.6 Tubulin polymerization assay 
For investigation of the ability of the drug to inhibit the polymerization of tubulin in its 
caged ([2](PF6)2) and uncaged form (1), the fluorescence-based Tubulin Polymerization 
Assay (Cat. # BK011P) from Cytoskeleton, Inc. Prior was used to conduct the assay, a 2 mM 
stock solutions of paclitaxel and 16.7 mM solutions of the caged drug and the uncaged drug 
were prepared in DMSO. These drug stock solutions were then diluted to 250 µM with 
water to provide aqueous solutions of each drug with a constant DMSO content of 1.5% v/v. 
At this point, 40 µL samples of the caged drug were pipetted into separate black 96-well 
plates for irradiation with blue or green light independently. The solutions of the caged 
drug were then irradiated with either a blue LED (LED Engin LZ1-00B200, 450 nm) or a 
green LED (LED Engin LZ1-10G102-0000, 523 nm) driven with a BK Precision DC power 
supply 1630. Light power was measured with a Thorlabs PM50 photometer. Specifically, the 
appropriate power (W) of light were detected through a 0.6 cm-diameter circular well from 
a 96-well plate. The green light was used at a power density of 21 mW.cm−2 (6 mW, 0.28 cm2 
well). The samples were irradiated for a total of 30 minutes in 10-minute intervals for a total 
laser exposure of 38 J.cm−2. The absorption spectrum of the drug solutions were collected 
before and after each 10 minutes of irradiation.  
For the assay, the following reagents were used. Buffer A contained 80 mM piperazine-
N,N’-bis[2-ethanesulfonic acid] sequisodium salt, 2 mM MgCl2, 0.5 mM ethylene glycol-
bis(B-amino-ethyl ether)-N,N,N’,N’-tetraacetic acid pH 6.9, and 10 µM fluorescent reporter. 
Tubulin glycerol buffer contains 80 mM piperazine-N,N’-bis[2-ethanesulfonic acid] 
sequisodium salt, 2 mM MgCl2, 0.5 mM ethylene glycol-bis(B-amino-ethyl ether)-N,N,N’,N’-
tetraacetic acid pH 6.9, and 60% v/v glycerol. Guanosine triphosphate (GTP) stock contains 
100 mM. Finally, a tubulin protein stock solution at 10 mg/mL was prepared in a 0.001% v/v 
solution of GTP in buffer A.  
The tubulin reaction mixture used in the assay was prepared by combining 243 µL of buffer 
A, 112 tubulin glycerol buffer, 4.4 µL of GTP stock, and 85 µL of tubulin stock. This reaction 
mixture was kept on ice until used within 30 minutes of preparation. A Biotek Synergy H4 
hybrid multi-mode plate reader was pre-heated to 37 °C. Prior to starting the assay, a half-
area black 96-well plate was preheated within the plate reader. A volume of 5 µL of each of 
the samples was pipetted into separate wells of the plate and incubated in the warm plate 
reader for 1 minute. A volume of 45 µL of the tubulin reaction mixture was then mixed into 
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each of the wells, thereby diluting the drug solutions to the final concentration of 25 µM 
(total DMSO content of 0.15%). The fluorescence of the samples (λirr = 360/20 nm, λem = 
485/20 nm) was then recorded every minute for 60 minutes. Paclitaxel at a final 
concentration of 3 µM was used as a tubulin polymerization inducing control. 
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In classical chemotherapy side effects are a burden for patients, limit treatment 
doses, and thus lower chances on a successful outcome. Light-activated anticancer 
prodrugs have appeared as an alternative strategy to increase the selectivity of 
chemotherapeutic agents.1-6 Ideally, their inactive form should interact minimally 
with biological molecules to limit the toxicity of the prodrug to non-irradiated 
tissues. Upon in vivo light irradiation these prodrugs are locally activated to 
selectively kill tumor cells. Light-activated ruthenium(II)-based compounds have 
been extensively studied due to their superior light absorption properties and rich 
photoreactivity. The majority of light-activated ruthenium-based anticancer 
compounds described to date belong to the class of photodynamic therapeutic 
agents (PDT agents) that generate singlet oxygen (1O2) as a means to locally kill 
cancer cells.7-15 For example, phase II clinical trials were recently completed with 
ruthenium-oligothiophene dyads TLD1411 and TLD1433, which are red-light-
activated, water-soluble, and resistant to photobleaching.9 A less common family of 
ruthenium compounds consists of photoactivated chemotherapy agents (PACT 
agents), where visible light excitation (350-800 nm) leads to the cleavage of a 
protecting group. This irreversible photoreaction releases a toxic ligand,16, 17 
modifies part of this ligand,18, 19 or generates open coordination sites on the metal 
center, which enables biological ligands to bind.20, 21 In PACT a light-induced 
modification of the interaction between the metal compound and biological 
molecules triggers cell death.17, 18, 20, 22-25 The major advantage of this mechanism of 
activation, compared to PDT, is that it does not depend on the presence of 
molecular oxygen, and hence may be applied to treat hypoxic tumors, a type of 
tumor characterized by low response to standard chemotherapy and fast cancer 
progression.26 
Many ruthenium PACT agents known to date contain two bidentate ligands based 
on the 2,2’-bipyridine scaffold.20, 27-30 After irradiation, bis-aqua photoproducts are 
formed with a cis configuration to mimic the binding pattern of cisplatin to DNA.31, 
32 Transplatin on the other hand, is not active in vivo and less cytotoxic than 
cisplatin in vitro. Therefore, anticancer metallodrugs with a trans geometry, usually 
based on platinum(II), have not been considered until recently.33-36 New trans 
platinum(IV) compounds have also been prepared as PACT agents that can be 
activated with UV A (320-400 nm) or high-energy visible light (400-450 nm).21, 37 
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This type of light is, however, harmful to cells38-40 and penetrates biological tissues 
sub-optimally.41 We embarked on developing ruthenium-based PACT agents with 
a trans geometry that can be activated at higher wavelengths, i.e., closer to the 
photodynamic window.42 
In this chapter we report on two trans ruthenium-based PACT compounds that can 
be activated using green light. The two ruthenium complexes, 
[Ru(H2biqbpy)(dmso)Cl]Cl ([1]Cl, H2biqbpy = 6,6-‘-bis[N-(isoquinolyl)1-amino]-
2,2’-bipyridine) and [Ru(H2biqbpy)(Amet)(HAmet)]PF6 ([2]PF6, HAmet = N-acetyl-
L-methionine, see Scheme 4.1), are based on a tetrapyridyl ligand (H2biqbpy) 
specifically developed to coordinate in the basal plane of octahedral metal 
complexes and to leave two trans positions for the coordination of monodentate 
ligands.43 In order to minimize interactions of the metal center with biomolecules 
in the dark, sulfur-based monodentate ligands were selected, i.e., one dmso in 
[1]Cl, and a HAmet and Amet− ligand in [2]PF6, that can be removed by visible 
light irradiation.44, 45 The synthesis, photochemistry, and biological properties of 
these compounds are reported demonstrating that they can trigger apoptosis in 
human cancer cell lines upon green light irradiation. 
 Results and Discussion 4.2
4.2.1 Synthesis and characterization  
Complex [1]Cl was synthesized by reacting H2biqbpy with 1.1 equivalents of 
[Ru(dmso)4Cl2] in ethanol overnight at 80 °C (Scheme 4.1). After filtration [1]Cl was 
obtained as a red-brown powder. Slow vapor diffusion of a methanol solution 
containing [1]Cl into ethyl acetate gave ruby-colored crystals suited for X-ray 
diffraction (Figure 4.1). In the structure of [1]Cl the ligand H2biqbpy is coordinated 
to ruthenium(II) in a highly distorted fashion with an N1-N3-N4-N6 torsion angle 
of 12.78(9)°. The difference between the bond angle N1-Ru1-N6 = 97.90(8)° at the 
open-ended site of the complex and the angle N4-Ru1-N3 = 80.78(8)° at the bpy site 
demonstrates the distortion of the coordination octahedron. Strain is caused by the 
repulsion between the hydrogen atoms bound to C1 and C28, and forces [1]+ to 
assume a helical, thus chiral configuration. The crystal structure of [1]Cl∙MeOH is a 
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This type of light is, however, harmful to cells38-40 and penetrates biological tissues 
sub-optimally.41 We embarked on developing ruthenium-based PACT agents with 
a trans geometry that can be activated at higher wavelengths, i.e., closer to the 
photodynamic window.42 
In this chapter we report on two trans ruthenium-based PACT compounds that can 
be activated using green light. The two ruthenium complexes, 
[Ru(H2biqbpy)(dmso)Cl]Cl ([1]Cl, H2biqbpy = 6,6-‘-bis[N-(isoquinolyl)1-amino]-
2,2’-bipyridine) and [Ru(H2biqbpy)(Amet)(HAmet)]PF6 ([2]PF6, HAmet = N-acetyl-
L-methionine, see Scheme 4.1), are based on a tetrapyridyl ligand (H2biqbpy) 
specifically developed to coordinate in the basal plane of octahedral metal 
complexes and to leave two trans positions for the coordination of monodentate 
ligands.43 In order to minimize interactions of the metal center with biomolecules 
in the dark, sulfur-based monodentate ligands were selected, i.e., one dmso in 
[1]Cl, and a HAmet and Amet− ligand in [2]PF6, that can be removed by visible 
light irradiation.44, 45 The synthesis, photochemistry, and biological properties of 
these compounds are reported demonstrating that they can trigger apoptosis in 
human cancer cell lines upon green light irradiation. 
 Results and Discussion 4.2
4.2.1 Synthesis and characterization  
Complex [1]Cl was synthesized by reacting H2biqbpy with 1.1 equivalents of 
[Ru(dmso)4Cl2] in ethanol overnight at 80 °C (Scheme 4.1). After filtration [1]Cl was 
obtained as a red-brown powder. Slow vapor diffusion of a methanol solution 
containing [1]Cl into ethyl acetate gave ruby-colored crystals suited for X-ray 
diffraction (Figure 4.1). In the structure of [1]Cl the ligand H2biqbpy is coordinated 
to ruthenium(II) in a highly distorted fashion with an N1-N3-N4-N6 torsion angle 
of 12.78(9)°. The difference between the bond angle N1-Ru1-N6 = 97.90(8)° at the 
open-ended site of the complex and the angle N4-Ru1-N3 = 80.78(8)° at the bpy site 
demonstrates the distortion of the coordination octahedron. Strain is caused by the 
repulsion between the hydrogen atoms bound to C1 and C28, and forces [1]+ to 
assume a helical, thus chiral configuration. The crystal structure of [1]Cl∙MeOH is a 
racemate containing both the right-handed (P) and left-handed (M) helices.  
 
70 
Reacting [1]Cl with 20 equivalents of HAmet in water overnight at 80 °C was 
required to substitute both apical ligands by the monodentate thioethers (Scheme 
4.1). Anion exchange to the PF6 salt increased the lipophilicity of [2]+ allowing 
extraction of the compound using ethyl acetate. Purification using size exclusion 
chromatography resulted in analytically pure [2]PF6. Coordination of two N-acetyl-
L-methionine ligands was confirmed using high-resolution mass spectrometry 
(HRMS), NMR, and elemental analysis. 
 
Scheme 4.1 Synthesis of [1]Cl and [2]PF6. Conditions: i) 1.1 eq. [Ru(dmso)4Cl2], 80 °C, in 
EtOH under argon, 16 h, yield 43%; ii) 20 eq. HAmet, 80 °C, in water under argon, 16 h, 
yield, 43%. 
 
Figure 4.1 Displacement ellipsoid of cationic M-[1]+ (50% probability level) as observed in 
the crystal structure of ([1]Cl·CH3OH). Chloride counter-anions, H atoms, lattice CH3OH, 
and disorder, have been omitted for clarity. 
4.2.2 Dark Stability  
Testing the dark stability of anticancer metallodrugs under conditions relevant for 
biological testing is critical for interpreting uptake and cytotoxicity data. Stability 
assays were thus performed in the dark in aqueous and DMSO solutions. Like for 
cisplatin the dark stability of [1]Cl in aqueous solution depends on chloride 
concentration. According to 1H NMR (Figure SIV.1) and mass spectrometry upon 
dissolution in deionized water or D2O the chloride ligand of [1]+ immediately 
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dissociated to afford [Ru(H2biqbpy)(dmso)(H2O)]2+ ([1a]2+, see Scheme 4.2). Upon 
adding NaCl the concentration of [1]+ increased, to reach a ratio [1]+:[1a]2+ in 
solution of 1:3 at 0.15 M of NaCl. The dark behavior of [2]PF6 was quite different. 
Although the protonation of one HAmet ligand in the solid state is corroborated by 
elemental analysis, in aqueous solution at neutral pH the complex is deprotonated 
into the neutral species [2a] (Scheme 4.2). In D2O, this species remained stable in 
the dark (Figure SIV.2). Overall, in aqueous solution [2]PF6 appears as a ‘protected’ 
version of [1]Cl, as the hydrolysable Ru-Cl bond of [1]Cl has been replaced by a 
thermally stable Ru-S bond. 
 
Scheme 4.2 Ligand exchange processes upon dilution of [1]Cl and [2]PF6 in aqueous 
solutions, and upon green light irradiation. 
4.2.3 Photoreactivity of [1]Cl and [2]PF6 
Green light irradiation (λirr = 520 nm) under argon of a solution of [1]Cl in water 
resulted in a shift of the absorption maximum from 305 nm to 320 nm, and a slight 
increase of the absorbance in the visible region (Figure 4.2A). Mass spectrometry 
after light irradiation showed new peaks at m/z = 288.7 corresponding to 
[Ru(H2biqbpy)(H2O)2]2+ ([1b]2+ in Scheme 4.2, calc. m/z = 288.8). Thus, the dmso 
ligand was photosubstituted by water. This reactivity is typical for geometrically 
distorted ruthenium(II) compounds that possess low-lying triplet metal-centered 
(3MC) excited states with a strongly dissociative character.46 1H NMR confirmed 
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4.2.3 Photoreactivity of [1]Cl and [2]PF6 
Green light irradiation (λirr = 520 nm) under argon of a solution of [1]Cl in water 
resulted in a shift of the absorption maximum from 305 nm to 320 nm, and a slight 
increase of the absorbance in the visible region (Figure 4.2A). Mass spectrometry 
after light irradiation showed new peaks at m/z = 288.7 corresponding to 
[Ru(H2biqbpy)(H2O)2]2+ ([1b]2+ in Scheme 4.2, calc. m/z = 288.8). Thus, the dmso 
ligand was photosubstituted by water. This reactivity is typical for geometrically 
distorted ruthenium(II) compounds that possess low-lying triplet metal-centered 
(3MC) excited states with a strongly dissociative character.46 1H NMR confirmed 
this analysis, as a new resonance at 2.72 ppm, characteristic of free dmso, appeared 
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after green light irradiation, but not in the dark (Figure SIV.3). Similar evolutions 
were observed upon blue light irradiation (450 nm, Figure SIV.5), which also 
allowed to determine a photosubstitution quantum yield (ΦPS) of 0.3%. Overall, 
cleavage of the Ru-S bond of [1]+ is a photochemical process, and compound [1]Cl 
can be seen as a semi-protected light-activated prodrug. One of the two apical 




Figure 4.2 Evolution of the electronic absorption spectra of a solution of [1]Cl (a) and 
[2]PF6 (b) in demineralized water upon green light irradiation under argon (λ = 530 nm, 
Δλ1/2 = 25 nm, 3.02 mW, 2.1 × 10−8 mol.s−1). Time: 0 min (red curve) to 120 min (black curve, 
a) or 160 min (black curve, b). Conditions [Ru]0 = 0.025 mM (a), 0.078 mM (b), irradiated 
volume was 3.00 mL at 298 K. 
For [2]PF6, green light irradiation in aqueous solution under argon (Figure 4.2B) 
was accompanied by a higher intensity of the metal-to-ligand charge transfer 
(MLCT) absorption band near 400 nm and of the transition near 325 nm, and 
several isosbestic points. Mass spectrometry gave a clearer indication about the 
photoreaction occurring under these conditions. The initial peak at m/z = 923.4 
characteristic for [2]+ (calc. m/z = 923.2) was gradually replaced by a signal at m/z = 
732.4, characteristic for [Ru(H2biqbpy)(Amet)]+ (calc. m/z = 732.1), indicating the 
formation of [Ru(H2biqbpy)(Amet)(H2)]+, [2b]+. A signal at m/z = 605.1 for 
[Ru(H2biqbpy)(MeOH)(OMe)]+ (calc. m/z = 605.1) or m/z = 386.6 for 
[Ru(H2biqbpy)(CH3CN)2]2+ (calc. m/z = 387.1) could only be obtained under 
extensive blue light irradiation (450 nm, see Figure SIV.6; MeOH and CH3CN were 
solvents used for MS, respectively). Irradiation with high-energy visible light was 
hence necessary to form the bis-aqua complex [1b]2+ from [2b]+ (Scheme 4.2). Under 
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our conditions the formation of [1b]2+ under green light irradiation was too slow to 
be observed. This result was confirmed by 1H NMR (Figure SIV.4), as only one 
ligand was photosubstituted by water under green light irradiation at a dose of 75 
J.cm−2. In conclusion, complex [2]PF6 is a water-soluble, fully protected complex: 
both trans N-acetyl-L-methionine ligands remain coordinated to the metal in the 
dark, while one of them is cleaved off by green light irradiation, and the second 
one is removed by high doses of blue light. 
4.2.4 (Photo)cytotoxicity Studies 
The cytotoxicity of compounds [1]Cl and [2]PF6 was investigated against three cell 
lines, i.e., A549 (human adenocarcinoma alveolar basal epithelial cells), A431 
(human epidermoid carcinoma cells), and MRC-5 (noncancerous human foetal 
lung fibroblasts). The effective concentrations (EC50), defined as the compound 
concentration that reduces cell viability by 50% compared to untreated wells, were 
measured, in the dark and after light activation, following a protocol described in 
details by Hopkins et al.38 These studies aimed at establishing whether the 
photosubstitution reactions observed in a chemical environment may translate into 
in vitro light activation. Although both blue and green light resulted in 
photosubstitution, green light (520 nm) was chosen for the photocytotoxicity tests 
because it is much less toxic to human cell lines than blue light38 and it penetrates 
further into biological tissues. Preliminary studies in a 96-well plate (Figure SIV.7, 
Figure SIV.8) demonstrated that under the conditions of the cell-irradiation setup 
(21 mW.cm−2) a 60 min irradiation time, corresponding to a dose of 75 J.cm−2, was 
necessary to activate 0.8-1.6 nmol of the compounds (the maximum amount 
present in each well for concentrations of 40-80 µM). The EC50 of complexes [1]Cl, 
[2]PF6, and cisplatin, against A431, A549, and MRC-5 cell lines, measured in the 
dark and after green light irradiation, are reported in Table 4.1. 
In the dark, the EC50 values of ~10 and ~35 µM were observed for [1]Cl and [2]PF6, 
respectively in A431 cells (Table 4.1). For the A549 cell line similar trends were 
observed with EC50 values of 6-9 µM for [1]Cl and 11-20 µM for [2]PF6. Thus, [1]Cl 
has similar cytotoxicity in the dark as cisplatin, whereas the two thioether ligands 
in [2]PF6 decreased the cytotoxicity by a factor of two to four compared to [1]Cl. 
This result suggested that coordination of the sulfur ligands slows down or 
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details by Hopkins et al.38 These studies aimed at establishing whether the 
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in vitro light activation. Although both blue and green light resulted in 
photosubstitution, green light (520 nm) was chosen for the photocytotoxicity tests 
because it is much less toxic to human cell lines than blue light38 and it penetrates 
further into biological tissues. Preliminary studies in a 96-well plate (Figure SIV.7, 
Figure SIV.8) demonstrated that under the conditions of the cell-irradiation setup 
(21 mW.cm−2) a 60 min irradiation time, corresponding to a dose of 75 J.cm−2, was 
necessary to activate 0.8-1.6 nmol of the compounds (the maximum amount 
present in each well for concentrations of 40-80 µM). The EC50 of complexes [1]Cl, 
[2]PF6, and cisplatin, against A431, A549, and MRC-5 cell lines, measured in the 
dark and after green light irradiation, are reported in Table 4.1. 
In the dark, the EC50 values of ~10 and ~35 µM were observed for [1]Cl and [2]PF6, 
respectively in A431 cells (Table 4.1). For the A549 cell line similar trends were 
observed with EC50 values of 6-9 µM for [1]Cl and 11-20 µM for [2]PF6. Thus, [1]Cl 
has similar cytotoxicity in the dark as cisplatin, whereas the two thioether ligands 
in [2]PF6 decreased the cytotoxicity by a factor of two to four compared to [1]Cl. 
This result suggested that coordination of the sulfur ligands slows down or 
diminishes the cellular response to these ruthenium compounds. 
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Whereas identical doses of green light did not induce photocytotoxicity by 
themselves (Figure SIV.9), nor modify the cytotoxicity of cisplatin (Table 4.1), a 
dramatically decreased cell population was observed when the cells were 
incubated with compound [1]Cl or [2]PF6 for 6 h or 24 h, and then irradiated with 
75 J.cm−2 of green light (Table 4.1, Figure 4.4). For complex [1]Cl, EC50 values close 
to 1 µM or lower were observed for all cell lines independently of when irradiation 
was performed. For A549 cells treated with complex [2]PF6, the EC50 decreased 
from 20 µM to 3.6 µM when irradiation occurred 6 h after treatment, and from 11 
µM to 5 µM when it was done 24 h after treatment. Similar trends were observed 
for A431 cells. 
After green light irradiation, complex [2]PF6 showed cytotoxicity comparable to the 
dark toxicity of [1]Cl, although compound [2]PF6 was less toxic in the dark than 
[1]Cl. For both compounds, the photo index (PI) was higher when irradiation 
occurred 6 h after treatment, compared to 24 h. This effect was mostly a 
consequence of lower EC50 values in the dark after 24 h incubation, which 
suggested a higher degree of thermal activation with longer dark incubation times. 
Overall, these results suggest that the sulfur ligands of [1]Cl (dmso) and of [2]PF6 
(HAmet) partially inhibit the cytotoxicity of the ruthenium center in the dark, and 
that ligand photosubstitution is accompanied by an increase of the cytotoxicity of 





Table 4.1 Cytotoxicity (EC50 with confidence interval (CI, 95%) in μM) of [1]Cl, [2]PF6, and 
cisplatin on skin (A431) and lung (A549) cancer cell lines given with photo index (PI). In 
addition, the complexes were tested against a non-cancerous lung cell line (MRC-5) for 
comparison. 
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4.2.5 Singlet Oxygen Production 
Due to the long-lived triplet excited states of many photostable ruthenium 
polypyridyl complexes, singlet oxygen (1O2) generation is often a dominant 
pathway leading to cytotoxicity upon light irradiation.5, 9, 47-50 However, 
photosubstitution reactions observed with distorted octahedral ruthenium(II) 
complexes often lead to quenching of their long-lived 3MLCT states by nearby 3MC 
excited states, which lowers the quantum yields of phosphorescence and 1O2 
generation. These trends present a unique opportunity for PACT, as the hypoxic 
conditions in many tumor tissues requires new oxygen-independent 
photoactivation strategies. In order to test whether compounds [1]Cl and [2]PF6 
would qualify better as PDT or as PACT agents their quantum yields of 1O2 
generation (Φ1O2) were measured by Sven Askes under 450 nm excitation by direct 
detection of the 1274 nm infrared emission of 1O2 in CD3OD. The prototypical 
[Ru(bpy)3]Cl2 complex was used as a reference (Φ1O2 = 73%).51 Φ1O2 values of 1.3% 
and 2.3% were found for [1]Cl and [2]PF6, respectively (Table SIV.1 and Figure 
SIV.11). According to these results, both [1]Cl and [2]PF6 are extremely poor 1O2 
generators, and the photoactivation observed in vitro is not a PDT effect. 
4.2.6 Light-induced Apoptosis  
To investigate which type of cell death occurred, the morphology of A549 cells 
were inspected by Dr. Bianka Siewert in the dark and after green light irradiation 
using bright field microscopy (Figure 4.3 and Figure SIV.13). Directly after 
irradiation (520 nm, 75 J.cm−2), cells treated with [1]Cl (1.5 µM) displayed cell 
shrinkage, loss of cell-cell contact, and membrane blebbing as depicted in Figure 
4.3B. An enhanced effect was detected when the cells were incubated for an 
additional 24 h after light irradiation (Figure 4.3D). The changes in cell 




Figure 4.3 Bright field microscopy images (40× magnification) of A549 cells treated with 
[1]Cl (1.5 µM) for 6 + 1 h in the dark (A) and 6 h in the dark followed by 1 h green light 
irradiation (B, 520 nm, 75 J.cm−2). Images (C) and (D show sample A) and B) after an 
additional 24 h incubation in the dark. Arrows in (B) show examples of membrane-
blebbing, which is characteristic for early apoptosis. 
To confirm that a majority of the A549 cells treated with [1]Cl or [2]PF6 and 
irradiated with green light died by apoptosis, their fate was investigated by Dr. 
Bianka Siewert using the Annexin V–propidium iodide assay and analyzed using 
flow cytometry (FC).54 Figure 4.4 shows representative density plots of non-
irradiated A549 cells treated with [1]Cl (1.5 µM, Figure 4.4A) or [2]PF6 (10 µM, 
Figure 4.4C). The majority of the cells are in the lower left quadrant, i.e., alive. 
However, upon green light irradiation (1 h, 75 J.cm−2) a clear shift of the cell 
population to the bottom right quadrant indicates Annexin V binding for both 
[1]Cl and [2]PF6 treated cells, thus apoptotic cells. The lack of cells in the top left 
quadrant indicates the absence of purely necrotic cells. Cells in the top right are 
commonly referred to as ‘secondary necrotic’, and are a known artefact in in vitro 
assays. 
According to the FC data, the photocytoxicity of [1]Cl and [2]PF6 occurs via 
apoptosis without any sign of necrosis. In addition, confocal microscopy of A549 
cells stained with tetramethylrhodamine ethyl ester (mitochondria) and DRAQ5 
(nuclear DNA) showed that light irradiation diminished the mitochondrial 
membrane potential and induced chromosomal condensation, especially for [1]Cl 




4.2.5 Singlet Oxygen Production 
Due to the long-lived triplet excited states of many photostable ruthenium 
polypyridyl complexes, singlet oxygen (1O2) generation is often a dominant 
pathway leading to cytotoxicity upon light irradiation.5, 9, 47-50 However, 
photosubstitution reactions observed with distorted octahedral ruthenium(II) 
complexes often lead to quenching of their long-lived 3MLCT states by nearby 3MC 
excited states, which lowers the quantum yields of phosphorescence and 1O2 
generation. These trends present a unique opportunity for PACT, as the hypoxic 
conditions in many tumor tissues requires new oxygen-independent 
photoactivation strategies. In order to test whether compounds [1]Cl and [2]PF6 
would qualify better as PDT or as PACT agents their quantum yields of 1O2 
generation (Φ1O2) were measured by Sven Askes under 450 nm excitation by direct 
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SIV.11). According to these results, both [1]Cl and [2]PF6 are extremely poor 1O2 
generators, and the photoactivation observed in vitro is not a PDT effect. 
4.2.6 Light-induced Apoptosis  
To investigate which type of cell death occurred, the morphology of A549 cells 
were inspected by Dr. Bianka Siewert in the dark and after green light irradiation 
using bright field microscopy (Figure 4.3 and Figure SIV.13). Directly after 
irradiation (520 nm, 75 J.cm−2), cells treated with [1]Cl (1.5 µM) displayed cell 
shrinkage, loss of cell-cell contact, and membrane blebbing as depicted in Figure 
4.3B. An enhanced effect was detected when the cells were incubated for an 
additional 24 h after light irradiation (Figure 4.3D). The changes in cell 




Figure 4.3 Bright field microscopy images (40× magnification) of A549 cells treated with 
[1]Cl (1.5 µM) for 6 + 1 h in the dark (A) and 6 h in the dark followed by 1 h green light 
irradiation (B, 520 nm, 75 J.cm−2). Images (C) and (D show sample A) and B) after an 
additional 24 h incubation in the dark. Arrows in (B) show examples of membrane-
blebbing, which is characteristic for early apoptosis. 
To confirm that a majority of the A549 cells treated with [1]Cl or [2]PF6 and 
irradiated with green light died by apoptosis, their fate was investigated by Dr. 
Bianka Siewert using the Annexin V–propidium iodide assay and analyzed using 
flow cytometry (FC).54 Figure 4.4 shows representative density plots of non-
irradiated A549 cells treated with [1]Cl (1.5 µM, Figure 4.4A) or [2]PF6 (10 µM, 
Figure 4.4C). The majority of the cells are in the lower left quadrant, i.e., alive. 
However, upon green light irradiation (1 h, 75 J.cm−2) a clear shift of the cell 
population to the bottom right quadrant indicates Annexin V binding for both 
[1]Cl and [2]PF6 treated cells, thus apoptotic cells. The lack of cells in the top left 
quadrant indicates the absence of purely necrotic cells. Cells in the top right are 
commonly referred to as ‘secondary necrotic’, and are a known artefact in in vitro 
assays. 
According to the FC data, the photocytoxicity of [1]Cl and [2]PF6 occurs via 
apoptosis without any sign of necrosis. In addition, confocal microscopy of A549 
cells stained with tetramethylrhodamine ethyl ester (mitochondria) and DRAQ5 
(nuclear DNA) showed that light irradiation diminished the mitochondrial 
membrane potential and induced chromosomal condensation, especially for [1]Cl 
(Figure SIV.14). All of the tested cellular responses clearly demonstrate that 
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compounds [1]Cl and [2]PF6 belong to a rare sub-family of metallodrugs that can 
trigger apoptosis with green light.55, 56 
 
 
Figure 4.4 Representative flow cytometry density plots (Annexin V-FITC (525 
nm)/Propidium iodide (670 nm) of A549 cells incubated with [1]Cl (1.5 μM) in the dark 
for 6 + 1 + 24 h (a), or in the dark for 6 h, followed by irradiation with green light for 1 h, 
followed by 24 h incubation (b) or treated with [2]PF6 (10 μM) and left in the dark for 31 h 
(c) or irradiated 1 h with green light 6 h after treatment and further incubated for 24 h in 
the dark (d). Irradiation conditions: 520 nm, 60 min, 75 J.cm−2. Quantification: see Figure 
SIV.12. 
4.2.7 Intracellular Distribution and Uptake 
In order to gather information on the intracellular localization of [1]Cl and [2]PF6, 
and to investigate whether the difference in cytotoxicity between [1]Cl and [2]PF6 
in the dark was due to differences in cell-uptake and/or of intracellular 
distribution, cell fractionation was performed. For this experiment, A549 cells were 
incubated with [1]Cl or [2]PF6 for 6 h in the dark at concentrations corresponding 
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to the EC50 value. The cells were then harvested, the cytosol, membrane, nuclei, 
and cytoskeleton fractions were separated by Anja Busemann (see Experimental 
section), and the ruthenium concentration in each fraction was measured by ICP-
MS (Figure SIV.15). The observed total uptake of [2]PF6 (7.5 ng/106 cells) was 
significantly lower compared to that of [1]Cl (16 ng/106 cells). As the effect of both 
treatments was identical (i.e., reducing the cell population by 50%), [2]PF6 seems to 
be more potent than [1]Cl, although larger EC50 values were found for [2]PF6. This 
result suggests that the dark cytotoxicity of [2]PF6 might be limited by a lower 
uptake. In terms of intracellular distribution both complexes were found in all 
fractions, with a slight ([2]PF6) to strong ([1]Cl) preference for the membrane 
fraction, and to a lesser extent in the nuclear fractions. The membrane fraction does 
not only contain the cell membrane but also mitochondria, endosomes, and 
lysosomes. These results are in agreement with contemporary literature suggesting 
an endocytosis-dependent uptake mechanism for polypyridyl metal complexes 
(thus high Ru content in endosomes and lysosomes), and accumulation of 
lipophilic cationic species in the mitochondrial membranes.57, 58 
4.2.8 Cell-free DNA Binding Studies 
Thermal and photoinduced DNA binding studies were performed by Dr. 
Samantha L. Hopkins to establish whether the photolabile sulfur ligands in [1]Cl 
and [2]PF6 were protecting the compounds from interaction with biomolecules. 
The pUC19 plasmid used for this study (2686 bp) exists in three forms: supercoiled 
(SC, most condensed form, migrates the fastest), single-nicked open circular (OC, 
relaxed form of the SC, migrates in between the SC and LD) and linear dimer (LD, 
largest form at 5372 bp, migrates the slowest). For both the thermal and 
photoinduced DNA binding studies, phosphate buffer was used to model a 
pseudo intracellular environment. For the dark thermal binding experiments, [1]Cl 
and [2]PF6 were incubated at varied DNA base pair (BP) to metal complex (MC) 
ratios for 24 h (Figure SIV.16). Both [1]Cl and [2]PF6 showed negligible binding 
(minimal change in migration of the OC or SC forms), even at the largest 
concentration of metal complex (5:1 BP:MC ratio). Cisplatin was included as a 
positive control (5:1 BP:MC ratio) and displayed typical DNA binding results as 
those observed in literature.59 In the dark, [1]Cl and [2]PF6 have a low affinity and 




compounds [1]Cl and [2]PF6 belong to a rare sub-family of metallodrugs that can 
trigger apoptosis with green light.55, 56 
 
 
Figure 4.4 Representative flow cytometry density plots (Annexin V-FITC (525 
nm)/Propidium iodide (670 nm) of A549 cells incubated with [1]Cl (1.5 μM) in the dark 
for 6 + 1 + 24 h (a), or in the dark for 6 h, followed by irradiation with green light for 1 h, 
followed by 24 h incubation (b) or treated with [2]PF6 (10 μM) and left in the dark for 31 h 
(c) or irradiated 1 h with green light 6 h after treatment and further incubated for 24 h in 
the dark (d). Irradiation conditions: 520 nm, 60 min, 75 J.cm−2. Quantification: see Figure 
SIV.12. 
4.2.7 Intracellular Distribution and Uptake 
In order to gather information on the intracellular localization of [1]Cl and [2]PF6, 
and to investigate whether the difference in cytotoxicity between [1]Cl and [2]PF6 
in the dark was due to differences in cell-uptake and/or of intracellular 
distribution, cell fractionation was performed. For this experiment, A549 cells were 
incubated with [1]Cl or [2]PF6 for 6 h in the dark at concentrations corresponding 
 
79 
to the EC50 value. The cells were then harvested, the cytosol, membrane, nuclei, 
and cytoskeleton fractions were separated by Anja Busemann (see Experimental 
section), and the ruthenium concentration in each fraction was measured by ICP-
MS (Figure SIV.15). The observed total uptake of [2]PF6 (7.5 ng/106 cells) was 
significantly lower compared to that of [1]Cl (16 ng/106 cells). As the effect of both 
treatments was identical (i.e., reducing the cell population by 50%), [2]PF6 seems to 
be more potent than [1]Cl, although larger EC50 values were found for [2]PF6. This 
result suggests that the dark cytotoxicity of [2]PF6 might be limited by a lower 
uptake. In terms of intracellular distribution both complexes were found in all 
fractions, with a slight ([2]PF6) to strong ([1]Cl) preference for the membrane 
fraction, and to a lesser extent in the nuclear fractions. The membrane fraction does 
not only contain the cell membrane but also mitochondria, endosomes, and 
lysosomes. These results are in agreement with contemporary literature suggesting 
an endocytosis-dependent uptake mechanism for polypyridyl metal complexes 
(thus high Ru content in endosomes and lysosomes), and accumulation of 
lipophilic cationic species in the mitochondrial membranes.57, 58 
4.2.8 Cell-free DNA Binding Studies 
Thermal and photoinduced DNA binding studies were performed by Dr. 
Samantha L. Hopkins to establish whether the photolabile sulfur ligands in [1]Cl 
and [2]PF6 were protecting the compounds from interaction with biomolecules. 
The pUC19 plasmid used for this study (2686 bp) exists in three forms: supercoiled 
(SC, most condensed form, migrates the fastest), single-nicked open circular (OC, 
relaxed form of the SC, migrates in between the SC and LD) and linear dimer (LD, 
largest form at 5372 bp, migrates the slowest). For both the thermal and 
photoinduced DNA binding studies, phosphate buffer was used to model a 
pseudo intracellular environment. For the dark thermal binding experiments, [1]Cl 
and [2]PF6 were incubated at varied DNA base pair (BP) to metal complex (MC) 
ratios for 24 h (Figure SIV.16). Both [1]Cl and [2]PF6 showed negligible binding 
(minimal change in migration of the OC or SC forms), even at the largest 
concentration of metal complex (5:1 BP:MC ratio). Cisplatin was included as a 
positive control (5:1 BP:MC ratio) and displayed typical DNA binding results as 
those observed in literature.59 In the dark, [1]Cl and [2]PF6 have a low affinity and 
negligible association with any of the forms of the plasmid DNA.  
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In a second experiment, the ruthenium complexes and cisplatin were photolysed 
(λirr = 520 nm) for different amounts of time (0-60 min) in the presence of pUC19 
plasmid (Figure 4.5). For these experiments, a 50:1 BP:MC ratio was used, which 
displayed insignificant dark thermal binding. However, following green light 
irradiation complex [1]Cl showed significant retardation of the SC form (Figure 
4.5A, lanes 5-9) compared to [2]PF6 (Figure 4.5B, lanes 5-9), which itself showed 
slight changes in the OC and SC forms compared to the control. Additionally, a 
change in the intensity of the staining indicates that increased photoinduced 
binding of the metal complexes interferes with the intercalation of ethidium 
bromide. These studies clearly show that after light activation, [1]Cl interacts 
strongly with the pUC19 plasmid, whereas [2]PF6 interacts less but still 
significantly more than in the dark. Clearly, 1O2-based DNA cleavage was not 
observed under irradiation in presence of either ruthenium compound. Although 
these simple results neither allow to specify in details the binding mode of [1]Cl 
and [2]PF6 to DNA, nor to say whether this interaction is relevant for cell death, 
they clearly demonstrate that the photosubstitution reactions occurring under 
green light irradiation induces critical changes the two ruthenium compounds and 
the way they interact with biomolecules.60 
 
Figure 4.5 Agarose gel of photoinduced binding of [1]Cl (a) and [2]PF6 (b) to pUC19 
plasmid DNA. The lanes correspond to (1) λ DNA MW marker, (2) dark DNA only 
control, (3) irradiated DNA only control, (4) dark 50:1 BP:MC control, (5-9) 5, 15, 30, 45, 
and 60 min irradiated 50:1 BP:MC samples, respectively. The bands of the λ MW marker 
correlate to 23, 9.4, 6.6, 4.4, 2.3, and 2.0 kbp. The dark DNA control bands are labelled 




Complexes [1]Cl and [2]PF6 are the first light-activated trans ruthenium-based 
anticancer prodrugs. In the dark these water-soluble complexes are well taken up 
and display mild cytotoxicity to A431 and A549 cancer cells. However, upon green 
light irradiation, [1]Cl and [2]PF6 are activated resulting in highly cytotoxic 
compounds, with EC50 values below 1 µM and PIs of up to 22. Clearly the 
combination of these compounds and green light irradiation induces apoptosis, 
and the low 1O2 generation efficiency and the absence of DNA photocleavage make 
us conclude that cell death is not due to a photodynamic effect. The dose of light 
necessary to activate [1]Cl and [2]PF6 in vitro (75 J.cm−2) is somewhat higher 
compared to values published for other photoactivated ruthenium or trans-
platinum complexes (typically 10 J.cm−2). However, the green light used in this 
work (520 nm) is much less harmful to cells than the shorter wavelength (UV or 
blue light) reported previously,18, 21, 38, 40, 49, 61-65 so that high doses do not necessarily 
represent a problem. Green light also penetrates deeper into the skin tissue,41 
which makes it more relevant for phototherapy.  
Overall, the data presented in this chapter suggests that the activation mechanism 
for this new type of trans ruthenium polypyridyl complexes relies on ligand 
photosubstitution reactions. The ruthenium species [2a] bound to two sulfur 
protecting ligands is the least cytotoxic, followed by the two mono-protected 
species [1a]2+ and [2b]+ bound to a single sulfur ligand, while the bis-aqua, fully 
deprotected species [1b]2+ shows the highest cytotoxicity. Although cell-free DNA 
studies showed clear photoinduced DNA-binding by [1]Cl and, to a lesser extent, 
by [2]PF6, DNA only represents one of the possible biological target(s) of these 
compounds, as they distribute in the whole cell. It will be necessary to follow for 
example chemical biological methods described by Hartinger et al.,59 to determine 
which interaction with which biomolecule is actually responsible for the green 
light-induced apoptosis observed with [1]Cl and [2]PF6. 
 Experimental 4.4
4.4.1 Materials and methods 
All NMR spectra were recorded on a Bruker DMX-400 or a Bruker AV-600 spectrometer. 
Chemical shifts are indicated in ppm relative to tetramethylsilane. Mass spectra were 
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Complexes [1]Cl and [2]PF6 are the first light-activated trans ruthenium-based 
anticancer prodrugs. In the dark these water-soluble complexes are well taken up 
and display mild cytotoxicity to A431 and A549 cancer cells. However, upon green 
light irradiation, [1]Cl and [2]PF6 are activated resulting in highly cytotoxic 
compounds, with EC50 values below 1 µM and PIs of up to 22. Clearly the 
combination of these compounds and green light irradiation induces apoptosis, 
and the low 1O2 generation efficiency and the absence of DNA photocleavage make 
us conclude that cell death is not due to a photodynamic effect. The dose of light 
necessary to activate [1]Cl and [2]PF6 in vitro (75 J.cm−2) is somewhat higher 
compared to values published for other photoactivated ruthenium or trans-
platinum complexes (typically 10 J.cm−2). However, the green light used in this 
work (520 nm) is much less harmful to cells than the shorter wavelength (UV or 
blue light) reported previously,18, 21, 38, 40, 49, 61-65 so that high doses do not necessarily 
represent a problem. Green light also penetrates deeper into the skin tissue,41 
which makes it more relevant for phototherapy.  
Overall, the data presented in this chapter suggests that the activation mechanism 
for this new type of trans ruthenium polypyridyl complexes relies on ligand 
photosubstitution reactions. The ruthenium species [2a] bound to two sulfur 
protecting ligands is the least cytotoxic, followed by the two mono-protected 
species [1a]2+ and [2b]+ bound to a single sulfur ligand, while the bis-aqua, fully 
deprotected species [1b]2+ shows the highest cytotoxicity. Although cell-free DNA 
studies showed clear photoinduced DNA-binding by [1]Cl and, to a lesser extent, 
by [2]PF6, DNA only represents one of the possible biological target(s) of these 
compounds, as they distribute in the whole cell. It will be necessary to follow for 
example chemical biological methods described by Hartinger et al.,59 to determine 
which interaction with which biomolecule is actually responsible for the green 
light-induced apoptosis observed with [1]Cl and [2]PF6. 
 Experimental 4.4
4.4.1 Materials and methods 
All NMR spectra were recorded on a Bruker DMX-400 or a Bruker AV-600 spectrometer. 
Chemical shifts are indicated in ppm relative to tetramethylsilane. Mass spectra were 
recorded by using a Thermoquest Finnagen AQA Spectrometer and a MSQ Plus 
 
82 
Spectrometer positive ionization mode. See Figure S1 for the specific NMR-assignments of 
[1a]2+ and [2]+. For NMR experiments under argon, J. Young NMR tubes with PTFE stopper 
were used. UV-vis experiments were performed on a Cary 50 Varian spectrometer equipped 
with a Cary Single Cell Peltier for temperature control. The elemental ultra-trace analyses 
were performed with an FAST (Elemental Scientific, Ohama, Nebraska, USA), i-CAP-Q ICP-
MS (Thermo Scientific, Walthem, Massachusetts, USA) MP2 peristaltic pump controlled 
flow 110 µl/min standardized setup.  
The ligand 6,6’-bis[N-(isoquinolyl)-1-amino]-2,2’-bipyridine (H2biqbpy), [Ru(dmso)4Cl2], and 
[Ru(bpy)3]Cl2 were synthesized according to literature procedures.43, 66 N-acetyl-L-
methionine (HAmet) was purchased from Alfa Aesar. The complexes were synthesized in 
dim light and stored in the dark in the freezer. 
4.4.2 Synthesis of [Ru(H2biqbpy)(dmso)Cl]Cl ([1]Cl)  
In a 2-necked round-bottom flask [Ru(dmso)4Cl2] (86 mg, 0.34 mmol) and H2biqbpy (71 mg, 
0.34 mmol) were added in degassed ethanol (10 mL). The solution was stirred overnight at 
80 °C under argon resulting in a dark red suspension. Then, the flask was cooled in an ice 
bath and the red suspension was filtered over a membrane filter, washed with cold ethanol 
(3 × 10 mL), diethylether (3 × 10 mL), and hexanes (3 × 10 mL). The complex was obtained as 
a red brown powder. Yield: 48 mg (43%). 1H NMR (600 MHz, D2O, 293 K, in ppm): δ = 8.66 
(dd, J = 8.6, 0.9 Hz, 2H, qi-4), 8.37 (d, J = 7.9 Hz, 1.0 Hz, 2H, H3), 8.36 (d, J = 7.3 Hz, 2H, qi-10), 
8.25 (dd, J = 8.4, 7.7 Hz, 2H, H4), 8.05 (d, J = 8.0 Hz, 2H, qi-7), 7.96 (ddd, J = 8.1, 7.0, 1.0 Hz, 
2H, qi-6), 7.89 (ddd, J = 8.4, 7.0, 1.3 Hz, 2H, qi-5), 7.86 (dd, J = 8.4, 0.9 Hz, 2H, H5), 7.60 (d, J = 
6.7 Hz, 2H, qi-9), 2.41 (s, 6H, Hα) ppm; 13C NMR (150 MHz, D2O, 293K, in ppm): δ = 156.3 (C2), 
151.9 (qi-2), 151.7 (C6), 144.3 (qi-10), 140.0 (C4), 137.0 (qi-3), 133.4 (qi-6), 129.8 (qi-5), 128.3 
(qi-7), 123.3 (qi-4), 120.6 (qi-8), 119.5 (C3), 118.0 (qi-9), 117.2 (C5), 44.6 (Cα) ppm; UV-vis: λmax 
(ε in M−1.cm−1) in H2O: 308 nm (2.3 × 104); High resolution ES MS m/z (calc): 310.0465 (310.0464, 
[M – 2×Cl]2+). Elem. Anal. Calcd. for C30H26Cl2N6O2RuS,H2O: C, 50.85; H, 3.98; N, 11.86. Found: 
C, 50.85; H, 4.23; N, 11.76. 
4.4.3 Synthesis of [Ru(H2biqbpy)(HAmet)(Amet)]PF6 ([2]PF6)  
In a 2-necked round-bottom flask [1]Cl (30 mg, 0.043 mmol) and N-acetyl-L-methionine (160 
mg, 0.87 mmol) were added in degassed demineralized water (15 mL). The solution was 
stirred overnight at 80 °C under argon resulting in a red solution. Solid KPF6 (2.0 g) was 
added and the complex was extracted using ethyl acetate. After rotary evaporation at 30 °C 
the compound was purified using size exclusion chromatography (Sephadex, LH-20 in 
MeOH). After rotary evaporation at 30 °C the compound was obtained as a red powder. 
Yield: 20 mg (43%). 1H NMR (400 MHz, CD3OD, 293 K, in ppm): δ = 8.75 (d, J = 8.4 Hz, 2H, qi-
4), 8.53 (d, J = 8.4 Hz, 2H, qi-7), 8.47 (d, J = 8.4 Hz, 2H, qi-9), 8.28 (t, J = 7.8 Hz, 2H, qi-6), 8.07 
(d, J = 7.8 Hz, 2H, H3/5), 8.00-7.88 (m, 6H, qi-5-H4-H3/5), 7.67 (d, J = 6.6 Hz, 2H, qi-10), 3.99 (dd, 
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J = 7.8, 3.0 Hz, 2H, Hδ), 1.58 (s, 6H, Hζ), 1.76-1.22 (m, 4H, Hγ), 1.42 (t, J = 6.9 Hz, 4H, Hβ), 1.40 
(s, 6H, Hα). 13C NMR (100 MHz, CD3OD, 293 K, in ppm): δ = 173.8 (COOH), 173.0 (CON), 
156.9 (C2), 152.8 (C6), 152.0 (qi-2), 146.1 (qi-9), 139.4 (qi-6), 137.7 (qi-8), 133.7 (*), 130.5 (*), 
129.0 (C3/5), 124.1 (qi-4), 121.3 (qi-3), 120.6 (qi-7), 118.8 (qi-10), 117.8 (*), 51. 7 (Cδ), 33.2 (Cβ), 
31.2 (Cγ), 22.2 (Cα), 16.1 (Cζ). UV-vis: λmax (ε in M−1.cm−1) in H2O: 363 nm (8.9 × 103). High 
resolution ES MS m/z (calc): 923.1954 (923.1951, [M – PF6]+), 462.1008 (462.1012, [M – PF6 + 
H]2+). Elem. Anal. Calcd. for C42H45F6N8O6PRuS2 + 3×MeOH: C, 46.43; H, 4.94; N, 9.63 Found: C, 
46.20; H, 5.05; N, 9.30. 
 
Figure 4.6 Schematic representation of [Ru(H2biqbpy)(dmso)(H2O)]Cl2 and of 
[Ru(H2biqbpy) (HAmet)(Amet)]PF6 with atom numbering used in NMR attribution. 
4.4.4 Crystal structure determination 
For X-ray diffraction all reflection intensities were measured at 110(2) K using a SuperNova 
diffractometer (equipped with Atlas detector) with Cu Kα radiation (λ= 1.54178 Å) under 
the program CrysAlisPro. The program CrysAlisPro was used to refine the cell dimensions. 
Data reduction was done using the program CrysAlisPro (Version 1.171.36.32 Agilent 
Technologies, 2013). The structure was solved with the program SHELXS-2014/7 and was 
refined on F2 with SHELXL-2014/7.67 Analytical numeric absorption corrections based on a 
multifaceted crystal model were applied using CrysAlisPro. The temperature of the data 
collection was controlled using the system Cryojet (manufactured by Oxford Instruments). 
The H atoms were placed at calculated positions using the instructions AFIX 43 or AFIX 137 
with isotropic displacement parameters having values 1.2 or 1.5 times Ueq of the attached C 
atoms. The H atoms attached to N2, N5 and O1S were found from difference Fourier maps, 
and their coordinates and isotropic temperature factors were refined freely. 
4.4.5 Details of crystal structure 
The X-ray crystal structure is ordered. [1]Cl: Fw = 722.64, orange plate, 0.23 × 0.15 × 0.04 
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8.25 (dd, J = 8.4, 7.7 Hz, 2H, H4), 8.05 (d, J = 8.0 Hz, 2H, qi-7), 7.96 (ddd, J = 8.1, 7.0, 1.0 Hz, 
2H, qi-6), 7.89 (ddd, J = 8.4, 7.0, 1.3 Hz, 2H, qi-5), 7.86 (dd, J = 8.4, 0.9 Hz, 2H, H5), 7.60 (d, J = 
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J = 7.8, 3.0 Hz, 2H, Hδ), 1.58 (s, 6H, Hζ), 1.76-1.22 (m, 4H, Hγ), 1.42 (t, J = 6.9 Hz, 4H, Hβ), 1.40 
(s, 6H, Hα). 13C NMR (100 MHz, CD3OD, 293 K, in ppm): δ = 173.8 (COOH), 173.0 (CON), 
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129.0 (C3/5), 124.1 (qi-4), 121.3 (qi-3), 120.6 (qi-7), 118.8 (qi-10), 117.8 (*), 51. 7 (Cδ), 33.2 (Cβ), 
31.2 (Cγ), 22.2 (Cα), 16.1 (Cζ). UV-vis: λmax (ε in M−1.cm−1) in H2O: 363 nm (8.9 × 103). High 
resolution ES MS m/z (calc): 923.1954 (923.1951, [M – PF6]+), 462.1008 (462.1012, [M – PF6 + 
H]2+). Elem. Anal. Calcd. for C42H45F6N8O6PRuS2 + 3×MeOH: C, 46.43; H, 4.94; N, 9.63 Found: C, 
46.20; H, 5.05; N, 9.30. 
 
Figure 4.6 Schematic representation of [Ru(H2biqbpy)(dmso)(H2O)]Cl2 and of 
[Ru(H2biqbpy) (HAmet)(Amet)]PF6 with atom numbering used in NMR attribution. 
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For X-ray diffraction all reflection intensities were measured at 110(2) K using a SuperNova 
diffractometer (equipped with Atlas detector) with Cu Kα radiation (λ= 1.54178 Å) under 
the program CrysAlisPro. The program CrysAlisPro was used to refine the cell dimensions. 
Data reduction was done using the program CrysAlisPro (Version 1.171.36.32 Agilent 
Technologies, 2013). The structure was solved with the program SHELXS-2014/7 and was 
refined on F2 with SHELXL-2014/7.67 Analytical numeric absorption corrections based on a 
multifaceted crystal model were applied using CrysAlisPro. The temperature of the data 
collection was controlled using the system Cryojet (manufactured by Oxford Instruments). 
The H atoms were placed at calculated positions using the instructions AFIX 43 or AFIX 137 
with isotropic displacement parameters having values 1.2 or 1.5 times Ueq of the attached C 
atoms. The H atoms attached to N2, N5 and O1S were found from difference Fourier maps, 
and their coordinates and isotropic temperature factors were refined freely. 
4.4.5 Details of crystal structure 
The X-ray crystal structure is ordered. [1]Cl: Fw = 722.64, orange plate, 0.23 × 0.15 × 0.04 
mm3, triclinic, P-1 (no. 2), a = 9.5443(3), b = 12.2675(3), c = 13.2983(4) Å, α = 68.395(3), β = 
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89.878(2), γ = 84.475(2)°, V = 1439.98(8) Å3, Z = 2, Dx = 1.667 g cm−3, µ = 7.139 mm−1, abs. corr. 
Range: 0.309−0.765. 22804 Reflections were measured up to a resolution of (sin θ/λ)max = 0.62 
Å−1. 5599 Reflections were unique (Rint = 0.0365), of which 5286 were observed [I > 2σ(I)]. 403 
Parameters were refined using 3 restraints. R1/wR2 [I > 2σ(I)]: 0.0283/0.0743. R1/wR2 [all 
refl.]: 0.0301/0.0760. S = 1.043. Residual electron density found between −0.60 and 0.98 e Å−3. 
4.4.6 Photochemistry monitored by UV-vis spectroscopy 
The UV-vis spectroscopy study of Figure 4.2 was performed using a UV-vis spectrometer 
equipped with temperature control set to 298 K and a magnetic stirrer. The measurements 
were performed in a quartz cuvette, containing 3 mL of solution (10−5 M). The stirred sample 
was degassed by argon, irradiated perpendicularly to the axis of the spectrometer with the 
beam of a green (λ = 530 nm, Δλ1/2 = 25 nm, 3.02 mW, 2.1 × 10−8 mol.s−1) or blue LED (450 nm, 
Δλ1/2 = 25 nm, 0.65 mW, 8.53 × 10−9 mol.s−1) fitted to the top of the cuvette, and an absorption 
spectrum was measured at regular time intervals and analyzed using Microsoft Excel. Mass 
spectrometry was performed at the beginning and at the end of the irradiation to confirm 
the nature of the reagent and products. 
4.4.7 Green light irradiation in the wells of a 96-well plate, followed by 1H NMR 
Green light irradiation experiments in D2O were performed in a 96-well plate with the LED 
source described in details by Hopkins et al.38 for the photocytotoxicity assay. Three adjacent 
wells per compound were loaded with 200 µL of a 38 µM solution of [1]Cl or [2]PF6, and 
irradiated for 60 min (520 ±20 nm, 75 J.cm−2) at 37 °C, while control wells were kept in the 
dark at the same temperature. For each condition the content of the 3 wells was mixed, and 
1H NMR spectroscopy was performed on the 4 samples (2 compounds, dark or light). As 
shown in Figure SIV.3, for [1]Cl clear release of free dmso is observed (new peak at 2.71 
ppm) and a complete reorganization of the aromatic peaks indicate that full conversion to 
[1b]2+ is achieved under these conditions. For [2]PF6 (Figure SIV.4) the photosubstitution is 
demonstrated by the formation of the characteristic peak of the proton on the chiral carbon 
of free HAmet at 4.5 ppm (square). The remaining peak at 3.7 ppm indicated by a circle 
represents the chiral proton of the coordinated HAmet. Photosubstitution under the 
irradiation conditions used for cell testing (1 h green light) does not lead to 
photosubstitution of the second Amet− ligand, i.e., the photoproduct is [2b]+ (Scheme 2), 
which is in line with our other photochemical experimental data under green light (only ~1 
eq. HAmet is photosubstituted). 
4.4.8 Green light activation under biological conditions 
The photochemical reactivity of [1]Cl (38 µM) and [2]PF6 (88 µM) was measured in 96-well 
plates by dissolving each compound in Opti-MEM complete and by irradiating with green 
light (520 nm, 75 J.cm−²) to mimic the conditions of the photocytotoxicity assay. Figure SIV.7 
and Figure SIV.8 show that the absorbance change at 315 nm for [1]Cl and 320 nm for [2]PF6 
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after 60 min irradiation with green light are levelling off for [1]Cl, i.e., that no further 
activation occurs after 1 h irradiation, and is significantly activated for [2]PF6. Since further 
activation for [2]PF6 would become experimentally impractical, 60 minutes was chosen as 
the green light irradiation time in the photocytotoxity assay. 
4.4.9 Cell culturing and EC50 (photo)cytotoxicity assay 
See Appendix I for extensive description of the assay.  
4.4.10 Singlet oxygen quantum yield measurements 
The quantum yield of singlet oxygen generation was determined in a custom-built setup 
(Figure SIV.10), in which both UV-vis absorption and UV-vis and NIR emission 
spectroscopy could be performed. All optical parts were connected with optical fibers from 
Avantes (Apeldoorn, The Netherlands), with a diameter of 200-600 µm. 2 mL of sample, 
consisting of the compound in CD3OD, was placed in a stirred 111-OS macro fluorescence 
cuvette from Hellma in a CUV-UV/VIS-TC temperature-controlled cuvette holder from 
Avantes. The sample was allowed to equilibrate for 5 minutes. Emission spectroscopy was 
performed with a 450 nm fiber-coupled laser (Laser system LRD-0450 from Laserglow, 
Toronto, Canada), which was set to 101 mW at the cuvette (4 mm beam diameter; 0.4 
W.cm−2) at a 90° angle with respect to the spectrometers. The excitation power was 
measured using a S310C thermal sensor connected to a PM100USB power meter (Thorlabs). 
Two spectrometers that were coupled to the cuvette holder with a bifurcated optical fiber, 
visualized the emission spectrum from 300 nm to 900 nm (Avantes 2048L StarLine 
spectrometer) and from 1000 nm to 1700 nm (Avantes NIR256-1.7TEC spectrometer). The 
infrared emission spectrum was acquired in ≤ 50 seconds, after which the laser was turned 
off directly. UV-vis absorption spectra before and after emission spectroscopy were 
measured using an Avalight-DHc halogen-deuterium lamp (Avantes) as light source 
(turned off during emission spectroscopy) and the Avantes UV-vis spectrometer (2048L 
StarLine spectrometer) as detector, both connected to the cuvette holder at a 180° angle. All 
spectra were recorded with Avasoft software from Avantes and further processed with 
Microsoft Office Excel 2010 and Origin Pro software.  
4.4.11 Annexin V-FITC/PI assay 
200 × 103 A549 cells were seeded in 35 mm petri dishes in Opti-MEM complete media (2 
mL). After 24 h, the media was replaced with drug loaded media (2 ml) using the following 
concentrations: Rose Bengal 10 µM, Staurosporine 0.3 µM, [1]Cl 1.5 µM, [2]PF6 10 µM. The 
non-light sensitive protein kinase inhibitor Staurosporine, and Rose Bengal, a green light 
absorbing PDT reagent, were used as positive controls.68, 69 As control also compound-free 
Opti-MEM complete was added to one dish. Cells were irradiated (520 nm, 75 J.cm−2) using 
the same irradiation setup as for the EC50 determination, leading to a set of light irradiated 
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4.4.11 Annexin V-FITC/PI assay 
200 × 103 A549 cells were seeded in 35 mm petri dishes in Opti-MEM complete media (2 
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with PBS, and suspended in Annexin V binding buffer (1 × 106 cells/mL). The cell suspension 
(100 µL) was stained with propidium iodide (5 µL, 10 µg/ml) and the Annexin V-FITC 
conjugate (3 µL, Bio connect) in the dark for 15 minutes. After addition of Annexin V 
binding buffer (200 µL) the cells were submitted to FACS measurement.70 Quantification of 
the induced cell death was performed with FlowJo, using a standard protocol.71 
4.4.12 Investigation of the mitochondrial membrane potential  
A549 cells were seeded at 10,000 cell/well in a eight chamber (ibidi, µ-Slide 8 well). After 24 
h, the media was replaced with drug loaded media (300 µL, OMEM complete) using the 
following concentrations: Rose Bengal 10 µM, Staurosporine 0.3 µM, cisplatin 5 µM, [1]Cl 
1.5 µM, [2]PF6 10 µM. The non-light sensitive protein kinase inhibitor Staurosporine, and the 
green light absorbing PDT agent Rose Bengal were used as positive controls. Further, 
compound-free Opti-MEM complete was added to one chamber as control. Cells were 
irradiated (520 nm, 75 J.cm−2) using the same irradiation setup as for the EC50 determination, 
leading to a set of light irradiated cells and a set of dark controls. Directly after irradiation 
the media was replaced by fluorescence-dyes loaded media. Tetramethylrhodamine ethyl 
(600 µM), a mitochondrial sensitive dye, and Draq5 (1 µM), a DNA-staining fluorophore 
were used. After 30 min of incubation the media was removed and replaced with TMRE 
loaded media (150 µM). Subsequently, the microscope slides were transferred to a Leica SPE 
confocal microscope.  
4.4.13 Cell fractionation 
Cell fractionation for intracellular distribution studies for complexes [1]Cl and [2]PF6 were 
conducted on A549 lung cancer cells. 3 × 106 cells were seeded at t = 0 h in Opti-MEM 
complete in 175 cm2 flasks. At t = 24 h cells were treated with complexes to give a final 
concentration corresponding to the EC50 values in the dark after 6 h in a total volume of 24 
mL. After 6 h of drug incubation at 37 °C, the medium was aspirated, the cells were washed 
with PBS-buffer, trypsinized, counted and pelleted by centrifugation 700 × g for 5 min. Then, 
the pellets were fractionated using to FractionPREP cell fractionation kit from BioVision 
according to the suppliers’s instructions. Samples were digested overnight in concentrated 
HNO3 (> 65%) and diluted with MilliQ water to obtain a final concentration of 5% HNO3. 
For ICP-MS measurements, the system was optimized with a ruthenium-platinum solution. 
The calibration range was from 0 to 25 µg/l, and the obtained detection limit for all isotopes 
ensued 0.01 µg/l. Silver and Indium were used for internal standard, to correct for the 
sample dependent matrix effects. No reference sample was available; therefore several 
samples were spiked with a standard concentration. The recoveries of the spiked 
accustomed concentrations were all within a 10% deviation. The data from three 




4.4.14 DNA (photo)binding studies 
The pUC19 plasmid used for this study (2686 bp) exists in three forms: supercoiled (SC), 
single-nicked open circular (OC) and linear dimer (LD). Of particular interest are the SC and 
OC forms. Although these two forms have the same number of BP, the SC form migrates 
faster through the agarose gel compared to the OC form due to the condensed SC form. 
However, when the positively charged metal complexes associates with the SC form, the 
shape may become larger and it will be less negatively charged, ultimately resulting in 
slower migration. Alternatively, if metal complexes coordinatively modify the OC form, it 
may induce coiling or a condensed structure causing an increase in migration and thus 
coalescence of the SC and OC form on increasing metal complex concentration. However, if 
there is no condensation of the OC plasmid structure, but the positively charged metal 
complexes associate with the OC form then the observed migration would be retarded. 
Finally, if the metal complexes generate enough singlet oxygen, then upon irradiation the SC 
form is converted via a nick in one of the DNA strands to the relaxed OC form. However, 
due to the low Φ1O2, DNA photocleaveage was unexpected. 
Agarose gel electrophoresis was used to assay the thermal and photoinduced binding of 
[1]Cl and [2]PF6 to pUC19 plasmid DNA. Two buffers were used for the experiments: 5X 
tris-boric acid buffer (TBA) and phosphate buffer (PB). The TBA buffer (45 mM 
tris(hydroxymethyl)amino methane and 45 mM boric acid, pH = 7.4) was used in the gel and 
running buffer. PB (100 mM NaH2PO4, pH = 7.0) was used for DNA-MC interactions. The 
agarose gels were 0.8% w/w agarose gel (0.24 g agarose, 24 g DI H2O, and 6 mL TBA) and 
were cast in the OWL B1A Easycast system. 
The molar concentration of the pUC19 plasmid DNA base pairs (BP) was determined using 
the extinction coefficient (ε260 nm = 13,200 M−1cm−1).58 All aliquots were prepared with a final 
volume of 20 μL and prior to loading 4 μL of 6X loading dye was added. The λ DNA-HindIII 
digest molecular weight (MW) marker was prepared by adding 2 µL (1 µg) of the DNA MW 
marker, 18 µL PB, and 4 µL 6X loading dye. The MW marker was heated for 3 min at 60 °C 
prior to loading. In each well, 12 µL (1 µg of pUC19 DNA or 0.5 µg of MW marker) of each 
sample was loaded. 
For each gel, the electrophoresis chamber was filled with 50 mL TBA and 210 mL deionized 
water. Each gel was run at a constant voltage of 105 V for 90 min. All gels were stained 
using 10 µL (10 mg/mL) ethidium bromide in 200 mL deionized water for 30 min with slight 
shaking and then destained in 200 mL deionized water for 20 min. Immediately following 
destaining, the gel was imaged using a BioRad ChemiDoc imaging system (ethidium 
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tris-boric acid buffer (TBA) and phosphate buffer (PB). The TBA buffer (45 mM 
tris(hydroxymethyl)amino methane and 45 mM boric acid, pH = 7.4) was used in the gel and 
running buffer. PB (100 mM NaH2PO4, pH = 7.0) was used for DNA-MC interactions. The 
agarose gels were 0.8% w/w agarose gel (0.24 g agarose, 24 g DI H2O, and 6 mL TBA) and 
were cast in the OWL B1A Easycast system. 
The molar concentration of the pUC19 plasmid DNA base pairs (BP) was determined using 
the extinction coefficient (ε260 nm = 13,200 M−1cm−1).58 All aliquots were prepared with a final 
volume of 20 μL and prior to loading 4 μL of 6X loading dye was added. The λ DNA-HindIII 
digest molecular weight (MW) marker was prepared by adding 2 µL (1 µg) of the DNA MW 
marker, 18 µL PB, and 4 µL 6X loading dye. The MW marker was heated for 3 min at 60 °C 
prior to loading. In each well, 12 µL (1 µg of pUC19 DNA or 0.5 µg of MW marker) of each 
sample was loaded. 
For each gel, the electrophoresis chamber was filled with 50 mL TBA and 210 mL deionized 
water. Each gel was run at a constant voltage of 105 V for 90 min. All gels were stained 
using 10 µL (10 mg/mL) ethidium bromide in 200 mL deionized water for 30 min with slight 
shaking and then destained in 200 mL deionized water for 20 min. Immediately following 
destaining, the gel was imaged using a BioRad ChemiDoc imaging system (ethidium 
bromide setting). Image Lab software was used to process the images. 
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µM), (5) Ru complex (50:1 BP:MC, [Ru]f = 40 µM), (6) Ru complex (25:1 BP:MC, [Ru]f = 80 
µM), (7) Ru complex (15:1 BP:MC, [Ru]f = 130 µM), (8) Ru complex (10:1 BP:MC, [Ru]f = 195 
µM), (9) Ru complex (5:1 BP:MC, [Ru]f = 390 µM), and (10) DNA only control. The gels were 
run, stained, and processed as described above (Figure SIV.16). 
The samples for photoinduced binding were prepared under ambient light and then 
irradiated in a well of a 96-well plate using the LED array system described for cell culturing 
(λirr = 520 nm). A 50:1 BP:MC ratio ([BP]f = 1.95 × 10−3 M and [Metal complex]f = 40 µM) was 
used for all metal complexes. For each gel, a dark DNA only control, irradiated DNA only 
control, dark 50:1 BP:MC control ([Metal complex]f = 40 µM), and irradiated 50:1 BP:MC 
sample were prepared. The DNA only controls consisted of 8 µL pUC19 plasmid DNA and 
72 µL PB. The dark 50:1 BP:MC controls were composed of 4 µL pUC19 plasmid DNA, 33 
µL PB, and 3 µL of the metal complex in PB (0.5 mM). A total volume of 200 µL (20 µL 
pUC19 plasmid DNA, 164 µL PB, and 16 µL metal complex in PB (0.5 mM) was prepared for 
the irradiated 50:1 BP:MC samples and 20 µL aliquots were removed for each time point. 
The time points were 5, 15, 30, 45, and 60 min correlating to light doses of 6.3, 18.8, 37.6, 56.4, 
and 75.2 Jcm−2, respectively. At the end of the experiment, 20 µL of the dark DNA control, 
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Loading dye was added to each of the aliquots and the gel was loaded. The lanes were as 
follows: (1) λ MW marker, (2) dark DNA control, (3) irradiated DNA control (75.2 Jcm−2), (4) 
dark 50:1 BP:MC control, (5) irradiated 50:1 BP:MC (5 min, 6.3 Jcm−2), (6) irradiated 50:1 
BP:MC (15 min, 18.8 Jcm−2), (7) irradiated 50:1 BP:MC (30 min, 37.6 Jcm−2), (8) irradiated 50:1 
BP:MC (45 min, 56.4 Jcm−2), and (9) irradiated 50:1 BP:MC (60 min, 75.2 Jcm−2. The gels were 
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The leading anticancer drug cisplatin is one of the landmarks in modern inorganic 
chemistry.1 In the body cisplatin enters cells, hydrolyzes, and forms irreversible 
adducts with DNA, ultimately triggering cell death via apoptosis.2-4 However, 
because of their lack of selectivity, severe side effects are commonly associated 
with the use of cisplatin, including nephrotoxicity, neurotoxicity, ototoxicity, and 
nausea.5 Furthermore, cancer cells can acquire increasing levels of cisplatin-
resistance.6 Alternatively, as transplatin is not active in vivo and less cytotoxic than 
cisplatin in vitro, anticancer metallodrugs with a trans configuration have not been 
seriously considered until recently.7-10 
Photodyamic therapy (PDT) is used in the clinics to locally activate anticancer 
prodrugs, improve their selectivity, and reduce their side effects. PDT relies on the 
local activation of ground state triplet oxygen to highly reactive excited state 
singlet oxygen, and thus critically depends on the presence of dioxygen. In 
anticancer therapy photoactivated chemotherapy (PACT) is an emerging 
alternative strategy based on compounds that are chemically modified upon light 
irradiation without depending on the presence of dioxygen.11-19 Platinum-based 
PACT compounds have been described and often rely on the photoreduction of an 
octahedral platinum(IV) center to a square-planar platinum(II) complex. 12, 20-23 
However, they usually lack strong absorption in the visible region; thus ruthenium 
polypyridyl compounds have emerged as a promising alternative due to their 
excellent visible light absorption properties.24, 25 Most of the ruthenium-based 
PACT agents known to date contain two bidentate ligands based on the 2,2’-
bipyridine scaffold.11, 26-29 After light activation a cis bisaqua complex is obtained 
that can bind to DNA in a fashion similar to cisplatin.30 
The compound [Ru(H2biqbpy)(dmso)Cl]Cl ([1]Cl) (H2biqbpy = 6,6’-bis[N-
(isoquinolyl)-1-amino]-2,2’-bipyridine) has recently been reported as a phototoxic 
PACT agent that induces apoptosis upon green light activation.31 This type of trans 
octahedral ruthenium complex contains a tetrapyridyl H2biqbpy ligand that 
coordinates in one plane of the octahedron, allowing coordination of two axial 
monodentate ligands that can be photochemically or thermally substituted. In an 
initial study we reported that a significant amount of the ruthenium complex ends 
up in the nucleus of the cell, which justified DNA-binding studies using gel 
electrophoresis and circular pUC19 plasmid DNA. These studies clearly showed 
that interaction with DNA was switched on by light irradiation. However, the 
nature of the metal-DNA adducts was unclear. In this work three new derivatives 
of [1]Cl are reported: [Ru(H2biqbpy)(Hmte)2](PF6)2 ([3](PF6)2, Hmte = 2-
methylthioethanol), and their two H2bapbpy analogues 
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[Ru(H2bapbpy)(dmso)Cl]Cl ([2]Cl) and [Ru(H2bapbpy)(Hmte)2](PF6)2 ([4](PF6)2 
(H2bapbpy = 6,6’-bis[N-(pyridyl)-1-amino]-2,2’-bipyridine), and the study of their 
interactions, in the dark and after light activation, with the 
oligodeoxyribonucleotide (ODN) s(5’CTACGGTTTCAC3’) (ODN1). 
Oligonucleotides have been widely used as models for DNA, to study its 
interaction with potential anticancer compounds.32-36 A combined approach of gel 
electrophoresis and high resolution electrospray injection mass spectrometry is 
introduced to study the binding of a light-activated drug to oligonucleotides. 
 Results  5.2
5.2.1 Synthesis  
[2]Cl was synthesized by reacting H2bapbpy with 1.1 equivalents of [Ru(dmso)4Cl2] 
in ethanol overnight at 80 °C (Scheme 5.1) following the synthetic method of 
[1]Cl.31 Reacting [1]Cl or [2]Cl with an excess of Hmte overnight at 80 °C in water, 
followed by anion exchange using KPF6, and size exclusion chromatography, 
afforded [3](PF6)2 and [4](PF6)2, respectively (Scheme 5.1). In this reaction the 
chloride ligand instantly dissociates, but an excess of thioether and heat are 
required to also substitute thermally the dmso ligand. In [3](PF6)2 and [4](PF6)2 an 
upfield shift of the 1H NMR signals corresponding to the methyl group of Hmte is 
observed (1.53 and 1.56 ppm in acetone-d6), compared to free Hmte (2.11 ppm). 
This upfield shift is characteristic for the shielding cone of polypyridyl ligands 
coordinated to the metal center, and indicates that Hmte is coordinated to 
ruthenium.31, 37  
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5.2.2 Crystal structures   
Slow vapor diffusion of ethyl acetate into a methanol solution containing [2]Cl, and 
vapor diffusion of diethyl ether into an acetone solution of [3](PF6)2 or [4](PF6)2 
yielded ruby-colored crystals suitable for X-ray structure determination. In the 
structure of [2]Cl, [3](PF6)2, and [4](PF6)2 the dmso or Hmte ligands were found to 
bind via their sulfur atom to ruthenium, as expected from the softness of the sulfur 
and ruthenium(II) atoms (Figure 5.1). In the structure of [2]Cl, two independent 
molecules with slightly different geometries were found in the asymmetric unit. 
Selected bond distances, angles, torsion angles, and dihedral angles, are 
summarized in Table 5.1 and Table 5.2. The bond distances Ru-N1 and Ru-N6 fall 
between 2.09-2.11 Å, compared to 2.02-2.04 Å for Ru-N3 and Ru-N4. For [2]Cl like 
for [1]Cl (Van Rixel et al.31) the Ru-S1 bond is 2.2266(13) Å, whereas the Ru-S1 
bonds for [3](PF6)2 and [4](PF6)2 are 2.3661(7) and 2.3822(8) Å, respectively. This 
difference in bond length can be explained by the more electron-accepting 
character of the sulfoxide ligand, and the better electron donating character of the 
chloride ligand trans to dmso, compared to Hmte.  
 
Figure 5.1 Displacement ellipsoid plots (50% probability level) of the cationic part, as 
observed in [2]Cl (A), [3](PF6)2 (B), and [4](PF6)2 (C). Counter anions and H atoms have 
been omitted for clarity. 
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Table 5.1 Selected bond lengths (Å) for [1]Cl, [2]Cl, [3](PF6)2, and [4](PF6)2. See Figure 5.1 
for atom labeling. 
Bond [1]Cla [2]Cl [3](PF6)2 [4](PF6)2 
Ru-N1 2.1018(19) 2.102(4) 2.109(3) 2.101(3) 
Ru-N3 2.020(2) 2.027(4) 2.036(2) 2.029(3) 
Ru-N4 2.0220(19) 2.031(4) 2.025(3) 2.029(3) 
Ru-N6 2.087(2) 2.098(4) 2.098(2) 2.101(3) 
Ru-Cl 2.4363(5) 2.4513(13) - - 
Ru-S1 2.2262(6) 2.2266(13) 2.3661(7) 2.3822(8) 
Ru-S2 - - 2.3847(7) 2.3847(7) 
a Values taken from Van Rixel et al.31  
Table 5.2 Selected angles (°) and torsion angles (°) for [1]Cl, [2]Cl, [3](PF6)2, and [4](PF6)2. 
See Figure 5.1 for atom labeling. 
Angle [1]Cla [2]Cl [3](PF6)2 [4](PF6)2 
N1-Ru-N3 91.77(8) 89.89(14) 90.13(9) 91.56(11) 
N1-Ru-N4 170.80(8) 165.10(15) 166.35(10) 169.80(10) 
N1-Ru-N6 97.90(8) 97.98(15) 99.08(9) 96.68(14) 
N3-Ru-N4 80.78(8) 80.63(14) 80.77(10) 80.94(15) 
N3-Ru-N6 164.83(8) 170.92(14) 168.14(9) 169.80(10) 
N4-Ru-N6 90.51(8) 92.51(14) 91.38(10) 91.56(11) 
N1-N3-N4-N6 12.78(9) 12.5(2) 13.7(1) 9.9(1) 
α-βb 45.38 42.89 44.50 30.43 
a Values taken from Van Rixel et al.31  
b Dihedral angle α-β is formed by the planes between the terminal pyridyls (N1-C1-C2-C3-
C4-C5 and N6-C16-C17-C18-C19-C20) or quinolyls (N1-C1-C2-C3-C4-C5-C6-C7-C8-C9 and 
N6-C20-C21-C22-C23-C24-C25-C26-C27-C28).  
The torsion angle N1-N3-N4-N6 in all four complexes varied between 9.88-13.72°. 
The dihedral angle between the average planes of the terminal pyridyl or quinolyl 
moiety of the ligand labelled as α-β (Table 5.2) is also a measure for the flatness of 
the tetrapyridyl ligand. For [1]Cl, [2]Cl, [3](PF6)2, and [4](PF6)2 these angles are 
45.38, 42.89, 44.50, and 30.40°, respectively. These values for [4](PF6)2 strongly 
deviate due to crystal lattice effects (polar π and hydrogen bonding interactions). 
Nonetheless, the data demonstrates that the ruthenium complexes are distorted, 
due to the steric hindrance between the two hydrogen atoms bound to the C1 and 
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helical fashion around the metal center.38, 39 Neither the nature of the apical ligands 
(Hmte vs. dmso) nor the replacement of the terminal pyridyl moiety (in H2bapbpy) 
by an isoquinolyl moiety (in H2biqbpy) has a strong effect on the bond angles and 
coordination bond distances of the tetrapyridyl ligand.  
5.2.3 Photoreactivity of [2]Cl, [3](PF6)2, and [4](PF6)2 
The photoreactivity of [2]Cl, [3](PF6)2, and [4](PF6)2 was tested under blue light 
irradiation (λirr = 445 nm) in aqueous solution and monitored by mass spectrometry 
and UV-vis spectroscopy. For [2]Cl, initially dissolved in CD3OD, mass 
spectrometry before irradiation and for dark control samples (Figure 5.2A) showed 
peaks at m/z = 280.3 corresponding to [Ru(H2bapbpy)(dmso) + CD3OD]2+ (calc. m/z 
= 280.1), indicating that the chloride ligand dissociates quickly and spontaneously 
upon dissolution in water, but that the dmso l igand remains coordinated. After 
light irradiation, however, a new set of peaks is observed at m/z = 249.7 
corresponding to [Ru(H2bapbpy)(H2O) + CD3OD]2+ (calc. m/z = 250.0). This 
indicates that the dmso ligand in [2]Cl (similar to [1]Cl) is quantitatively 
photosubstituted by a solvent molecule upon irradiation. When the photoreaction 
was monitored by UV-vis spectroscopy, irradiation of [2]Cl was characterized by 
isosbestic points at 281 and 302 nm, and resulted in a final spectrum characterized 
by absorption maxima at 306, 335, 404, and 495 nm. The quantum yield for the 
photosubstitution of dmso by water was found to be 0.004, and comparable to that 
for [1]Cl.31  
For [3](PF6)2 and [4](PF6)2 blue light irradiation in aqueous solution analyzed 
afterwards by mass spectrometry showed peaks at m/z = 317.2 and m/z = 266.9 
corresponding to [3 – Hmte]2+ and [4 – Hmte]2+, respectively (calc. m/z = 317.1 and 
267.0, respectively). Dark control samples also contained these peaks, but in 
addition peaks at m/z = 363.0 and m/z = 313.1 corresponding to [3]2+ and [4]2+ (calc. 
m/z = 363.1 and 313.1) were detected. This data indicates that blue light irradiation 
of complexes [3](PF6)2 and [4](PF6)2 results in the photosubstitution of one Hmte 
ligand for a solvent molecule. When the irradiation reaction of [3](PF6)2 was 
monitored by UV-vis spectroscopy the spectrum evolved over time showed an 
overall increase in intensity and a slight red-shift of the metal-to-ligand-charge 
transfer (MLCT) from 451 nm to 465 nm (Figure 5.2B). Upon irradiation of a 
solution of [4](PF6)2 a general increase in the visible domain through an isosbestic 
point at 398 nm was observed (Figure SV.2). Overall, the three new complexes 
show and confirm that coordination of H2bapbpy or H2biqbpy to ruthenium 




Figure 5.2 Evolution of the electronic absorption spectra of a solution of [2]Cl (A) in 
demineralized water (5% v/v CD3OD) and of [3](PF6)2 (B) in demineralized water upon 
(5% v/v acetone-d6) upon blue light irradiation (λirr = 445 nm, Δλ1/2 = 22 nm, photon flux Φ 
= 1.81 × 10−7 mol.s−1, tirr = 15 min). Time: 0 min (red curve) to 15 min (black curve). 
Conditions [Ru]0 = 0.05 mM, irradiated volume was 3.0 mL at 298 K. Inset: Plot of the 
absorbance at 350 nm (A) or 480 nm (B) as a function of irradiation time.  
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ODNs have proven to be valuable model targets for anticancer compounds 
because they can be specifically designed, and easily studied by for instance mass 
spectrometry.40, 41 As [1]Cl is phototoxic, cytotoxic, and enters the nucleus, we 
aimed to study our small library of tetrapyridyl ruthenium complexes in their 
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5.2.4 Gel electrophoresis with ODN1 
ODNs have proven to be valuable model targets for anticancer compounds 
because they can be specifically designed, and easily studied by for instance mass 
spectrometry.40, 41 As [1]Cl is phototoxic, cytotoxic, and enters the nucleus, we 
aimed to study our small library of tetrapyridyl ruthenium complexes in their 
reactions with a standard ODN. Thus, ODN1 (s(5’CTACGGTTTCAC3’)) was reacted 
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with [1]Cl, [2]Cl, [3](PF6)2, and [4](PF6)2 to start building a structure-activity 
relationship. Like in previous studies ODN1 contains a GG-box, an important 
binding motif for cisplatin.40  
The outcomes of the dark and photochemical reactions were analyzed using gel 
electrophoresis to study the influence of light on the interaction of the ruthenium 
complexes with ODN1 and were performed by Geri F. Moolenaar. The binding of a 
ruthenium complex to ODN1 significantly adds to the molecular weight of the 
oligonucleotide, and can add up to two positive charges per ruthenium complex to 
an otherwise negatively charged oligonucleotide. Both factors contribute to 
retardation of migration of ODN1 on the gel. In these experiments three 
equivalents of [1]Cl, [2]Cl, [3](PF6)2, or [4](PF6)2 were added to ODN1, light-
activated, and incubated for 6 hours with ODN1 ([ODN] = 0.25 mM, [Ru] = 0.75 
mM]). The mixtures were then pipetted on to a gel, the gel was run, and the 
adducts were visualized using toluidine blue (Figure 5.3).42 Without light 
activation all complexes (Figure 5.3, lane 1, 3, 5, and 7) showed band migration 
identical to the untreated ODN1 (lane 9), indicating that under such conditions no 
ruthenium-ODN1 adducts formed, irrespective of the structure of the complex. 
When the compounds were light-activated in the presence of ODN1, all free ODN1 
bands decreased in intensity, and two extra bands appeared above the original 
ODN1 band (Figure 5.3, lane 2, 4, 6, and 8). This strongly indicates that each light-
activated ruthenium complex forms two distinct adducts with ODN1.  
Another gel electrophoresis measurement was performed including 19-, 23-, 24-, 
and 31-mer oligonucleotides, together with an irradiated but untreated ODN1 (12-
mer) control sample (Figure SV.7). The first ruthenium-ODN1 adduct band ended 
up between the bands of the 24-mer and 31-mer control ODNs. The second 
ruthenium-ODN1 adduct band ended up between the 19-mer control and the 
untreated ODN1 control. As coordination of ruthenium complexes to ODN1 
would add the molecular weight equivalent of 1-2 base pairs, the band of such an 
adduct would be at the level of a 13- or 14-mer in the case of a monoruthenium 
adduct, and at the level of a 15- or 16-mer for a bisruthenium adduct. As migration 
of the adduct bands did not correspond to these levels, the (di)cationic charge of 
the ruthenium must have an extra lagging effect of the adduct band in gel 
migration. Lastly, the irradiated ODN1 control band runs at the same level as the 
dark ODN1 control band, indicating that irradiation does not have any effect on 
the ODN1 itself. Overall, whereas no reaction occurred in the dark, light activation 
of all four ruthenium complexes induced strong interactions with ODN1. 




Figure 5.3 Polyacrylamide gel of mixtures of ODN1 (5‘CTACGGTTTCAC3’) and [2]Cl, 
[1]Cl, [4](PF6)2, or [3](PF6)2. Lane 1, 3, 5, and 7 correspond to dark reaction between ODN1 
and [2]Cl, [1]Cl, [4](PF6)2, or [3](PF6)2, respectively. Lane 2, 4, 6, and 8 have the same 
composition but were irradiated. Lane 9 and 10 correspond to ODN1 and 19-24 mer 
controls, respectively (in the dark). Conditions: T = 25 °C, [Ru] = 0.75 mM, [ODN] = 0.25 
mM, Staining agent: Toluidine blue. Conditions: irradiation λirr = 445 nm, Δλ1/2 = 22 nm, 
photon flux Φ = 2.2 × 10−7 mol.s−1, tirr = 10 min, tinc = 6 h. 
5.2.5 High resolution mass spectrometry  
In order to identify the ruthenium-ODN1 adducts similar experiments were run 
but samples were investigated using high resolution mass spectrometry (HRMS). 
For dark reaction ODN1 was incubated in LC-MS grade water at 25 °C for 6 hours 
– while shielded from light – in the presence of three equivalents of one of the four 
ruthenium complexes. Then, mass spectra in negative mode were recorded, and 
deconvoluted for clarity.43-45 Incubation of ODN1 with [1]Cl or [2]Cl without light 
activation resulted in major signals at m = 3595.7 corresponding to free ODN (calc. 
m = 3594.6). Minor signals at m = 4213.6 corresponding to [ODN1 + 
Ru(biqbpy)(dmso)] (calc. m = 4212.7, see Figure 5.4A and Figure SV.10A), or at m = 
4113.1 corresponding to [ODN1 + Ru(bapbpy)(dmso)] (calc. m = 4112.7, see Figure 
SV.11A), respectively, indicated that limited adduct formation in the dark was 
possible, but that the dmso stayed bound to ruthenium. When comparing [1]Cl 
and [2]Cl the ratio between the adduct signals and that of the free ODN1 was 
found to be lower for [1]Cl than for [2]Cl, indicating that under such conditions 
[2]Cl was more susceptible for adduct formation with ODN1 than [1]Cl. When 
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SV.11A), respectively, indicated that limited adduct formation in the dark was 
possible, but that the dmso stayed bound to ruthenium. When comparing [1]Cl 
and [2]Cl the ratio between the adduct signals and that of the free ODN1 was 
found to be lower for [1]Cl than for [2]Cl, indicating that under such conditions 
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3595.7 corresponding to the free ODN1 (calc. m = 3594.6, Figure SV.12A and Figure 
SV.13A, respectively). Whereas incubation with [3](PF6)2 resulted in virtually no 
ruthenium adduct signals, with [4](PF6)2 a minor signal at m = 4034.7 
corresponding to ruthenium adducts [ODN1 + Ru(bapbpy)] (calc. m = 4034.7) was 
found. It appears that Hmte ligands do not stay coordinated to the ruthenium 
center in such adducts; but these signals were of lower intensity compared to that 
of the ruthenium adducts found with [2]Cl (Figure SV.11A). Overall, for both the 
H2bapbpy and H2biqbpy complexes coordination of two trans thioethers strongly 
inhibits the formation of ODN1-ruthenium adducts, compared to the coordination 
of dmso and a trans chloride ligand that is hydrolyzed thermally in water.  
Adduct-formation was also measured by HRMS after mixing ODN1 and 
ruthenium complex, after visible light activation (λirr = 445 nm) and 6 hours 
incubation. With [1]Cl the signals for free ODN1 were still dominant but a new set 
of peaks was present at m = 4136.3 that corresponded to the adduct [ODN1 + 
Ru(biqbpy)] (calc. m = 4136.7, see Figure 5.4B and Figure SV.10B). This peak is 
different from the peak observed in the dark, since the dmso ligand appeared to be 
removed. With [2]Cl the strongest signals were observed at m = 4035.6 
corresponding to a similar adduct [ODN1 + Ru(bapbpy)] (calc. m = 4034.7), while a 
minor set of peaks at m = 4475.0 corresponds to the dinuclear adduct [ODN1 + 
2(Ru(bapbpy))] (calc. m = 4474.7, Figure 5.4C and Figure SV.11B). Noteworthy, the 
signals at m = 3617.0 corresponding to [ODN1 + Na] (calc. m = 3617.6) remained, 
but it was significantly less intense compared to the dark control. These results 
show that the ligand dmso in these tetrapyridyl ruthenium complexes has an 
inhibiting effect on adduct-formation with ODN1.  
With [3](PF6)2 upon light irradiation new signals were observed at m = 4135.3 
corresponding to the adduct [ODN1 + Ru(biqbpy)] (calc. m = 4134.7, see Figure 
SV.12). However, the signals at m = 3617.4 correspond to [ODN1 + Na] are still 
dominant. This behavior was similar to that found for [1]Cl in presence of light, 
which confirmed the observations using gel electrophoresis that [1]Cl and [3](PF6)2 
are, after light irradiation, similar. With [4](PF6)2 like with [2]Cl dominant signals 
were observed, after light activation, at m = 4034.8 corresponding to the adduct 
[ODN1 + Ru(bapbpy)] (calc. m = 4034.7, see Figure SV.13). Here as well, both 
thioether ligands had been photosubstituted and traces of a dinuclear-ODN1 
adduct were observed. This result confirmed that [4](PF6)2 and [2]Cl interact in a 
similar fashion with ODN1 after light irradiation, and that the H2bapbpy-based 
complexes interact better with ODN1 than the H2biqbpy-based analogues. 
Overall, from these HRMS experiments three well-defined trends can be 
delineated. First, light activation of the complex strongly enhances adduct 
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formation between tetrapyridyl ruthenium complexes and ODN1, which depends 
on whether none, one, or two axial protecting ligands are coordinated. Second, the 
nature of the tetrapyridyl ligand, H2bapbpy vs. H2biqbpy, influences significantly 
the degree of adduct formation after light activation: H2bapbpy complexes are 
more prone to interact with ODN1 than H2biqbpy complexes. Third, light 
activation of [2]Cl and [4](PF6)2 leads to the formation of adducts with ODN1 that 
can have either one or two bound ruthenium complexes.  
 
Figure 5.4 Representative scheme of the deconvoluted mass spectrometry data of ODN1 
incubated with [1]Cl (A), incubated with light-activated [1]Cl (B), and incubated with 
light-activated [2]Cl. Full data set and interpretation can be found in the Supplementary 
Information. Conditions: [ODN] = 0.03 mM, [Ru] = 0.09 mM, tirr = 10 min, tinc = 6 h, T = 298 
K, λirr = 445 nm (Δλ1/2 = 22 nm), photon flux Φ = 2.2 × 10-7 mol.s-1 
 Discussion & Conclusion 5.3
In this work it has been demonstrated that light can be used to control the 
interaction between ruthenium complexes with a H2bapbpy or H2biqbpy ligand 
and an oligonucleotide. The absence of adduct formation in the dark demonstrates 
that a single dmso ligand, or two trans thioether ligands, strongly inhibit the 
interaction of the metal complex with nucleotides. Meanwhile, by combining gel 
electrophoresis and mass spectrometry results, we observed that the adducts 
formed upon light activation consist of a single strand containing one or two 
complexes. No traces of adducts containing one ruthenium center and two 
oligonucleotides were found, indicating that no inter-strand crosslinking occurs.  
Trans ruthenium complexes cannot mimic the cisplatin binding mode, which 
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Trans ruthenium complexes cannot mimic the cisplatin binding mode, which 
implies a different type of DNA binding. While the HRMS data in our study 
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suggests that after light activation the complexes have two coordination sites 
available for DNA interaction, it is hard to imagine both being employed by 
coordination to adjacent DNA bases like cisplatin. Transplatin, on the other hand, 
is known to form crosslinks between different strands, but we found no indication 
that the trans ruthenium complexes [1]+-[4]2+ form adducts with more than one 
strand. Another interaction responsible for DNA binding of metallodrugs is their 
ability to form hydrogen bonds with especially the phosphate backbone of DNA.2, 
46, 47 All four compounds are similar in having non-coordinated amines that may 
engage into H-bonding. Thus, the differences observed between the H2biqbpy and 
H2bapbpy complexes can probably not be explained by differences in H-bonding; it 
is unclear whether such H-bonding is taking place for this series of complexes. On 
the other hand, the trans tetrapyridyl complexes, and in particular the ones based 
on H2biqbpy, have a strong lipophilic character due to their tetrapyridyl ligands, 
that are often involved in stacking or intercalation interactions.48-50 Despite the lack 
of stacking surface and flatness, the complexes do interact differently with 
oligonucleotides when either a H2bapbpy or H2biqbpy tetrapyridyl ligand is 
employed under the same conditions. As other compound parameters, such as 
bond distances and bond angles, are similar for all investigated ruthenium 
complexes, it follows that non-coordinating interactions may play an important 
role in DNA interaction and could explain the essential differences observed 
between H2bapbpy and H2biqbpy complexes.51 Further studies are currently 
ongoing investigate this question.  
 Experimental 5.4
5.4.1 Synthesis of [Ru(H2bapbpy)(dmso)Cl]Cl ([2]Cl)  
In a 2-necked round-bottom flask [Ru(dmso)4Cl2] (200 mg, 0.413 mmol) and H2bapbpy (144 
mg, 0.413 mmol) were added in degassed ethanol (30 mL). The solution was stirred 
overnight at 80 °C, upon which a dark red suspension was formed. After filtration and 
drying a red powder was obtained. Yield: 121 mg (50%). 1H NMR (300 MHz, D2O, 293 K, in 
ppm): δ = 8.54 (dd, 2H J = 6.1, 1.1 Hz, Hpy-6), 8.24 (dd, 2H, J = 7.8, 0.9 Hz, H5), 8.15 (t, 2H, J = 8.1 
Hz, H4), 8.05 (m, 2H, Hpy-5), 7.51 (dd, 2H, J = 8.3, 0.8 Hz, H3), 7.45 (dd, 2H, J = 8.4, 0.8 Hz, Hpy-
3), 7.28 – 7.18 (m, 2H, Hpy-4), 2.43 (s, 6H, Hα). 13C NMR (100 MHz, 300 K, D2O, in ppm): δ = 
152.69 (Cpy-3), 140.16 (Cpy-5), 139.85 (C4), 119.46 (Cpy-4), 118.33 (C5), 116.17 (Cpy-6), 115.79 (C3), 
44.44 (Cα). High resolution ES MS m/z (calc): 555.0304 (555.0308 for [M – Cl – H]+), 519.053 
(519.054 for [M – 2Cl – H]+). Elem. anal. calcd. for C22H22Cl2N6ORuS: C, 44.75; H, 3.76; N, 14.23. 
Found: C, 44.71; H, 3.76; N, 14.17.  
Single crystals of [2]Cl were obtained by crystallization via liquid-vapor diffusion using 
MeOH as solvent and EtOAc as counter-solvent. In short, 1.0 mg of [2]Cl was dissolved in 1 
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mL of MeOH and placed in a small GC vial. This vial was placed in a larger vial containing 
2.8 mL EtOAc. The large vial was closed and vapor diffusion occurred within a few days to 
afford X-ray quality crystals. 
5.4.2 Synthesis of [Ru(H2biqbpy)(Hmte)2](PF6)2 ([3](PF6)2) 
In a 2-necked round-bottom flask [1]Cl (19 mg, 0.028 mmol) and Hmte (0.24 mL, 2.7 mmol) 
were added in degassed demineralized water (10 mL). The reaction mixture was stirred 
overnight at 80 °C, resulting in a red solution. After full conversion was checked by TLC 
(eluent: acetone/water/aqueous KPF6 (sat.), 5:2:2), the reaction was cooled down to room 
temperature and KPF6 (0.4 g, 2.2 mmol) was added. Then, the aqueous layer was extracted 
with dichloromethane (3 × 15 mL), and the organic layer was evaporated in vacuo. The 
compound was purified using size exclusion chromatography (Sephadex LH-20, acetone). 
After evaporation the product was reprecipitated from acetone (0.5 mL) by the addition of 
diethyl ether (10 mL). Yield: 19 mg (68%). 1H NMR (400 MHz, acetone-d6, 293 K): δ = 10.42 (s, 
2H, NH), 8.87 (d, 2H, J = 8.8 Hz, Hqi-4), 8.68 (d, 2H, J = 7.6 Hz, Hqi-7), 8.64 (d, 2H, J = 6.8 Hz, 
Hqi-9), 8,40 (t, 2H, J = 8.4 Hz, Hqi-6), 8.16 (d, 4H, J = 7.6 Hz, H3 and H5), 8.02 (t, 2H, J = 7. 2 Hz, 
Hqi-5), 7.94 (t, 2H, J = 8.4 Hz, Hqi-10), 3.39-3.32 (m, 4H, Hβ), 2.10-2.00 (m, 4H, Hγ), 2.10-2.00 (m, 
4H, Hγ), 1.53 (s, 6H, Hα). 13C NMR (125 MHz, acetone-d6, 293 K, in ppm): δ = 156.70 (C2), 152.45 
(C6), 151.62 (Cqi-2), 146.11 (Cqi-9), 139.01 (Cqi-6), 137.23 (Cqi-8), 133.42 (C*), 130.09 (Cqi-5), 128.77 
(C5), 123.75 (C4), 120.90 (Cqi-3), 120.84 (Cqi-7), 120.35 (Cqi-10), 118.26 (C3), 59.28 (Cβ), 38.78 (Cγ), 
16.85 (Cα). High resolution ES MS m/z (calc): 725.1301 (725.1309, [M – 2PF6 – H]+). Elem. anal. 
calcd. for C34H36F12N6O2P2RuS2 + ½ Acetone: C, 40.81; H, 3.76; N, 8.04. Found: C, 40.53; H, 4.11; 
N, 8.37. 
Single crystals of [3](PF6)2 were obtained by crystallization via liquid-vapor diffusion using 
acetone as solvent and diethylether as counter-solvent. In short, 1.0 mg of [3](PF6)2 was 
dissolved in 0.4 mL of acetone and placed in a small GC vial. This vial was placed in a larger 
vial containing 2.8 mL diethyl ether. The large vial was closed and vapor diffusion occurred 
within a few days to afford X-ray quality crystals. 
5.4.3 Synthesis of [Ru(H2bapbpy)(Hmte)2](PF6)2 ([4](PF6)2) 
In a 2-necked round-bottom flask [2]Cl (50 mg, 0.085 mmol) and Hmte (1.47 mL, 16 mmol) 
were added in degassed demineralized water (15 mL). The reaction mixture was stirred 
overnight at 80 °C, resulting in a red solution. After full conversion was ensured by TLC 
(eluent: acetone/water/aqueous KPF6 (sat.), 5:2:2), the reaction mixture was cooled down to 
room temperature and KPF6 (0.5 g, 2.7 mmol) was added. Then, the aqueous layer was 
extracted with ethyl acetate (3 × 15 mL), and the organic layer was evaporated in vacuo. The 
compound was purified using size exclusion chromatography (Sephadex LH-20, acetone). 
After evaporation the product was precipitated from acetone (0.5 mL) by the addition of 




suggests that after light activation the complexes have two coordination sites 
available for DNA interaction, it is hard to imagine both being employed by 
coordination to adjacent DNA bases like cisplatin. Transplatin, on the other hand, 
is known to form crosslinks between different strands, but we found no indication 
that the trans ruthenium complexes [1]+-[4]2+ form adducts with more than one 
strand. Another interaction responsible for DNA binding of metallodrugs is their 
ability to form hydrogen bonds with especially the phosphate backbone of DNA.2, 
46, 47 All four compounds are similar in having non-coordinated amines that may 
engage into H-bonding. Thus, the differences observed between the H2biqbpy and 
H2bapbpy complexes can probably not be explained by differences in H-bonding; it 
is unclear whether such H-bonding is taking place for this series of complexes. On 
the other hand, the trans tetrapyridyl complexes, and in particular the ones based 
on H2biqbpy, have a strong lipophilic character due to their tetrapyridyl ligands, 
that are often involved in stacking or intercalation interactions.48-50 Despite the lack 
of stacking surface and flatness, the complexes do interact differently with 
oligonucleotides when either a H2bapbpy or H2biqbpy tetrapyridyl ligand is 
employed under the same conditions. As other compound parameters, such as 
bond distances and bond angles, are similar for all investigated ruthenium 
complexes, it follows that non-coordinating interactions may play an important 
role in DNA interaction and could explain the essential differences observed 
between H2bapbpy and H2biqbpy complexes.51 Further studies are currently 
ongoing investigate this question.  
 Experimental 5.4
5.4.1 Synthesis of [Ru(H2bapbpy)(dmso)Cl]Cl ([2]Cl)  
In a 2-necked round-bottom flask [Ru(dmso)4Cl2] (200 mg, 0.413 mmol) and H2bapbpy (144 
mg, 0.413 mmol) were added in degassed ethanol (30 mL). The solution was stirred 
overnight at 80 °C, upon which a dark red suspension was formed. After filtration and 
drying a red powder was obtained. Yield: 121 mg (50%). 1H NMR (300 MHz, D2O, 293 K, in 
ppm): δ = 8.54 (dd, 2H J = 6.1, 1.1 Hz, Hpy-6), 8.24 (dd, 2H, J = 7.8, 0.9 Hz, H5), 8.15 (t, 2H, J = 8.1 
Hz, H4), 8.05 (m, 2H, Hpy-5), 7.51 (dd, 2H, J = 8.3, 0.8 Hz, H3), 7.45 (dd, 2H, J = 8.4, 0.8 Hz, Hpy-
3), 7.28 – 7.18 (m, 2H, Hpy-4), 2.43 (s, 6H, Hα). 13C NMR (100 MHz, 300 K, D2O, in ppm): δ = 
152.69 (Cpy-3), 140.16 (Cpy-5), 139.85 (C4), 119.46 (Cpy-4), 118.33 (C5), 116.17 (Cpy-6), 115.79 (C3), 
44.44 (Cα). High resolution ES MS m/z (calc): 555.0304 (555.0308 for [M – Cl – H]+), 519.053 
(519.054 for [M – 2Cl – H]+). Elem. anal. calcd. for C22H22Cl2N6ORuS: C, 44.75; H, 3.76; N, 14.23. 
Found: C, 44.71; H, 3.76; N, 14.17.  
Single crystals of [2]Cl were obtained by crystallization via liquid-vapor diffusion using 
MeOH as solvent and EtOAc as counter-solvent. In short, 1.0 mg of [2]Cl was dissolved in 1 
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mL of MeOH and placed in a small GC vial. This vial was placed in a larger vial containing 
2.8 mL EtOAc. The large vial was closed and vapor diffusion occurred within a few days to 
afford X-ray quality crystals. 
5.4.2 Synthesis of [Ru(H2biqbpy)(Hmte)2](PF6)2 ([3](PF6)2) 
In a 2-necked round-bottom flask [1]Cl (19 mg, 0.028 mmol) and Hmte (0.24 mL, 2.7 mmol) 
were added in degassed demineralized water (10 mL). The reaction mixture was stirred 
overnight at 80 °C, resulting in a red solution. After full conversion was checked by TLC 
(eluent: acetone/water/aqueous KPF6 (sat.), 5:2:2), the reaction was cooled down to room 
temperature and KPF6 (0.4 g, 2.2 mmol) was added. Then, the aqueous layer was extracted 
with dichloromethane (3 × 15 mL), and the organic layer was evaporated in vacuo. The 
compound was purified using size exclusion chromatography (Sephadex LH-20, acetone). 
After evaporation the product was reprecipitated from acetone (0.5 mL) by the addition of 
diethyl ether (10 mL). Yield: 19 mg (68%). 1H NMR (400 MHz, acetone-d6, 293 K): δ = 10.42 (s, 
2H, NH), 8.87 (d, 2H, J = 8.8 Hz, Hqi-4), 8.68 (d, 2H, J = 7.6 Hz, Hqi-7), 8.64 (d, 2H, J = 6.8 Hz, 
Hqi-9), 8,40 (t, 2H, J = 8.4 Hz, Hqi-6), 8.16 (d, 4H, J = 7.6 Hz, H3 and H5), 8.02 (t, 2H, J = 7. 2 Hz, 
Hqi-5), 7.94 (t, 2H, J = 8.4 Hz, Hqi-10), 3.39-3.32 (m, 4H, Hβ), 2.10-2.00 (m, 4H, Hγ), 2.10-2.00 (m, 
4H, Hγ), 1.53 (s, 6H, Hα). 13C NMR (125 MHz, acetone-d6, 293 K, in ppm): δ = 156.70 (C2), 152.45 
(C6), 151.62 (Cqi-2), 146.11 (Cqi-9), 139.01 (Cqi-6), 137.23 (Cqi-8), 133.42 (C*), 130.09 (Cqi-5), 128.77 
(C5), 123.75 (C4), 120.90 (Cqi-3), 120.84 (Cqi-7), 120.35 (Cqi-10), 118.26 (C3), 59.28 (Cβ), 38.78 (Cγ), 
16.85 (Cα). High resolution ES MS m/z (calc): 725.1301 (725.1309, [M – 2PF6 – H]+). Elem. anal. 
calcd. for C34H36F12N6O2P2RuS2 + ½ Acetone: C, 40.81; H, 3.76; N, 8.04. Found: C, 40.53; H, 4.11; 
N, 8.37. 
Single crystals of [3](PF6)2 were obtained by crystallization via liquid-vapor diffusion using 
acetone as solvent and diethylether as counter-solvent. In short, 1.0 mg of [3](PF6)2 was 
dissolved in 0.4 mL of acetone and placed in a small GC vial. This vial was placed in a larger 
vial containing 2.8 mL diethyl ether. The large vial was closed and vapor diffusion occurred 
within a few days to afford X-ray quality crystals. 
5.4.3 Synthesis of [Ru(H2bapbpy)(Hmte)2](PF6)2 ([4](PF6)2) 
In a 2-necked round-bottom flask [2]Cl (50 mg, 0.085 mmol) and Hmte (1.47 mL, 16 mmol) 
were added in degassed demineralized water (15 mL). The reaction mixture was stirred 
overnight at 80 °C, resulting in a red solution. After full conversion was ensured by TLC 
(eluent: acetone/water/aqueous KPF6 (sat.), 5:2:2), the reaction mixture was cooled down to 
room temperature and KPF6 (0.5 g, 2.7 mmol) was added. Then, the aqueous layer was 
extracted with ethyl acetate (3 × 15 mL), and the organic layer was evaporated in vacuo. The 
compound was purified using size exclusion chromatography (Sephadex LH-20, acetone). 
After evaporation the product was precipitated from acetone (0.5 mL) by the addition of 
diethyl ether (10 mL). Yield: 45 mg (58%). 1H NMR (400 MHz, acetone-d6, 293 K, in ppm): δ = 
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10.56 (s, 2H, N-H), 8.80 (d, 2H, J = 6.0 Hz py-6), 8.51 (d, 2H, J = 7.6 Hz, H5), 8.27 (d, 2H, J = 8.4 
Hz, H4), 8.07 (dd, 2H, J = 8.8 Hz, py-4), 7.62 (d, 2H, J = 8.4 Hz, H5), 7.50 (d, 2H, J = 8.4 Hz, py-
3), 7.36 (dd, 2H, J = 7.2 Hz, py-5), 3.42 (t, 4H, J = 5.6 Hz, Hγ), 2.01 (t, 4H, J = 5.6 Hz, Hβ), 1.56 
(s, 6H, Hα). 13C NMR (100 MHz, acetone-d6, 293 K, in ppm): δ = 162.1 (C2), 154.3 (Cpy-6), 139.9 
(Cpy-4), 139.2 (C4), 133.9 (C6), 130.5 (Cpy-2), 120.3 (Cpy-5), 119.2 (C5), 117.7 (Cpy-3), 116.6 (Cpy-3), 
116.1 (C3), 59.5 (Cγ), 38.9 (Cβ), 17.0 (Cα). High resolution ES MS m/z (calc): 574.0961 (574.0963, 
[M – PF6 – H – Hmte + CH3CN]+). Elem. anal. calcd. for C26H32F12N6O2P2RuS2 + ½ acetone + ½ 
H2O: C, 34.63; H, 3.80; N, 8.81. Found: C, 34.44; H, 4.33; N, 9.01. 
Single crystals of [4](PF6)2 were obtained by crystallization through liquid-vapor diffusion 
using acetone as solvent and diethyl ether as counter-solvent. In short, 1.0 mg of [4](PF6)2 
was dissolved in 0.4 mL of acetone and placed in a small vial. This vial was placed in a 
larger vial containing 2.8 mL diethyl ether. The large vial was closed and vapor diffusion 
occurred within a few days to afford X-ray quality crystals. 
5.4.4 Crystal data for [2]Cl 
All reflection intensities were measured at 110(2) K using a KM4/Xcalibur (detector: 
Sapphire3) with enhance graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) under 
the program CrysAlisPro (Version 1.171.35.11 Oxford Diffraction Ltd., 2011). The program 
CrysAlisPro was used to refine the cell dimensions. Data reduction was done using the 
program CrysAlisPro. The structure was solved with the program SHELXS-2014/7 and was 
refined on F2 with SHELXL-2014/7.52 Analytical numeric absorption corrections based on a 
multifaceted crystal model were applied using CrysAlisPro. The temperature of the data 
collection was controlled using the system Cryojet (manufactured by Oxford Instruments). 
The H atoms (except when specified) were placed at calculated positions using the 
instructions AFIX 43 or AFIX 137 with isotropic displacement parameters having values 1.2 
or 1.5 times Ueq of the attached C atoms. The H atoms attached to N2n and N5n (n = A, B) 
were located from difference Fourier maps; their atomic coordinates were refined freely 
using some restraints (DFIX instructions). 
The structure is ordered. The crystal was found to be twinned non-merohedrally, and the 
twin relationship is a twofold axis found along the direct-space vector 0.0044 0.0086 1.0000. 
The batch scale factor of the minor component refines to 0.3188(11). The final structure 
refinement was performed using the HKL5 instruction (true hkl files including reflection 
sets for the twinned component 1 and the associated overlapped reflections from component 
2). 
Fw = 590.48, small orange block, 0.22 × 0.17 × 0.14 mm3, triclinic, P-1 (no. 2), a = 12.6164(2), b 
= 13.6053(3), c = 14.3404(3) Å, α = 100.1729(17), β = 92.9120(16), γ = 106.0391(17)°, V = 
2315.57(8) Å3, Z = 4, Dx = 1.694 g cm−3, µ = 1.027 mm−1, Tmin-Tmax: 0.831−0.900. 36503 
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Reflections were measured up to a resolution of (sin θ/λ)max = 0.59 Å−1. 9478 Reflections were 
unique (Rint = 0.031, including overlapped reflections from twin component 2), of which 7962 
were observed [I > 2σ(I)]. 616 Parameters were refined using 4 restraints. R1/wR2 [I > 2σ(I)]: 
0.0410/0.1012. R1/wR2 [all refl.]: 0.0536/0.1091. S = 1.096. Residual electron density found 
between − 0.75 and 0.87 e.Å−3. 
5.4.5 Crystal data for [3](PF6)2 
All reflection intensities were measured at 110(2) K using a SuperNova diffractometer 
(equipped with Atlas detector) with Cu Kα radiation (λ = 1.54178 Å) under the program 
CrysAlisPro (Version 1.171.37.35 Agilent Technologies, 2014). The same program was used 
to refine the cell dimensions and for data reduction. The structure was solved with the 
program SHELXS-2014/7 and was refined on F2 with SHELXL-2014/7.52 Analytical numeric 
absorption correction based on a multifaceted crystal model was applied using CrysAlisPro. 
The temperature of the data collection was controlled using the system Cryojet 
(manufactured by Oxford Instruments). The H atoms were placed at calculated positions 
(unless otherwise specified) using the instructions AFIX 23, AFIX 43, AFIX 137 or AFIX 147 
(for the disordered O-H group) with isotropic displacement parameters having values 1.2 or 
1.5 Ueq of the attached C or O atoms. The H atoms attached to N2, N5 and O1 were found 
from difference Fourier maps, and their coordinates were refined freely using the DFIX 
restraints. 
The structure is partly disordered. One of the two counter-ions, and O2/O2’ (OH group) are 
disordered over two orientations. The occupancy factors of the major components of the 
disorder refine to 0.624(13) and 0.77(5), respectively. The crystal that was mounted on the 
diffractometer was non-merohedrally twinned, and the twin relationship corresponds to a 
twofold axis along the 0.0009a* + 0.9998b* + 0.0201c* vector. The BASF scale factor refines to 
0.2115(9). 
Fw = 1015.82, red block, 0.21 × 0.19 × 0.14 mm3, monoclinic, P21/n (no. 14), a = 9.54745 (18), b 
= 21.8432(4), c = 18.4565 (3) Å, β = 98.2773(17)°, V = 3808.95(12) Å3, Z = 4, µ = 6.08 mm−1, Tmin-
Tmax: 0.401-0.563. 27773 reflections were measured up to a resolution of (sin θ/λ)max = 0.616 
Å−1. 10943 reflections were unique (Rint = 0.022), of which 9630 were observed [I > 2σ(I)]. 620 
Parameters were refined using 256 restraints. R1/wR2 [I > 2σ(I)]: 0.029/0.0943. R1/wR2 [all 
refl.]: 0.0333/0.0963. S = 0.99. Residual electron density found between −0.66 and 0.64 e.Å−3. 
5.4.6 Crystal data for [4](PF6)2 
All reflection intensities were measured at 110(2) K using a SuperNova diffractometer 
(equipped with Atlas detector) with Cu Kα radiation (λ = 1.54178 Å) under the program 
CrysAlisPro (Version 1.171.36.32 Agilent Technologies, 2013). The same program was used 




10.56 (s, 2H, N-H), 8.80 (d, 2H, J = 6.0 Hz py-6), 8.51 (d, 2H, J = 7.6 Hz, H5), 8.27 (d, 2H, J = 8.4 
Hz, H4), 8.07 (dd, 2H, J = 8.8 Hz, py-4), 7.62 (d, 2H, J = 8.4 Hz, H5), 7.50 (d, 2H, J = 8.4 Hz, py-
3), 7.36 (dd, 2H, J = 7.2 Hz, py-5), 3.42 (t, 4H, J = 5.6 Hz, Hγ), 2.01 (t, 4H, J = 5.6 Hz, Hβ), 1.56 
(s, 6H, Hα). 13C NMR (100 MHz, acetone-d6, 293 K, in ppm): δ = 162.1 (C2), 154.3 (Cpy-6), 139.9 
(Cpy-4), 139.2 (C4), 133.9 (C6), 130.5 (Cpy-2), 120.3 (Cpy-5), 119.2 (C5), 117.7 (Cpy-3), 116.6 (Cpy-3), 
116.1 (C3), 59.5 (Cγ), 38.9 (Cβ), 17.0 (Cα). High resolution ES MS m/z (calc): 574.0961 (574.0963, 
[M – PF6 – H – Hmte + CH3CN]+). Elem. anal. calcd. for C26H32F12N6O2P2RuS2 + ½ acetone + ½ 
H2O: C, 34.63; H, 3.80; N, 8.81. Found: C, 34.44; H, 4.33; N, 9.01. 
Single crystals of [4](PF6)2 were obtained by crystallization through liquid-vapor diffusion 
using acetone as solvent and diethyl ether as counter-solvent. In short, 1.0 mg of [4](PF6)2 
was dissolved in 0.4 mL of acetone and placed in a small vial. This vial was placed in a 
larger vial containing 2.8 mL diethyl ether. The large vial was closed and vapor diffusion 
occurred within a few days to afford X-ray quality crystals. 
5.4.4 Crystal data for [2]Cl 
All reflection intensities were measured at 110(2) K using a KM4/Xcalibur (detector: 
Sapphire3) with enhance graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) under 
the program CrysAlisPro (Version 1.171.35.11 Oxford Diffraction Ltd., 2011). The program 
CrysAlisPro was used to refine the cell dimensions. Data reduction was done using the 
program CrysAlisPro. The structure was solved with the program SHELXS-2014/7 and was 
refined on F2 with SHELXL-2014/7.52 Analytical numeric absorption corrections based on a 
multifaceted crystal model were applied using CrysAlisPro. The temperature of the data 
collection was controlled using the system Cryojet (manufactured by Oxford Instruments). 
The H atoms (except when specified) were placed at calculated positions using the 
instructions AFIX 43 or AFIX 137 with isotropic displacement parameters having values 1.2 
or 1.5 times Ueq of the attached C atoms. The H atoms attached to N2n and N5n (n = A, B) 
were located from difference Fourier maps; their atomic coordinates were refined freely 
using some restraints (DFIX instructions). 
The structure is ordered. The crystal was found to be twinned non-merohedrally, and the 
twin relationship is a twofold axis found along the direct-space vector 0.0044 0.0086 1.0000. 
The batch scale factor of the minor component refines to 0.3188(11). The final structure 
refinement was performed using the HKL5 instruction (true hkl files including reflection 
sets for the twinned component 1 and the associated overlapped reflections from component 
2). 
Fw = 590.48, small orange block, 0.22 × 0.17 × 0.14 mm3, triclinic, P-1 (no. 2), a = 12.6164(2), b 
= 13.6053(3), c = 14.3404(3) Å, α = 100.1729(17), β = 92.9120(16), γ = 106.0391(17)°, V = 
2315.57(8) Å3, Z = 4, Dx = 1.694 g cm−3, µ = 1.027 mm−1, Tmin-Tmax: 0.831−0.900. 36503 
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Reflections were measured up to a resolution of (sin θ/λ)max = 0.59 Å−1. 9478 Reflections were 
unique (Rint = 0.031, including overlapped reflections from twin component 2), of which 7962 
were observed [I > 2σ(I)]. 616 Parameters were refined using 4 restraints. R1/wR2 [I > 2σ(I)]: 
0.0410/0.1012. R1/wR2 [all refl.]: 0.0536/0.1091. S = 1.096. Residual electron density found 
between − 0.75 and 0.87 e.Å−3. 
5.4.5 Crystal data for [3](PF6)2 
All reflection intensities were measured at 110(2) K using a SuperNova diffractometer 
(equipped with Atlas detector) with Cu Kα radiation (λ = 1.54178 Å) under the program 
CrysAlisPro (Version 1.171.37.35 Agilent Technologies, 2014). The same program was used 
to refine the cell dimensions and for data reduction. The structure was solved with the 
program SHELXS-2014/7 and was refined on F2 with SHELXL-2014/7.52 Analytical numeric 
absorption correction based on a multifaceted crystal model was applied using CrysAlisPro. 
The temperature of the data collection was controlled using the system Cryojet 
(manufactured by Oxford Instruments). The H atoms were placed at calculated positions 
(unless otherwise specified) using the instructions AFIX 23, AFIX 43, AFIX 137 or AFIX 147 
(for the disordered O-H group) with isotropic displacement parameters having values 1.2 or 
1.5 Ueq of the attached C or O atoms. The H atoms attached to N2, N5 and O1 were found 
from difference Fourier maps, and their coordinates were refined freely using the DFIX 
restraints. 
The structure is partly disordered. One of the two counter-ions, and O2/O2’ (OH group) are 
disordered over two orientations. The occupancy factors of the major components of the 
disorder refine to 0.624(13) and 0.77(5), respectively. The crystal that was mounted on the 
diffractometer was non-merohedrally twinned, and the twin relationship corresponds to a 
twofold axis along the 0.0009a* + 0.9998b* + 0.0201c* vector. The BASF scale factor refines to 
0.2115(9). 
Fw = 1015.82, red block, 0.21 × 0.19 × 0.14 mm3, monoclinic, P21/n (no. 14), a = 9.54745 (18), b 
= 21.8432(4), c = 18.4565 (3) Å, β = 98.2773(17)°, V = 3808.95(12) Å3, Z = 4, µ = 6.08 mm−1, Tmin-
Tmax: 0.401-0.563. 27773 reflections were measured up to a resolution of (sin θ/λ)max = 0.616 
Å−1. 10943 reflections were unique (Rint = 0.022), of which 9630 were observed [I > 2σ(I)]. 620 
Parameters were refined using 256 restraints. R1/wR2 [I > 2σ(I)]: 0.029/0.0943. R1/wR2 [all 
refl.]: 0.0333/0.0963. S = 0.99. Residual electron density found between −0.66 and 0.64 e.Å−3. 
5.4.6 Crystal data for [4](PF6)2 
All reflection intensities were measured at 110(2) K using a SuperNova diffractometer 
(equipped with Atlas detector) with Cu Kα radiation (λ = 1.54178 Å) under the program 
CrysAlisPro (Version 1.171.36.32 Agilent Technologies, 2013). The same program was used 
to refine the cell dimensions and for data reduction. The structure was solved with the 
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program SHELXS-2014/7 and was refined on F2 with SHELXL-2014/7.52 Analytical numeric 
absorption correction based on a multifaceted crystal model was applied using CrysAlisPro. 
The temperature of the data collection was controlled using the system Cryojet 
(manufactured by Oxford Instruments). The H atoms were placed at calculated positions 
(unless otherwise specified) using the instructions AFIX 23, AFIX 43 or AFIX 137 with 
isotropic displacement parameters having values 1.2 or 1.5 Ueq of the attached C atoms. The 
H atoms attached to N2 and O1 were found from difference Fourier maps, and their 
coordinates were refined freely using the DFIX instruction.  
The structure is ordered. The ruthenium complex is found at sites of twofold axial 
symmetry, and only one half of the molecule is found to be crystallographically 
independent. 
Fw = 915.70, orange-red needle, 0.25 × 0.05 × 0.02 mm3, monoclinic, I2/a, a = 18.9321(3), b = 
11.23471(18), c = 15.6066(2) Å, β = 96.7047(15)°, V = 3296.77(9) Å3, Z = 4, µ = 6.94 mm−1, Tmin-
Tmax: 0.391-0.881. 10972 reflections were measured up to a resolution of (sin θ/λ)max = 0.616 
Å−1. 3243 reflections were unique (Rint = 0.024), of which 3045 were observed [I > 2σ(I)]. 239 
Parameters were refined using 2 restraints. R1/wR2 [I > 2σ(I)]: 0.0378/ 0.1016. R1/wR2 [all 
refl.]: 0.0399/0.1034. S = 1.06. Residual electron density found between −0.74 and 2.11 e.Å−3. 
Additional notes: 
(i) The residual electron density peak of 2.11 e− Å-3 found at 0.75 Å from Ru1 is chemically 
meaningless. All remaining residual electron density peaks are lower than 1 e− Å-3. 
(ii) The occupancy factor of Ru1 was refined freely (its value was 1.034(3)*0.5 = 0.517(2)) 
before being constrained to 0.5 in the final refinement. 
5.4.7 UV-vis spectroscopy absorbance studies 
Photoreactivity and stability studies were monitored using a UV-vis spectrometer equipped 
with temperature control set to 298 K and a magnetic stirrer. The measurements were 
performed in a quartz cuvette, containing 3 mL of solution (0.010-0.050 mM). The stirred 
sample was irradiated perpendicularly to the axis of the spectrometer with a blue LED (λ = 
445 nm, Δλ1/2 = 22 nm, photon flux Φ = 1.8 × 10−8 mol.s−1, tirr = 10 minutes) fitted to the top of 
the cuvette, and an absorption spectrum was measured at regular time intervals and 
analyzed using Microsoft Excel. Mass spectrometry was performed at the beginning and at 
the end of the irradiation to confirm the nature of the reagent and products. 
5.4.8 Gel studies 
HPLC purified ODN1 was ordered from Sigma-Aldrich and received as a solid (fixed 
amount), and LC-MS water was added in such amounts that a 1 mM solution was obtained. 
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[1]Cl and [2]Cl were dissolved in methanol, [3](PF6)2 and [4](PF6)2 were dissolved in acetone 
to obtain 1 mM solutions. Then, 5 µL of ODN solution, 15 µL Ru solution, and 5 µL MilliQ 
water were transferred to a 1 mL quartz cuvette, and irradiated for 10 minutes by blue LED 
(λirr = 445 nm, Δλ1/2 = 22 nm, photon flux Φ = 2.2 × 10−7 mol.s−1, tirr = 10 minutes). Following 
irradiation, the sample was transferred to a 1.5 mL Eppendorf microtube and incubated in 
the dark for 6 hours at 298 K. Then, 1-2 µl of the mixture (containing 400 pmol of ODN1 per 
lane) was added to 3 µl formamide/dye solution (formamide 0.01% (w/v), bromophenol 
blue and 0.01% (w/v), Xylenecyanol 0.01% (w/v)) and loaded (without heating) on a 20% 
polyacrylamide gel containing 8 M Urea in 1x Tris/Borate/EDTA buffer. After 
electrophoresis (22 mA/gel) the gel was stained for 5 min in 0.01% w/v Toluidine Blue O ((7-
amino-8-methyl- phenothiazin-3-ylidene)-dimethyl-ammonium) in water on a rotary shaker. 
The background staining was removed by washing the gel multiple times with tap water. 
The procedure was adapted from Popa and Bosch.42 
5.4.9 HRMS ODN experiments 
HPLC purified ODN1 ((s(5’CTACGGTTTCAC3’)) was ordered from Sigma-Aldrich and 
received as a solid (fixed amount). LC-MS water was added in such amounts that a 1 mM 
solution was obtained. [1]Cl and [2]Cl were dissolved in methanol, [3](PF6)2 and [4](PF6)2 
were dissolved in acetone to obtain 1 mM solutions. Then, 15 µL of ODN1 aqueous solution, 
45 µL Ru solution, and 450 µL LC-MS grade water, were transferred to a 1 mL quartz 
cuvette, and irradiated for 10 minutes by blue a LED (λirr = 445 nm, Δλ1/2 = 22 nm, photon 
flux Φ = 2.2 × 10−7 mol.s−1, tirr = 10 minutes). Following irradiation, the sample was transferred 
to a 1.5 mL Eppendorf microtube and incubated in the dark for 6 hours at 298 K. For every 
sample a control sample shielded from light in a parallel experiment was performed. Then, 
the solutions were directly injected (flowrate = 5 µl min-1, 1:1 water/methanol) in an Orbitrap 
high-resolution mass spectrometer (Thermo, San Jose, CA, USA), equipped with a 
conventional ESI source. The mass spectra have been recorded in the range 300-2000 m/z 
values. The following standardized working conditions were applied: spray voltage 2.7 kV, 
tube lens voltage −113 V, capillary voltage −20 V and capillary temperature 280 °C. Sheath 
and auxiliary gases were set at 23 a.u. and 4 a.u., respectively. The mass spectra were 
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The anticancer drug cisplatin is one of the landmarks in medicinal inorganic 
chemistry.1 Cisplatin has an over 95% cure rate for patient diagnosed with 
testicular, bladder, or ovarian cancer.2 However, undesired side effects associated 
with cisplatin are severe (e.g., nephrotoxicity, neurotoxicity, ototoxicity, or 
nauseas), and tumors sometimes exhibit or acquire cisplatin resistance.3  
To counter resistances and minimize side effects associated with cisplatin, much 
research effort has been invested in determining the mechanism of action (MoA). 
The usually accepted MoA is that after cisplatin is administered intravenously the 
high extracellular chloride concentration (> 100 mM) ensures that the chloride 
ligands remain coordinated. Cisplatin then enters the cell either through passive 
diffusion or via copper(II) transporters.4 In the cell the chloride concentration is 
much lower (3-20 mM) resulting in hydrolysis of cisplatin first to form 
[Pt(NH3)2(OH2)Cl]+.5 Once inside the nucleus this species can form coordination 
bonds with nucleobases, mainly guanines. In this process the DNA is structurally 
altered, shielded from DNA excision repair by HMG-proteins, and consequentially 
the cell is sensitized for apoptosis.6-8 DNA therefore is one of the important 
intracellular targets for metal based anticancer compounds, including second and 
third generation cisplatin derivatives. Alternatively, the so-called intercalating 
agents do not rely on 2-electron bonding to DNA, but their flat and aromatic 
nature enables π-π stacking interactions with the DNA base pairs.9, 10  
The biochemical effects of metallodrugs are not limited to DNA-damage induced 
apoptosis. Coordination of the biologically available thiol glutathione to the 
platinum center is associated with detoxification.11, 12 Cisplatin can also disturb 
cellular homeostasis and cell redox balance, and increases the presence of reactive 
oxygen species (ROS).13, 14 In this context metallodrugs specifically designed to 
disturb the intracellular redox balance have been developed as anticancer 
compounds.15 As cancer cells already exhibit high metabolic activity and low level 
of antioxidants they have an increased sensitivity toward such perturbations.16  
In this chapter three novel and analogous complexes based on the same 
tetradentate ligand H2bapbpy (6,6’-bis[N-(pyridyl)-1-amino]-2,2’-bipyridine) are 
presented, but coordinated to Ni2+, Pd2+, or Pt2+ that all in column 10 of the periodic 
table. Palladium complexes as analogues of platinum complexes are often 
 
113 
discarded as anticancer drugs due to their unfavorably fast ligand exchange 
kinetics,17 which is a feature crucial for its success as a homogenous catalysts for 
many coupling reactions. Nickel compounds suffer from the same problem, and 
also have a wider range of coordination geometries compared to palladium and 
platinum. In this work the structurally related complexes [Ni(H2bapbpy)(OH2)2]Cl2 
([1]Cl2), [Pd(H2bapbpy)](PF6)2 ([2](PF6)2), and [Pt(H2bapbpy)](PF6)2 ([3](PF6)2) show 
strikingly different biological activities: whereas [1]Cl2 harbors only moderate 
biologically activity, [3](PF6)2 exhibits high cytotoxicity comparable to cisplatin, 
while [2](PF6)2 shows activities against a wide range of human cancer cell lines in 
the nanomolar range. Remarkably, the palladium compound [2](PF6)2 is not only 
much more cytotoxic than its platinum analogue; it exerts a distinctively different 
mechanism of action. It represents the first palladium anticancer drug that causes a 
complete collapse of the cell redox balance and shows promising in vivo anticancer 
activity. 
 Results 6.2
6.2.1 Synthesis and crystal structures 
The nickel complex [1]Cl2 was synthesized by reacting H2bapbpy with 1.1 
equivalent of NiCl2 • 6H2O in ethanol overnight at 80 °C (Scheme 6.1). After 
filtration [1]Cl2 was obtained as a light brown powder. Mass spectrometry of an 
acetonitrile solution showed clear signals corresponding to [1 – 2×H2O + 
2×CH3CN]2+ (m/z = 240.2, calc. m/z = 240.1) indicating that the axial water ligands 
are labile and are easily replaced by CH3CN, whereas virtually no signals for [1]2+ 
are observed (Figure SVI.1.). This result suggests that in vitro or in vivo water can 
easily be substituted in the presence of competing biological ligands. The 
palladium and platinum complexes [2](PF6)2 and [3](PF6)2 were synthesized by 
reacting H2bapbpy with 1.3 equivalents of K2[PdCl4] or K2[PtCl4], respectively, in 
an ethanol-water mixture overnight at 80 °C (Scheme 6.1). After filtration the 
filtrate was treated with KPF6 yielding yellow precipitates. 
Slow vapor diffusion of diethyl ether into a solution of [1]Cl2 in methanol gave 
brown-colored crystals suited for X-ray diffraction (Figure 6.1A). The nickel(II) 
center is in an octahedral geometry with the ligand H2bapbpy in the basal plane 
and two water ligand in the apical positions. Vapor diffusion of an acetonitrile 
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ray diffraction (Figure 6.1BC). Both complexes were found to have a square-planar 
geometry, and interestingly the crystals obtained from the [3](PF6)2 solution 
resulted in the structure of [Pt(Hbapbpy)]PF6. The pKa of the amines in the 
H2bapbpy ligand when coordinated will be further discussed in Chapter 7. In all 
three structures the tetradentate H2bapbpy or Hbapbpy ligand coordinates to the 
metal in a non-planar fashion. Selected bond distances and angles are reported in 
Table SVI.1 and Table SVI.2. The distance between the palladium(II) or 
platinum(II) center and their coordinating nitrogen atoms are all around 2.0 Å. 
Overall. whereas the nickel(II) complex stands out due to its octahedral geometry, 
the palladium(II) and platinum(II) are highly similar.  
 
Scheme 6.1 Synthesis of [1]Cl2, [2](PF6)2, and [3](PF6)2. 
 
Figure 6.1 Displacement ellipsoid of cationic parts of [1]2+ (A), [2]2+ (B), and [Pt(Hbapbpy)]+ 
(C) (50% probability level) as observed in the crystal structure of respectively [1]Cl2, 
[2](PF6)2 · 2 × CH3CN, and [Pt(Hbapbpy)]PF6. Counter anions and lattice solvent molecules 
have been omitted for clarity. Selected bond distances and angles are reported in Table 
SVI.1 and Table SVI.2. 
6.2.2 Cytotoxic properties 
The cytotoxicity of the three complexes was tested against five different cancer cell 
lines (A375, A431, A549, MCF-7, MDA-MB231) and one non-malignant lung cell 
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line (MRC-5). The cell testing protocol was adapted from Hopkins et al.18 as 
follows: 24 h after seeding, the cells were incubated for 24 h with the drug, then the 
drug-containing medium was removed, and finally the cells were incubated with 
drug-free medium for another 48 h. An SRB cell-counting assay was performed at 
96 h, and effective concentrations (EC50) were determined by comparison with 
drug-free control cells. The cytotoxicity results are summarized in Table 6.1. EC50 
values for [1]Cl2 range between 35 µM for A375 cells and 74 µM for A549 cells, i.e. 
the nickel complex is mildly cytotoxic. For [3](PF6)2 EC50 values between 0.80 µM 
for MCF-7 cells and 1.4 µM for MRC-5 cells were found, which makes the platinum 
complex [3](PF6)2 slightly more cytotoxic than cisplatin and much more cytotoxic 
than [1]Cl2. For [2](PF6)2 the EC50 values ranged between 0.058 µM for A375 cells 
and 0.19 µM for A549 cells, which is remarkably low. It is 5-20 times more toxic 
than its platinum analogue [3](PF6)2 or cisplatin over the full panel of tested cell 
lines in spite of the almost identical structural features.17, 19, 20 This makes 
compound [2](PF6)2 one of the most cytotoxic palladium compounds known to 
date. 
Table 6.1 Cytotoxicity expressed as effective concentrations (EC50 with 95% confidence 
intervals, in μM) of [1]Cl2, [2](PF6)2, [3](PF6)2, and cisplatin on skin (A375, A431), lung 
(A549), and breast (MCF-7, MDA-MB231) cancer cell lines, and on non-cancerous lung 
fetal cell line (MRC-5). 
Cell Line [1]Cl2 [2](PF6)2 [3](PF6)2 cisplatin 
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6.2.3 Cell Imaging 
The distinctly differing cytotoxic properties of [2](PF6)2 and [3](PF6)2 suggest 
different mechanisms of action for the two analogues, and thus prompted further 
investigations performed by Dr. Bianka Siewert. A549 cells were first treated with 
0.5 µM [2](PF6)2 or 1.0 µM [3](PF6)2 for 26 h and then inspected by bright field 
microscopy (Figure 6.2). Compared to the untreated controls (Figure 6.2A) the cells 
treated with [2](PF6)2 displayed cell shrinkage, loss of cell-cell contact, and 
membrane blebbing as depicted in Figure 6.2B, suggesting apoptosis. Nevertheless, 
the formation of ‘balloon cells’ (big bubbles, highlighted with white arrows in 
Figure 6.2B) indicated on the one hand that membrane modulation may cause 
disturbances of the osmotic balance, and on the other hand that also necrotic cell 
death might occur. For cells treated with [3](PF6)2 these effects were clearly not 
observed. Despite the structural similarity of the two compounds, only treatment 
with the platinum compound leads to contraction patterns and appearance of 
enlarged, flat cells typically associated with DNA-damage in p53 wild-type cells 
like A549.21, 22 
 
 
Figure 6.2 Bright field microscopy images (20 × magnification) of A549 cells without 
treatment (A) or after 26 h treatment with 0.5 μM [2](PF6)2 (B) or with 1.0 μM [3](PF6)2 (C).  
6.2.4 Uptake and subcellular fractionation studies with A549 cells 
To determine uptake and localization of the non-emissive compounds [1]Cl2, 
[2](PF6)2, and [3](PF6)2, A549 lung cancer cells were treated for 24 hours close to the 
EC50 concentration, trypsinized, and fractionated by Anja Busemann into the 
following four fractions: the cytosol, the membranes, the nuclei, and the 
cytoskeleton. The metal content of each fraction was measured by ICP-MS and is 
reported in Table 6.2, Figure SVI.2 and Figure SVI.3. Total uptake for [1]Cl2, 
[2](PF6)2, and [3](PF6)2 was 720, 132, and 1586 pmol/106 cells, respectively, which 
corresponded to an uptake efficiency with respect to the total dose added to each 
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well of 0.3, 20, and 47%, respectively. Thus, [1]Cl2 was poorly taken up, [2](PF6)2 
had a moderate uptake efficiency, and [3](PF6)2 had a very high uptake efficiency. 
Compared to cisplatin that showed an uptake of 22.9 pmol/106 cells (< 0.1%), all 
three complexes are taken up well. To conclude, the amount of palladium complex 
necessary to kill half of the cells is extraordinary low compared to the amount of 
nickel or platinum complex necessary to induce a comparable effect. 
Table 6.2 Uptake in the different fractions of A549 cells for compounds [1]Cl2, [2](PF6)2, 

















[1]Cl2 70 720 ± 251 0.3 
Cytosol 9 66.4 ± 12.6 
Membrane 74 533 ± 197 
Nucleus 13 96.5 ± 43.4 
Cytoskeleton 3 23.6 ± 7.7 
[2](PF6)2 0.20 132 ± 37.4 20 
Cytosol 5 6.1 ± 1.4 
Membrane 86 113 ± 34.8 
Nucleus 6 7.55 ± 2.0 
Cytoskeleton 4 5.07 ± 3.0 
[3](PF6)2 1.0 1586 ± 667 47 
Cytosol 2 28.8 ± 8.5 
Membrane 35 555 ± 180 
Nucleus 15 236 ± 140 
Cytoskeleton 48 766 ± 350 
Cisplatin 3.3 22.9 ± 6.1 < 0.1 
Cytosol 8 1.89 ± 0.7 
Membrane 64 14.6 ± 3.1 
Nucleus 14 3.13 ± 1.1 
Cytoskeleton 14 3.28 ± 1.3 
 
Concerning the subcellular compartmentalization of the complexes, 74% of [1]Cl2 
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Concerning the subcellular compartmentalization of the complexes, 74% of [1]Cl2 
and 86% of [2](PF6)2 were localized in the membrane fraction (533 pmol/106 cells 
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and 113 pmol/106 cells respectively). Uptake in the membrane fraction for [3](PF6)2 
was 555 pmol/106 cells (35% of total) and comparable to [1]Cl2, but much higher 
than [2](PF6)2. [3](PF6)2 is also highly abundant in the other fractions: in the nucleus 
at 236 pmol/106 cells (15%), and in the cytoskeleton at 766 pmol/106 cells (48%) 
unlike [1]Cl2 and [2](PF6)2. Due to the high general uptake of all complexes, the 
compounds are quite abundant in all cell fractions. However, the highest fraction 
preference was witnessed for [2](PF6)2 for the membrane fraction (86%) while this 
highly cytotoxic compound exhibited the lowest nuclear localization making it 
questionable whether DNA represents the major target of this palladium complex. 
Since all complexes were substantially present in the membrane fraction that 
includes mitochondria, mitochondria in A549 cells were isolated, digested, and the 
metal concentration was measured by ICP-MS. No substantial metal uptake was 
found in the mitochondria (Table SVI.4). Thus, treatment around the EC50 
concentration [3](PF6)2 has the highest uptake efficiency (47%) and is abundantly 
present in the membrane, nucleus, and cytoskeleton fractions. Treatment with 
[2](PF6)2 also resulted in a high uptake efficiency (20%), and the metal was mainly 
localized in the membrane fraction (86%), relatively minor in the nucleus (6%) but 
absent in the mitochondria. [1]Cl2 has the poorest uptake efficiency (0.3%) of the 
complexes, but due to a much higher treatment concentration still 720 pmol/106 
cells was taken up, which represents a five-fold higher uptake than complex 
[2](PF6)2. Clearly, the differences in absolute metal uptake cannot explain the 
remarkable difference in cytotoxicity between the three compounds. [2](PF6)2 is 
despite its low intracellular presence of the three presented H2bapbpy complexes 
by far the most cytotoxic. These results confirmed the initial indications that 
[2](PF6)2 and [3](PF6)2 are cytotoxic via different mechanisms. 
6.2.5 Thermal binding with pUC19 plasmid DNA 
Photomicrographs of A549 cells treated with [3](PF6)2 suggested that – similar to 
cisplatin – cell death or cell cycle arrest might occurred due to DNA damage. As all 
three H2bapbpy complexes were significantly present in the nucleus, DNA-binding 
studies were performed by Dr. Samantha L. Hopkins using gel electrophoresis to 
determine the affinity of [1]Cl2, [2](PF6)2, and [3](PF6)2 for DNA. The pUC19 
plasmid used for this study (2686 BP) exists in three forms: supercoiled (SC, most 
condensed form, migrates the fastest), single-nicked open circular (OC, relaxed 
form of the SC, migrates in between the SC and LD), and linear dimer (LD, largest 
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form at 5372 bp, migrates the slowest). Complex [1]Cl2, [2](PF6)2, and [3](PF6)2 were 
incubated at varied DNA base pair (BP) to metal complex (MC) ratios for 24 h 
(Figure 6.3). Each gel included a cisplatin control in lane 3 that only showed a band 
that migrated slightly less compared to the untreated SC DNA. For [1]Cl2 at all 
tested BP:MC ratios (Figure 6.3A, lane 4-9) identical migration through the gel of 
SC, OC, and LD compared to the untreated control (lane 2 and lane 10) was 
observed. [1]Cl2 has thus no affinity for pUC19 plasmid DNA. Complexes [2](PF6)2 
and [3](PF6)2 showed no binding to DNA at 200:1 BP:MC ratio (Figure 6.3B and C, 
lane 4), but at a 75:1 or lower BP:MC ratio migration of the SC-plasmid was 
severely retarded (Figure 6.3B and C, lane 5-9). At the highest concentrations in 
metal (10:1-5:1 BP:MC, Figure 6.3B, lane 8-9), the binding of [2](PF6)2 strongly 
deviated from that of [3](PF6)2 at the same concentrations (Figure 6.3C, lane 8-9). 
However, both square-planar complexes [2](PF6)2 and [3](PF6)2 interacted strongly 
with pUC19 plasmid DNA. As expected from the tetradentate nature of the 
H2bapbpy ligand that coordinates around the metal ion without leaving any space 
for the coordination of a base pair, their interaction with DNA differ strongly from 
cisplatin at higher concentrations of the metal.  
 
Figure 6.3 Agarose gel of pUC19 plasmid DNA incubated with [1]Cl2 (A), [2](PF6)2 (B), or 
[3](PF6)2 (C). The lanes correspond to (1) λ DNA MW marker, (2 and 10) DNA control, (3) 
5:1 BP:MC cisplatin control, (4-9) 200:1, 75:1, 50:1, 25:1, 10:1, 5:1 BP:MC ratio. The bands of 
the λ MW marker correlate to 23, 9.4, 6.6, 4.4, 2.3, and 2.0 kpb. The DNA control bands are 
labelled according to the form the linear dimer (LD), open circular (OC), and supercoiled 
(SC) DNA. tincubation = 24 h, Tincubation = 37 °C.  
6.2.6 Oxidative stress 
Disturbance of the cellular redox balance as a result of oxidative stress is often one 
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6.2.6 Oxidative stress 
Disturbance of the cellular redox balance as a result of oxidative stress is often one 
of the main drivers of cytotoxicity induced by metal complexes.23 To determine 
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whether the MoA of [2](PF6)2 and [3](PF6)2 involves infliction of oxidative stress by 
for example generation of reactive oxygen species (ROS), A549, CH1 (ovarian 
cancer), and MG63 (osteosarcoma) cells were treated with [2](PF6)2 and [3](PF6)2 at 
various concentrations by Prof. dr. Walter Berger. These cancer cell lines represent 
high (A549), low (CH1), and intermediate (MG63) resistance towards oxidative 
stress. Furthermore, co-treatment of the palladium or platinum complex with non-
toxic doses of N-acetyl-L-cysteine (NAC, 2.0 mM) or L-buthylsulfoximine (BSO, 1.0 
µM) was performed to evaluate the role of oxidative stress on cell death. In cells 
glutathione (GSH) mediates homeostasis imbalance and oxidative stress. As a 
precursor of GSH, co-treatment with NAC increases the capacity of cells to control 
oxidative stress. Co-treatment with BSO on the other hand reduces GSH levels by 
inhibiting GSH synthesis, and consequently sensitizes cells toward oxidative stress. 
The results of the co-treatment assay are summed up in Table 6.3. Co-treatment of 
[2](PF6)2 with NAC resulted in an EC50 value of > 1 µM for A549 and CH1 cells, and 
of 0.441 µM for MG63 cells, whereas without co-treatment [2](PF6)2 showed much 
higher cytotoxicity (EC50 = 0.055, < 0.01, and < 0.01 µM, respectively). Thus, co-
treatment with NAC strongly inhibited the cytotoxicity of [2](PF6)2. When co-
treated with BSO the measured EC50 values of [2](PF6)2 were 0.007, < 0.01, and < 
0.01 µM for A549, CH1, and MG63 cells. Thus, only for A549 cells an increase in 
cytotoxicity was observable in the presence of BSO. For [3](PF6)2 the measured EC50 
values for A549 cells with and without co-treatment of NAC or BSO were always > 
1 µM. For CH1 and MG63 cells treated only with [3](PF6)2, EC50 values were 0.028 
and 0.128 µM, with NAC 0.097 and 0.151 µM, and with BSO 0.009 and 0.120 µM, 
respectively, indicating minor cytotoxicity decrease by NAC and statistically 
insignificant effects of BSO. Overall, NAC does have a strongly inhibiting effect on 
the cytotoxicity of [2](PF6)2, whereas for [3](PF6)2 this effect is much weaker. Co-
treatment with BSO increased the activity in case of A549 cells treated with 
[2](PF6)2 and CH1 cells treated with [3](PF6)2. Additionally, both compounds were 
much more active against CH1 cells compared to A549 cells. The data 
demonstrates that the presence of GSH in the cells plays a crucial role in the MoA 
of both compounds, but that this effect is by far more significant for [2](PF6)2 than 
for [3](PF6)2. The complete protective effect of NAC against the toxicity of [2](PF6)2 
suggests a MoA depending highly on the induction of oxidative stress, whereas 
this effect is much less important for the toxicity of [3](PF6)2. 
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Table 6.3 Cell growth inhibition effective concentrations (EC50 with 95% confidence 
intervals, in μM) of [2](PF6)2 and [3](PF6)2 when co-treated with NAC (2.0 mM) or BSO (1.0 
μM) on cancer cells with high (A549), low (CH1), or intermediate (MG63) resistance 
toward oxidative stress. 
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6.2.7 Impact of the p53 mutation status on cytotoxicity 
Expression of tumor suppressor protein p53 is often crucial for the anticancer 
activity of DNA damaging agents like cisplatin.24 Thus, testing the cytotoxic 
activity of the palladium and platinum compounds against RKO (colon carcinoma) 
cells with different p53 statuses can provide clues on DNA-damage dependence of 
the MoAs. Therefore, RKO cells with wild-type (low protein expression in 
unstressed cells), mutated (high expression due to lack of protein degradation), 
and knock-out (no protein expression) p53-status were treated by Prof. dr. Walter 
Berger with [2](PF6)2 or [3](PF6)2, and co-treated with NAC (0, 1, or 2 mM). The 
results are of this assay are summarized in Table 6.4. For [2](PF6)2 the measured 
EC50 values were 0.016, 0.028, and 0.016 µM for wild-type, mutated, and knock-out 
RKO cells, respectively. When co-treated with NAC, no EC50 value could be 
determined, due to the absence of cytotoxicity under those conditions, which 
indicates a minimal 6-fold loss in cytotoxicity. Absence of p53 in RKO cells did not 
change the cytotoxicity of [2](PF6)2, but with mutated p53 the cytotoxic activity 
decreased almost 2-fold. For [3](PF6)2 the measured EC50 values were 0.258, 0.298, 
and 0.088 µM for wild-type, mutated, and knock-out RKO cells, respectively. Thus, 
mutation of p53 did again induce a minor decrease of the cytotoxicity compared to 
the wild-type, and almost a 3-fold increased cytotoxic activity compared to knock-
out cells. The stronger activity in the knock-out cells suggests, that wild-type p53-
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out cells. The stronger activity in the knock-out cells suggests, that wild-type p53-
mediated DNA damage response and cell cycle arrest (supported by the 
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appearance of large flat cells indicative for cell cycle arrest at G2 phase) might 
protect cells from [3](PF6)2-mediated cell death. These observations point toward a 
MoA based on DNA damage for [3](PF6)2. Co-treatment with 1 or 2 mM NAC 
induced no significant change in cytotoxicity for [3](PF6)2 in wild-type, mutated, 
and knock-out RKO cells. Together the data confirms that the MoA of [2](PF6)2 
probably relies on raising oxidative stress levels in cells. In contrast, according to 
this p53 expression assay the MoA of [3](PF6)2 might involve DNA-damage and 
seems to be highly independent from infliction of oxidative stress.  
Table 6.4 Cell growth inhibition effective concentrations (EC50 values with 95% 
confidence interval, in μM) of [2](PF6)2 and [3](PF6)2 alone or co-treated with NAC (1 or 2 
mM) on RKO cancer cells with regular (wt), high (mut), and knock-out (ko) expression of 
tumor suppressor p53. 
Cell Line [2](PF6)2 [2](PF6)2  
+ NAC 1 
mM 
[2](PF6)2  
+ NAC 2 
mM 
[3](PF6)2 [3](PF6)2 
 + NAC 1 
mM 
[3](PF6)2  




























































6.2.8 In vivo experiments 
The in vivo anticancer activity of [2](PF6)2 and [3](PF6)2 was evaluated in CT-26 
colon cancer-bearing mice by Prof. dr. Walter Berger using methods as recently 
published.25 Treatment consisted of equimolar dosages [2](PF6)2 (2.5 mg/kg) or 
[3](PF6)2 (2.8 mg/kg), which was found to be the maximum-tolerated dose for 
[2](PF6)2. The complexes were administered by intraperitoneal injections for 5 times 
(on day 3, 5, 7, 10, and 12) and mice were sacrificed 24 h after the last application. 
The impact of the metal complexes on tumor growth was determined by 
measuring the tumor volume (mm3) and the results are shown in Figure 6.4. 
Compared to untreated control BALB/c mice, [3](PF6)2 treatment had no effect on 
tumor growth, indicating that in this treatment regime [3](PF6)2 is inactive at the 
doses used. In contrast, [2](PF6)2 induced from the first day a significant delay in 
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tumor growth and on day 12 a 37% reduction compared to the control group. 
Thus, as previously witnessed in in vitro experiments, treatment with [2](PF6)2 or 




Figure 6.4 Tumor volume of Balb/c mice treated with [2](PF6)2 and [3](PF6)2. CT-26 cells 
were injected subcutaneously into the right flank of Balb/c mice. Mice were treated on 
day 3, 5, 7, 10, and 12 (indicated by black triangles) with either compound [2](PF6)2 at 
concentrations of 2.5 mg/kg (i.p.) or [3](PF6)2 at concentrations of 2.8 mg/kg (i.p). ***, p < 
0.001, two-way ANOVA, Bonferroni post-test. 
 Conclusion 6.3
H2bapbpy complexes [1]Cl2, [2](PF6)2, and [3](PF6)2 demonstrate very diverse 
cytotoxicity patterns. Exposure of various cancer cell lines to the drugs results in 
EC50 values for [2](PF6)2 in the nanomolar range, for [3](PF6)2 in the submicromolar 
to low micromolar range, and for [1]Cl2 in high micromolar range. Whereas the 
distinct differences in cytotoxicity and uptake of [1]Cl2 can be explained by the 
coordination geometry, the differences in cytotoxicity and uptake between the 
square-planar complexes palladium [2](PF6)2 and platinum [3](PF6)2 is unexpected 
and enigmatic.  
Palladium complexes are regularly dismissed as potential (anticancer) drugs due to 
the much higher ligand exchange rates compared to their platinum analogues. As a 
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square-planar complexes palladium [2](PF6)2 and platinum [3](PF6)2 is unexpected 
and enigmatic.  
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the much higher ligand exchange rates compared to their platinum analogues. As a 
result monodentate (chloride) ligands are already extracellularly substituted 
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(hydrolyzed), and make a cisplatin-like prodrug approach that requires 
intracellular activation unlikely. However, coordination of a tetradentate ligand to 
ensure compound stability potentially prevents this problem. With the ligand 
H2bapbpy a remarkably high uptake (also for the platinum analogue) is observed. 
Furthermore, the results in this chapter have demonstrated that the MoA of the 
palladium complex [2](PF6)2 might involve the disturbance of the cellular redox 
balance without intracellular activation. The unchanged activity of the 
geometrically identical [3](PF6)2 when co-treated with oxidative stress regulators 
NAC or BSO indicate that interference with the redox balance in cancer cells does 
not seem to be a major player in the MoA of [3](PF6)2. 
In vivo experiments further confirmed that different activity of the structurally 
similar complexes [2](PF6)2 and [3](PF6)2 is not limited to cell culturing 
experiments. In CT-26-bearing mice models [2](PF6)2 is superior in reducing tumor 
volume compared to [3](PF6)2 in an equimolar low-dosage treatment regime. 
However, as this regime was a consequence of dose-limiting toxicities of [2](PF6)2, 
treatment with higher dosages of [3](PF6)2 are necessary to clarify whether also the 
platinum complex is a viable anticancer drug. Experiments to investigate whether 
[3](PF6)2 is able to reduce tumor volume in a higher dosage treatment regime are 
currently planned.  
 Experimental  6.4
6.4.1 Materials and methods 
All NMR spectra were recorded on a Bruker DPX-300 or AV-500 spectrometer. Chemical 
shifts are indicated in ppm relative to tetramethylsilane. Mass spectra were recorded by 
using a positive ionization mode. The elemental ultra-trace analyses were performed with 
an FAST (Elemental Scientific, Omaha, Nebraska, USA), i-CAP-Q ICP-MS (Thermo 
Scientific, Walthem, Massachusetts, USA) MP2 peristaltic pump controlled flow 110 µl/min 
standardized setup.  
The ligand 6,6’-bis[N-(pyridyl)-1-amino]-2,2’-bipyridine (H2bapbpy), was synthesized 
according to literature procedures.26 NiCl2 • 6H2O was purchased from J.T. Baker. K2[PdCl4] 
was purchased from Acros. K2[PtCl4] and cisplatin were purchased from Sigma-Aldrich.  
6.4.2 Synthesis of [Ni(H2bapbpy)(OH2)2]Cl2 ([1]Cl2) 
In a 2-necked round-bottom flask [NiCl2 • 6H2O] (42 mg, 0.18 mmol), H2bapbpy (60 mg, 0.18 
mmol), and degassed ethanol (15 mL) were added. The brown suspension was stirred 
 
125 
overnight at 80 °C under argon resulting in a brown suspension. A brown powder was 
collected by filtration, washed with 10 mL EtOH, 10 mL Et2O, and 10 mL hexanes. The 
complex was dried overnight in vacuo. Yield: 56 mg (63%). 1H NMR (500 MHz, D2O, 293 K, in 
ppm): δ = 136.6 (s), 65.8 (s), 58.9 (s), 51.8 (s), 36.1 (s), 17.0 (s), 13.7 (s). Due to the paramagnetic 
properties of this compound, no 1H NMR assignment or 13C NMR measurement could be 
performed. High resolution ES MS m/z (calc): 397.0700 (397.0706, [M – 2×H2O – 2×Cl – H]+). 
Elem. Anal. Calcd. For C20H20Cl2N6NiO2 + C20H18N6NiO2: C, 51.16; H, 4.08; N, 17.90. Found: C, 
51.30; H, 4.31; N, 17.40. 
6.4.3 Synthesis of [Pd(H2bapbpy)](PF6)2 ([2](PF6)2) 
In a 2-necked round-bottom flask K2[PdCl4] (48 mg, 0.15 mmol), H2bapbpy (40 mg, 0.11 
mmol) and degassed ethanol-water mixture (7 : 3; 10 mL) were added. The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension. A 
precipitate was filtered off and the filtrate was concentrated in vacuo. Then, a saturated 
aqueous solution of KPF6 (5 mL) was added to the filtrate inducing the precipitation of a 
yellow solid. The suspension was filtered over a membrane filter and the complex was 
obtained as a yellow powder and dried in vacuo. Yield: 45 mg (51%). 1H NMR (300 MHz, 
DMSO-d6, 293 K, in ppm): δ = 12.25 (s, 2H, NH), 8.37 (dd, J = 7.8 Hz, 2H, H4), 8.29 (d, J = 6.9 
Hz, 2H, H3), 8.19 (dd, J = 7.8 Hz, 2H, py-4), 8.14 (d, J = 6.3 Hz, 2H, py-6), 7.63 (d, J = 8.1 Hz, 
2H, H5), 7.58 (d, J = 8.4 Hz, 2H, py-3), 7.29 (dd, J = 6 Hz, 2H, py-5). 13C NMR (75 MHz, 
DMSO-d6, 293 K, in ppm): δ = 149.47 (Cpy-6), 141.84 (C4), 141.37 (Cpy-4), 119.84 (Cpy-5), 117.44 
(C3), 116.01 (C5), 115.79 (Cpy-3). High resolution ES MS m/z (calc.): 445.0393 (445.0395, [M – 
2×PF6 – H]+). Elem. Anal. Calcd. for C20H16F12N6P2Pd: C, 32.61; H, 2.19; N, 11.41. Found: C, 32.74; 
H, 2.23; N, 11.68. 
6.4.4 Synthesis of [Pt(H2bapbpy)](PF6)2 ([3](PF6)2) 
In a 2-necked round bottom flask K2PtCl4 (305 mg, 0.73 mmol) H2bapbpy, (200 mg, 0.59 
mmol), and degassed ethanol-water mixture (3 : 2; 30 mL) were added. The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension. Then, 
the suspension was cooled to room temperature, and subsequently cooled on ice. The 
precipitate was filtered off and the filtrate was concentrated in vacuo. Then, a saturated 
aqueous solution of KPF6 (3.5 mL) was added to the filtrate inducing a yellow solid to 
precipitate. The suspension was filtered over a membrane filter, and washed with 10 mL 
water, 10 mL Et2O, and 10 mL hexanes. The complex was obtained as a yellow powder and 
dried in vacuo. Yield: 150 mg (75%). 1H NMR (500 MHz, DMSO-d6, 293 K, in ppm): δ = 12.32 
(s, 2H, NH), 8.48 (dd, J = 8 Hz, 2H, H4), 8.41 (d, J = 7.6 Hz, 2H, H3), 8.36 (d, J = 6.4 Hz, 2H, 
Hpy-6), 8.27 (dd, J = 8.8 Hz, 2H, Hpy-4), 7.69 (d, J = 8 Hz, 2H, H5), 7.62 (d, J = 8.4 Hz, 2H, Hpy-3), 
7.28 (dd, J = 6.8 Hz, 2H, Hpy-5). 13C NMR (126 MHz, DMSO-d6, 293 K, in ppm): δ = 152.42, 




(hydrolyzed), and make a cisplatin-like prodrug approach that requires 
intracellular activation unlikely. However, coordination of a tetradentate ligand to 
ensure compound stability potentially prevents this problem. With the ligand 
H2bapbpy a remarkably high uptake (also for the platinum analogue) is observed. 
Furthermore, the results in this chapter have demonstrated that the MoA of the 
palladium complex [2](PF6)2 might involve the disturbance of the cellular redox 
balance without intracellular activation. The unchanged activity of the 
geometrically identical [3](PF6)2 when co-treated with oxidative stress regulators 
NAC or BSO indicate that interference with the redox balance in cancer cells does 
not seem to be a major player in the MoA of [3](PF6)2. 
In vivo experiments further confirmed that different activity of the structurally 
similar complexes [2](PF6)2 and [3](PF6)2 is not limited to cell culturing 
experiments. In CT-26-bearing mice models [2](PF6)2 is superior in reducing tumor 
volume compared to [3](PF6)2 in an equimolar low-dosage treatment regime. 
However, as this regime was a consequence of dose-limiting toxicities of [2](PF6)2, 
treatment with higher dosages of [3](PF6)2 are necessary to clarify whether also the 
platinum complex is a viable anticancer drug. Experiments to investigate whether 
[3](PF6)2 is able to reduce tumor volume in a higher dosage treatment regime are 
currently planned.  
 Experimental  6.4
6.4.1 Materials and methods 
All NMR spectra were recorded on a Bruker DPX-300 or AV-500 spectrometer. Chemical 
shifts are indicated in ppm relative to tetramethylsilane. Mass spectra were recorded by 
using a positive ionization mode. The elemental ultra-trace analyses were performed with 
an FAST (Elemental Scientific, Omaha, Nebraska, USA), i-CAP-Q ICP-MS (Thermo 
Scientific, Walthem, Massachusetts, USA) MP2 peristaltic pump controlled flow 110 µl/min 
standardized setup.  
The ligand 6,6’-bis[N-(pyridyl)-1-amino]-2,2’-bipyridine (H2bapbpy), was synthesized 
according to literature procedures.26 NiCl2 • 6H2O was purchased from J.T. Baker. K2[PdCl4] 
was purchased from Acros. K2[PtCl4] and cisplatin were purchased from Sigma-Aldrich.  
6.4.2 Synthesis of [Ni(H2bapbpy)(OH2)2]Cl2 ([1]Cl2) 
In a 2-necked round-bottom flask [NiCl2 • 6H2O] (42 mg, 0.18 mmol), H2bapbpy (60 mg, 0.18 
mmol), and degassed ethanol (15 mL) were added. The brown suspension was stirred 
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overnight at 80 °C under argon resulting in a brown suspension. A brown powder was 
collected by filtration, washed with 10 mL EtOH, 10 mL Et2O, and 10 mL hexanes. The 
complex was dried overnight in vacuo. Yield: 56 mg (63%). 1H NMR (500 MHz, D2O, 293 K, in 
ppm): δ = 136.6 (s), 65.8 (s), 58.9 (s), 51.8 (s), 36.1 (s), 17.0 (s), 13.7 (s). Due to the paramagnetic 
properties of this compound, no 1H NMR assignment or 13C NMR measurement could be 
performed. High resolution ES MS m/z (calc): 397.0700 (397.0706, [M – 2×H2O – 2×Cl – H]+). 
Elem. Anal. Calcd. For C20H20Cl2N6NiO2 + C20H18N6NiO2: C, 51.16; H, 4.08; N, 17.90. Found: C, 
51.30; H, 4.31; N, 17.40. 
6.4.3 Synthesis of [Pd(H2bapbpy)](PF6)2 ([2](PF6)2) 
In a 2-necked round-bottom flask K2[PdCl4] (48 mg, 0.15 mmol), H2bapbpy (40 mg, 0.11 
mmol) and degassed ethanol-water mixture (7 : 3; 10 mL) were added. The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension. A 
precipitate was filtered off and the filtrate was concentrated in vacuo. Then, a saturated 
aqueous solution of KPF6 (5 mL) was added to the filtrate inducing the precipitation of a 
yellow solid. The suspension was filtered over a membrane filter and the complex was 
obtained as a yellow powder and dried in vacuo. Yield: 45 mg (51%). 1H NMR (300 MHz, 
DMSO-d6, 293 K, in ppm): δ = 12.25 (s, 2H, NH), 8.37 (dd, J = 7.8 Hz, 2H, H4), 8.29 (d, J = 6.9 
Hz, 2H, H3), 8.19 (dd, J = 7.8 Hz, 2H, py-4), 8.14 (d, J = 6.3 Hz, 2H, py-6), 7.63 (d, J = 8.1 Hz, 
2H, H5), 7.58 (d, J = 8.4 Hz, 2H, py-3), 7.29 (dd, J = 6 Hz, 2H, py-5). 13C NMR (75 MHz, 
DMSO-d6, 293 K, in ppm): δ = 149.47 (Cpy-6), 141.84 (C4), 141.37 (Cpy-4), 119.84 (Cpy-5), 117.44 
(C3), 116.01 (C5), 115.79 (Cpy-3). High resolution ES MS m/z (calc.): 445.0393 (445.0395, [M – 
2×PF6 – H]+). Elem. Anal. Calcd. for C20H16F12N6P2Pd: C, 32.61; H, 2.19; N, 11.41. Found: C, 32.74; 
H, 2.23; N, 11.68. 
6.4.4 Synthesis of [Pt(H2bapbpy)](PF6)2 ([3](PF6)2) 
In a 2-necked round bottom flask K2PtCl4 (305 mg, 0.73 mmol) H2bapbpy, (200 mg, 0.59 
mmol), and degassed ethanol-water mixture (3 : 2; 30 mL) were added. The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension. Then, 
the suspension was cooled to room temperature, and subsequently cooled on ice. The 
precipitate was filtered off and the filtrate was concentrated in vacuo. Then, a saturated 
aqueous solution of KPF6 (3.5 mL) was added to the filtrate inducing a yellow solid to 
precipitate. The suspension was filtered over a membrane filter, and washed with 10 mL 
water, 10 mL Et2O, and 10 mL hexanes. The complex was obtained as a yellow powder and 
dried in vacuo. Yield: 150 mg (75%). 1H NMR (500 MHz, DMSO-d6, 293 K, in ppm): δ = 12.32 
(s, 2H, NH), 8.48 (dd, J = 8 Hz, 2H, H4), 8.41 (d, J = 7.6 Hz, 2H, H3), 8.36 (d, J = 6.4 Hz, 2H, 
Hpy-6), 8.27 (dd, J = 8.8 Hz, 2H, Hpy-4), 7.69 (d, J = 8 Hz, 2H, H5), 7.62 (d, J = 8.4 Hz, 2H, Hpy-3), 
7.28 (dd, J = 6.8 Hz, 2H, Hpy-5). 13C NMR (126 MHz, DMSO-d6, 293 K, in ppm): δ = 152.42, 
149.25, 147.19, 146.10, 141.05, 119.85, 117.76, 116.43, 116.01. High resolution ES MS m/z (calc.): 
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534.0998 (534.1001, [M – 2×PF6 – H]+). Elem. Anal. Calcd. For C20H16F12N6P2Pt + ½ EtOH + ½ 
H2O: C, 30.71; H, 2.45; N, 10.23. Found: C, 30.62; H, 2.31; N, 10.09.  
 
Figure 6.5 Schematic representation of [1]Cl2, [2](PF6)2, and [3](PF6)2 with atom numbering 
used in NMR attribution.  
6.4.5 Crystallography 
Single crystals were obtained by the vapor diffusion method. In short, [1]Cl2 was dissolved 
MeOH (1 mg/mL) or [2](PF6)2 and [3](PF6)2 in acetonitrile (0.5 mg/mL) and put in a small 
vial. This vial was placed in a larger vial containing 2.8 mL Et2O (for [1]Cl2 and [2](PF6)2) or 
toluene (for [3](PF6)2). The large vial was closed and vapor diffusion occurred within a few 
days to afford X-ray quality crystals. 
All reflection intensities were measured at 110(2) K using a SuperNova diffractometer 
(equipped with Atlas detector) with Mo Kα radiation (λ = 0.71073 Å) for [1]Cl2 and [2](PF6)2 
and with Cu Kα radiation (λ = 1.54178 Å) for [3](PF6)2 under the program CrysAlisPro 
(Version 1.171.36.32 Agilent Technologies, 2013). The temperature of the data collection was 
controlled using the system Cryojet (manufactured by Oxford Instruments). CrysAlisPro 
program was used to refine the cell dimensions and for data reduction. The structure was 
solved by direct methods with SHELXS-2014/7 (Sheldrick, 2015) and was refined on F2 with 
SHELXL-2014/7 (Sheldrick, 2015). Analytical numeric absorption correction based on a 
multifaceted crystal model was applied using CrysAlisPro. The H atoms were placed at 
calculated positions (unless otherwise specified) using the instructions AFIX 43 with 
isotropic displacement parameters having values 1.2 Ueq of the attached C atoms. The 
structure is ordered 
Additional notes for [1]Cl2: The asymmetric unit contains 1.5 molecules of [1]2+, threw Cl− 
counteranions One of the two complex molecules is found at sites of twofold axial 
symmetry, and only one half of the molecule is crystallographically independent. Cl3 and 
Cl4 have occupancies of 0.5 as both are located at sites of twofold axial symmetry. 
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Additional notes for [2](PF6)2: One of the two PF6− counteranions is disordered over three 
orientations. The occupancy factors of the three components of the disorder refine to 
0.491(3), 0.292(3) and 0.217(3) 
Additional notes for [Pt(Hbapbpy)]PF6: The PF6− counteranion is disordered over two 
orientations. The occupancy factors of the major component of the disorder refines to 
0.661(10). Checks for H atoms attached to N2 and N5 were performed looking at difference 
Fourier maps. The H atom on N5 could be found, and there are intermolecular N−H…F 
interactions. On the other hand, there is no H atom attached to N2. The N2−C distances 
(C5−N2 = 1.354(7), C6−N2 = 1.336(7)) are significantly shorter than the N5−C distances 
(C15−N5 = 1.373(8), C16−N5 = 1.398(8)).  
6.4.6 Cell culturing and EC50 cytotoxicity assay 
See Appendix I for extensive description of the assay.  
6.4.7 Cell fractionation and isolation of mitochondria 
Cell fractionation for intracellular distribution studies for complexes [1]Cl2, [2](PF6)2, 
[3](PF6)2, and cisplatin were conducted on A549 lung cancer cells. 3 × 106 cells were seeded at 
t = 0 h in Opti-MEM complete in 175 cm2 flasks. At t = 24 h cells were treated with complexes 
to give final concentrations of 70, 0.2, 1.0, and 3.3 µM for respectively [1]Cl2, [2](PF6)2, 
[3](PF6)2, and cisplatin in a total volume of 24 mL. After 24 h of drug incubation at 37 °C, the 
medium was removed, the cells were washed with PBS-buffer, trypsinized, counted and 
pelleted by centrifugation (700 × g, 5 min, at room temperature). Then, the pellets were 
fractionated using the FractionPREP cell fractionation kit from BioVision or Mitochondria 
Isolation Kit for Cultured Cells from ThermoFisher according to the instruction of the 
supplier. Samples were digested overnight in concentrated nitric acid (> 65%) and diluted 
with MilliQ water to obtain a final concentration of 5% HNO3. For ICP-MS measurements, 
the system was optimized with a palladium-platinum solution. The calibration range was 
from 0 to 25 µg/l, and obtained detection limit for all isotopes was 0.01 µg/l. Silver and 
indium were used for internal standard, to correct for sample dependent matrix effects. The 
recoveries of the spiked concentrations were all within a 10% deviation. The data from three 
independent biological replications was used to obtain the values shown in Table 6.2.  
6.4.8 DNA binding studies 
The pUC19 plasmid used for this study (2686 bp) exists in three forms: supercoiled (SC), 
single-nicked open circular (OC) and linear dimer (LD). Of particular interest are the SC and 
OC forms. Although these two forms have the same number of bp, the SC form migrates 
faster through the agarose gel than the OC form due to the condensed SC form. However, as 
positively charged metal complexes associate with the SC form, the shape may become 
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(equipped with Atlas detector) with Mo Kα radiation (λ = 0.71073 Å) for [1]Cl2 and [2](PF6)2 
and with Cu Kα radiation (λ = 1.54178 Å) for [3](PF6)2 under the program CrysAlisPro 
(Version 1.171.36.32 Agilent Technologies, 2013). The temperature of the data collection was 
controlled using the system Cryojet (manufactured by Oxford Instruments). CrysAlisPro 
program was used to refine the cell dimensions and for data reduction. The structure was 
solved by direct methods with SHELXS-2014/7 (Sheldrick, 2015) and was refined on F2 with 
SHELXL-2014/7 (Sheldrick, 2015). Analytical numeric absorption correction based on a 
multifaceted crystal model was applied using CrysAlisPro. The H atoms were placed at 
calculated positions (unless otherwise specified) using the instructions AFIX 43 with 
isotropic displacement parameters having values 1.2 Ueq of the attached C atoms. The 
structure is ordered 
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counteranions One of the two complex molecules is found at sites of twofold axial 
symmetry, and only one half of the molecule is crystallographically independent. Cl3 and 
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Additional notes for [2](PF6)2: One of the two PF6− counteranions is disordered over three 
orientations. The occupancy factors of the three components of the disorder refine to 
0.491(3), 0.292(3) and 0.217(3) 
Additional notes for [Pt(Hbapbpy)]PF6: The PF6− counteranion is disordered over two 
orientations. The occupancy factors of the major component of the disorder refines to 
0.661(10). Checks for H atoms attached to N2 and N5 were performed looking at difference 
Fourier maps. The H atom on N5 could be found, and there are intermolecular N−H…F 
interactions. On the other hand, there is no H atom attached to N2. The N2−C distances 
(C5−N2 = 1.354(7), C6−N2 = 1.336(7)) are significantly shorter than the N5−C distances 
(C15−N5 = 1.373(8), C16−N5 = 1.398(8)).  
6.4.6 Cell culturing and EC50 cytotoxicity assay 
See Appendix I for extensive description of the assay.  
6.4.7 Cell fractionation and isolation of mitochondria 
Cell fractionation for intracellular distribution studies for complexes [1]Cl2, [2](PF6)2, 
[3](PF6)2, and cisplatin were conducted on A549 lung cancer cells. 3 × 106 cells were seeded at 
t = 0 h in Opti-MEM complete in 175 cm2 flasks. At t = 24 h cells were treated with complexes 
to give final concentrations of 70, 0.2, 1.0, and 3.3 µM for respectively [1]Cl2, [2](PF6)2, 
[3](PF6)2, and cisplatin in a total volume of 24 mL. After 24 h of drug incubation at 37 °C, the 
medium was removed, the cells were washed with PBS-buffer, trypsinized, counted and 
pelleted by centrifugation (700 × g, 5 min, at room temperature). Then, the pellets were 
fractionated using the FractionPREP cell fractionation kit from BioVision or Mitochondria 
Isolation Kit for Cultured Cells from ThermoFisher according to the instruction of the 
supplier. Samples were digested overnight in concentrated nitric acid (> 65%) and diluted 
with MilliQ water to obtain a final concentration of 5% HNO3. For ICP-MS measurements, 
the system was optimized with a palladium-platinum solution. The calibration range was 
from 0 to 25 µg/l, and obtained detection limit for all isotopes was 0.01 µg/l. Silver and 
indium were used for internal standard, to correct for sample dependent matrix effects. The 
recoveries of the spiked concentrations were all within a 10% deviation. The data from three 
independent biological replications was used to obtain the values shown in Table 6.2.  
6.4.8 DNA binding studies 
The pUC19 plasmid used for this study (2686 bp) exists in three forms: supercoiled (SC), 
single-nicked open circular (OC) and linear dimer (LD). Of particular interest are the SC and 
OC forms. Although these two forms have the same number of bp, the SC form migrates 
faster through the agarose gel than the OC form due to the condensed SC form. However, as 
positively charged metal complexes associate with the SC form, the shape may become 
larger and it will be less negatively charged, ultimately resulting in slower migration. 
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Alternatively, if metal complexes coordinatively modify the OC form, it may induce coiling 
or a condensed structure causing an increase in migration and thus coalescence of the SC 
and OC form on increasing metal complex concentration. However, if there is no 
condensation of the OC plasmid structure, but the positively charged metal complexes 
associate with the OC form then the observed migration would be retarded.  
Agarose gel electrophoresis was used to assay the binding of [1]Cl2, [2](PF6)2, and [3](PF6)2 to 
pUC19 plasmid DNA. Two buffers were used for the experiments: 5X tris-boric acid buffer 
(TBA) and phosphate buffer (PB). TBA (45 mM tris(hydroxymethyl)amino methane and 45 
mM boric acid, pH = 7.4) was used in the gel and running buffer. PB (100 mM NaH2PO4, pH 
= 7.0) was used for DNA-MC interactions. The agarose gels were 0.8% w/w agarose gel (0.24 
g agarose, 24 g DI H2O, and 6 mL TBA) and were cast in the OWL B1A Easycast system. 
The molar concentration of the pUC19 plasmid DNA base pairs (BP) was determined using 
its extinction coefficient (ε260 nm = 13,200 M−1cm−1).27 All aliquots were prepared with a final 
volume of 20 µL and prior to loading 4 µL of 6X loading dye was added. The λ DNA-
HindIII digest molecular weight (MW) marker was prepared by adding 2 µL (1 µg) of the 
DNA MW marker, 18 µL PB, and 4 µL 6X loading dye. The MW marker was heated for 3 
min at 60 °C prior to loading. In each well, 12 µL (1 µg of pUC19 DNA or 0.5 µg of MW 
marker) of each sample was loaded. 
For each gel, the electrophoresis chamber was filled with 50 mL TBA and 210 mL 
demineralized H2O. Each gel was run at a constant voltage of 105 V for 90 min. All gels were 
stained using 10 µL (10 mg/mL) ethidium bromide in 200 mL demineralized H2O for 30 min 
with slight shaking and then destained in 200 mL demineralized H2O for 20 min. 
Immediately following destaining, the gel was imaged using a BioRad ChemiDoc imaging 
system (ethidium bromide setting). Image Lab software was used to process the images. 
The samples for thermal binding were prepared under ambient light in amber centrifuge 
tubes. For each sample 2 µL of pUC19 plasmid (2 µg, [BP]f = 1.95 × 10-3 M) was used and the 
amount of metal complex and PB were adjusted to a final volume of 20 µL. Several ratios of 
base pairs of the plasmid (BP) to metal complex (MC) (200:1, 75:1, 50:1, 25:1, 10:1, and 5:1 
BP:MC) were incubated at 37 °C for 24 h. Additionally, the negative control (DNA without 
metal complex) and a positive control (cisplatin, 5:1 BP:MC ratio) were incubated under the 
same conditions. Lanes were loaded as follows: (1) λ MW marker, (2) DNA only control, (3) 
cisplatin (5:1 BP:MC, [cisplatin]f = 390 µM) control, (4) M complex ([1]Cl2, [2](PF6)2, or 
[3](PF6)2) (200:1 BP:MC, [M]f = 10 µM), (5) M complex (75:1 BP:MC, [M]f = 26 µM), (6) M 
complex (50:1 BP:MC, [M]f = 39 µM), (7) M complex (25:1 BP:MC, [M]f = 78 µM), (8) M 
complex (10:1 BP:MC, [M]f = 195 µM), (9) M complex (5:1 BP:MC, [M]f = 391 µM), and (10) 
DNA only control. The gels were run, stained, and processed as described above. 
 
129 
6.4.9 Impact of alterations in cellular glutathione (GSH) levels on metal drug activity 
The cytotoxic impact of the investigated metal compounds alone or in combination with the 
GSH precursor N-acetyl-L-cysteine (NAC) and the GSH-depleting agent buthionine 
sulfoximine (BSO) was investigated based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT)-based viability assay (EZ4U, Biomedica) as published.28 In 
short, cells were seeded in 96-well plates (2 × 103/well) and after a 24 h recovery period, 
pretreated with NAC (1 or 2 mM) or BSO (1 µM) for 1 h. Then solutions of the metal 
complexes were added to the preincubated cells for a 72 h continuous exposure alone or in 
presence of NAC or BSO and viability was determined by MTT assay. 
6.4.10 Impact of the genomic p53 status on metal drug sensitivity of colon cancer RKO 
cells 
Evaluation of the anticancer activity of [2](PF6)2 and [3](PF6)2 was performed for isogenic 
RKO cell sublines harboring wild-type, mutant, and knock-out status of the tumor 
suppressor gene p53. Cells were seeded and processed as indicated under section 6.4.9.  
6.4.11 Animal experiments 
All animal experiments were approved by the local ethics committee and carried out 
according to the Austrian and FELASA guidelines for animal care and protection and 
performed under supervision of prof. dr. Walter Berger of the Institute of Cancer Research, 
Vienna. 6- to 8-week-old Balb/c mice (weighing 25–30 g) were purchased from Harlan 
Laboratories, San Pietro al Natisone, Italy. The animals were kept in a pathogen-free 
environment and every procedure was done in a laminar airflow cabinet.  
6.4.12 Anticancer activity against CT-26 cells 
Murine CT-26 cells (5 × 105) were injected subcutaneously into the right flank of female 
Balb/c mice. At the day of measurable tumor appearance, treatment was started. Mice were 
treated with the drug intraperitoneally (solutions freshly prepared in water with 10% v/v 
DMSO) at indicated drug concentrations on days 3, 5, 7, 10, and 12. Animals were controlled 
for distress development every day and tumor size was assessed regularly by caliper 
measurement. Tumor volume was calculated using the formula: length × width2/2. 






Alternatively, if metal complexes coordinatively modify the OC form, it may induce coiling 
or a condensed structure causing an increase in migration and thus coalescence of the SC 
and OC form on increasing metal complex concentration. However, if there is no 
condensation of the OC plasmid structure, but the positively charged metal complexes 
associate with the OC form then the observed migration would be retarded.  
Agarose gel electrophoresis was used to assay the binding of [1]Cl2, [2](PF6)2, and [3](PF6)2 to 
pUC19 plasmid DNA. Two buffers were used for the experiments: 5X tris-boric acid buffer 
(TBA) and phosphate buffer (PB). TBA (45 mM tris(hydroxymethyl)amino methane and 45 
mM boric acid, pH = 7.4) was used in the gel and running buffer. PB (100 mM NaH2PO4, pH 
= 7.0) was used for DNA-MC interactions. The agarose gels were 0.8% w/w agarose gel (0.24 
g agarose, 24 g DI H2O, and 6 mL TBA) and were cast in the OWL B1A Easycast system. 
The molar concentration of the pUC19 plasmid DNA base pairs (BP) was determined using 
its extinction coefficient (ε260 nm = 13,200 M−1cm−1).27 All aliquots were prepared with a final 
volume of 20 µL and prior to loading 4 µL of 6X loading dye was added. The λ DNA-
HindIII digest molecular weight (MW) marker was prepared by adding 2 µL (1 µg) of the 
DNA MW marker, 18 µL PB, and 4 µL 6X loading dye. The MW marker was heated for 3 
min at 60 °C prior to loading. In each well, 12 µL (1 µg of pUC19 DNA or 0.5 µg of MW 
marker) of each sample was loaded. 
For each gel, the electrophoresis chamber was filled with 50 mL TBA and 210 mL 
demineralized H2O. Each gel was run at a constant voltage of 105 V for 90 min. All gels were 
stained using 10 µL (10 mg/mL) ethidium bromide in 200 mL demineralized H2O for 30 min 
with slight shaking and then destained in 200 mL demineralized H2O for 20 min. 
Immediately following destaining, the gel was imaged using a BioRad ChemiDoc imaging 
system (ethidium bromide setting). Image Lab software was used to process the images. 
The samples for thermal binding were prepared under ambient light in amber centrifuge 
tubes. For each sample 2 µL of pUC19 plasmid (2 µg, [BP]f = 1.95 × 10-3 M) was used and the 
amount of metal complex and PB were adjusted to a final volume of 20 µL. Several ratios of 
base pairs of the plasmid (BP) to metal complex (MC) (200:1, 75:1, 50:1, 25:1, 10:1, and 5:1 
BP:MC) were incubated at 37 °C for 24 h. Additionally, the negative control (DNA without 
metal complex) and a positive control (cisplatin, 5:1 BP:MC ratio) were incubated under the 
same conditions. Lanes were loaded as follows: (1) λ MW marker, (2) DNA only control, (3) 
cisplatin (5:1 BP:MC, [cisplatin]f = 390 µM) control, (4) M complex ([1]Cl2, [2](PF6)2, or 
[3](PF6)2) (200:1 BP:MC, [M]f = 10 µM), (5) M complex (75:1 BP:MC, [M]f = 26 µM), (6) M 
complex (50:1 BP:MC, [M]f = 39 µM), (7) M complex (25:1 BP:MC, [M]f = 78 µM), (8) M 
complex (10:1 BP:MC, [M]f = 195 µM), (9) M complex (5:1 BP:MC, [M]f = 391 µM), and (10) 
DNA only control. The gels were run, stained, and processed as described above. 
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6.4.9 Impact of alterations in cellular glutathione (GSH) levels on metal drug activity 
The cytotoxic impact of the investigated metal compounds alone or in combination with the 
GSH precursor N-acetyl-L-cysteine (NAC) and the GSH-depleting agent buthionine 
sulfoximine (BSO) was investigated based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT)-based viability assay (EZ4U, Biomedica) as published.28 In 
short, cells were seeded in 96-well plates (2 × 103/well) and after a 24 h recovery period, 
pretreated with NAC (1 or 2 mM) or BSO (1 µM) for 1 h. Then solutions of the metal 
complexes were added to the preincubated cells for a 72 h continuous exposure alone or in 
presence of NAC or BSO and viability was determined by MTT assay. 
6.4.10 Impact of the genomic p53 status on metal drug sensitivity of colon cancer RKO 
cells 
Evaluation of the anticancer activity of [2](PF6)2 and [3](PF6)2 was performed for isogenic 
RKO cell sublines harboring wild-type, mutant, and knock-out status of the tumor 
suppressor gene p53. Cells were seeded and processed as indicated under section 6.4.9.  
6.4.11 Animal experiments 
All animal experiments were approved by the local ethics committee and carried out 
according to the Austrian and FELASA guidelines for animal care and protection and 
performed under supervision of prof. dr. Walter Berger of the Institute of Cancer Research, 
Vienna. 6- to 8-week-old Balb/c mice (weighing 25–30 g) were purchased from Harlan 
Laboratories, San Pietro al Natisone, Italy. The animals were kept in a pathogen-free 
environment and every procedure was done in a laminar airflow cabinet.  
6.4.12 Anticancer activity against CT-26 cells 
Murine CT-26 cells (5 × 105) were injected subcutaneously into the right flank of female 
Balb/c mice. At the day of measurable tumor appearance, treatment was started. Mice were 
treated with the drug intraperitoneally (solutions freshly prepared in water with 10% v/v 
DMSO) at indicated drug concentrations on days 3, 5, 7, 10, and 12. Animals were controlled 
for distress development every day and tumor size was assessed regularly by caliper 
measurement. Tumor volume was calculated using the formula: length × width2/2. 
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Metal complexes containing the tetrapyridyl ligand 2,2’:6’,2”:6”,2”’-quaterpyridine 
(qtpy, Figure 7.1) were first reported in the 1970s, and were based on iron(III).1 
Since then qtpy has been coordinated to various metal centers (FeII, CoII, NiII, ZnII, 
RuII, PdII, and AgI),2-6 and for example [Pt(qtpy)]2+ was found to be the best DNA 
intercalator of a series of platinum complexes with mono-, bi-, tri-, and tetradentate 
pyridyl ligands.7 The absence of reports on the cytotoxicity of these complexes, as 
well as the absence of further development of [M(qtpy)]2+ square-planar complexes 
as anticancer compounds, may imply that they exhibit poor anticancer activity. 
According to the cisplatin paradigm, a saturated coordination sphere such as that 
of square-planar qtpy metal complexes does not allow the metal to coordinate 
DNA, which may have discouraged the development of this type of complexes.8, 9 
It was recently suggested that octahedral qtpy complexes such as trans-
[Ru(qtpy)Cl2] may alleviate this issue, as the two axial positions do allow for 
binding to biomolecules.6 
Unlike qtpy complexes of column 10 transition metals, those based on the 
H2bapbpy ligand (N,N’-di(pyrid-2-yl)-2,2’-bipyridine-6,6’-diamine, Figure 7.1) 
have shown high to extremely high cytotoxic activity in vitro and promising tumor-
reducing activity in vivo as shown in Chapter 6. As they share with qtpy metal 
complexes a fully saturated coordination sphere, the introduction of the two non-
coordinating amine bridges thus has a remarkable effect on their interaction with 
biological systems (see Chapter 6). Meanwhile, Ni2+, Cu2+, Ru2+, Pt4+, or Os2+ metal 
complexes based on the bidentate ligand 2,2’-dipyridylamine (Hdpa, Figure 7.1), 
also containing a non-coordinating secondary amine, (and) have recently been 
reported to exhibit interesting in vitro anticancer activity.10-16 Thus, non-
coordinating amine bridges may play a specific role in tuning the biological and 
anticancer activity of metal compounds.  
The research described in this chapter is dedicated to unraveling the reactivity of 
non-coordinated amine bridges in Pd2+ and Pt2+ complexes of the H2bapbpy ligand. 
More specifically, the overall depletion of electron density of H2bapbpy upon metal 
binding leads to enhanced acidity of the amine bridge. As deprotonation of the 
[M(H2bapbpy)]2+ complex lowers the overall charge of the complex and thus may 
contribute to modifying cellular uptake, the pKa of [Pd(H2bapbpy)]2+ ([1]2+) and 
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[Pt(H2bapbpy)]2+ ([2]2+) was determined, and the influence of amine deprotonation 
forming [Pd(Hbapbpy)]+ ([3]+) and [Pt(Hbapbpy)]+ ([4]+), on their spectroscopic 
properties was studied. We were notably able to isolate the two neutral complexes 
[Pd(bapbpy)] ([5]) and [Pt(bapbpy)] ([6]), in which both amine bridges of the 
H2bapbpy ligand are deprotonated, and monitored the equilibria between [5] or 
[6], their monoprotonated monocationic forms [3]+ or [4]+, and their bis-protonated, 
dicationic forms [1]2+ or [2]2+, respectively. 
 
Figure 7.1 Chemical structures of the polypyridyl qtpy, H2bapbpy, and Hdpa ligands. 
 Results  7.2
7.2.1 pKa determination  
Addition of a base such as NaOH to aqueous solutions of [1]Cl2 or [2]Cl2 was 
accompanied by instantaneous color changes, which was spectroscopically 
characterized by the rise of a wide absorption band between 420 and 550 nm. For 
both complexes this color change was reversed by addition of an excess acid. Such 
instantaneous and reversible change of the absorbance spectra upon pH variation 
suggested that an acid-base reaction was taking place, as supramolecular stacking 
interactions and ligand exchange reactions on transition metal complexes typically 
occur over longer time scales.17 The pKa of the deprotonation equilibrium of [1]2+ or 
[2]2+ to form [3]+ or [4]+, respectively (Scheme 7.1), was determined by controlled 
titration of aqueous solution of [1]Cl2 or [2]Cl2 (67 µM) in hydrochloric acid (33 
mM) using aliquots of aqueous sodium hydroxide. The evolution of the UV-vis 
spectra of both solutions as a function of pH is plotted in Figure 7.2. Next to the 
new bands appearing in the visible region, the absorption of both complexes in the 
UV domain diminished in intensity and shifted slightly hypsochromically. The 
pKa values for the first deprotonation of [1]2+ and [2]2+ were found to be 7.8 and 8.3, 
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UV domain diminished in intensity and shifted slightly hypsochromically. The 
pKa values for the first deprotonation of [1]2+ and [2]2+ were found to be 7.8 and 8.3, 
respectively. Thus, at physiological pH (7.4) the palladium complex [1]2+ is partially 
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deprotonated, while its platinum analogue [2]2+ is mostly in the dicationic form. 
For both complexes increasing the pH above 9.5 led to precipitation. These 
precipitates were hypothesized to be the neutral forms of the complexes: [5] and 
[6].  
 
Scheme 7.1 General scheme of different protonation states of palladium and platinum 
H2bapbpy complexes.  
To confirm this hypothesis, both solids were prepared by first reacting H2bapbpy 
with K2[PdCl4] or K2[PtCl4] in a hot ethanol-water mixture, filtering the reaction 
mixture, and treating the filtrate with an excess NaOH (5.0 M). The resulting 
precipitate was washed and dried. Double deprotonation was confirmed by NMR 
spectroscopy and X-ray crystallography (see section 7.2.4). Of all solvents tried, 
THF was the only one which would dissolve [5] or [6]. Thus, a reverse titration was 
repeated in a 1:1 THF-water mixture, starting from the isolated solids [5] or [6] by 
adding hydrochloric acid. Under these conditions, all species stayed in solution 
while the secondary amine bridges were gradually protonated. Figure 7.3A shows 
the UV-vis spectrum of [5], which is characterized by absorbance maxima in the 
visible region at 463 and 490 nm. Addition of six equivalents of HCl, resulted in the 
spectrum of the monocationic complex [3]+ (dotted curve in Figure 7.3A) via 
isosbestic points at 345 and 383 nm (Figure SVII.3A). Addition of two more 
equivalents of HCl was accompanied by well-defined isosbestic points at 318, 345, 
and 416 nm (Figure SVII.3B), to yield the characteristic UV-vis spectrum of [1]2+ 
(Figure 7.3A, dashed curve). Further acidification did not induce any extra change, 
indicating that the protonation was completed and that the complex is stable in 
acidic medium. The presence of two series of well-defined isosbestic points during 
acid addition allowed for clear distinction of conversion from [5] to [3]+ from that 
from [3]+ to [1]2+ (Scheme 7.1). Identical experiments with the platinum complex 
demonstrated that protonation from [6] to [4]+ and from [4]+ to [2]2+ also occurred 
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via similar isosbestic points, to re-form the platinum complex [2]2+ (Figure 7.3B, 
Figure SVII.4).  
Compounds [1]2+ and [2]2+ both show only low absorbance in the visible area (395-
580 nm). Upon deprotonation of one amine bridge the absorbance in this area 
increases, and the complexes in their monocationic forms have absorption maxima 
at 412 and 458 nm, respectively. Upon deprotonation of the second amine bridge, 
[5] and [6] are obtained and are characterized by new maxima at respectively 463 
and 490 nm, and 476 and 506 nm extending their absorbance tail up to 545 and 556 
nm. Experiments in 10 mM aqueous solutions of the sodium salts of either NO2−, 
NO3− , SO4−, Cl−, or I− resulted in no change in the UV-vis spectra indicating that 
these changes in absorbance are exclusively based on acid-base reactions and are 
not induced by coordination reaction or changes in ionic strength. Although the 
absorbance of the platinum species are bathochromatically shifted by 10-20 nm 
compared to the palladium species, the overall trends in acid-base evolutions of 
absorbance maxima are highly similar.  
7.2.2 Temperature effects on electronic absorption spectra 
Since [1]2+ and [2]2+ have been reported as potential anticancer drugs in a system at 
37 °C, the temperature dependence of their electronic absorbance spectra was 
studied. The complexes were dissolved in a 0.1 M phosphate buffer (10% v/v 
DMSO, pH = 7.4) and their UV-vis spectra were recorded at different temperatures. 
At 20 °C (blue curve, Figure 7.4) both complexes exhibited significant absorbance 
in the visible domain, indicating that a mixture between [1]2+ and [3]+ or [2]2+ and 
[4]+ was present. Heating [1]2+ and [2]2+ in the phosphate buffer up to 80 °C (red 
curve) showed an increase in absorbance between 420 and 580 nm for both 
compounds in a fashion very similar to the transition from [1]2+ to [3] + (Figure 
7.4A), and from [2]2+ to [4]+ (Figure 7.4B). The same experiment was performed in 
demineralized water yielding the same trends, though less pronounced (Figure 
SVII.5). As the pH of phosphate buffers does not deviate much (i.e., less than 0.05 
pH unit in the experimental range),18 these changes in the UV-vis spectra upon 
increasing the temperature can be attributed to temperature-induced 
deprotonation of the amine bridges. Thus, the conversion of [1]2+ to [3]+ or [2]2+ to 
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via similar isosbestic points, to re-form the platinum complex [2]2+ (Figure 7.3B, 
Figure SVII.4).  
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Figure 7.2 UV-vis absorbance spectra of a solution of [1]Cl2 (A) and [2]Cl2 (B) upon 
increasing pH using NaOH. Solvent: H2O. T = 293 K, [Pd] = [Pt] = 67 μM. 
 
Figure 7.3. UV-vis absorbance spectra of the different protonated states of the palladium 
(A) and platinum complexes (B). Neutral, monocationic, and dicationic species 
represented respectively as continuous, dotted, and dashed curve. Solvent: THF-water 
(1:1). T = 293 K, [Pd] = [Pt] = 67 μM. 
 
Figure 7.4 Evolution of UV-vis absorbance spectra of [1](PF6)2 (A) and [2](PF6)2 (B) in 
phosphate buffer at different temperatures (20 (blue) to 80 °C (red)). [Pd] = [Pt] = 0.1 mM, 
pH = 7.4.  
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7.2.3 Excited state calculations for [1]2+, [3]+, and [5] 
The color changes upon temperature and pH variation triggered us to perform 
TDDFT (Time-dependent density functional theory) calculations to characterize the 
singlet transitions of [1]2+, [3]+, and [5].19, 20 The theoretical electronic absorbance 
spectra were obtained by Dr. Sylvestre Bonnet by calculating the first 50 transitions 
(Figure SVII.6), which provided the basis for the spectra shown in Figure 7.5. The 
calculated electronic absorbance spectrum of [5] (black curve) shows clear 
absorbance in the visible region up to 485 nm. The calculated spectrum of [3]+ also 
shows absorbance in the visible region to a similar wavelength as [5] (490 nm) but 
much less intense. Finally, the calculated electronic absorption spectrum of [1]2+ 
only absorbs visible light up to 431 nm, but also at very low oscillator strength, and 
its absorbance spectrum is dominated by strong bands in the UV. These calculated 
spectra fit well the experimentally observed spectra (Figure 7.3A), and confirm that 
absorbance of the compounds indeed depends on the protonation state of the 
H2bapbpy ligand coordinated to palladium. 
 
Figure 7.5 TDDFT-calculated spectra for [1]2+ (dashed), [3]+ (dotted), and [5] (continuous) 
at the CAM-B3LYP/TZP/COSMO level in water. The theoretical curves were calculated 
and plotted in ADF with Gaussian Fixed Oscillator strengths. Scaling factor = 1.0, peak 
width = 30 nm. 
The excited states (Figure SVII.6) responsible for the main changes in the visible 
part of the absorbance spectra of [1]2+, [3]+, and [5] were visualized using ADF. All 
excited states relevant for absorbance in the visible domain have major 
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SVII.7, Figure SVII.8, and Figure SVII.9). In all protonation states the HOMO is 
localized on the non-coordinating amine bridge, whereas the LUMO is mainly on 
the bpy part of the ligand, and LUMO+1 mainly on the palladium center involving 
the dx2-y2 orbital. Because of steric repulsion between the two terminal pyridyl 
groups, these rings hardly provide any stabilization. Their orientation out of the 
bpy conjugation plane, strongly enhances the sp3 character of the amine bridge. To 
conclude, Intra-Ligand-Charge-Transfer HOMO  LUMO and Ligand-to-Metal-
Charge-Transfer HOMO LUMO+1 transitions are responsible for the increased 
absorbance in the visible domain when [1]2+ is deprotonated once or twice.  
7.2.4 X-ray structures of [1]2+, [3]+, and [5] 
Single crystals suitable for X-ray diffraction where obtained for all protonation 
states of the palladium compound. Vapor diffusion of diethyl ether into a solution 
of [1](PF6)2 in acetonitrile yielded single crystals of [1](PF6)2 (see also Chapter 6); 
apart from the complex cation and the hexafluorophosphate anions the asymmetric 
unit contains two molecules of acetonitrile. Surprisingly, diffusion of diethyl ether 
vapors into an acetone solution of [1](PF6)2 resulted in ruby-colored crystals of 
[3]2(HCOO)(PF6); the presence of the formate anion could be explained by CO2 
capture from the atmosphere. Diffusion of pentane vapors into a THF solution 
containing [5] yielded amber-colored, needle-shaped crystals suitable for X-ray 
diffraction; apart from the neutral complex the asymmetric unit contains three 
molecules of water. Projections of the complexes are provided in Figure 7.6; 
relevant bond distances and angles of the three complexes are reported in Table 7.1 
and Table 7.2, respectively.  
In all three compounds the palladium(II) ion is coordinated by the tetradentate 
ligand in a distorted square-planar geometry, with highly similar bond lengths and 
angles (Table 7.1 and Table 7.2). The bond length of Pd1-N1 and Pd1-N6 falls 
between 2.025(2)-2.047(6) Å and for Pd1-N3 and Pd1-N4 between 1.975(6)-1.994(3) 
Å. The coordination angles N1-Pd1-N4 and N3-Pd1-N6 were used to calculate τ4 
(Table 7.2). This value is indicative for the geometry of four-coordinate 
complexes.21 On a scale from 0 to 1, 0 represents a perfect square-planar geometry 
and 1 represents a perfect tetrahedral geometry. The compounds [1]2+, [3]+, and [5] 
have τ4 values of 0.193, 0.177, and 0.187, respectively, confirming that protonation 
or deprotonation of the complex barely affects the square-planar geometry. In 
addition, the torsion angles of the coordinating N1-N3-N4-N6 atoms, which are 
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17.3, 15.5, and 16.8° for [1]2+, [3]+, and [5], respectively, indicate the flatness of the 
coordination plane.22 As the total content of the unit cell must be charge neutral, 
the charges of the cationic complexes and counter anions should be balanced. The 
two PF6− counter anions in the structure of [1](PF6)2 suggest that the palladium 
complex is dicationic, with both amine nitrogen atoms protonated. Surprisingly, in 
[3]2(HCOO)(PF6) two counter anions were found per two palladium molecules, 
suggesting a monocationic form for each metal complex, thus with one of the two 
amine nitrogen atoms deprotonated. However, it may not be excluded that this 
structure contains one dicationic complex [1]2+ and one neutral complex [5]. 
Finally, for the third structure no counter anions were found, confirming that the 
palladium complex [5] is neutral.  
Table 7.1 Selected distances (Å) of [1]2+, [3]+, and [5], for atom-labelling see Figure 7.6. 
Bond [1]2+ [3]+ [5] 
Pd1-N1 2.0251(16) 2.047(3) 2.047(6) 
Pd1-N2 3.207(2) 3.235(3) 3.283(6) 
Pd1-N3 1.9846(16) 1.994(3) 1.974(7) 
Pd1-N4 1.9802(16) 1.978(3) 1.997(7) 
Pd1-N5 3.214(2) 3.305(3) 3.288(6) 
Pd1-N6 2.0312(16) 2.027(3) 2.032(7) 
N2-C5 1.390(3) 1.381(5) 1.335(10) 
N2-C6 1.372(3) 1.373(5) 1.359(10) 
N5-C15 1.363(3) 1.338(5) 1.338(10) 
N5-C16 1.372(3) 1.354(5) 1.345(10) 
 
As X-ray spectroscopy cannot always unequivocally confirm the presence of single 
protons, the deprotonation state of the amine bridges in the three structures was 
further checked by taking a closer look at the bond distances around the secondary 
amine nitrogen atoms. The distances between the amine nitrogen atoms and the 
connected pyridine carbon atoms clearly reflect the protonation state of the amines: 
whereas the C-N distances in [1]2+ range between 1.390(3) and 1.363(3) Å, these 
bond distances are significantly shorter in [5] (ranging from 1.335(10) to 1.359(10) 
Å, Table 7.1). These shorter distances are indicative of a higher double-bond 
character in the C-N bonds in [5], as would be expected upon deprotonation. In the 
structure of [3]2(HCOO)(PF6) two sets of C-N bond distances are observed within 
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protonated and one deprotonated amine nitrogen. Deprotonation of the amine 
bridges should also influence C-N-C angles. Indeed, these angles appear to be 
slightly smaller for the deprotonated amines (126.1(3)-127.5(7)°) than for the 
protonated amine nitrogens (129.5(2)-132.2(2)°). 
Table 7.2 Selected angles and structural parameters of [1]2+, [3]+, and [5], for atom-labelling 
see Figure 7.6.  
Angle [1]2+ [3]+ [5] 
N1-Pd1-N3 91.43(7) 91.00(12) 90.9(3) 
N3-Pd1-N4 82.19(7) 82.43(12) 83.0(3) 
N4-Pd1-N6 92.33(7) 91.81(12) 91.7(3) 
N6-Pd1-N1 96.38(7) 96.62(12) 96.5(3) 
N1-Pd1-N4 165.35(7) 167.06(12) 166.9(3) 
N3-Pd1-N6 167.38(7) 167.85(12) 166.7(3) 
C5-N2-C6 129.52(17) 130.0(3) 126.7(7) 
C15-N5-C16 132.22(18) 126.1(3) 127.5(7) 
N1-N3-N4-N6 17.3 15.5 16.8 





Overall, these structural observations clearly confirm that the palladium 
compound must be formulated as dicationic [1]2+, monocationic [3]+, and neutral 
[5], but protonation of the amine does not significantly influence the coordination 
mode of the ligand and geometry of the central metal ion. Finally, the solvent 
molecules and anions that are present in the crystal lattices of the compounds 
demonstrate specific H-bonding interactions that are in agreement with the 
protonation states of the compounds discussed above. In [1](PF6)2 the two lattice 
acetonitrile molecules form hydrogen bonds with the two amine nitrogens with N-
H∙∙∙N distances of 2.171 and 2.026 Å. By contrast, in the structure of [5] two of the 
lattice water molecules act as hydrogen bond donors to the amine nitrogens with 
N∙∙∙H-O distances of 1.985 and 2.055 Å. The formate ion in [3]+ forms two hydrogen 
bonds to the protonated amine nitrogens of two independent molecules, with N-






Figure 7.6 Displacement ellipsoid of [1]2+ (top), [3]+ (middle), and [5] (bottom) (all 50% 
probability level) as observed in the crystal structure of {[1](PF6)2 · 2×CH3CN}, 
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 Discussion & Conclusion 7.3
We have demonstrated in this chapter that the potential anticancer complexes [1]2+ 
and [2]2+ containing the H2bapbpy ligand have three distinct protonation states 
with increasing absorption in the visible region of the spectrum when the ligand is 
deprotonated. In water the pKa of the first deprotonation takes place close to 
physiological conditions (at 7.8 and 8.3 respectively for [1]2+ and [2]2+, Scheme 7.1). 
Such pH dependence of absorption has been reported in the literature for both 
organic and inorganic compounds, in which for instance protonation results in a 
positively charged amine that disturbs conjugation.23, 24 The difference in acidity 
between the palladium and platinum complexes may be of paramount importance 
for the different in vitro and in vivo activities of these complexes (see Chapter 6).  
Intracellular variation of the charge of these complexes, driven by local variations 
of the pH and of the polarity of the cellular medium (i.e. membranes vs. cytosol), 
may result in different compound configuration, uptake mechanisms, and 
biological activities in different cells and different parts of the cells. The ability to 
obtain a neutral, monocationic, or dicationic state, and thus the possibility to be 
taken up via passive diffusion, monocation transporters, or dication transporters, 
the absence of steric hindrances and the relatively flat geometry of these 
complexes, could explain the high uptake efficiency reported in Chapter 6. 
Furthermore, the crystal structures of [1]2+, [3]+, and [5] show that hydrogen 
bonding with the secondary bridging amines can occur either as donor or as 
acceptor or as both, which opens many routes to interact for example with nuclear 
DNA, contrary to the qtpy complexes that lack the possibility to engage in 
hydrogen bonding interactions. For a metal complex with a saturated coordination 
sphere that does not allow for the formation of coordination bonds with 
biomolecules, the ability to establish H-bonding interactions could strongly 
influence for instance binding to the phosphate backbone or DNA bases,25, 26 which 





7.4.1 Synthesis of [Pd(H2bapbpy)]Cl2 ([1]Cl2) and [Pd(H2bapbpy)]Cl2 ([2]Cl2) 
[1]Cl2 and [2]Cl2 were synthesized as described in Chapter 6. After isolation as PF6-salt in a 
flask the complexes were fully dissolved in CH3CN. Then, upon addition of aqueous HCl 
(10 M) precipitation occurred and a powder was filtered off which turned out to be [1]Cl2 or 
[2]Cl2 
7.4.2 Synthesis and crystallization of [Pd(bapbpy)] ([5]) 
K2[PdCl4] (163 mg, 0.15 mmol) and H2bapbpy (127 mg, 0.11 mmol) were added into a 2-neck 
25 ml round bottom flask containing a degassed ethanol-water mixture (3:2, 10 mL). The 
brown suspension was stirred overnight at 80 °C under argon resulting in a red suspension 
that was filtered. Then, aqueous NaOH (5.0 M) was added to the filtrate upon which a red 
solid precipitated. The suspension was filtered, washed with water, and redissolved in THF. 
After rotary evaporation the compound was dried in vacuo and obtained as a yellow 
powder. Yield: 45 mg (51%). Amber yellow needle-shaped crystals suitable for X-ray 
diffraction were obtained by dissolving 2.0 mg of [5] in 0.8 mL of THF in a small GC vial. 
This vial was placed in a larger vial containing 2.8 mL pentane. The large vial was closed 
and vapor diffusion occurred within a few days to afford X-ray quality crystals. 1H NMR 
(500 MHz, THF-d8, 293 K, in ppm): δ = 7.75 (dd, J = 6.5, 1.5 Hz, 2H, Hpy-6 ), 7.55 (dd, J = 8.5, 1.5 
Hz, 2H, H4), 7.41 (ddd, J = 8.5, 2.0, 1.0 Hz, 2H, Hpy-4), 7.27 (dd, J = 7.0, 1.0 Hz, 2H, H3), 6.99 (m, 
4H, H5/Hpy-3), (ddd, J = 6.5, 6.5, 1.5 Hz, Hpy-5). 13C NMR (126 MHz, THF-d8, 293 K, in ppm): δ = 
148.74 (Cpy-6), 136.76 (C4), 136.71 (Cpy-4), 124.56 (Cpy-3), 124.03 (C5), 113.16 (Cpy-5), 110.60 (C3).  
7.4.3 Crystallization of [Pd(Hbapbpy)]2(HCOO)(PF6) ([3]2(HCOO)(PF6)) 
Ruby red crystals suitable for X-ray diffraction were obtained by diffusion of diethyl ether 
into an acetone solution of [1](PF6)2. 0.3 mg of [1](PF6)2 was dissolved in 0.4 mL of acetone 
and placed in a small GC vial. This vial was placed in a larger vial containing 2.8 mL diethyl 
ether. The large vial was closed and vapor diffusion occurred after 7 days to afford X-ray 
quality crystals of [3]2(HCOO)(PF6) 
7.4.4 Synthesis of [Pt(bapbpy)] ([6]) 
K2[PtCl4] (48 mg, 0.15 mmol) and H2bapbpy (40 mg, 0.11 mmol) were added into a 2-neck 25 
ml round bottom flask containing a degassed ethanol-water mixture (7:3, 10 mL). The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension that 
was filtered. Then, aqueous NaOH (5.0 M) was added upon which a red solid to 
precipitated. The suspension was filtered, washed with water, and dissolved in THF. After 
rotary evaporation the compound was dried in vacuo and obtained as a yellow powder. 
Yield: 42 mg (46%). 1H NMR (500 MHz, 293 K, THF-d8, in ppm): δ = 7.91 (d, 6.5 Hz, 2H, Hpy-6), 




 Discussion & Conclusion 7.3
We have demonstrated in this chapter that the potential anticancer complexes [1]2+ 
and [2]2+ containing the H2bapbpy ligand have three distinct protonation states 
with increasing absorption in the visible region of the spectrum when the ligand is 
deprotonated. In water the pKa of the first deprotonation takes place close to 
physiological conditions (at 7.8 and 8.3 respectively for [1]2+ and [2]2+, Scheme 7.1). 
Such pH dependence of absorption has been reported in the literature for both 
organic and inorganic compounds, in which for instance protonation results in a 
positively charged amine that disturbs conjugation.23, 24 The difference in acidity 
between the palladium and platinum complexes may be of paramount importance 
for the different in vitro and in vivo activities of these complexes (see Chapter 6).  
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7.4.1 Synthesis of [Pd(H2bapbpy)]Cl2 ([1]Cl2) and [Pd(H2bapbpy)]Cl2 ([2]Cl2) 
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7.4.3 Crystallization of [Pd(Hbapbpy)]2(HCOO)(PF6) ([3]2(HCOO)(PF6)) 
Ruby red crystals suitable for X-ray diffraction were obtained by diffusion of diethyl ether 
into an acetone solution of [1](PF6)2. 0.3 mg of [1](PF6)2 was dissolved in 0.4 mL of acetone 
and placed in a small GC vial. This vial was placed in a larger vial containing 2.8 mL diethyl 
ether. The large vial was closed and vapor diffusion occurred after 7 days to afford X-ray 
quality crystals of [3]2(HCOO)(PF6) 
7.4.4 Synthesis of [Pt(bapbpy)] ([6]) 
K2[PtCl4] (48 mg, 0.15 mmol) and H2bapbpy (40 mg, 0.11 mmol) were added into a 2-neck 25 
ml round bottom flask containing a degassed ethanol-water mixture (7:3, 10 mL). The brown 
suspension was stirred overnight at 80 °C under argon resulting in a red suspension that 
was filtered. Then, aqueous NaOH (5.0 M) was added upon which a red solid to 
precipitated. The suspension was filtered, washed with water, and dissolved in THF. After 
rotary evaporation the compound was dried in vacuo and obtained as a yellow powder. 
Yield: 42 mg (46%). 1H NMR (500 MHz, 293 K, THF-d8, in ppm): δ = 7.91 (d, 6.5 Hz, 2H, Hpy-6), 
7.68 (t, 8.0, 8.0 Hz, 2H, H4), 7.49 (dd, 7.5, 1.0 Hz, 2H, Hpy-4), 7.36 (d, 2H, 7.0 Hz, H3), 7.03 (d, 
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8.5 Hz, 2H, H5), 6.35 (dd, 6.5, 6.5 Hz, 2H, Hpy-5). 13C NMR (126 MHz, THF-d8, in ppm): δ = 
148.52 (Cpy-6), 135.63 (C4), 125.94 (Cpy-4), 124.81 (Cpy-3), 124.40 (C5), 112.99 (Cpy-5), 111.51 (C3). 
 
Figure 7.7 Schematic representation of [5] and [6] with atom numbering for NMR 
attribution. 
7.4.5 Absorbance measurements 
UV-vis experiments were performed on a Cary 50 Varian spectrometer equipped with a 
Cary Single Cell Peltier for temperature control. All spectra were recorded with Cary 
WinUV software from Cary and further processed with Microsoft Office Excel 2010.  
7.4.6 pKa determination for [1]2+ to [3]+ and [2]2+ to [4]+ 
pH titration: 6 mL of a 67 µM solution of [1]Cl2 or [2]Cl2 in hydrochloric acid (0.033 M) was 
put in a 15 mL vial. A pH measurement electrode was added and when stable the pH was 
logged, aliquots (0.5-10 µL) of aqueous NaOH (0.05 – 5M) were added to give a range of pH 
values while stirring. After each stable pH a UV-vis absorbance spectrum was measured. 
The relative concentration of [Pd(H2bapbpy)]2+or [Pt(H2bapbpy)]2+ was determined using the 
Lambert-Beer Law, and then plotted as a function of the pH. The pKa was determined by 




7.4.7 Absorbance spectroscopy for [5] and [6] 
2.5 mL of a 67 µM solution of [5] or [6] in a 1:1 THF-water mixture was prepared. 2 µL 
aliquots of NaOH (0.05 M) were added to the solutions until no more changes in the spectra 
were observed to ensure full deprotonation of the metal complex. Then, 2 µL aliquots of 
aqueous HCl (33 mM) were added, after each addition a UV-vis absorption spectrum was 
recorded.  
7.4.8 Absorbance spectroscopy for [1](PF6)2 and [2](PF6)2 at different temperatures 
Typically, 2.5 mL of a 100 µM solution of [1](PF6)2 or [2](PF6)2 was prepared, and 
subsequently an absorbance spectrum was recorded at 20, 40, 60, 80, and again 20 °C in 
demineralized water or phosphate buffer (pH = 7.4). Upon cooling back down to 20 °C 




ADF was used to minimize the structures of [1]2+, [3]+, and [5] using PBEO as functional, 
TZP as basis set, and COSMO to simulate the water solvent.19, 20, 27, 28 TDDFT was then used 
at the CAM-B3LYP/TZP/COSMO level to calculate the first 50 singlet transition of the three 
ground state geometries.  
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Inorganic anticancer compounds typically interact with biomolecules following 
two different modes. The first mode is direct binding of biomolecules such as DNA 
or proteins to the metal center to form a metal-ligand coordination bond.1 The 
formation of these coordination bonds is commonly preceded by the release of a 
ligand present in the original or intermediate complex. The anticancer drug 
cisplatin and most of its derivatives rely on this mechanism of action.2 Chloride 
ligands initially bound to the metal center in cisplatin are first substituted by water 
molecules, before the main target in the nucleus, specifically the N7 atom of 
guanine DNA base pairs, coordinates to the metal ion.3, 4  
The second type of interaction is an indirect binding mode of the complex with its 
biomolecular target. Typically, one of the ligands of a metal complex intercalates 
via π-π or hydrophobic interactions to DNA or proteins. Typical intercalators 
consist of planar polyaromatic and extended polypyridyl ligands.5, 6 Whereas 
organic intercalators such as daunorubicin are widely used in the clinics as cancer-
treatment, no inorganic intercalators have made it to the clinic yet. 7-9 
In this chapter the use of coordinatively saturated tetrapyridyl palladium(II) and 
platinum(II) complexes as potentially intercalating anticancer drugs is described. 
In Chapter 6 and Chapter 7 it was demonstrated that for complexes based on the 
ligand H2bapbpy (N,N’-di(pyrid-2-yl)-2,2’-bipyridine-6,6’-diamine, Figure 8.1) the 
choice of the metal center had a strong influence on the biological activity of the 
complex in vitro and in vivo, on its cellular uptake, and on its pKa. H2bapbpy is 
characterized by the presence of two non-coordinating amine bridges that can be 
deprotonated easily in water upon metal coordination. The influence of the 
deprotonation of these bridging amines on the physico-chemical and biological 
properties of these complexes has been extensively discussed in Chapter 7. In this 
chapter the palladium(II) and platinum(II) complexes of Hbbpya (N,N-bis(2,2’-
bipyrid-6-yl)amine), Figure 8.1) are presented,10, 11 a tetrapyridyl ligand similar to 




Figure 8.1 Chemical structures of the three tetrapyridyl ligands H2bapbpy, Hbbpya, and 
qtpy. 
 Results  8.2
8.2.1 Synthesis and crystal structure  
The square-planar complexes [Pd(Hbbpya)]Cl2 ([1]Cl2) and [Pt(Hbbpya)]Cl2 ([2]Cl2) 
were synthesized by reacting the ligand Hbbpya with K2[PdCl4] and K2[PtCl4], 
respectively, in an ethanol-water mixture (Scheme 8.1). After purification using 
size exclusion chromatography, analysis with NMR spectroscopy, elemental 
analysis, and high resolution mass spectrometry confirmed that the compounds 
were analytically pure. Vapor diffusion of acetone into a solution of [1]Cl2 in 
methanol yielded yellow-colored crystals suitable for X-ray diffraction studies 
(Figure 8.2). 
 
Scheme 8.1 Synthesis of [1]Cl2 and [2]Cl2. 
The compound [1]Cl2 crystallizes with one molecule of MeOH. Pd1-N1 and Pd1-
N5 bond distances of the terminal pyridyl groups are 2.0600(18) and 2.0680(18) Å, 
respectively (Table 8.1), whereas the Pd1-N2 and Pd1-N4 bond distances of the 
internal pyridines are 1.9887(10) and 1.9933(18) Å, respectively, thus much shorter. 
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chapter the palladium(II) and platinum(II) complexes of Hbbpya (N,N-bis(2,2’-
bipyrid-6-yl)amine), Figure 8.1) are presented,10, 11 a tetrapyridyl ligand similar to 




Figure 8.1 Chemical structures of the three tetrapyridyl ligands H2bapbpy, Hbbpya, and 
qtpy. 
 Results  8.2
8.2.1 Synthesis and crystal structure  
The square-planar complexes [Pd(Hbbpya)]Cl2 ([1]Cl2) and [Pt(Hbbpya)]Cl2 ([2]Cl2) 
were synthesized by reacting the ligand Hbbpya with K2[PdCl4] and K2[PtCl4], 
respectively, in an ethanol-water mixture (Scheme 8.1). After purification using 
size exclusion chromatography, analysis with NMR spectroscopy, elemental 
analysis, and high resolution mass spectrometry confirmed that the compounds 
were analytically pure. Vapor diffusion of acetone into a solution of [1]Cl2 in 
methanol yielded yellow-colored crystals suitable for X-ray diffraction studies 
(Figure 8.2). 
 
Scheme 8.1 Synthesis of [1]Cl2 and [2]Cl2. 
The compound [1]Cl2 crystallizes with one molecule of MeOH. Pd1-N1 and Pd1-
N5 bond distances of the terminal pyridyl groups are 2.0600(18) and 2.0680(18) Å, 
respectively (Table 8.1), whereas the Pd1-N2 and Pd1-N4 bond distances of the 
internal pyridines are 1.9887(10) and 1.9933(18) Å, respectively, thus much shorter. 
These trends are similar to those in [Pd(H2bapbpy)](PF6)2 ([3](PF6)2), but are even 
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more pronounced in the analogue palladium(II) complex without any amine 
bridge, i.e. [Pd(qtpy)](PF6)2.12  
 
 
Figure 8.2 Displacement ellipsoid of the cationic part of [1]Cl2 (50% probability level). 
Counter anions, and the lattice solvent molecule have been omitted for clarity. 
Table 8.1 Selected bond lengths (Å) in the crystal structures of [1]Cl2, of the H2bapbpy 
analogue [3](PF6)2, and of [Pd(qtpy)](PF6)2.  
Bond [1]Cl2 Bond [3](PF6)2a Bond [Pd(qtpy)](PF6)2b 
Pd1-N1 2.0600(18) Pd1-N1 2.0251(16) Pd1-N2 2.056 
Pd1-N2 1.9887(18) Pd1-N3 1.9846(16) Pd1-N1 1.928 
Pd1-N4 1.9933(18) Pd1-N4 1.9802(16) Pd1-N1B 1.928 
Pd1-N5 2.0680(18) Pd1-N6 2.0312(16) Pd1-N2B 2.056 
Pd1-Navec 2.028 Pd1-Nave 2.005 Pd1-Nave 1.992 
a: Values taken from Chapter 6 
b: Values taken from Constable et al.12  
c: Average value of the four coordinating Pd-N bonds in each complex. 
The differences between the open and closed side of the tetrapyridyl ligands are 
also apparent when comparing the bond angles. For [1]Cl2 the N1-Pd1-N5 angle on 
the open side is 108.84(7)°, while the angle N2-Pd1-N4 on the closed side is 
93.22(7)°, thus more than 15° smaller. In [3](PF6)2 and [Pd(qtpy)](PF6)2 bond 
internal angles N3-Pd1-N4 and N1-Pd1-N5 are 82.19(7) and 81.2°, respectively. 
These differences can be explained by the formation of one 6-membered ring and 
two 5-membered rings with Hbbpya, while coordination of H2bapbpy generates 
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one 5-membered ring and two 6-membered rings, and qtpy generates only 5-
membered rings. Such differences increase the opening of the ligands as follows: 
H2bapbpy < Hbbpya < qtpy: in [3](PF6)2 N6-Pd1-N1 is 96.38(7)°, in [1]Cl2 N1-Pd1-
N5 is 105.84(7)°, and in [Pd(qtpy)](PF6)2 N2-Pd1-N2B is 117.8°. 
Table 8.2 Selected bond angles, torsion angles (°), and τ4 values for [1]Cl2, [3](PF6)2, and 
[Pd(qtpy)](PF6)2. 
Angle [1]Cl2 Angle [3](PF6)2a Angle [Pd(qtpy)](PF6)2b 
N1-Pd1-N2 80.38(7) N1-Pd1-N3 91.43(7) N2-Pd1-N1 80.5 
N2-Pd1-N4 93.22(7) N3-Pd1-N4 82.19(7) N1-Pd1-N1B 81.2 
N4-Pd1-N5 80.48(7) N4-Pd1-N6 92.34(7) N1B-Pd1-N2B 80.8 
N5-Pd1-N1 105.84(7) N6-Pd1-N1 96.38(7) N2B-Pd1-N2 117.8 
N1-Pd1-N4 173.35(7) N1-Pd1-N4 165.35(6) N2-Pd1-N1B 161.7 
N2-Pd1-N5 173.37(7) N3-Pd1-N6 167.38(6) N1-Pd1-N2B 161.7 
N1-N2-N4-N5 0.20 N1-N3-N4-N6 17.30 N2-N1-N1B-N2B 0.54 
τ4* 0.090 τ4* 0.193 τ4* 0.260 
* τ4 is obtained using the equation 𝟑𝟑𝟑𝟑𝟑𝟑
𝒐𝒐−(𝜶𝜶+ 𝜷𝜷)
𝟏𝟏𝟒𝟒𝟏𝟏𝒐𝒐
; a value of 0 corresponds to a square-
planar coordination geometry and a value of 1 to a tetrahedral coordination geometry. 
a Values taken from Chapter 6 
b Values taken from Constable et al.12 
As a result of the different chelating rings generated by the three ligands the 
distortions of the square-planar coordination sphere also greatly vary. A perfect 
square-planar coordination geometry can be defined as a four-coordinate complex 
with ligands that coordinate in a single plane, and it should contain bond angles of 
only 90 and 180°. The τ4 value introduced by Houser and co-workers quantifies the 
square-planarity of tetracoordinated metal complexes by distinguishing complexes 
with a τ4 value of 0 that are perfectly square-planar, and complexes with a τ4 value 
of 1 that have a perfect tetrahedral geometry. Using the crystal structures of [1]Cl2, 
[3](PF6)2, and [Pd(qtpy)](PF6)2 τ4 values of respectively 0.090, 0.193, and 0.260 
(Table 8.2) were calculated indicating that [1]Cl2 is by far the most square-planar 
geometry, while [3](PF6)2 and [Pd(qtpy)](PF6)2 have both severely distorted 
geometries. The torsion angle of the coordinating nitrogen atoms is a measure of 
the degree of flatness of the coordination plane of square-planar complexes. For 
[1]Cl2, [3](PF6)2, and [Pd(qtpy)](PF6)2 these torsion angles are 0.20, 17.30, and 0.54°, 
respectively. Thus, whereas in [1]2+ and [Pd(qtpy)]2+ the tetrapyridyl ligands are 
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bridge, i.e. [Pd(qtpy)](PF6)2.12  
 
 
Figure 8.2 Displacement ellipsoid of the cationic part of [1]Cl2 (50% probability level). 
Counter anions, and the lattice solvent molecule have been omitted for clarity. 
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a: Values taken from Chapter 6 
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c: Average value of the four coordinating Pd-N bonds in each complex. 
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These differences can be explained by the formation of one 6-membered ring and 
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a Values taken from Chapter 6 
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As a result of the different chelating rings generated by the three ligands the 
distortions of the square-planar coordination sphere also greatly vary. A perfect 
square-planar coordination geometry can be defined as a four-coordinate complex 
with ligands that coordinate in a single plane, and it should contain bond angles of 
only 90 and 180°. The τ4 value introduced by Houser and co-workers quantifies the 
square-planarity of tetracoordinated metal complexes by distinguishing complexes 
with a τ4 value of 0 that are perfectly square-planar, and complexes with a τ4 value 
of 1 that have a perfect tetrahedral geometry. Using the crystal structures of [1]Cl2, 
[3](PF6)2, and [Pd(qtpy)](PF6)2 τ4 values of respectively 0.090, 0.193, and 0.260 
(Table 8.2) were calculated indicating that [1]Cl2 is by far the most square-planar 
geometry, while [3](PF6)2 and [Pd(qtpy)](PF6)2 have both severely distorted 
geometries. The torsion angle of the coordinating nitrogen atoms is a measure of 
the degree of flatness of the coordination plane of square-planar complexes. For 
[1]Cl2, [3](PF6)2, and [Pd(qtpy)](PF6)2 these torsion angles are 0.20, 17.30, and 0.54°, 
respectively. Thus, whereas in [1]2+ and [Pd(qtpy)]2+ the tetrapyridyl ligands are 
coordinated almost in one single plane, in [3]2+ the ligand assumes a more helical 
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geometry. To conclude, [1]Cl2 is highly square-planar and very flat. The distance 
between the hydrogen atoms of C1 and C20 is 1.905 Å, which is apparently long 
enough to prevent distortion of the coordinated Hbbpya ligand. Previously, 
Hbbpya has already demonstrated a high degree of planarity in octahedral iron(II) 
complexes, and preliminary data shows that it is also highly planar in nickel(II) 
and ruthenium(II) complexes (Figure SVIII.3).13 This planar geometry significantly 
differs from the H2bapbpy ligand that coordinates to metal ions in a distorted 
fashion. Although a crystal structure of [2]Cl2 was not obtained, similar geometric 
features are expected as palladium(II) and platinum(II) complexes with identical 
ligands are usually very similar (Chapter 6). Overall, the removal of an amine 
bridge in H2bapbpy, results in the ligand Hbbpya that can coordinate to 
palladium(II) or platinum(II) with a highly square-planar geometry.  
8.2.2 Cytotoxic properties of [1]Cl2 and [2]Cl2 
The similar coordination mode of Hbbpya and H2bapbpy to palladium(II) and 
platinum(II) ions may predict similar activities for these metal complexes in vitro. 
To check this hypothesis, the cytotoxicity of the two new Hbbpya metal complexes 
[1]Cl2 and [2]Cl2 was tested against three different cancer cell lines (A375 skin, 
A549 lung, and MDA-MB231 breast cancer) and one non-malignant lung cell line 
(MRC-5). The cell-testing protocol was adapted from Hopkins et al.14: 24 h after 
seeding, the cells were incubated for 24 h with the drug, the media was refreshed, 
and the cells were further incubated with drug-free medium for 48 h. A 
sulforhodamine B (SRB) cell-counting assay was performed at 96 h, and effective 
concentrations (EC50) were determined by comparing cell viability of treated wells 
with drug-free control wells. The EC50 values are summarized in Table 8.3. EC50 
values for A375 and A549 cancer cell lines for [1]Cl2 and [2]Cl2 were similar and 
ranged between 1.6-1.9 µM. For MDA-MB231 and MRC-5 cancer cells both 
compounds showed lower cytotoxicty in the 4.7-6.8 µM range. Overall, the 
cytotoxicity of [1]Cl2 and [2]Cl2 was found comparable with that of cisplatin, i.e. in 
the low micromolar range. The cytotoxity of [2]Cl2 is comparable with that of 
[Pt(H2bapbpy)](PF6)2 ([4](PF6)2, but the cytotoxicity of [1]Cl2 was nowhere near the 
exceptional activity of [3](PF6)2, that showed EC50 values below 0.2 µM for all the 
cell lines tested in this panel. Although the ligands are highly similar, once 




Table 8.3 Cytotoxicity expressed as cell growing inhibition effective concentrations (EC50 
with 95% confidence intervals, in μM) for [1]Cl2, [2]Cl2, and cisplatin on skin (A375), lung 
(A549), and breast (MDA-MB231) cancer cell lines, and on non-cancerous lung fetal cell 
line (MRC-5). 
Cell Line [1]Cl2 [2]Cl2  cisplatin  
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8.2.3 Cellular Uptake  
Considering the different in vitro activity of [1]Cl2 and [3](PF6)2 uptake studies were 
performed to determine whether the differences in cytotoxicity are caused by 
different intracellular concentrations of both palladium compounds. A375 or A549 
cells were seeded, and treated with [1]Cl2, [2]Cl2, [3](PF6)2, [4](PF6)2, or cisplatin at 
their EC50 concentrations. After 24 h drug incubation, cells were washed, 
trypsinized, counted, digested and the amount of metal content was measured 
using ICP-MS (see Experimental section for the full procedure). [1]Cl2 and [2]Cl2 
showed similar uptake by A375 or A549 cells (7.2 and 9.4 nmol/106 cells) with an 
uptake efficiency of 8 and 16%. [3](PF6)2 showed an uptake of 1.2 (54%) and 5.3 
nmol/106 cells (39%) for A375 and A549 cells, respectively. For [4](PF6)2 a similar 
trend was observed with 19 and 22 nmol/106 cells for A375 and A549 cells, 
respectively, corresponding to an uptake efficiency of 58% in both cell lines. 
Cisplatin, by comparison, showed very low metal uptake (0.06 and 0.07 nmol/106 
cells for A375 and A549 cells, respectively), which demonstrates that once in the 
cell cisplatin is much more harmful than the tetrapyridyl complexes. The lower 
cytotoxicity of the Hbbpya complexes compared to the H2bapbpy complexes does 
not seem to be related to a lower metal uptake: treatment at the EC50 the uptake 
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8.2.3 Cellular Uptake  
Considering the different in vitro activity of [1]Cl2 and [3](PF6)2 uptake studies were 
performed to determine whether the differences in cytotoxicity are caused by 
different intracellular concentrations of both palladium compounds. A375 or A549 
cells were seeded, and treated with [1]Cl2, [2]Cl2, [3](PF6)2, [4](PF6)2, or cisplatin at 
their EC50 concentrations. After 24 h drug incubation, cells were washed, 
trypsinized, counted, digested and the amount of metal content was measured 
using ICP-MS (see Experimental section for the full procedure). [1]Cl2 and [2]Cl2 
showed similar uptake by A375 or A549 cells (7.2 and 9.4 nmol/106 cells) with an 
uptake efficiency of 8 and 16%. [3](PF6)2 showed an uptake of 1.2 (54%) and 5.3 
nmol/106 cells (39%) for A375 and A549 cells, respectively. For [4](PF6)2 a similar 
trend was observed with 19 and 22 nmol/106 cells for A375 and A549 cells, 
respectively, corresponding to an uptake efficiency of 58% in both cell lines. 
Cisplatin, by comparison, showed very low metal uptake (0.06 and 0.07 nmol/106 
cells for A375 and A549 cells, respectively), which demonstrates that once in the 
cell cisplatin is much more harmful than the tetrapyridyl complexes. The lower 
cytotoxicity of the Hbbpya complexes compared to the H2bapbpy complexes does 
not seem to be related to a lower metal uptake: treatment at the EC50 the uptake 
values were overall similar. Compound [4](PF6)2 may owe its higher cytotoxicity 
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compared to [1]Cl2 and [2]Cl2 due to a higher uptake, but [3](PF6)2 clearly has a 
much lower metal uptake and much higher cytotoxicity. These uptake results 
emphasize the remarkable cytotoxicity of [3](PF6)2 as its cellular concentrations in 
this experiment are the lowest by far, while it exhibited the highest cytotoxicity.  
Table 8.4 Cellular uptake for A375 and A549 for compounds [1]Cl2, [2]Cl2, [3](PF6)2, 
[4](PF6)2, and cisplatin. 
Cell 
line 
Compound Treatment Concentration 
(µM) 
Metal Uptake  
(nmol/106 
cells) 
Rel. Uptake Efficiency 
(%) 
A375 
[1]Cl2 1.9 9.4 ± 2.8 16 
[2]Cl2 1.7 7.9 ± 1.8 12 
[3](PF6)2 0.05 1.2 ± 0.2 54 
[4](PF6)2 1.0 19 ± 4.4 58 
cisplatin 1.6 < 0.01 < 1 
A549 
[1]Cl2 1.9 8.6 ± 2.1 13 
[2]Cl2 1.7 7.2 ± 0.8 8 
[3](PF6)2 0.2 5.3 ± 0.5 39 
[4](PF6)2 1.0 22 ± 2.1 58 
cisplatin 3.3 < 0.01 < 1 
 
8.2.4 Lipophilicity and pKa  
In medicinal chemistry higher uptake and improved cytotoxicity are often 
associated with higher lipophilicitiy. The octanol-water partition coefficient (logP 
value) is widely used as an indicator of lipophilicity (positive logP value) or 
hydrophilicity (negative logP value). The PF6 salts of the H2bapbpy complexes 
were first converted to [3]Cl2 and [4]Cl2, respectively, as DMSO would be required 
for initial solubilization of the PF6 salts. Full details regarding the counter ion 
exchange procedure are provided in the Experimental section. The logP values for 
complexes [1]Cl2 to [4]Cl2 are shown in Table 8.5. The logP value for [4]Cl2 (−0.45) 
was the highest of all the complexes, and also corresponded with the highest 
cellular uptake of [4](PF6)2. [3]Cl2 with a logP value of −1.63 is the most hydrophilic 
of the compounds, and as the PF6- salt was taken up second highest. The logP 
values of [1]Cl2 and [2]Cl2 were found to be −0.96 and −1.59, respectively. In 
conclusion, all four tested complexes are rather hydrophilic, and no obvious 
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relationship between metal uptake and logP could be observed for this series of 
complexes. 
Each amine bridge in the tetrapyridyl ligands H2bapbpy and Hbbpya bears an 
acidic proton. Consecutive deprotonation of the two amine bridges in H2bapbpy 
can result in dicationic, monocationic, or neutral complexes, whereas the single 
amine bridge in Hbbpya complexes can only lead to dicationic or monocationic 
species. Of course, the acid-base equilibrium may influence both the logP values 
and the uptake of these complexes in vitro. In Chapter 7 the pKa for the first 
deprotonation of [3]2+ and [4]2+ was found to be 7.8 and 8.3 in water. For [1]2+ and 
[2]2+ the pKa in water was also determined by monitoring with UV-vis 
spectroscopy the titration of [1]Cl2 and [2]Cl2 in HCl (33 mM) with NaOH. Under 
acidic conditions the UV-vis spectra of [1]2+ and [2]2+ only show absorption in the 
visible region with a tail up to 423 nm and 425 nm, respectively (green curves in 
Figure 8.3). Upon base addition a significant increase in absorbance was observed, 
characterized by a new absorption maximum at 416 nm for [1]2+ and 430 nm for 
[2]2+. Simultaneously, a major decrease in absorbance was found at 261 and 362 nm 
for [1]2+ and at 239 and 372 nm for [2]2+. The evolution of the absorbance spectra for 
both complexes occurred with isosbestic points at 316 and 397 nm for [1]2+, and at 
312 and 405 nm for [2]2+, indicating that only one reaction takes place. Further 
basification did not lead to any further change in the absorbance. The pH-
dependence of the absorbance spectra of [1]2+ and [2]2+ in water can be explained by 
the deprotonation of [1]2+ or [2]2+ to form [Pd(bbpya)]+ or [Pt(bbpya)]+, respectively. 
The corresponding pKa was determined to be 5.5 and 4.6 for [1]2+ and [2]2+, 
respectively. Thus, [1]2+ and [2]2+ have much lower pKa’s compared to [3]2+ and 
[4]2+. Such higher acidity can be explained by a difference in steric repulsion: 
Hbbpya complexes have an almost perfect square-planar geometry (τ = 0.090), 
whereas complexes of H2bapbpy are much more distorted (τ = 0.193, Figure 8.2 and 
Figure 7.2). As a result the negative charge located on the deprotonated bbpya− 
ligand in [Pd(bbpya)]+ and [Pt(bbpya)]+ is much better delocalized than the 
negative charge located on Hbapbpy− in [Pd(Hbapbpy)]+ and [Pt(Hbapbpy)]+. 
Another reason for the lower pKa of [1]2+ and [2]2+ compared to [3]2+ and [4]2+ is that 
the negative charge of the [Pd(bbpya)]+ and [Pt(bbpya)]+ complexes may be 
delocalized over two bpy moieties, whereas that of the [Pd(Hbapbpy)]+ and 
[Pt(Hbapbpy)]+ complexes is delocalized over only one bpy moiety and two 




compared to [1]Cl2 and [2]Cl2 due to a higher uptake, but [3](PF6)2 clearly has a 
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Table 8.4 Cellular uptake for A375 and A549 for compounds [1]Cl2, [2]Cl2, [3](PF6)2, 
[4](PF6)2, and cisplatin. 
Cell 
line 
Compound Treatment Concentration 
(µM) 
Metal Uptake  
(nmol/106 
cells) 
Rel. Uptake Efficiency 
(%) 
A375 
[1]Cl2 1.9 9.4 ± 2.8 16 
[2]Cl2 1.7 7.9 ± 1.8 12 
[3](PF6)2 0.05 1.2 ± 0.2 54 
[4](PF6)2 1.0 19 ± 4.4 58 
cisplatin 1.6 < 0.01 < 1 
A549 
[1]Cl2 1.9 8.6 ± 2.1 13 
[2]Cl2 1.7 7.2 ± 0.8 8 
[3](PF6)2 0.2 5.3 ± 0.5 39 
[4](PF6)2 1.0 22 ± 2.1 58 
cisplatin 3.3 < 0.01 < 1 
 
8.2.4 Lipophilicity and pKa  
In medicinal chemistry higher uptake and improved cytotoxicity are often 
associated with higher lipophilicitiy. The octanol-water partition coefficient (logP 
value) is widely used as an indicator of lipophilicity (positive logP value) or 
hydrophilicity (negative logP value). The PF6 salts of the H2bapbpy complexes 
were first converted to [3]Cl2 and [4]Cl2, respectively, as DMSO would be required 
for initial solubilization of the PF6 salts. Full details regarding the counter ion 
exchange procedure are provided in the Experimental section. The logP values for 
complexes [1]Cl2 to [4]Cl2 are shown in Table 8.5. The logP value for [4]Cl2 (−0.45) 
was the highest of all the complexes, and also corresponded with the highest 
cellular uptake of [4](PF6)2. [3]Cl2 with a logP value of −1.63 is the most hydrophilic 
of the compounds, and as the PF6- salt was taken up second highest. The logP 
values of [1]Cl2 and [2]Cl2 were found to be −0.96 and −1.59, respectively. In 
conclusion, all four tested complexes are rather hydrophilic, and no obvious 
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relationship between metal uptake and logP could be observed for this series of 
complexes. 
Each amine bridge in the tetrapyridyl ligands H2bapbpy and Hbbpya bears an 
acidic proton. Consecutive deprotonation of the two amine bridges in H2bapbpy 
can result in dicationic, monocationic, or neutral complexes, whereas the single 
amine bridge in Hbbpya complexes can only lead to dicationic or monocationic 
species. Of course, the acid-base equilibrium may influence both the logP values 
and the uptake of these complexes in vitro. In Chapter 7 the pKa for the first 
deprotonation of [3]2+ and [4]2+ was found to be 7.8 and 8.3 in water. For [1]2+ and 
[2]2+ the pKa in water was also determined by monitoring with UV-vis 
spectroscopy the titration of [1]Cl2 and [2]Cl2 in HCl (33 mM) with NaOH. Under 
acidic conditions the UV-vis spectra of [1]2+ and [2]2+ only show absorption in the 
visible region with a tail up to 423 nm and 425 nm, respectively (green curves in 
Figure 8.3). Upon base addition a significant increase in absorbance was observed, 
characterized by a new absorption maximum at 416 nm for [1]2+ and 430 nm for 
[2]2+. Simultaneously, a major decrease in absorbance was found at 261 and 362 nm 
for [1]2+ and at 239 and 372 nm for [2]2+. The evolution of the absorbance spectra for 
both complexes occurred with isosbestic points at 316 and 397 nm for [1]2+, and at 
312 and 405 nm for [2]2+, indicating that only one reaction takes place. Further 
basification did not lead to any further change in the absorbance. The pH-
dependence of the absorbance spectra of [1]2+ and [2]2+ in water can be explained by 
the deprotonation of [1]2+ or [2]2+ to form [Pd(bbpya)]+ or [Pt(bbpya)]+, respectively. 
The corresponding pKa was determined to be 5.5 and 4.6 for [1]2+ and [2]2+, 
respectively. Thus, [1]2+ and [2]2+ have much lower pKa’s compared to [3]2+ and 
[4]2+. Such higher acidity can be explained by a difference in steric repulsion: 
Hbbpya complexes have an almost perfect square-planar geometry (τ = 0.090), 
whereas complexes of H2bapbpy are much more distorted (τ = 0.193, Figure 8.2 and 
Figure 7.2). As a result the negative charge located on the deprotonated bbpya− 
ligand in [Pd(bbpya)]+ and [Pt(bbpya)]+ is much better delocalized than the 
negative charge located on Hbapbpy− in [Pd(Hbapbpy)]+ and [Pt(Hbapbpy)]+. 
Another reason for the lower pKa of [1]2+ and [2]2+ compared to [3]2+ and [4]2+ is that 
the negative charge of the [Pd(bbpya)]+ and [Pt(bbpya)]+ complexes may be 
delocalized over two bpy moieties, whereas that of the [Pd(Hbapbpy)]+ and 
[Pt(Hbapbpy)]+ complexes is delocalized over only one bpy moiety and two 
pyridyl fragments. Overall, at physiological pH (7.4) the Hbbpya complexes will be 
 
156 
fully deprotonated, thus monocationic, whereas the H2bapbpy complexes will be 
mixtures of dicationic and monocationic species.  
Table 8.5 LogP and pKa values for [1]Cl2, [2]Cl2, [3]Cl2, and [4]Cl2. 
Compound logP pKa 
[1]Cl2  −0.96 5.5 
[2]Cl2 −1.59 4.6 
[3]Cl2 −1.63 7.8 
[4]Cl2 −0.45 8.3 
 
 
Figure 8.3 Evolution of the UV-vis spectrum of [1]2+ (left) and [2]2+ (right) upon increasing 
the pH of an HCl aqueous solution (33 mM) of the metal complex using NaOH. [Pd] = [Pt] 
= 67 μM. 
8.2.5 Excited stated calculations for [1]2+ and [Pd(bbpya)]+ 
Although the differences in pKa between Hbbpya and H2bapbpy complexes are 
large, their deprotonation was accompanied by similar changes of the absorption 
spectra in the visible domain. DFT and TDDFT calculations were performed by Dr. 
Sylvestre Bonnet to characterize the singlet excited states of [Pd(Hbbpya)]2+ and 
[Pd(bbpya)]+ and to confirm the hypothesis presented in the previous section.15, 16  
After structure minimization of both molecules in water at the PBE0/TZP/COSMO 
level the first singlet excited states were calculated by TDDFT and visualized using 
ADF (Figure 8.4 and Figure 8.5). All excited states absorbing in the visible domain 
have major contributions of HOMO  LUMO and HOMO  LUMO+1 transitions 
(Table SVIII.1, Table SVIII.2). In both the protonated and the deprotonated states 
the HOMO is localized on the non-coordinated amine bridge and its adjacent 
pyridyl rings. The LUMO and LUMO+1 are conjugated across the full (H)bbpya 
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ligand in contrast to H2bapbpy that only does so on half of the atoms (essentially 
the bpy part). Excited states at 402 and 429 nm calculated for the deprotonated 
palladium complex are absent in the protonated complex (Figure SVIII.4, Table 
SVIII.1, and Table SVIII.2). In fact, not any excited states in the visible domain were 
found for [1]2+, and confirm the experimental finding of low absorption in the 
visible part in Figure 8.3. Thus, Intra-Ligand-Charge-Transfers HOMO  LUMO 
and HOMO  LUMO+1 transitions are responsible for the increased absorbance of 
[1]2+ upon deprotonation. The flatness of the coordinating Hbbpya is responsible 
for increased stabilization of the deprotonated species, which explains the lower 
pKa measured for Hbbpya complex [1]2+, compared to its H2bapbpy analogue. 
 
Figure 8.4 Selected orbital isodensity surfaces calculated by ADF for [1]2+. 
 
Figure 8.5 Selected orbital isodensity surfaces calculated by ADF for [Pd(bbpya)]+. 
 Discussion and Conclusion 8.3
Although the tetrapyridyl ligands Hbbpya and H2bapbpy structurally are highly 
similar, the coordination to palladium(II) or platinum(II) centers results in 
complexes with significant differences in coordination geometry, acidity, cellular 
uptake, and cytotoxicity. The crystal structures of the palladium(II) complexes with 
qtpy, Hbbpya, or H2bapbpy show that the palladium Hbbpya complex is the most 




fully deprotonated, thus monocationic, whereas the H2bapbpy complexes will be 
mixtures of dicationic and monocationic species.  
Table 8.5 LogP and pKa values for [1]Cl2, [2]Cl2, [3]Cl2, and [4]Cl2. 
Compound logP pKa 
[1]Cl2  −0.96 5.5 
[2]Cl2 −1.59 4.6 
[3]Cl2 −1.63 7.8 
[4]Cl2 −0.45 8.3 
 
 
Figure 8.3 Evolution of the UV-vis spectrum of [1]2+ (left) and [2]2+ (right) upon increasing 
the pH of an HCl aqueous solution (33 mM) of the metal complex using NaOH. [Pd] = [Pt] 
= 67 μM. 
8.2.5 Excited stated calculations for [1]2+ and [Pd(bbpya)]+ 
Although the differences in pKa between Hbbpya and H2bapbpy complexes are 
large, their deprotonation was accompanied by similar changes of the absorption 
spectra in the visible domain. DFT and TDDFT calculations were performed by Dr. 
Sylvestre Bonnet to characterize the singlet excited states of [Pd(Hbbpya)]2+ and 
[Pd(bbpya)]+ and to confirm the hypothesis presented in the previous section.15, 16  
After structure minimization of both molecules in water at the PBE0/TZP/COSMO 
level the first singlet excited states were calculated by TDDFT and visualized using 
ADF (Figure 8.4 and Figure 8.5). All excited states absorbing in the visible domain 
have major contributions of HOMO  LUMO and HOMO  LUMO+1 transitions 
(Table SVIII.1, Table SVIII.2). In both the protonated and the deprotonated states 
the HOMO is localized on the non-coordinated amine bridge and its adjacent 
pyridyl rings. The LUMO and LUMO+1 are conjugated across the full (H)bbpya 
 
157 
ligand in contrast to H2bapbpy that only does so on half of the atoms (essentially 
the bpy part). Excited states at 402 and 429 nm calculated for the deprotonated 
palladium complex are absent in the protonated complex (Figure SVIII.4, Table 
SVIII.1, and Table SVIII.2). In fact, not any excited states in the visible domain were 
found for [1]2+, and confirm the experimental finding of low absorption in the 
visible part in Figure 8.3. Thus, Intra-Ligand-Charge-Transfers HOMO  LUMO 
and HOMO  LUMO+1 transitions are responsible for the increased absorbance of 
[1]2+ upon deprotonation. The flatness of the coordinating Hbbpya is responsible 
for increased stabilization of the deprotonated species, which explains the lower 
pKa measured for Hbbpya complex [1]2+, compared to its H2bapbpy analogue. 
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Figure 8.5 Selected orbital isodensity surfaces calculated by ADF for [Pd(bbpya)]+. 
 Discussion and Conclusion 8.3
Although the tetrapyridyl ligands Hbbpya and H2bapbpy structurally are highly 
similar, the coordination to palladium(II) or platinum(II) centers results in 
complexes with significant differences in coordination geometry, acidity, cellular 
uptake, and cytotoxicity. The crystal structures of the palladium(II) complexes with 
qtpy, Hbbpya, or H2bapbpy show that the palladium Hbbpya complex is the most 
square-planar as well as the flattest of the three complexes. In the H2bapbpy 
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complexes electronic conjugation in the distorted ligand is less possible, making 
deprotonation less favorable compared to Hbbpya complexes. As a result [1]2+ and 
[2]2+ will not be present as dicationic species in vitro whereas [3]2+ and [4]2+ are 
present in both dicationic and monocationic forms. Under the hypothesis that the 
complexes described in this chapter are taken up via passive diffusion, both the 
charge state and the lipophilicity may play a key role.17-19 Specifically in case of the 
H2bapbpy complexes, their pKa values close to physiological conditions makes the 
complexes flexible regarding charge-dependent biochemical interactions with for 
instance negatively charged DNA.  
The observed differences in cytotoxicity can be explained by differences in uptake 
for [1]Cl2, [2]Cl2, and [4](PF6)2 assuming that these complexes have similar 
mechanism of actions (MoAs). However, the cytotoxicity and uptake of [3](PF6)2 
demonstrate that [3](PF6)2 is orders of magnitude more efficient in killing the cell 
once taken up, and that it has a distinct MoA compared to the other complexes. 
[1]Cl2 and [2]Cl2, albeit less cytotoxic than [3](PF6)2, also show that the class of non-
cyclic tetrapyridyl complexes is promising as anticancer agents when the ligand is 
functionalized with a single non-coordinating amine bridge. These complexes also 
show that non-coordinated chloride counter-anions, combined with the amine 
bridges, result in much more water-soluble complexes compared to cisplatin. 
Future work to extend, functionalize, and improve on this class of complexes may 
involve: (i) variation of the metal center, to iridium(III),20 rhenium(I),21 
osmium(II),22, 23 or gold(III);24, 25 (ii) the use of palladium(IV) or platinum(IV) centers 
to facilitate a prodrug (photo)reduction strategy,26-33 (iii) or the use of 
cyclometallated versions of the H2bapbpy and Hbbpya ligands, to determine 
whether subsequent changes of the charge of these complexes results in higher or 
lower uptake and cytotoxicity.  
 Experimental 8.4
8.4.1 General procedures 
Chemicals were bought from Alfa Aesar (K2PtCl4), Acros organics (K2PdCl4), and Sigma-
Aldrich. Reactions were performed under a nitrogen atmosphere using standard Schlenk 
techniques. NMR spectra were recorded on a Bruker DPX-500 spectrometer. Chemical shifts 
are indicated in ppm relative to TMS. Mass spectra were recorded by using a Thermoquest 
Finnagen AQA Spectrometer. UV-vis experiments were performed on a Cary Varian 
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spectrometer. pH measurements were performed using a PHM220 lab pH meter. Metal 
concentrations for logP determination were measured on a Vista MPX ICP-OES.  
8.4.2 Synthesis of [Pd(Hbbpya)]Cl2 ([1]Cl2) 
In a 2-necked round bottom flask K2PdCl4 (304 mg, 0.72 mmol) and Hbbpya (171 mg, 0.53 
mmol) were added into a degassed ethanol-water mixture (7:3, 100 mL) preheated at 80 °C. 
The resulting yellow suspension was stirred overnight at 80 °C in a nitrogen atmosphere 
resulting in a dark green/black suspension. The solution was cooled down to room 
temperature, filtered, and from the filtrate all solvents were rotary evaporated. The solids 
were dissolved in MeOH (5 mL) and purified by size exclusion chromatography (Sephadex 
L-20) using MeOH as eluent. The yellow band was collected and MeOH was removed by 
rotary evaporation, which resulted in [1]Cl2 as a yellow powder. Yield: 42% (111 mg). 1H 
NMR (500 MHz, D2O, 293 K, in ppm): δ = 8.55 (d, J = 5.5 Hz, 2H, H5’), 8.36 (m, 2H, H3’,H6’), 
8.19 (t, J = 8.0 Hz, 2H, H4), 8.00 (d, J = 7.5 Hz, 2H, H3), 7.71 (m, 2H, H4’), 7.44 (d, J = 8.5 Hz, 2H, 
H5). 13C NMR (126 MHz, D2O, 293 K, in ppm): δ = 155.5 (C6), 152.0 (C2), 148.7 (C5’), 145.1 (C2’), 
143.0 (C3’), 142.4 (C4), 128.4 (C4’), 124.6 (C6’), 118.3 (C3), 118.2 (C5). High resolution ES MS m/z 
(calc): 430.0286 (430.0284 = [M − H − 2×Cl]+). Elem. Anal. Calcd. For C20Cl2H15N5Pd + MeOH + 
H2O: C, 45.63; H, 3.83; N, 12.67. Found: C, 45.11; H, 3.94; N, 12.86. 
8.4.3 Synthesis of [Pt(Hbbpya)]Cl2 ([2]Cl2) 
In a 2-necked round bottom flask K2PtCl4 (300 mg, 0.730 mmol) and Hbbpya (200 mg, 0.590 
mmol) were added into a degassed ethanol-water mixture (3:2, 100 mL) preheated at 80 °C. 
The resulting yellow suspension was stirred overnight at 80 °C in a nitrogen atmosphere 
resulting in a dark red suspension. The suspension was cooled to room temperature, 
subsequently cooled on ice, and then filtered. From the filtrate all solvents were rotary 
evaporated. The solids were dissolved in MeOH (5 mL) and purified by size exclusion 
chromatography (Sephadex L-20) using MeOH as eluent. The yellow band was collected 
and MeOH was removed by rotary evaporation, which resulted in [2]Cl2 as a a red/orange 
powder. Yield 42% (155 mg), 1H NMR (500 MHz, CD3OD and DCl, 293 K, in ppm): δ = 8.99 (d, 
J = 5.5 Hz, 2H, H6’), 8.58 (d, J = 7.5 Hz, 2H, H3’), 8.50 (t, J = 7.5 Hz, 2H, H4’), 8.39 (t, J = 8.0 Hz, 
2H, H4), 8.23 (d, J = 6.5 Hz, 2H, H4’), 7.99 (m, 2H, H5’), 7.77 (d, J = 8.5 Hz, 2H, H5). 13C NMR 
(126 MHz, 293 K, CD3OD and DCl): δ = 156.4 (C6), 152.4 (C2), 150.4 (C5’), 144.4 (C2’), 143.7 (C3’), 
142.4 (C4), 129.6 (C4’), 125.6 (C6’), 119.9 (C3), 118.8 (C5) ppm. High resolution ES MS (H2O) m/z 
(calc.): 519.0893 (519.0897 = [M − H − 2×Cl]+). Elem. Anal. Calcd. For C20ClH14N5Pt + ½ H2O: C, 
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Figure 8.6 Schematic representation of [1]Cl2 and [2]Cl2 with atom numbering for NMR 
attribution. 
8.4.4 pKa determination 
pH titration: 6 mL of a 67 µM solution of [1]Cl2 or [2]Cl2 in hydrochloric acid (0.033 M) was 
put in a 15 mL vial. A pH measurement electrode was added and when stable the pH was 
logged, aliquots of aqueous NaOH (0.05 – 5M) were added to give a range of pH values 
while stirring. After each stable pH a UV-vis absorbance spectrum was recorded. The 
relative concentration of [M(Hbbpya]2+ was calculated using the Lambert-Beer law and then 
plotted vs. pH. The pKa was determined by modelling the curve using a simplified two-
parameter Hill-slope equation: 100
(1+10((𝑙𝑙𝑙𝑙𝑙𝑙10𝑝𝑝𝑝𝑝𝑝𝑝−𝑋𝑋)·𝐻𝐻𝐻𝐻𝑙𝑙𝑙𝑙 𝑆𝑆𝑙𝑙𝑙𝑙𝑝𝑝𝑆𝑆))
. 
8.4.5 Log P value determination 
1.00 mM stock solutions of [1]Cl2 and [2]Cl2 in octanol-saturated water were prepared. 0.2 
mL aliquots were transferred to 15 mL corning centrifugation tubes and diluted with 
octanol-saturated water to 1.0 mL, to give 0.2 mM solutions (in threefold). Then, 1.0 mL 
water-saturated octanol was added to each solution (not for the control samples, which 
remained at a volume of 1 mL). The solutions were shaken for 60 minutes on a GFL 3016 
shaker at maximum speed and centrifuged for 10 minutes at RCF = 2800 g at T = 293 K. 
Then, 100 µL of the aqueous phase (in threefold) was transferred into a vial, and 1.0 ml 65% 
nitric acid was added to degrade the compounds overnight. 0.8 mL of the resulting solution 
was then diluted with 11 mL MilliQ water in corning tubes. Then the metal concentration of 
each sample was measured using ICP-JOS, and the initial equilibrium metal concentration in 
the water and octanol phases was calculated from the dilution factors. Finally, the logP 




8.4.6 Cell culturing and EC50 cytotoxicity assay 
See Appendix I for extensive description of the assay  
8.4.7 Cellular uptake of [1]Cl2, [2]Cl2, [3](PF6)2, and [4](PF6)2 
Uptake studies for complexes [1]Cl2, [2]Cl2, [3](PF6)2, and [4](PF6)2 were conducted on A375 
and A549 lung cancer cells. 10 × 103 A375 cells and 17 × 103 A549 cells were seeded at t = 0 h 
in Opti-MEM complete in each well of a 6-well plate. At t = 48 h cells were treated with 
 
161 
complexes to give a final concentration close to the EC50 values (1.9, 1.7, 0.05 or 0.2, and 1.0 
µM for respectively [1]Cl2, [2]Cl2, [3](PF6)2, and [4](PF6)2 in the dark after 24 h in a total 
volume of 4 mL. After 24 h of drug incubation at 37 °C, the medium was aspirated, the cells 
were washed with PBS-buffer, trypsinized, counted using BioRad Cell Counting Slides on a 
BioRad TC10 automated cell counter, and pelleted by centrifugation (700 × g, 5 min). The 
supernatant was removed, and each sample was digested overnight in concentrated nitric 
acid at room temperature (> 65%). MilliQ water was added to each sample to obtain a final 
concentration of 5% HNO3. For ICP-MS measurements, the system was optimized with a 
palladium-platinum solution. The calibration range was from 0 to 25 µg/l, and obtained 
detection limit for all isotopes was 0.01 µg/l. Silver and indium were used for internal 
standard, to correct for sample-dependent matrix effects. No reference sample was 
available; therefore several samples were spiked with a known concentration. The 
recoveries of the spiked concentrations were all within a 10% deviation. 
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Figure 8.6 Schematic representation of [1]Cl2 and [2]Cl2 with atom numbering for NMR 
attribution. 
8.4.4 pKa determination 
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8.4.6 Cell culturing and EC50 cytotoxicity assay 
See Appendix I for extensive description of the assay  
8.4.7 Cellular uptake of [1]Cl2, [2]Cl2, [3](PF6)2, and [4](PF6)2 
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in Opti-MEM complete in each well of a 6-well plate. At t = 48 h cells were treated with 
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µM for respectively [1]Cl2, [2]Cl2, [3](PF6)2, and [4](PF6)2 in the dark after 24 h in a total 
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supernatant was removed, and each sample was digested overnight in concentrated nitric 
acid at room temperature (> 65%). MilliQ water was added to each sample to obtain a final 
concentration of 5% HNO3. For ICP-MS measurements, the system was optimized with a 
palladium-platinum solution. The calibration range was from 0 to 25 µg/l, and obtained 
detection limit for all isotopes was 0.01 µg/l. Silver and indium were used for internal 
standard, to correct for sample-dependent matrix effects. No reference sample was 
available; therefore several samples were spiked with a known concentration. The 
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9.1.1 Ruthenium polypyridyl complexes as photoactivated chemotherapeutic 
agents 
In this thesis several approaches are described to develop ruthenium polypyridyl 
complexes for photoactivated chemotherapy (PACT). In PACT a non-toxic drug is 
activated upon light irradiation to become cytotoxic, enabling local activation of a 
cytotoxic compound in the body, and hence more control over side effects and 
dosage (Scheme 9.1). In the case of photoactivated metal-based anticancer 
complexes this strategy commonly relies on a photosubstition reaction, during 
which a ligand is photosubstituted by a solvent molecule. In PACT both the metal 
product and the released ligand may act as the chemotherapeutic agent. When the 
metal-based photoproduct bears the toxicity load, photoactivation releases a 
protecting non-toxic organic ligand, allowing the coordination of other 
biomolecules to the metal center. When the photoreleased organic ligand bears the 
toxicity load, coordination of the metal to the toxic ligand inhibits, or ‘cages’, its 
biological activity by sterically preventing interaction with the protein target. 
 
 
Scheme 9.1 Mechanism of PACT: A chemical bond between a drug and a protecting 
group renders the conjugate inactive, while light activation induces bond breaking and 
enables the drug to exerts its biological activity. 
In the research described in this thesis we first set out functionalizing ruthenium 
polypyridyl complexes of the [Ru(tpy)(bpy)(L)]2+ family (Figure 9.1), where L is a 
monodentate ligand. First, as described in Chapter 2, thiol ligands L were 
investigated as potential protecting ligands for the [Ru(tpy)(bpy)(OH2)]2+ species, 
but these proved not to be suitable for that purpose. Once coordinated, the thiolate 
ligand oxidized easily into sulfenyl and sulfinyl derivatives, rendering the complex 
thermally unstable. Furthermore, photosubstitution of the thiol ligand proved to be 
much less effective than that of thioether ligands.1  
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In the course of this research in vitro cytoxicity data confirmed that 
[Ru(tpy)(bpy)(OH2)]2+ is essentially non-toxic, despite its ability to interact with 
DNA.2-4 Therefore, this complex was used as a photocaging agent for a cytotoxic 
microtubili-inhibiting (MTI) anticancer agent developed by the group of Dr. 
Alexander Kornienko from Texas State University, USA. This inhibitor contains a 
thioether functional group (SRR’) that can be used to coordinate to 
[Ru(tpy)(bpy)(OH2)]2+. The resulting complex, [Ru(tpy)(bpy)(MTI-SRR’)](PF6)2, 
proved to be 40-60 times less toxic in the dark than the free organic ligand, while 
green light irradiation of the caged complex recovered the high toxicity of the 
uncaged ligand. EC50 values for cell viability in the low nanomolar range were 
measured after light activation. Microtubule polymerization assays confirmed that 
upon photorelease of the ligand microtubule polymerization was inhibited, while 
in the dark microtubules were polymerizing normally. These results confirm that 
the photocytotoxicity observed in cells is indeed induced by the photochemical 
release of a microtubule polymerization inhibitor.  
Besides the [Ru(tpy)(bpy)(L)]2+ scaffold, [Ru(bpy)2(LL)]2+ complexes have also been 
the subject of intense research for potential use in PACT (Figure 9.1). Substitution 
of on (sterically demanding) bidentate ligand LL or two monodentate ligands by 
water molecules to form cis-[Ru(bpy)2(OH2)2]2+ has resulted in many light-
activatable complexes with toxic metal complexes and/or toxic ligands as 
photoproducts. The photoproduct cis-[Ru(bpy)2(OH2)2]2+ also allows for a binding 
mode to DNA similar to that of cisplatin. By contrast, polypyridyl ruthenium 
compounds with two labile ligands in mutual trans positions have been rarely 
investigated in anticancer research, although this configuration is commonly used 
in ruthenium chemistry, for example as water oxidation catalysts (with salen as a 
tetradentate ligand).5 In fact, one of the first ruthenium complexes that was 
proposed as anticancer compound, KP1019, also contains two indazole ligands in 
mutual trans positions.6 However, due to intracellular reduction into ruthenium(II), 
and to the monodentate character of the ligands bound to ruthenium, its 
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Figure 9.1 Chemical structures of [Ru(tpy)(bpy)L]2+ and [Ru(bpy)2(LL)]2+. 
In Chapter 4, anticancer complexes are presented based on the H2biqbpy ligand 
(Figure 9.2), a tetrapyridyl ligand that coordinates in the basal plane to 
ruthenium(II). Not only did coordination of H2biqbpy to ruthenium(II) lead to the 
cytotoxic and light-activatable complex [Ru(H2biqbpy)(dmso)(Cl)]Cl, but 
coordination of two axial monodentate thioether ligands resulted in 
[Ru(H2biqbpy)(HAmet)(Amet)]PF6. The [Ru(H2biqbpy)(HAmet)(Amet)]PF6 
protected complex exhibited significant reduced toxicity compared to 
[Ru(H2biqbpy)(dmso)(Cl)]Cl. Green light irradiation of various cancer cell lines 
treated with [Ru(H2biqbpy)(dmso)(Cl)]Cl resulted in an up to 20-fold increase of 
cytotoxicity compared to the dark control. It was further demonstrated that this 
type of complexes are poor singlet oxygen generators. Photodynamic therapy 
(PDT), which relies on the generation of singlet oxygen, may fall short in treating 
certain tumors characterized by low oxygen concentrations. In this scenario, PACT 
compounds based on the [Ru(H2biqbpy)(L)(L’)]2+ structure provide an interesting 
alternative for PDT, as their mechanism of activation does not rely on the presence 
of dioxygen. Furthermore, the H2biqbpy ruthenium complexes induced cell death 
upon light irradiation by apoptosis, which may be interesting for solving some of 
the clinical problems of PDT. PDT treatment induces significant side effects due to 
the mode of cell death on the irradiation site, which is often non-programmed cell 
death or necrosis. These types of cell death are characterized by a loss in cell 
membrane integrity and lead to the release of cells contents in the extracellular 
environment, which usually triggers a painful inflammation reaction. Treatment 
with ruthenium complexes based on H2biqbpy induce programmed cell death or 
apoptosis and may prevent such undesired inflammation reactions and thus lower 
pain for the patient.  
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Cellular uptake and cell fractionation assays described in Chapter 4 have 
demonstrated that 7.5-16 ng Ru/106 cells of these ruthenium complexes were taken 
up by A549 cancer cells, and that the complex predominantly accumulated in the 
membrane fraction that includes organelles, lysosomes, and membranes. 
Significant amounts were also present in the nucleus (1.7-3.2 ng Ru/106 cells), 
which justified DNA interaction experiments. Gel electrophoresis measurements 
demonstrated that the interaction between [Ru(H2biqbpy)(dmso)Cl]Cl or 
[Ru(H2biqbpy)(HAmet)(Amet)]PF6 and pUC19 plasmid DNA is controlled by light 
irradiation, which confirmed the protecting role of the sulfur-based ligands. 
Increasing light dosages corresponded to increasing activation of the compounds, 
which confirmed that the fully activated complex showed the highest degree of 
interaction with pUC10 plasmid DNA. However, the adducts between the 
complexes and the plasmid DNA could not be characterized. Further studies using 
HRMS and a well-defined single strand oligonucleotide (ODN) confirmed, in 
collaboration with Prof. Luigi Messori from Florence University, Italy, that it was 
possible to characterize these adducts by mass spectrometry. As expected the 
inactivated complex shows negligible interaction with the ODN, while blue light 
activation resulted in oligonucleotides containing either one or two bound 
ruthenium complexes, without the sulfur ligand.  
  
Figure 9.2 Chemical structures of [Ru(H2biqbpy)(dmso)Cl]Cl, [Ru(H2biqbpy)(HAmet) 
(Amet)]PF6, and [Ru(H2bapbpy)(dmso)Cl]Cl. 
Overall, the results described in Chapters 2-5 demonstrate that ruthenium 
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Cellular uptake and cell fractionation assays described in Chapter 4 have 
demonstrated that 7.5-16 ng Ru/106 cells of these ruthenium complexes were taken 
up by A549 cancer cells, and that the complex predominantly accumulated in the 
membrane fraction that includes organelles, lysosomes, and membranes. 
Significant amounts were also present in the nucleus (1.7-3.2 ng Ru/106 cells), 
which justified DNA interaction experiments. Gel electrophoresis measurements 
demonstrated that the interaction between [Ru(H2biqbpy)(dmso)Cl]Cl or 
[Ru(H2biqbpy)(HAmet)(Amet)]PF6 and pUC19 plasmid DNA is controlled by light 
irradiation, which confirmed the protecting role of the sulfur-based ligands. 
Increasing light dosages corresponded to increasing activation of the compounds, 
which confirmed that the fully activated complex showed the highest degree of 
interaction with pUC10 plasmid DNA. However, the adducts between the 
complexes and the plasmid DNA could not be characterized. Further studies using 
HRMS and a well-defined single strand oligonucleotide (ODN) confirmed, in 
collaboration with Prof. Luigi Messori from Florence University, Italy, that it was 
possible to characterize these adducts by mass spectrometry. As expected the 
inactivated complex shows negligible interaction with the ODN, while blue light 
activation resulted in oligonucleotides containing either one or two bound 
ruthenium complexes, without the sulfur ligand.  
  
Figure 9.2 Chemical structures of [Ru(H2biqbpy)(dmso)Cl]Cl, [Ru(H2biqbpy)(HAmet) 
(Amet)]PF6, and [Ru(H2bapbpy)(dmso)Cl]Cl. 
Overall, the results described in Chapters 2-5 demonstrate that ruthenium 
polypyridyl complexes containing sulfur-based monodentate ligands have great 
potential as photoactivatable compounds for chemotherapy. The photosubstitution 
of thioether or sulfoxide ligands can be used to control cytotoxicity, the type of cell 
death, and the interaction of ruthenium complexes with biological molecules. 
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These features provide an excellent basis for the further development of PACT 
compounds in the treatment of hypoxic tumors.  
9.1.2 Square-planar tetrapyridyl complexes as anticancer compounds 
By far most research on anticancer metallodrugs is devoted to platinum 
compounds largely inspired by the success story of cisplatin. This enthusiasm for 
platinum has resulted in nine cisplatin analogues that are currently used in the 
clinics (see Chapter 1). Platinum complexes that are structurally very different 
from cisplatin, as well as non-platinum transition-metal based complexes, have the 
disadvantage in terms of clinical development that their mechanism of action must 
strongly differ from that of cisplatin to allow for treating platinum-resistant 
tumors. Furthermore, metal-based medicines also have to deal with the often 
aversive response of the general public toward heavy metals.  
Notwithstanding these trends, we investigated the coordination of the ligand 
H2bapbpy to palladium(II) and platinum(II), which resulted in the metal 
complexes [Pd(H2bapbpy)]2+ and [Pt(H2bapbpy)]2+ (Chapter 6) that are structurally 
similar to the light-activatable ruthenium complex [Ru(H2bapbpy)(dmso)Cl]Cl for 
example, except for the missing axial monodentate ligands. These column 10 
complexes showed very interesting and very distinct in vitro cytotoxicity patterns. 
[Pd(H2bapbpy)](PF6)2, tested over a wide panel of cancer cell lines, exhibited 
exceptional cytotoxic activity, with EC50 values ranging from 200 nM to even 50 
nM. The EC50 values of [Pt(H2bapbpy)](PF6)2 were found to be 4-16 times higher, 
making the platinum complex significantly less active, but still as active as 
cisplatin. When co-treated with N-Acetyl-L-cysteine (NAC), a reactive oxygen 
species (ROS) scavenger, the activity of the palladium complex was quenched, 
whereas for the platinum complex this effect was much smaller. When co-treated 
with ROS sensitizer L-buthionine sulfoximine (BSO) the palladium complex 
showed spectacularly enhanced cytotoxicity, whereas this effect was much less 
pronounced for its platinum analogue. The platinum complex on the other hand, 
showed more enhancement on p53-gene deficient cancer cells than the palladium 
compound. Spectacularly high uptake was observed for both complexes, but 
[Pd(H2bapbpy)]2+ mostly accumulated in the membranes, whereas [Pt(H2bapbpy)]2+ 
was more evenly distributed among cytosol, membranes, nucleus, and 
cytoskeleton. In vivo equimolar dosages of [Pd(H2bapbpy)](PF6)2 or 
[Pt(H2bapbpy)](PF6)2 in CT-26 colon cancer Balb/c mice (in collaboration with Prof. 
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Walter Berger from the Medical University of Vienna, Austria) resulted in 
significant tumor reduction for the palladium complex, while for the platinum 
complex no such effect was observed. Overall, in vitro cytotoxicity, NAC, BSO, p53, 
uptake experiments, and in vivo experiments, all suggest that the structurally 
similar complexes act via different mechanisms of action. 
The excellent coordination properties of the tetradentate H2bapbpy ligand enforces 
a tetradentate coordination mode to square-planar metal centers such as Pd2+ or 
Pt2+. Thus neither the palladium nor the platinum complex are expected to operate 
in cancer cells via ligand substitution reactions. This stability of the coordination 
sphere was observed when for instance an aqueous solution of [M(H2bapbpy)]Cl2 
(0.10 mM, M = Pd or Pt) containing 100 eq. of NaCl was heated to 80 °C: no 
significant spectroscopic changes could be attributed to ligand substitution (Figure 
9.3). Thus, in vitro, in vivo, and in physiological conditions, these complexes are 
expected to be stable, without the occurrence of any ligand exchange.  
 
 
Figure 9.3 UV-vis absorbance spectra of [Pd(H2bapbpy)]Cl2 (A) and [Pt(H2bapbpy)]Cl2 (B) 
in a NaCl (aq, 10 mM) solution at 20 (continuous) and 80 °C (dotted). [Pd] = [Pt] = 0.10 
mM.  
In vitro studies were also performed with platinum and palladium complexes 
containing a tetrapyridyl ligand with one amine bridge (Hbbpya) instead of the 
two amine bridges in H2bapbpy: cytotoxicity was comparable to that of cisplatin, 
but nowhere near the cytotoxicity of [Pd(H2bapbpy)](PF6)2 (Chapter 8). 
Coordination of Hbbpya to a palladium(II) center resulted in a less distorted 
square-planar geometry than its H2bapbpy analogue (Figure 9.4). For square-
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of charged states of the molecule: either dicationic ([M(Hbbpya)]2+) or 
monocationic ([M(bbpya)]+) upon deprotonation of the amine. For H2bapbpy metal 
complexes a third, neutral state can also be obtained. The pKa of the first 
deprotonation is at 5.5 and 4.6 for [Pd(Hbbpya)]2+ and [Pt(Hbbpya)]2+, respectively, 
whereas for [Pd(H2bapbpy)]2+ and [Pt(H2bapbpy)]2+ this pKa is much higher (7.8 
and 8.3, respectively) and close to physiological conditions (Chapter 7). Thus, 
under physiological conditions the Hbbpya complexes are expected to be in the 
deprotonated, monocationic forms, whereas the H2bapbpy complexes are mixtures 
of the dicationic and monocationic forms. 
 
Figure 9.4 Displacement ellipsoid of [Pd(H2bapbpy)]2+ (A) and [Pd(Hbbpya)]2+ (B) (50% 
probability level) as observed in the crystal structure of respectively [Pd(H2bapbpy)](PF6)2 
and [Pd(Hbbpya)]Cl2. H atoms, counter anions, and lattice solvent molecules have been 
omitted for clarity. 
 Discussion 9.2
9.2.1 Trans influence and of sulfur-based monodentate ligands in 
[Ru(tpy)(bpy)(L)]n+ 
The trans effect and trans influence has been extensively discussed for square-
planar complexes such as cisplatin,8 but less for octahedral geometries. First, it is 
important to distinguish between the trans influence and the trans effect. The trans 
influence of a given ligand is defined as the weakening of the coordination bond of 
a second ligand positioned in trans position compared to this ligand in the ground 
state of the metal complex. This thermodynamic effect results in longer bond 
lengths for ligands that are coordinated trans to ligands having a stronger trans 
influence.9 The trans effect of a ligand is defined as the effect of this ligand on the 
relative stability of the transition state for the substitution of the ligand positioned 
in trans position. This kinetic effect can change ligand substitution rates by several 
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orders of magnitude, depending on the strength of the trans effect. σ-Donating and 
π-accepting properties of ligands play a crucial role in both phenomena. A σ-
donating ligand will bind more strongly to the metal center and can stabilize the 
transition state of the metal complex during substitution. On the other hand, a π-
accepting ligand can accept electron density from the metal center also stabilizing 
the transition state.  
In the [Ru(tpy)(bpy)(L)]n+ scaffold the monodentate ligand L is positioned trans to 
one of the coordinating N-atoms of the bidentate bpy ligand (Figure 9.1). In Table 
9.1, the Ru-N bond distances and the Ru-L distances are listed in which L can have 
different σ-donating as well as π-accepting properties. As the ligand L in these 
examples is expected to have little steric effects and all complexes have the same 
structure [Ru(tpy)(bpy)(L)]n+, Table 9.1 fairly describes the trans influence of ligand 
L on the Ru-N bond distances. In [Ru(tpy)(bpy)(OH2)]2+, the Ru-N length is 2.017 
Å, which is the shortest of the selected compounds, thus the aqua ligand has the 
lowest trans influence. This can be explained by the poor σ-donating properties of 
the aqua ligand. The longest Ru-N bond distance, thus with the highest trans 
influence of the L ligand, is observed in [Ru(tpy)(bpy)(κS-dmso)]2+ (2.085 Å), which 
can be explained by the stronger π-accepting properties of the dmso ligand. The 
Ru-N bond in [Ru(tpy)(bpy)(Hmte)]2+ with 2.064 Å falls between the pyridine and 
sulfoxide complexes, and confirms properties of a thioether as a (poorly) σ-
donating and (poorly) π-accepting ligand.10 No entries in the Cambridge Structural 
Database of [Ru(tpy)(bpy)(L)]n+ with a amine or thiol were found, which would 
have been relevant in the physiological context.  
Table 9.1 Selected bond lengths (Å) in complexes of the [Ru(tpy)(bpy)(L)]n+ scaffold. 
Compound Ru-N Ru-L 
[Ru(tpy)(bpy)(OH2)](BF4)2 2.017 L = O = 2.143 
[Ru(tpy)(bpy)Cl]Cl11 2.031 L = Cl = 2.397 
[Ru(tpy)(bpy)(py)]Cl212 2.047 L = N = 2.100 
[Ru(tpy)(bpy)(κS-Hmte)](PF6)213 2.064 L = S = 2.369 
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9.2.2 Trans influence in [Ru(N’NNN’)(L)(L’)]2+ scaffold 
The tetrapyridyl ligands H2bapbpy or H2biqbpy that coordinate in the basal plane 
in octahedral ruthenium(II) compounds, force the ruthenium complex to assume a 
configuration with trans axial monodentate ligands. As the trans effect and 
influence have mainly been described for square-planar complexes, and ruthenium 
complexes are most commonly synthesized with cis configurations, the structural 
and kinetic trans effects for trans ruthenium complexes have hardly been analyzed. 
In Table 9.2 the bond distances of the trans axial monodentate ligands of selected 
metal complexes are listed.  
On the one hand, compared to the [Ru(tpy)(bpy)(L)]n+ scaffold the 
[Ru(H2bapbpy)(L)2]n+ scaffold has more variations of the trans influence due to the 
presence of two potentially different trans ligands. On the other hand, both types of 
structures allow for comparing the stability and lability of sulfur-based ligands L, 
depending on the nature of the trans ligand. For example, the trans influence of 
thioether vs. pyridine ligands are similar: the Ru-S bond distances in 
[Ru(H2bapbpy)(Hmte)2]2+ and [Ru(H2bapbpy)(HAmet)2]2+ (Figure SIX.1) are all 
about 2.38 Å, close to the 2.369 Å of [Ru(tpy)(bpy)(Hmte)]2+, where the ligand trans 
to the thioether ligand is pyridine. However, a significant trans effect was observed 
for bis-thioether complexes that was absent in mono-thioether complexes. In 
[Ru(tpy)(bpy)(SRR’)]2+, where the trans ligand is pyridine, the Ru-S bond is 
thermally very stable in demineralized water1 or in chloride containing media2; no 
ligand substitution of the thioether is observed after 3 days. The 
[Ru(H2bapbpy)(Hmte)2]2+ complex is only stable in demineralized water, but in 
presence of chloride containing media one thioether is substituted over longer 
periods of time. It would thus be interesting to study the reactivity of asymmetric 
[Ru(H2bapbpy)(SRR’)(py)]2+ complexes, and to study whether the Ru-S bond is 






Table 9.2 Selected bond lengths (Å) for various complexes containing two monodentate 
axial ligands.  
Compound Ru-S Ru-L  
[Ru(H2bapbpy)(κS-dmso)Cl]Cl 2.227 L = Cl = 2.451  
[Ru(H2bapbpy)(κS-Hmte)2](PF6)2 2.382 L = S = 2.382  




L = O = 2.136 
L = Cl = 2.421 
L = Cl = 2.243 
 
trans-[Ru(κS-dmso)4Cl2]10 2.352 L = Cl = 2.402  
 
Sulfur-bound sulfoxides show a qualitatively similar but quantitatively stronger 
effect due to the stronger π-accepting properties of dmso compared to thioethers: 
κS-dmso induces a strong trans influence. In [Ru(tpy)(bpy)Cl]+ the Ru-Cl bond is 
significantly shorter (2.397 Å) than in [Ru(H2bapbpy)(dmso)Cl]+ (2.451 Å), and in 
[Ru(H2bapbpy)(κS-dmso)Cl]Cl the Ru-S bond is also shorter (2.227 Å) than that in 
trans-[Ru(κS-dmso)4Cl2] (2.352 Å). The better σ-donating and π-donating 
properties of the chloride ligand result in more electron density at the metal center 
for the π-accepting dmso. In addition, κS-dmso also has a strong trans effect and 
increases the lability of the trans ligand. For example, it was impossible to obtain a 
H2bapbpy ruthenium complex with two trans dmso ligands. In fact, the synthesis 
of [Ru(H2biqbpy)(dmso)2]Cl2 was attempted but was not successful. 1H NMR 
analysis showed that once DMSO-d6 was added to a solution of 
[Ru(H2biqbpy)(dmso)(OD2)]Cl2 a singlet peak at 2.71 ppm corresponding to free 
dmso () appeared next to the multiplet at 2.67 ppm corresponding to residual 
dmso-d5 (, Figure 9.5). The integral of the peak of the coordinated dmso () at 
2.44 ppm decreased from 6 to 4 protons, whereas the new singlet integrated for 2 
protons. Overall, these changes are clear signatures that the initially coordinated 
dmso ligand is removed. Furthermore, the unchanged aromatic spectrum upon 
dmso-d6 addition indicates that only coordination of a chemically identical ligand 
occurred. Thus, the coordinated dmso was replaced by DMSO-d6 and under these 
conditions [Ru(H2biqbpy)(dmso)2]Cl2 is unstable because competition for the metal 
π electrons between two π-accepting dmso ligands does not allow for 
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π electrons between two π-accepting dmso ligands does not allow for 
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and sulfoxide ligands are suitable monodentate ligands for protecting anticancer 
complexes based on ruthenium(II) provided the trans ligand is not itself another 
thioether of sulfoxide ligands.  
 
Figure 9.5 Reaction between [Ru(H2biqbpy)(dmso)(OD2)]Cl2 and DMSO-d6 (A). 1H NMR 
spectra (9.0-7.0, and 3.0-2.0 ppm) of [Ru(H2biqbpy)(dmso)(OD2)]Cl2 (0.15 mM) in D2O (B) 
and upon addition of 5 μL DMSO-D6 (C). T = 293 K, Solvent: D2O. Notations:  = 
coordinated dmso,  = free dmso;  = residual dmso-d5. 
9.2.3 Minor changes, major effects 
The research described in this thesis reveal that minor changes in a chemical 
structure, such as having one or two non-coordinating amine bridge(s) in the 
ligand, or substituting one metal center by another, may induce major changes in 
the biological effects of metal-based drugs. First, changing the tetrapyridyl ligand 
from H2biqbpy to H2bapbpy in [Ru(N’NNN’)(dmso)Cl]Cl resulted in similar 
photoreactivity with oligonucleotides, but a major decrease in dark cytotoxicity. 
The two additional phenyl rings in H2biqbpy is a significant difference that causes 
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the ruthenium complex to have a higher lipophilic and intercalating character. 
Second, when the ruthenium(II) center was replaced for nickel(II), the octahedral 
geometry was preserved, but the complex lost its absorption in the visible domain, 
and it did not exhibit significant dark cytotoxicity. Third, when the ruthenium 
center was replaced by a palladium(II) or platinum(II) center, the geometry of the 
metal complex changed from octahedral to square-planar, and the complexes 
became very (Pt2+) to extremely (Pd2+) cytotoxic. Finally, variation in the 
tetrapyridyl ligand from two amine bridges to one resulted in palladium(II) and 
platinum(II) complexes in which especially the cytotoxicity of the palladium(II) 
was reduced (Chapter 8). 
The remarkable differences in cytotoxicity between the H2bapbpy and Hbbpya 
palladium complexes can partially be explained by differences in cellular uptake. 
Without exception, the synthesized square-planar complexes are taken up very 
well (8-58%, Chapter 6 and 8), whereas for the octahedral complexes uptake 
efficiency was inferior to 0.3 % for [Ni(H2bapbpy)(OH2)2]Cl2 (Chapter 6) and even 
lower for the ruthenium(II) H2biqbpy complexes (Chapter 4). In comparison, the 
positive control cisplatin also showed similarly low uptake efficiency (< 0.1%), thus 
differences in cellular uptake cannot be attributed to coordination geometry alone. 
Although uptake assays were different across Chapter 4, 6, and 8, and notably as 
different cell numbers, metal complex concentrations, and relative volumes of the 
medium compared to the seeding area, were used, one interesting observation 
could be drawn: the square-planar tetrapyridyl complexes exhibit a (far) higher 
general cytotoxicity, but once inside the cell, octahedral (ruthenium) complexes 
(and cisplatin) were found much more efficient in cell killing, as they killed 50% of 
the cells at much lower intracellular concentrations (Table 9.3). A proposed 
explanation for the differences in cellular uptake is the possibility that 
deprotonation of the amine bridges can modulate the overall charge of the 
complex, and its ability to pass through the cellular membrane. In Chapter 7 and 8, 
it is shown that this deprotonation is notably relevant for the square-planar 
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Table 9.3 A549 cellular uptake for [Ru(H2biqbpy)(dmso)Cl]Cl, [Pd(H2bapbpy)](PF6)2, 
[Pt(H2bapbpy)](PF6)2, and cisplatin with treatment concentrations is close to the 
corresponding EC50 values. 
Compound Treatment 
Concentration (μM) 
tinc (h) Metal uptake  
(pmol/106 cells) 
[Ru(H2biqbpy)(dmso)Cl]Cl 9.3 6 11 
[Pd(H2bapbpy)](PF6)2 0.2 24 132  
[Pt(H2bapbpy)](PF6)2 1.0 24 1586  
cisplatin 3.3 24 23 
 
 Conclusion and Outlook 9.3
The success of cisplatin and all its clinically used derivatives have set the working 
standards in the field of anticancer metallodrugs. New metal-based anticancer 
drugs should either perform well against cancers with cisplatin-resistance, or have 
no side effects without loss of anticancer activity compared to cisplatin. In the first 
part of this thesis, a strategy has been presented that relies on light activation to 
increase selectivity; in the dark compounds are non-toxic and upon irradiation a 
ligand photosubstitution reaction takes place. Although [Ru(tpy)(bpy)(OH2)]2+ 
turned out to be a poorly cytotoxic agent, it appeared to be an excellent 
photocaging agent for a thioether-bearing anticancer microtubule inhibitor. 
Tetrapyridyl ruthenium complexes with trans axial monodentate ligands have 
proven to be cytotoxic and phototoxic. Recurring themes in photopharmacology 
are the question of the activation wavelength – red light penetrates human tissue 
deeper than blue light – and the difference in light activation strategies, which are 
based either on bond-breaking photoreactions or photochemical generation of 
reactive oxygen species. Lead compounds [Ru(tpy)(bpy)(MTI-SRR’)](PF6)2 and 
[Ru(H2biqbpy)(dmso)Cl]Cl are activatable by irradiating green light (520 nm), 
which offers decisive advantages over systems that require UV or blue light to be 
activated. Currently, experiments are performed to assess whether the 
phototoxicity can be translated to in vivo cancer models.  
Another consequence of the cisplatin doctrine is the widespread vision that 
anticancer metallodrugs should target DNA by means of coordination bonds. New 
directions where metal complexes target proteins, mitochondria, or non-DNA 
targets, are currently explored, although they still remain limited.15-20 A common 
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approach in inorganic chemistry research is to develop compounds that form 
coordination bonds with biomolecules. When cytotoxic responses are found in vitro 
against chemotherapy-resistant cancer cells in the low micromolar range, chemical 
biology approaches, ICP-MS, or imaging techniques, can be employed for target 
determination. However, such approaches possibly lead to targets that are not 
necessarily relevant for cancer therapy, contrary to medicinal organic chemistry in 
which drug design starts with selecting a target relevant for cancer therapy.21-25 On 
the other hand, in the second part of this thesis palladium(II) and platinum(II) 
complexes were presented with extraordinary cytotoxic properties that come from 
purely inorganic chemistry design principles. These complexes are a perfect 
example of drug design without pre-conceived biological targeting, but also 
deviate from the cisplatin doctrine as no ligand substitution reactions are expected 
to occur due to the tetradentate nature of the ligand and the square-planar metal 
centers. Perhaps as a consequence, a strong cytotoxic activity in vitro observed 
against several platinum-resistant cancer cell lines was discovered, which is both 
lucky and a problem for the clinical development of such compounds, as finding a 
biological target is often a tedious and time-consuming effort. At that stage, a 
structure-activity relationship will be required, as well as extensive biological 
studies to unravel possible mechanisms of action. In the end, drug discovery also 
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Cells were thawed and at least passaged twice before starting (photo)cytotoxicity 
experiments. Each cell line was cultured in Dulbecco’s Modified Eagle Medium 
with phenol red, supplemented with 8.0% v/v fetal calf serum (FCS), 0.2% v/v 
penicillin/streptomycin (P/S), and 0.9% v/v Glutamine-S (GM). Cells were cultured 
in either 25 cm2 or 75 cm2 flasks and split at 70-80% confluence (three times per 
week for 25 cm2 flasks, once per week for 75 cm2 flasks). The flasks were incubated 
at 37 °C at 7.0% CO2. The medium was refreshed three times a week. Cells used in 
all biological experiments were cultured for a maximum of eight weeks. 
Cell irradiation setup 
The cell irradiation system consists of a Ditabis thermostat (980923001) fitted with 
two flat-bottom microplate thermoblocks (800010600) and a 96-LED array fitted to 
a standard 96-well plate. The 520 nm LED (OVL-3324), fans (40 mm, 24 V DC, 
9714839), and power supply (EA-PS 2042-06B) were ordered from Farnell. Full 
description of the cell irradiation setup is given in Hopkins et al.1 Human cancer 
cell lines (A375, human malignant melanoma; A431, human epidermoid 
carcinoma; A549, human lung carcinoma; MCF-7, human mammary gland 
adenocarcinoma; MDA-MB-231, human mammary gland adenocarcinoma, MRC-5, 
fetal lung fibroblasts) were distributed by the European Collection of Cell Cultures 
(ECACC), and purchased through Sigma Aldrich. Dulbecco’s Minimal Essential 
Medium (DMEM, with and without phenol red, without glutamine), 200 mM GM, 
trichloroacetic acid (TCA), glacial acetic acid, sulforhodamine B (SRB), 
tris(hydroxylmethyl)aminomethane (tris base), 4,5,6,7-tetrachloro-2’,4’,5’,7’-
tetraiodofluorescein disodium salt (rose bengal), and cis-diamineplatinum(II) 
dichloride (cisplatin), were purchased from Sigma Aldrich. (2R,3R,4R,5R)-hexan-
1,2,3,4,5,6-hexol (D-mannitol) was purchased from Santa Cruz Biotechnology via 
Bio-Connect. FCS was purchased from Hyclone. Penicillin and streptomycin were 
purchased from Duchefa and were diluted to a 100 mg/mL solution. Trypsin and 
Opti-MEM® (without phenol red) were purchased from Gibco® Life Technologies. 
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trichloroacetic acid (TCA), glacial acetic acid, sulforhodamine B (SRB), 
tris(hydroxylmethyl)aminomethane (tris base), 4,5,6,7-tetrachloro-2’,4’,5’,7’-
tetraiodofluorescein disodium salt (rose bengal), and cis-diamineplatinum(II) 
dichloride (cisplatin), were purchased from Sigma Aldrich. (2R,3R,4R,5R)-hexan-
1,2,3,4,5,6-hexol (D-mannitol) was purchased from Santa Cruz Biotechnology via 
Bio-Connect. FCS was purchased from Hyclone. Penicillin and streptomycin were 
purchased from Duchefa and were diluted to a 100 mg/mL solution. Trypsin and 
Opti-MEM® (without phenol red) were purchased from Gibco® Life Technologies. 
Trypan blue (0.4% in 0.81% sodium chloride and 0.06% potassium phosphate 
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dibasic solution) was purchased from BioRad. Plastic disposable flasks and 96-well 
plates were from Sarstedt. Cells were counted using a BioRad TC10 automated cell 
counter with BioRad Cell Counting Slides. UV-vis measurements for analysis of 96-
well plates were performed on a M1000 Tecan Reader. Cells were inspected with 
an Olympus IX81 microscope. Cells were stained for fluorescence-assisted-cell-
sorting (FACS) using Annexin V-FITC purchased from Bioconnect and propidium 
iodide purchased from Sigma Aldrich and analyzed by a Cell Lab Quanta SC flow 
cytometer from Beckman Coulter. 
Optimized assay for the determination of (photo)cytotoxicity  
The (photo)cytotoxicity of cancer cell lines (A375, A431, A549, MCF-7, MDA-
MB231) or one non-cancerous lung cell line (MRC-5) was assessed using an assay 
adapted from Hopkins et al.1 Cell cultures with a maximum confluence of 70-80% 
were trypsinized and centrifuged (1.5 min, 1.2 relative centrifugal force), trypsin 
and DMEM complete were removed, and the cells were re-suspended using Opti-
MEM supplemented with 2.4% v/v FCS, 0.2% v/v P/S, and 1.0% v/v GM, (hereafter 
called Opti-MEM complete). 10 µL of cell suspension and 10 µL of trypan blue 
were mixed and pipetted into a cell counting slide, and cells were counted. The cell 
suspension was diluted to the appropriate seeding density (A375, 5 × 103; A431, 8 × 
103; A549, 5 × 103; MCF-7, 8 × 103; MDA-MB231, 12 × 103; MRC-5, 6 × 103 cells/well) 
and seeded in the wells of a 96-well plate. Cisplatin positive control solution was 
prepared from a stock solution based on clinical formulation (3.3 mM cisplatin, 55 
mM mannitol, 154 mM NaCl).2 In case of poor water solubility, sterilized 
dimethylsulfoxide (DMSO) was used to dissolve the complexes in such amounts 
that the maximum v/v% of DMSO per well did not exceed 0.5% v/v. 
A complete (photo)cytotoxicity experiment lasted 96 h: cells were seeded at t = 0 h, 
treated at t = 24 h, irradiated at t = 30 h, or irradiated and t = 48 h, the medium was 
refreshed at t = 48 h, and fixed at t = 96 h. For every irradiated plate a parallel 
control plate was prepared and treated identically to the irradiated plate, but 
without irradiation. To prevent border effects, cells were only seeded in the inner 
60 wells as shown in Figure SI.1 (unseeded wells indicated by blue). Border wells 
B12-F12 (Figure S18, grey, pink) were seeded with cells for qualitative positive 
controls such as cisplatin or Rose Bengal. In the remaining outer wells 200 µL of 
Opti-MEM complete was pipetted.  
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The cells were incubated in the dark for 24 h at 37 °C at 7.0% CO2. At t = 24 h the 
cells were treated with freshly prepared solutions of the compounds and dissolved 
in Opti-MEM complete. Different concentrations were prepared and of each 
concentration 100 µL was added to three wells (B3:G11, Figure SI.1, red). In case of 
the cytotoxicity assay, the medium was refreshed at t = 24 h. In case of the 
photocytoxicity assay, at t = 30 h or t = 48 h the 96-well plates were taken out of the 
incubator and were irradiated using the 96-well LED 520 nm array system. During 
irradiation the temperature of the wells was controlled at 35-37 °C by the 
thermoblock preheated to 39 °C coupled to LED cooling with a fan.1 After 
refreshing or irradiation, all 96-well plates were placed back into a standard (dark) 
incubator for the remainder of the experiment, until the cells were fixated by 
addition of 100 µL TCA (10% w/v). 
The plates were stored at 4 °C for at least 4 h as part of the SRB assay that was 
adapted from Vichai at al.3 In short, after fixation the TCA medium mixture was 
removed, rinsed with demineralized water three times, and air dried. Then, each 
well was stained with 100 µL SRB solution (0.6% w/v SRB in 1% v/v acetic acid) for 
30 min, the SRB solution was removed, and washed with acetic acid (1% v/v) until 
no SRB came off, normally requiring 3-5 times. Once air dry, 200 µL of tris base 
(tromethamine, 10 mM) was pipetted to each well. To determine the cell viability 
the absorbance at 510 nm was measured using a M1000 Tecan Reader. To make 
sure all the SRB was dissolved, this measurement was performed at least 30 
minutes after addition of tris base. The SRB absorbance data per compound per 
concentration was averaged over three identical wells (technical replicates, nt = 3) 
in Excel and made suitable for use in GraphPad Prism. Relative cell populations 
were derived from the average of the untreated controls (nt = 6). In any case, it was 
checked that the cell viability of the control cells of the samples irradiated without 
compound were similar (maximum difference of 10%) to the unirradiated samples 
without ruthenium compound to make sure no harm was done by the light. The 
data from three independent biological replications was used to obtain the dose-
response curves and EC50 values using non-linear regression of hills-slope equation 
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96-well plate layout used in (photo)cytotoxicity assay 
 
 
Figure SI.1 Layout of a 96-well plate used in the photocytotoxicity assay. All the wells are 
seeded with cells apart from the outer 36 blue wells that are filled with 200 μL Opti-MEM 
complete. The wells in green (B2:G2) are the untreated control cells, the wells colored by 
a different intensity of red (B3:B11), are cells treated with various concentration of the 
compound. The grey wells (B12:D12) are wells treated with the positive dark control 
cisplatin (3.3 μM). The pink wells (E12:G12) are wells treated with the positive light 
control Rose Bengal (5.0 μM).  
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Figure SII.1 Evolution of the 1H NMR spectra (region 10.3-9.3 ppm) of the reaction 
between [1]2+ and H2Cys at 298 K in phosphate buffer (pD = 7.8). The peaks around 10.00 
() and 9.54 () correspond to the A6 proton for complex [2]+ and [1]2+, respectively. 
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Figure SII.1 Evolution of the 1H NMR spectra (region 10.3-9.3 ppm) of the reaction 
between [1]2+ and H2Cys at 298 K in phosphate buffer (pD = 7.8). The peaks around 10.00 
() and 9.54 () correspond to the A6 proton for complex [2]+ and [1]2+, respectively. 




Figure SII.2 Composition of the reaction mixture during the reaction of 
[Ru(tpy)(bpy)(OH2)]2+ ([1]2+) and H2Acys at 353 K under an argon atmosphere. Relative 
integration of 1H NMR peaks at 10.12, 10.00, and 9.54 ppm for the unknown side product 
(), [3]+ (), and [1]2+ (), respectively. The 1H NMR peaks in this region correspond to 
the A6 proton for each complex. Conditions: phosphate buffer pD = 7.8, [Ru]0 = 5.0 mM, 
[H2Acys] = 5.0 mM. 
 
Figure SII.3 Evolution of the 1H NMR spectra (region 10.8-9.0 ppm) of the reaction 
between [1](PF6)2 and commercial HAcysMe after different time intervals at 353 K in 
CD3OD under an argon atmosphere. Notations: () [4]+, () unknown side product,  
[Ru(tpy)(bpy)Cl]+,() [1]2+. 1H NMR peaks in this region correspond to the A6 proton for 




Figure SII.4 Structures of the κS, κN, and κO isomers of [Ru(tpy)(bpy)(Hcys)]+ optimized 
in water (COSMO) by DFT. Top: most stable conformers in water. Bottom: second least 
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Table SII.1 Absolute and relative energies in vacuum and in water (COSMO) of the 





Figure SII.5 1H NMR spectrum (region 10.6-6.9 and 5.1-1.4 ppm) of a solution of [2]PF6 in 
CD3OD. Notation: # = EtOH. 








[κS-2]+  -2052.114793 -2052.197445 0.0 0.0 
[κS-2bis]+ -2052.108926 -2052.189717 3.7 4.8 
[κN-2]+ -2052.089841 -2052.187013 15.7 6.5 
[κN-2bis]+ -2052.076531 -2052.147804 24.0 31.2 
[κO-2]+ -2052.093757 -2052.176934 13.2 12.9 




Figure SII.6 1H NMR spectrum (region 10.6-6.9 and 5.1-1.4 ppm) of a solution of [3]PF6 in 
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Figure SII.6 1H NMR spectrum (region 10.6-6.9 and 5.1-1.4 ppm) of a solution of [3]PF6 in 




Figure SII.7 NOESY spectrum of [3]PF6 in CD3OD showing coupling between the α and β 
protons of cysteine (region 1.0-4.5 ppm, f1) and the bpy (A6) and tpy (T6) protons (region 
11.0-6.0 ppm, f2). Integrals of the of-diagonal NOESY peaks are indicated as percentage of 
the sum of the four peaks, and show that α is closer to Ru than β, thus that HAcys− is 




Figure SII.8 UV-vis spectra of the thiolato complex [Ru(tpy)(bpy)(HAcys)]PF6 (blue) and 
of the thioether analogue [Ru(tpy)(bpy)(HAmet)]Cl2 (red) in water. pH~7, 298 K. 
Table SII.2 Conversion of compound [3]+ into the aqua complex [1]2+ and into unknown 
side products as a function of time, under air and argon.[a], [b] 
time 


























0 hours 12 88 0 0  18 82 0 0 
4 hours 10 85 5 0  13 79 8 0 
1 day 9 84 7 0  19 67 14 0 
4 days 9 82 9 0  17 52 31 0 
3 weeks 9 77 14 0  26 0 55 19 
[a] Conditions: [Ru]0 = 6.4 mM, in D2O, in the dark, at 298 K.  
[b] Relative integration of the peak at 10.12, 10.00, 9.71, or 9.54 ppm for the side product, [3]+, 
the second side product, or [1]2+, respectively, versus the sum of all four peaks at 10.12, 10.00, 
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Figure SII.9 1H NMR spectra (region 10.3-9.3 ppm) of the reaction between [1](PF6)2 and 
the disulfide H2Acys2 (6) at different time intervals at 353 K in D2O. Notations:  = [1]2+. 
1H NMR peaks in this region correspond to the A6 proton for each complex. Conditions: 






Figure SII.10 Evolution of the 1H NMR spectra (region 10.2-9.4 ppm) of the reaction 
between [1]2+ and H2Cys in D2O. a) reaction according to Bugarčić et al.1 b) reaction in our 
hands; peaks at 10.00 and 9.54 ppm are expected as the A6 proton for complex [2]+ () and 
[1]2+ (), respectively (see main text). Conditions: a) [Ru]0 = 4.0 mM, [H2Cys] = 4.0 mM, pH 
= 7.4, T = 295 K. b) [Ru]0 = 7.7 mM, [H2Cys] = 7.7 mM, pH = 7.4, T = 298 K.  
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Figure SIII.1 ESI mass spectrum of [2](PF6)2 after light activation (A) and the dark control 
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Figure SIII.2 Evolution of the electronic absorption spectra of a solution of [2](PF6)2 in 
acetonitrile upon blue light irradiation under nitrogen (λ = 445 nm, Δλ1/2 = 11 nm, 10.5 
mW, 1.27 × 10−7 mol.s−1). Time: 0 min (red curve) to 30 min (black curve). Conditions: [Ru]0 
= 50 μM, irradiated volume was 3.0 mL at 293 K. 
 
Figure SIII.3 1H NMR spectra (500 MHz, CD3CN, region 10.7-6.5 ppm) of a solution of 
[2](PF6)2 before (top) and after (bottom) having been irradiated by white light. Notations: 
(∎) A6 proton of [2](PF6)2, () A6 proton of [Ru(tpy)(bpy)(CH3CN)](PF6)2. Conditions: T = 




Figure SIII.4 Evolution of the electronic absorption spectra of a solution of [2](PF6)2 in 
water upon blue light irradiation under nitrogen (λ = 445 nm, Δλ1/2 = 11 nm, 10.5 mW, 
photon flux 1.27 × 10−7 mol.s-1). Time: 0 min (red curve) to 30 min (black curve). 




Figure SIII.5 Evolution of the UV-vis spectrum of a well of a 96-well plate containing 
compound [2](PF6)2 ([Ru] = 60 μM) in the cell-culturing medium Opti‐MEM complete, 
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Figure SIII.5 Evolution of the UV-vis spectrum of a well of a 96-well plate containing 
compound [2](PF6)2 ([Ru] = 60 μM) in the cell-culturing medium Opti‐MEM complete, 






APPENDIX IV: SUPPORTING 
INFORMATION FOR CHAPTER 4 
 
 
Figure SIV.1 Evolution of the 1H NMR spectra (400 MHz, D2O, region 9.5-7.0 and 3.5-1.5 
ppm) of [1a]2+ under addition of NaCl at 298 K in D2O. The initial spectrum (at [NaCl] = 0 
M) is that of [1a]2+, the spectrum at [NaCl] = 0.08 M and [NaCl] = 0.17 M a mixture of [1a]2+ 
and [1]+. Notations:  = methyl group of dmso in [Ru(H2biqbpy)(dmso)(D2O)]2+, splitting 
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Figure SIV.1 Evolution of the 1H NMR spectra (400 MHz, D2O, region 9.5-7.0 and 3.5-1.5 
ppm) of [1a]2+ under addition of NaCl at 298 K in D2O. The initial spectrum (at [NaCl] = 0 
M) is that of [1a]2+, the spectrum at [NaCl] = 0.08 M and [NaCl] = 0.17 M a mixture of [1a]2+ 
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Figure SIV.2 Evolution of the 1H NMR spectra (400 MHz, D2O, region 9.0-1.0 ppm) of a 
solution of [2]PF6 in D2O under argon. Notations:  = characteristic chiral proton (δ) of 
free Amet-;  = characteristic chiral proton (δ) of ruthenium-coordinated Amet- in [2a] (see 
Scheme 4.2). [Ru]0 = 0.38 mM 
 
Figure SIV.3 1H NMR spectra (400 MHz, region 9.0-7.5 and 3.0-2.0 ppm) of a solution of 
[1]Cl in D2O that has been irradiated by green light (top) and stored in the dark (bottom) 
at 310 K in a 96-well plate. Notations:  = free dmso (CH3),  = sulfur-coordinated dmso 




Figure SIV.4 1H NMR spectra (400 MHz, D2O, region 9.0-7.0 and 4.5-1.0 ppm) of a solution 
of [2]PF6 in D2O that has been irradiated by green light (top) or stored in the dark 
(bottom) at 310 K in a 96-well plate. [Ru]0 = 0.087 mM. Light source: green LED array, 520 
nm, 75 J.cm−2. 
Notations: ∎ = characteristic chiral proton  (δ) of free Amet−;  = characteristic chiral 
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Figure SIV.2 Evolution of the 1H NMR spectra (400 MHz, D2O, region 9.0-1.0 ppm) of a 
solution of [2]PF6 in D2O under argon. Notations:  = characteristic chiral proton (δ) of 
free Amet-;  = characteristic chiral proton (δ) of ruthenium-coordinated Amet- in [2a] (see 
Scheme 4.2). [Ru]0 = 0.38 mM 
 
Figure SIV.3 1H NMR spectra (400 MHz, region 9.0-7.5 and 3.0-2.0 ppm) of a solution of 
[1]Cl in D2O that has been irradiated by green light (top) and stored in the dark (bottom) 
at 310 K in a 96-well plate. Notations:  = free dmso (CH3),  = sulfur-coordinated dmso 




Figure SIV.4 1H NMR spectra (400 MHz, D2O, region 9.0-7.0 and 4.5-1.0 ppm) of a solution 
of [2]PF6 in D2O that has been irradiated by green light (top) or stored in the dark 
(bottom) at 310 K in a 96-well plate. [Ru]0 = 0.087 mM. Light source: green LED array, 520 
nm, 75 J.cm−2. 
Notations: ∎ = characteristic chiral proton  (δ) of free Amet−;  = characteristic chiral 
proton (δ) of ruthenium-coordinated Amet−; * = ethanol originating from working in 






Figure SIV.5 Evolution of the UV-vis spectrum of a solution of [1]Cl in demineralized 
water, thus of [1a]+, upon blue light irradiation under argon. Conditions [Ru]0 = 0.025 mM 
irradiated volume 3.00 mL, 298 K. Light source: λ = 450 nm, Δλ1/2 = 25 nm, 0.65 mW, 8.53 × 
10−9 mol.s−1.  
 
Figure SIV.6 Evolution of the UV-vis spectrum of a solution of [2]PF6 in demineralized 
water upon blue irradiation under argon. Conditions [Ru]0 = 0.025 mM, irradiated volume 





Figure SIV.7 Evolution of the UV-vis spectra of [1]Cl (38 μM) in the medium Opti-MEM 
complete under green light irradiation (37 °C) in a well in a 96-well plate at 0 min (-·-), 5 
min (—··), 10 min (— —), 15 min (- - -), 30 min (···), and 60 min (—).  
 
 
Figure SIV.8 Evolution of the UV-vis spectra of [2]PF6 (88 μM) in the medium Opti-MEM 
complete under green light irradiation (37 °C) in a well of a 96-well plate at 0 min (-·-), 5 
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Figure SIV.9 Average absorbance at 510 nm (with standard deviation) of control cells 
used in photocytotoxicity assay for A431 and A549 cells kept in the dark (black bar) or 
irradiated with green light (520 nm, 60 min, 75 J.cm−²) indicated with a white bar. 
Phototoxicity assay outline: cells seeded at 8 × 103 (A431) or 5 × 103 (A549) cells/well at t = 0 
h, treated with Opti-MEM complete at t = 24 h, irradiated at t =30 h or 48 h, and SRB assay 
performed at t = 96 h. Incubation conditions: 37 °C and 7% CO2.  
 
Figure SIV.10 Schematic overview of the custom-built setup to determine singlet oxygen 

















The quantum yield of singlet oxygen production was calculated using the relative method 
with [Ru(bpy)3]Cl2 as the standard (Φ𝑠𝑠𝑜𝑜𝑠𝑠Δ = 0.73 in CD3OD), according to: 







where ΦΔ  is the quantum yield of singlet oxygen generation, A450 is the absorbance at 450 
nm (always kept below 0.1 for a 1 cm path length cuvette), E is the integrated emission peak 
of singlet oxygen at 1273 nm, and sam and std indexes denote the ‘sample’ and ‘standard’ 
respectively. 
 
Figure SIV.11 Time-integrated emission spectra of [Ru(bpy)3]Cl2 (— —), [1]Cl (···), [2]PF6 
(—) irradiated with blue light (450 nm, 101 mW, photon flux = 0.53 μmol.s−1), stirred under 
air in CD3OD at 298 K. Emission was measured and averaged over 4 × 40 s.  
Table SIV.1 Time-integrated emission data for [Ru(bpy)3]Cl2, [1]Cl, and [2]PF6 measured 
in CD3OD stirred under air at 298 K. Emission was averaged 4 × 40 s.  
Compound Concentration (μM) Absorbance  
at 450 nm 
Integrated Emission 
 (mW.cm−2) at 1273 nm 
Quantum yield (%) 
[Ru(bpy)3]Cl2 5.3 0.11 0.02192 73 a 
[1]Cl 23 0.14 0.00045 1.3 
[2]PF6 8.9 0.084 0.00065 2.3 
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Figure SIV.12 Annexin V FITC/propidium iodide FACS analysis of cells treated with 
Staurosporine (STS, 0.3 µM), Rose Bengal (10 µM), [1]Cl (1.5 µM), or [2]PF6 (10 µM). Cells 
were seeded at t = 0, grown for 24 h, treated with the appropriate compound for 6 h or 24 
h, then irradiated with green light (520 nm, 60 min, 75 J.cm−2, ‘Light’), then incubated for a 
further 24 h before flow cytometric analysis. In parallel, a second set of cells were treated 
with the same protocol, except that they were kept in the dark instead of irradiated 
(‘Dark’). The diagram shows the relative distribution (cell count) of vital, necrotic, 





Figure SIV.13 Micrographs (40×) of A549 cells 24 h after green light irradiation (520 nm, 60 
min, 75 J.cm−2). Cells seeded at t = 0 (200,000 cells per 35 mm petri dish), incubated in the 
dark for 24 h (7% CO2, 37 °C), treated with [1]Cl or [2]PF6 or with no drug (CTR) at t = 24 h, 
either irradiated at t = 6 h (LIGHT) or left in the dark (DARK), further incubated for 24 h 
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Figure SIV.13 Micrographs (40×) of A549 cells 24 h after green light irradiation (520 nm, 60 
min, 75 J.cm−2). Cells seeded at t = 0 (200,000 cells per 35 mm petri dish), incubated in the 
dark for 24 h (7% CO2, 37 °C), treated with [1]Cl or [2]PF6 or with no drug (CTR) at t = 24 h, 
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Figure SIV.14 Confocal micrographs of the emission of the mitochondrial dye 
tetramethylrhodamine ethyl ester (λex = 551 nm, λem = 593 nm) and the emission of the 
DNA intercalator Draq5 ((λex = 646 nm, λem = 681 nm) in A549 cells treated with Rose 
Bengal (10 µM) Staurosporine (STS, 0.3 µM), [1]Cl (1.5 µM), or [2]PF6 (10 µM) left in the 
dark (left column) or irradiated with green light 24 h after treatment (right column). 
Analysis was performed 24 h after light irradiation. Irradiation conditions: 520 nm, 60 




Figure SIV.15 Relative distribution of ruthenium in cytosol, membranes, nucleus, and 
cytoskeleton indicated by the green, red, blue, and white bar, respectively, of A549 cells 
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Lane BP:MC [DNA BP]f (M) [MC]f (M) 
1 λ MW marker 1.95 × 10−3  
2 37 °C control 1.95 × 10−3 0 
3 Cisplatin 5:1 BP:MC 1.95 × 10−3 1.95 × 10−5 
4 100:1 BP:MC 1.95 × 10−3 3.91 × 10−4 
5 50:1 BP:MC 1.95 × 10−3 1.95 × 10−4 
6 25:1 BP:MC 1.95 × 10−3 1.30 × 10−4 
7 15:1 BP:MC 1.95 × 10−3 7.82 × 10−4 
8 10:1 BP:MC 1.95 × 10−3 3.91 × 10−5 
9 5:1 BP:MC 1.95 × 10−3 1.95 × 10−5 
10 λ MW marker 1.95 × 10−3  
Figure SIV.16 Agarose gels showing the thermal binding of metal complexes [1a]2+ (A) 
and [2a]0 (B) to pUC19 plasmid DNA. The table below shows the lane assignment, 
description (DNA base pair (BP) to metal complex (MC) ratios), and the final 
concentrations. The λ MW marker bands correlate to 23, 9.4, 6.6, 4.4, 2.3, and 2.0 kbp. The 
control DNA band consists of three bands correlating to linear dimer (LD), open circular 




Lane BP:MC Time or irradiation (min) J.cm−2 
1 λ MW marker   
2 Dark DNA control   
3 Irr DNA control 60 75 
4 100:1 BP:MC 0 0 
5 50:1 BP:MC 5 6 
6 25:1 BP:MC 15 19 
7 15:1 BP:MC 30 38 
8 10:1 BP:MC 45 56 
9 5:1 BP:MC 60 75 
Figure SIV.17 Agarose gels showing the photoinduced binding of cisplatin to pUC19 
plasmid DNA. The table below shows the lane assignment, description (DNA base pair 
(BP) to metal complex (MC) ratios), time of irradiation (min), and calculated light doses 
(J.cm−2). The λ MW marker bands correlate to 23, 9.4, 6.6, 4.4, 2.3, and 2.0 kbp. The control 
DNA band consists of three bands correlating to linear dimer (LD), open circular (OC), 
and supercoiled (SC) forms. 
References 
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Figure SV.1 Chemical structure of [Ru(H2biqbpy)L2] and of [Ru(H2bapbpy)L2] and atom 
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Figure SV.2 Evolution of the electronic absorption spectra of a solution of [4](PF6)2 in 
demineralized water (5 v/v% acetone-d6) upon blue light irradiation (λirr = 445 nm, Δλ1/2 = 
22 nm, photon flux Φ = 1.81 × 10−7 mol.s−1, tirr = 15 min). Time: 0 min (red curve) to 15 min 
(black curve). Conditions [Ru]0 = 0.05 mM, irradiated volume was 3.0 mL at 298 K. Inset: 
Plot of the absorbance at 414 nm as a function of irradiation time.  
 
Figure SV.3 Stability of the UV-vis absorption spectrum of a solution of [2]Cl in 
demineralized water over 6 hours in the dark. Inset: Evolution of absorbance at 400 nm. 




Figure SV.4 Stability of the UV-vis absorption spectrum of a solution of [1]Cl in 
demineralized water over 6 hours in the dark. Inset: evolution of absorbance at 400 nm. 
Conditions: [Ru] = 0.05 mM, T = 298 K. 
 
 
Figure SV.5 Evolution of UV-vis spectrum of [3](PF6)2 over 6 hours in demineralized 
water in the dark. Inset: evolution of absorbance at 450 nm. Conditions: [Ru] = 0.05 mM, T 
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Figure SV.5 Evolution of UV-vis spectrum of [3](PF6)2 over 6 hours in demineralized 
water in the dark. Inset: evolution of absorbance at 450 nm. Conditions: [Ru] = 0.05 mM, T 





Figure SV.6 Evolution of UV-vis spectrum of [4](PF6)2 over 6 hours in demineralized 
water in the dark. Inset: evolution of absorbance at 450 nm. Conditions: [Ru] = 0.05 mM, T 




Figure SV.7 Gel electrophoresis of light-induced binding of [1]Cl, [2]Cl, or [4](PF6)2 (lane 
2, 3, and 4) analyzed by polyacrylamide gel including ODN1 (dark, lane 1), ODN1 
(irradiated, lane 5), 19, 23, 24, 31-mer control. Conditions: T = 25 °C, [Ru] = 0.75 mM, 
[ODN] = 0.25 mM, Staining agent: Toluidine blue, λirr = 445 nm, Δλ1/2 = 22 nm, photon flux 







Figure SV.6 Evolution of UV-vis spectrum of [4](PF6)2 over 6 hours in demineralized 
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Figure SV.8 Deconvoluted mass spectrometry data of ODN1 (s(5’CTACGGTTTCAC3’) or 
C116H149N40O72P11). Conditions: [ODN] = 0.03 mM, T = 298 K.  
 





Figure SV.10 Deconvoluted mass spectrometry data of ODN1 and [1]Cl incubated in the 
dark (A) or after light activation (B). Conditions: [ODN] = 0.03 mM, [Ru] = 0.09 mM, 
tincubation = 6 h, T = 298 K, λirr = 445 nm, Δλ1/2 = 22 nm, photon flux Φ = 2.17 × 10−7 mol.s−1. 
 
Figure SV.11 Deconvoluted mass spectrometry data of ODN1 and [2]Cl incubated in the 
dark (A) or after light activation (B). Conditions: [ODN] = 0.03 mM, [Ru] = 0.09 mM, 
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Figure SV.12 Deconvoluted mass spectrometry data of ODN1 and [3](PF6)2 incubated in 
the dark (A) or after light activation (B). Conditions: [ODN] = 0.03 mM, [Ru] = 0.09 mM, 
tincubation = 6 h, T = 298 K, λirr = 445 nm, Δλ1/2 = 22 nm, photon flux Φ = 2.17 × 10−7 mol.s−1. 
 
Figure SV.13 Deconvoluted mass spectrometry data of ODN1 and [4](PF6)2 incubated in 
the dark (A) or after light activation (B). Conditions: [ODN] = 0.03 mM, [Ru] = 0.09 mM, 
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Table SVI.1 Selected bond lengths (Å) for [1]Cl2, [2](PF6)2, and [Pt(Hbapbpy)](PF6) 
Bond [1]Cl2 [2](PF6)2 [Pt(Hbapbpy)](PF6) 
M-N1 2.0630(16) 2.0251(16) 2.013(4) 
M-N3 2.0348(16) 1.9846(16) 1.981(4) 
M-N4 2.0325(16) 1.9802(16) 1.990(4) 
M-N6 2.0579(16) 2.0312(16) 2.035(4) 
N2-C5 1.381(3) 1.390(3) 1.354(7) 
N2-C6 1.383(2) 1.372(3) 1.336(7) 
N5-C15 1.381(3) 1.363(3) 1.373(8) 
N5-C16 1.384(3) 1.372(3) 1.398(8) 
Ni-O1W 2.1225(15) - - 
Ni-O2W 2.1131(15) - - 
 
Table SVI.2 Selected angles (°) for [1]Cl2, [2](PF6)2, and [Pt(Hbapbpy)](PF6) 
Angle [1]Cl2 [2](PF6)2 [Pt(Hbapbpy)](PF6) 
N1-M-N3 90.06(6) 91.43(7) 92.50(18) 
N3-M-N4 80.42(6) 82.19(7) 81.77(19) 
N4-M-N6 90.03(6) 92.34(7) 91.53(19) 
N6-M-N1 101.75(7) 96.38(7) 96.42(18) 
N1-M-N4 164.36(6) 165.35(6) 167.67(17) 
N3-M-N6 164.37(7) 167.38(6) 165.28(18) 
C5-N2-C6 132.09(17) 129.52(17) 127.0(5) 
C15-N5-C16 132.23(18) 132.22(18) 128.5(4) 





Table SVI.3 Cytotoxicity (EC50 with 95% confidence interval, in μM) of H2bapbpy and 
cisplatin on skin (A375, A431), lung (A549), breast (MCF-7, MDA-MB231), and brain 
cancer cell lines, and non-cancerous lung fetal cell line (MRC-5). 
Cell Line H2bapbpy CI cisplatin CI 
















MDA-MB-231 66.43 −16.36 
+21.70 
> 25 - 






Figure SVI.2 General uptake of [1]Cl2, [2](PF6)2, [3](PF6)2, and cisplatin at respectively 70, 
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+21.70 
> 25 - 






Figure SVI.2 General uptake of [1]Cl2, [2](PF6)2, [3](PF6)2, and cisplatin at respectively 70, 




Figure SVI.3 Relative distribution of [1]Cl2, [2](PF6)2, [3](PF6)2, and cisplatin at respectively 
70, 0.20, 1.0, and 3.3 μM in A549 cells (expressed in pmol metal/106 cells) in cytosol (Cyt), 




Table SVI.4 Uptake in the cytosol, mitochondria, and cytoskeleton fractions of A549 cells 
for compound [1]Cl2, [2](PF6)2, [3](PF6)2, and cisplatin. 
Compound Fraction Distribution among cytosol, 
 mitochondria,  
and rest fraction (%) 
Distribution among cytosol, mitochondria,  
and rest fraction (pmol/106 cells) 
[1]Cl2 
Cytosol 21 338.2 ± 60.2 
Mitochondria 3 47.3 ± 70.6 
Rest 76 1239 ± 546 
[2](PF6)2 
Cytosol 13 30.7 ± 6.24 
Mitochondria 1 1.76 ± 0.63 
Rest 86 196 ± 40.4 
[3](PF6)2 
Cytosol 2 60.4± 43.6 
Mitochondria 1 16.1 ± 12.8 
Rest 97 2851 ± 380 
cisplatin 
Cytosol 25 13.8 ± 0.45 
Mitochondria 5 2.87 ± 0.44 
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Figure SVII.1 pH dependent presence of [1]2+ (%) at different pH in water. 
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Figure SVII.3 Evolution of the UV-vis spectrum of [5] to [3]+ (A) and from [3]+ to [1]2+ (B) 
upon decreasing pH using HCl (33 mM, 2 μL aliquots). Solvent: water-THF mixture (1:1) 
slightly basified with NaOH to ensure full initial deprotonation. T = 293 K, [Pd] = 67 μM. 
 
Figure SVII.4 Evolution of the UV-vis spectrum of [6] to [4]+ (A) and from [4]+ to [2]2+ (B) 
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Figure SVII.5 Evolution of UV-vis spectra of [1](PF6)2 (A) and [2](PF6)2 (B) in 






Figure SVII.6 TDDFT calculated excited states for [5] (A), [3]+ (B), and [1]2+ (C) at the 
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Figure SVII.6 TDDFT calculated excited states for [5] (A), [3]+ (B), and [1]2+ (C) at the 




Table SVII.1 Calculated (TDDFT) singlet transitions for [5] from ground singlet state 
geometry. 
Wavelength (nm) Oscillator strength  Major Contributions 
450 0.0685 HOMO  LUMO+1 (56 
%) 
HOMO  LUMO (30%) 
413 0.3367 HOMO  LUMO (61%) 
HOMO  LUMO+1 (28%) 
377 0.3371 HOMO−1  LUMO+1 
(53%) 
HOMO−1  LUMO (22%) 
HOMO  LUMO+2 (17%) 
365 0.0528 HOMO-3LUMO+1 
(47%) 
HOMO LUMO+4 (18%) 
 
Table SVII.2 Calculated (TDDFT) singlet transitions for [3]+ from ground singlet state 
geometry. 
Wavelength (nm) Oscillator strength  Major Contributions 
458 0.0261 HOMO  LUMO+1 (72%) 
HOMO  LUMO (16%) 
408 0.3510 HOMO  LUMO (73%) 
HOMO  LUMO+1 (14%) 
374 0.0516 HOMO−3  LUMO+1 
(55%) 
HOMO−4  LUMO+1 
(12%) 
 
Table SVII.3 Calculated (TDDFT) singlet transitions for [1]2+ from ground singlet state 
geometry. 
Wavelength (nm) Oscillator strength  Major Contributions 
 401  0.0153 HOMO  LUMO+1 (36%) 
HOMO  LUMO (31%)  
389 0.0038 HOMO−3  LUMO+1 
(52%) 
HOMO−3  LUMO (32%) 
358 0.5362 HOMO  LUMO (57%) 







Figure SVII.7 Selected orbital surfaces calculated by ADF of [5]. 
 
 
Figure SVII.8 Selected orbital surfaces calculated by ADF of [3]+. 
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Figure SVIII.1 pH dependent presence of [1]2+ (%) at different pH in water. 
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Figure SVIII.3 Displacement ellipsoid of the cationic part of [Ni(Hbbpya)(OH2)Cl]+(A) 
and [Ru(Hbbpya)(dmso)Cl]+ (B) (50% probability level) as observed in the crystal 
structure of [Ni(Hbbpya)(OH2)Cl]Cl and [Ru(Hbbpya)(dmso)Cl]Cl. Chloride counter 
anions, H atoms, and the lattice solvent molecule, have been omitted for clarity. Torsion 





Figure SVIII.4 TDDFT calculated excited states for [Pd(Hbbpya)]2+ (A) and [Pd(bbpya)]+ 
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Figure SVIII.4 TDDFT calculated excited states for [Pd(Hbbpya)]2+ (A) and [Pd(bbpya)]+ 




Table SVIII.1 Calculated (TDDFT) singlet transitions for [Pd(Hbbpya)]2+ from ground 
singlet state geometry. 
Wavelength (nm) Oscillator strength  Major Contributions 
388 0.0037 HOMO−4  LUMO (95%) 
368 0.0007 HOMO−1  LUMO (64%) 
HOMO−3  LUMO (24%) 
342 0.9778 HOMO  LUMO (90%) 
 
Table SVIII.2 Calculated (TDDFT) singlet transitions for [Pd(bbpya)]+ from ground 
singlet state geometry. 
Wavelength (nm) Oscillator strength  Major Contributions 
 429  0.0041 HOMO  LUMO (89%) 
402 0.6025 HOMO  LUMO (95%) 
388 0.1810 HOMO LUMO+1 (76%) 
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Figure SIX.1 Displacement ellipsoid of the cationic part of [Ru(H2bapbpy)(HAmet)]2+ 
(50% probability level) as observed in the crystal structure of 
[Ru(H2bapbpy)(HAmet)2](PF6)2. Counter anions, H atoms, and the lattice solvent 
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Ruthenium-polypyridylcomplexen als licht-activeerbare chemotherapeutisch 
geneesmiddel  
Dit proefschrift bevat de beschrijving van verscheidene ruthenium-
polypyridylcomplexen die kunnen worden toegepast in licht-activeerbare 
chemotherapie (PACT). In PACT wordt een niet biologisch-actieve verbinding 
geactiveerd tot een geneesmiddel door het te bestralen met zichtbaar licht (Schema 
1). Door zeer locale bestraling toe te passen kan de cytotoxiciteit van een 
verbinding worden beperkt tot de tumor, waardoor bijwerkingen worden 
geminimaliseerd en behandelingsdoses geoptimaliseerd kunnen worden. In het 
geval van licht-activeerbare metaalcomplexen veroorzaakt de bestraling vaak een 
uitwisselingsreactie waarbij een van de liganden wordt vervangen door een (labiel) 
watermolecuul. In PACT kunnen zowel het metaalcomplex als het ligand dienst 
doen als chemotherapeutisch medicijn. Indien het metaalcomplex de werkzame 
verbinding is, ontstaat door afsplitsing van het ligand de mogelijkheid tot 
bijvoorbeeld de vorming van een coördinatiebinding tussen het metaalion en een 
biomolecuul. Indien het door licht afgesplitste ligand het werkzame medicijn is, 
leidt een coördinatiebinding met een metaalion in de actieve plaats van een enzym 
tot belemmering van de biologische activiteit, doordat interactie met het 
doelwitmolecuul geblokkeerd wordt. De laatstgenoemde strategie staat ook wel 
bekend als ‘photocaging’. 
 
 
Schema 1. PACT-mechanisme: Een chemische verbinding tussen een medicijn en een 
beschermgroep deactiveert het medicijn. Bestraling met licht verbreekt de chemische 
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In dit proefschrift is eerst beschreven hoe de eigenschappen van ruthenium-
polypyridylcomplexen uit de [Ru(tpy)(bpy)(L)]n+ familie gevarieerd kunnen 
worden door de keuze van monodentaat ligand L (Figuur 1). In Hoofdstuk 2 wordt 
de studie beschreven naar de mogelijkheid om [Ru(tpy)(bpy)(OH2)]2+ te 
deactiveren door coördinatie met thiolbevattende liganden, maar helaas bleken 
deze liganden hiervoor ongeschikt. Eenmaal gecoördineerd aan het rutheniumion 
oxideert het thiolaatligand gemakkelijk tot de sulfenyl- en sulfinylvorm. Daarnaast 
bleek fotosubstitutie van het thiolaatligand veel minder efficiënt te gebeuren dan 
de fotosubstitutie van thioetherliganden.1 
Gedurende het onderzoek bleek dat [Ru(tpy)(bpy)(OH2)]2+ in vitro een geringe 
cytotoxische activiteit heeft, ook al is dit complex wel in staat interactie met DNA 
aan te gaan.2-4 Daarom lijkt dit complex een zeer geschikt ‘photocaging’ agens: het 
is met een coördinatiebinding gebonden aan een microtubili inhibitor (MTI), 
ontworpen in de groep van Dr. Alexander Kornienko van Texas State University 
(USA). Deze inhibitor is gefunctionaliseerd met een thioether donoratoom die 
gebruikt kan worden om de inhibitor aan [Ru(tpy)(bpy)(OH2)]2+ te binden 
(Hoofdstuk 3). Het hieruit ontstane complex [Ru(tpy)(bpy)(MTI-SRR’)](PF6)2 bleek 
40-60 keer minder toxisch dan het vrije MTI-SRR’ ligand. Wanneer 
[Ru(tpy)(bpy)(MTI-SRR’)](PF6)2 wordt geactiveerd door bestraling met groen licht, 
kan de toxiciteit van het ligand grotendeels worden herwonnen. De EC50 waarden 
voor cellevensvatbaarheid van het geactiveerde complex en vrij MTI-SRR’ 
bevonden zich in het nanomolair domein. Met behulp van een 
microtubulipolymerisatieassay kon worden bevestigd dat microtubuli 
polymerisatie stopte wanneer het toegediende [Ru(tpy)(bpy)(MTI-SRR’)](PF6)2 
geactiveerd werd met licht met als gevolg dat het vrijgekomen ligand de 
polymerisatie van de microtubili kon blokkeren. In het controle-experiment zonder 
lichtactivatie vond deze polymerisatie wel plaats. Deze resultaten wijzen erop dat 
de verkregen cytotoxiciteit na bestraling veroorzaakt wordt door een 
fotodissociatiereactie van [Ru(tpy)(bpy)(MTI-SRR’)](PF6)2 waarbij het vrijgekomen 
MTI-SRR’ de werkzame verbinding is.  
Naast de modelverbinding [Ru(tpy)(bpy)(L)]2+ is ook veel onderzoek gedaan naar 
de familie van complexen met algemene formule [Ru(bpy)2(LL)]2+ als potentiële 
PACT-kandidaten (Figuur 2). Substitutie van een (sterisch gehinderd) bidentaat 
ligand LL of twee monodentaat liganden in water leidt tot cis-[Ru(bpy)2(OH2)2]2+. 
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Het fotoproduct cis-[Ru(bpy)2(OH2)2]2+ kan net als cisplatina aan DNA binden met 
twee baseparen gebonden in cis-posities. Daarentegen zijn ruthenium-
polypyridylcomplexen met twee labiele, monodentaat liganden in wederzijdse 
trans-posities in anti-kankeronderzoek zeldzaam, terwijl deze veel voorkomen 
bijvoorbeeld in onderzoek naar wateroxidatie-katalysatoren.5 Verder heeft KP1019, 
één van de eerst gerapporteerde op ruthenium gebaseerde anti-kanker complexen, 
twee indazoolliganden in wederzijdse trans-posities.6  
 
Figuur 1. Chemische structuren van [Ru(tpy)(bpy)(L)]2+ en [Ru(bpy)2(LL)]2+. 
In Hoofdstuk 4 worden potentiële anti-kanker complexen beschreven die 
gebaseerd zijn op het H2biqbpy ligand (Figuur 2), een rigide tetrapyridyl ligand 
dat alleen met alle donoratomen in een vlak met een metaalion kan binden. 
Coördinatie van H2biqbpy aan ruthenium(II) leidde niet alleen tot het cytotoxische 
en licht-activeerbare complex [Ru(H2biqbpy)(dmso)Cl]Cl, maar coördinatie van 
twee axiale monodentaat thioetherliganden resulteerde in de verbinding 
[Ru(H2biqbpy)(HAmet)(Amet)]PF6, dat een significant lagere cytotoxiciteit heeft 
dan [Ru(H2biqbpy)(dmso)Cl]Cl. Activatie van de verbindingen met groen licht 
zorgde voor een cytotoxiciteit die tot 20 keer hoger is dan hetgeen gevonden is in 
het controle-experiment zonder licht-activatie. Verder is aangetoond dat deze 
complexen zeer inefficiënt zijn in het genereren van singletzuurstof. De vorming 
van singletzuurstof ligt aan de basis van fotodynamische therapie (PDT). PDT is 
hierdoor echter niet geschikt voor de behandeling van zuurstof-arme tumoren. 
Daarom kunnen als alternatief voor PDT, PACT-verbindingen gebaseerd op 
[Ru(H2biqbpy)(L)(L’)]2+ gebruikt worden als potentiële anti-kanker 
geneesmiddelen, omdat hun werking onafhankelijk is van de aanwezigheid van 
zuurstof. Daarnaast veroorzaken H2biqbpy-ruthenium complexen die met licht 
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behandeling heeft daarentegen als nadeel dat behandelde cellen via necrose 
doodgaan. Deze ongecontroleerde vorm van celdood leidt tot verlies van 
celmembraanintegriteit waardoor de inhoud van de cel vrijkomt in het 
extracellulaire milieu, met als mogelijk gevolg een pijnlijke ontstekingsreactie. 
Behandeling met H2biqbpy-ruthenium complexen leidt tot apoptose 
(geprogrammeerde celdood) waardoor zulke ongewenste ontstekingsreacties 
voorkomen worden. Uiteindelijk zou dit moeten leiden tot minder pijn bij de 
patiënt.  
Opname- en fractioneringsexperimenten zoals beschreven in Hoofdstuk 4 laten 
zien dat A549 cellen ongeveer 7,5-16 ng ruthenium opnemen per 106 cellen en dat 
de complexen overwegend accumuleren in de membraanfractie bestaande uit 
organellen, lysosomen en membranen. In de nucleus werden ook significante 
hoeveelheden ruthenium aangetroffen (1,7-3,2 ng Ru/106 cellen), wat het uitvoeren 
van DNA-interactie-experimenten rechtvaardigde. Met behulp van 
gelelektroforese experimenten is vastgesteld dat de interactie tussen 
[Ru(H2biqbpy)(dmso)Cl]Cl of [Ru(H2biqbpy)(HAmet)(Amet)]PF6 met pUC19 
plasmide DNA beinvloed kan worden door bestraling met licht. Deze controle 
wijst wederom op de beschermende rol van de thioetherliganden. Een toename 
van lichtdosis leidt tot meer ontscherming van de verbindingen en zorgt voor meer 
interactie met het pUC19 plasmide DNA. Deze ruthenium-DNA adducten konden 
helaas niet gekarakteriseerd worden. Studies naar de interactie van een 
gedefinieerde enkelstrengs oligonucleotide (ODN) met verschillende ruthenium-
tetrapyridylcomplexen (Figuur 2) zijn uitgevoerd in samenwerking met Prof. Luigi 
Messori aan de Universiteit van Florence. Hieruit bleek dat de adducten van de 
rutheniumverbindingen met de ODN wel goed gekarakteriseerd konden worden 
met HRMS. Zoals verwacht vertoonde niet-geactiveerde complexen 
verwaarloosbare interactie met de ODN, terwijl activatie met blauw licht 
resulteerde in adducten bestaande uit één ODN en één of twee 




Figuur 2. Chemische structuren van [Ru(H2biqbpy)(dmso)Cl]Cl, [Ru(H2biqbpy) 
(HAmet)(Amet)]PF6 en [Ru(H2bapbpy)(dmso)Cl]Cl. 
Over het geheel genomen tonen de resultaten uit Hoofdstuk 2-5 aan dat 
ruthenium-polypyridylcomplexen met zwavel bevattende monodentaat liganden 
veel potentie hebben als licht-activeerbare verbindingen voor chemotherapie. De 
fotosubstitutie van een thioether- of sulfoxideligand kan gebruikt worden om 
cytotoxiciteit, het type celdood en de interactie van rutheniumcomplexen met 
biologische moleculen te beïnvloeden. Deze kwaliteiten leggen de basis voor 
verdere ontwikkeling van PACT-verbindingen ter behandeling van hypoxische 
tumoren.  
Vlak-vierkante tetrapyridyl complexen als anti-kanker geneesmiddel 
In het onderzoeksveld van anti-kanker metallodrugs wordt veruit het meeste 
onderzoek gedaan naar verbindingen gebaseerd op platina, veelal geïnspireerd op 
het succes van cisplatina. Tot zover heeft dit geleid tot negen varianten op 
cisplatina die op dit moment toegepast worden in de kliniek (zie Hoofdstuk 1). 
Alternatieven voor cisplatinacomplexen moeten een ander werkingsmechanisme 
hebben om behandeling van cisplatina-resistente tumoren mogelijk te maken. De 
coördinatie van het ligand H2bapbpy met palladium(II) en platina(II) ionen is 
onderzocht, wat leidde tot de metaalcomplexen [Pd(H2bapbpy)]2+ en 
[Pt(H2bapbpy)]2+ (Hoofdstuk 6) die qua structuur vergelijkbaar zijn met het licht-
activeerbare rutheniumcomplex [Ru(H2bapbpy)(dmso)Cl]Cl, maar zonder axiale 
monodentaat liganden. Deze kolom 10 complexen vertoonden in vitro zeer hoge 
cytotoxiciteit. Over een brede selectie van verschillende kankercellijnen vertoonde 
[Pd(H2bapbpy)](PF6)2 ongekende cytotoxische activiteit met EC50 waarden van 200 
nM tot zelfs 50 nM. De EC50 waarden van [Pt(H2bapbpy)](PF6)2 waren 4-16 keer 
hoger en vergelijkbaar met de cytotoxische activiteit van cisplatina. Wanneer de 
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werden en gelijktijdig met N-Acetyl-L-cysteïne (NAC) – een vanger van reactieve 
zuurstofverbindingen (ROS) – werd de activiteit van het palladiumcomplex geheel 
teniet gedaan, terwijl de activiteit van het platina complex vrijwel gelijk bleef. 
Wanneer kankercellijnen met de palladium(II)- of platinum(II)verbindingen 
behandeld werden en gelijktijdig met L-buthionine sulfoximine (BSO) – een stof die 
de cellen meer ontvankelijk maakt voor ROS – vertoonde het palladium complex 
een spectaculair verhoogde activiteit, terwijl dit effect veel minder aanwezig was 
voor de platinaverbinding. Het platinacomplex vertoonde een hogere cytotoxische 
activiteit dan het palladiumcomplex in kankercellijnen waarin het p53-gen 
ontbrak. Beide complexen worden zeer goed opgenomen door de cellen, maar 
waar [Pd(H2bapbpy)]2+ vooral in de membranen accumuleert, is [Pt(H2bapbpy)]2+ 
gelijkmatiger verdeeld over de cytosol-, membraan-, nucleus- en cytoskeletfracties. 
In samenwerking met Prof. Walter Berger van de Medische Universiteit van 
Wenen zijn in vivo experimenten uitgevoerd. Hierin zijn CT-26 darmkanker Balb/c 
muizen behandeld met equimolaire doses van [Pd(H2bapbpy)](PF6)2 of 
[Pt(H2bapbpy)](PF6)2. Dit resulteerde in een significante reductie in tumorgroei bij 
behandeling met het palladiumcomplex, terwijl een dergelijk effect voor het 
platinacomplex niet gevonden werd. Over het geheel genomen suggereren in vitro 
cytotoxiciteit, NAC, BSO, p53, celopname experimenten, als ook in vivo 
experimenten dat de qua structuur vergelijkbare palladium- en platinacomplexen 
verschillende werkingsmechanismen hebben. 
Coördinatie van het tetradentaat ligand H2bapbpy aan Pd2+ of Pt2+ resulteert in een 
vlak-vierkante geometrie. Hierdoor is het onwaarschijnlijk dat het palladium- of 
platinacomplex in kankercellen werkzaam is via ligandsubstitutiereacties zoals in 
geval bij cisplatina. De stabiliteit van de coördinatieomgeving blijkt uit 
experimenten waarin oplossingen van [M(H2bapbpy)]Cl2 in water (0.10 mM, M = 
Pd of Pt) met 100 equivalenten NaCl werden verwarmd tot 80 °C. Hierna werden 
geen significante spectroscopische veranderingen waargenomen die zijn toe te 
schrijven aan ligandsubstitutie (Figuur 3). Gebaseerd op de waarnemingen mag 
worden aangenomen dat deze Pd(II)- en Pt(II)-complexen stabiel zijn in vitro, in 





Figuur 3. UV-vis absorptiespectra van [Pd(H2bapbpy)]Cl2 (A) en [Pt(H2bapbpy)]Cl2 (B) in 
een waterige NaCl-oplossing (10 mM) bij 20 (doorgetrokken lijn) en 80 °C (stippellijn). 
[Pd] = [Pt] = 0,10 mM.  
In vitro studies zijn ook uitgevoerd met platina- en palladiumcomplexen van een 
tetrapyridylligand met één aminebrug (Hbbpya) in plaats van de twee 
aminebruggen in H2bapbpy. De cytotoxiciteit van deze verbindingen was 
vergelijkbaar met die van cisplatina, maar was veel lager dan dat van 
[Pd(H2bapbpy)](PF6)2 (Hoofdstuk 7). Coördinatie van Hbbpya aan een 
palladium(II)-ion resulteerde in een veel minder verstoorde vlak-vierkante 
geometrie dan in de H2bapbpy-verbinding (Figuur 4). Door de aanwezigheid van 
slechts één aminebrug in vlak-vierkante Hbbpya complexen is het aantal 
ladingstoestanden beperkt tot dicationisch ([M(Hbbpya)]2+) of monocationisch 
wanneer het amine gedeprotoneerd is ([M(bbpya)]+). Voor H2bapbpy complexen is 
deprotonering van twee amines mogelijk, waardoor een derde, neutrale toestand 
bereikbaar is ([M(bapbpy)]). De pKa voor de eerste deprotonering is 5,5 en 4,6 voor 
respectievelijk [Pd(Hbbpya)]2+ en [Pt(Hbbpya)]2+, terwijl voor [Pd(H2bapbpy)]2+ en 
[Pt(H2bapbpy)]2+ de eerste pKa veel hoger is (respectievelijk 7,8 en 8,3). Er mag dus 
worden aangenomen dat de Hbbpya-complexen in fysiologische condities 
gedeprotoneerd en in hun monocationische vorm zijn, terwijl de H2bapbpy-
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Figuur 4. Projecties van [Pd(H2bapbpy)]2+ (A) en [Pd(Hbbpya)]2+ (B). Ter verduidelijking 
zijn H-atomen, anionen en oplosmiddelmoleculen weggelaten.  
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